<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Menopausal status, ultrasound and biomarker tests in combination for the diagnosis of ovarian cancer in symptomatic women - Davenport, C - 2022 | Cochrane Library</title> <meta content="Menopausal status, ultrasound and biomarker tests in combination for the diagnosis of ovarian cancer in symptomatic women - Davenport, C - 2022 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011964.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Menopausal status, ultrasound and biomarker tests in combination for the diagnosis of ovarian cancer in symptomatic women - Davenport, C - 2022 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011964.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD011964.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Menopausal status, ultrasound and biomarker tests in combination for the diagnosis of ovarian cancer in symptomatic women" name="citation_title"/> <meta content="Clare Davenport" name="citation_author"/> <meta content="University of Birmingham" name="citation_author_institution"/> <meta content="c.f.davenport@bham.ac.uk" name="citation_author_email"/> <meta content="Nirmala Rai&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="University of Birmingham" name="citation_author_institution"/> <meta content="Pawana Sharma&lt;sup&gt;a&lt;/sup&gt;" name="citation_author"/> <meta content="University of Birmingham" name="citation_author_institution"/> <meta content="Jonathan J Deeks" name="citation_author"/> <meta content="University of Birmingham" name="citation_author_institution"/> <meta content="Sarah Berhane" name="citation_author"/> <meta content="University Hospitals Birmingham NHS Foundation Trust and University of Birmingham" name="citation_author_institution"/> <meta content="Sue Mallett" name="citation_author"/> <meta content="University College London" name="citation_author_institution"/> <meta content="Pratyusha Saha" name="citation_author"/> <meta content="University of Birmingham" name="citation_author_institution"/> <meta content="Rita Champaneria" name="citation_author"/> <meta content="NHS Blood and Transplant" name="citation_author_institution"/> <meta content="Susan E Bayliss" name="citation_author"/> <meta content="University of Birmingham" name="citation_author_institution"/> <meta content="Kym IE Snell" name="citation_author"/> <meta content="Keele University" name="citation_author_institution"/> <meta content="Sudha Sundar" name="citation_author"/> <meta content="University of Birmingham " name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="7" name="citation_issue"/> <meta content="10.1002/14651858.CD011964.pub2" name="citation_doi"/> <meta content="2022" name="citation_date"/> <meta content="2022/07/26" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011964.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011964.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011964.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Biomarkers; Carcinoma, Ovarian Epithelial; Cross-Sectional Studies; Menopause; *Ovarian Neoplasms [diagnostic imaging]; Sensitivity and Specificity" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011964.pub2&amp;doi=10.1002/14651858.CD011964.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011964.pub2&amp;doi=10.1002/14651858.CD011964.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011964.pub2&amp;doi=10.1002/14651858.CD011964.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011964.pub2&amp;doi=10.1002/14651858.CD011964.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011964.pub2&amp;doi=10.1002/14651858.CD011964.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011964.pub2&amp;doi=10.1002/14651858.CD011964.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011964.pub2&amp;doi=10.1002/14651858.CD011964.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011964.pub2&amp;doi=10.1002/14651858.CD011964.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011964.pub2&amp;doi=10.1002/14651858.CD011964.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011964.pub2&amp;doi=10.1002/14651858.CD011964.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011964.pub2&amp;doi=10.1002/14651858.CD011964.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011964.pub2&amp;doi=10.1002/14651858.CD011964.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011964.pub2&amp;doi=10.1002/14651858.CD011964.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011964.pub2&amp;doi=10.1002/14651858.CD011964.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011964.pub2&amp;doi=10.1002/14651858.CD011964.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011964.pub2&amp;doi=10.1002/14651858.CD011964.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011964.pub2&amp;doi=10.1002/14651858.CD011964.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011964.pub2&amp;doi=10.1002/14651858.CD011964.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011964.pub2&amp;doi=10.1002/14651858.CD011964.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011964.pub2&amp;doi=10.1002/14651858.CD011964.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011964.pub2&amp;doi=10.1002/14651858.CD011964.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011964.pub2&amp;doi=10.1002/14651858.CD011964.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD011964.pub2&amp;doi=10.1002/14651858.CD011964.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="loVWuZlx";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD011964\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD011964\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011964\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011964\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","zh_HANT","ru","ms","ja","hr","fa","fr"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD011964.pub2",title:"Menopausal status, ultrasound and biomarker tests in combination for the diagnosis of ovarian cancer in symptomatic women",firstPublishedDate:"Jul 26, 2022 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=loVWuZlx&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011964.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011964.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD011964.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD011964.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011964.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD011964.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;},{&quot;language&quot;:&quot;zh_HANT&quot;,&quot;title&quot;:&quot;淺顯易懂的口語結論&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD011964.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD011964.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD011964.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD011964.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>4522 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD011964.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011964.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011964.pub2/full#CD011964-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011964.pub2/full#CD011964-sec-0092"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011964.pub2/full#CD011964-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011964.pub2/full#CD011964-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011964.pub2/full#CD011964-sec-0021"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011964.pub2/full#CD011964-sec-0027"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011964.pub2/full#CD011964-sec-0053"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011964.pub2/full#CD011964-sec-0082"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011964.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011964.pub2/appendices#CD011964-sec-0097"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011964.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011964.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/supinfo/CD011964StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/supinfo/CD011964StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011964.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011964.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD011964.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011964.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD011964.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD011964.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2022 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Diagnostic</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Menopausal status, ultrasound and biomarker tests in combination for the diagnosis of ovarian cancer in symptomatic women </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011964.pub2/information#CD011964-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Clare Davenport</a></li> <li class="author custom-tooltip" title="Joint first author"><a href="/cdsr/doi/10.1002/14651858.CD011964.pub2/information#CD011964-cr-0005">Nirmala Rai</a><sup>a</sup></li> <li class="author custom-tooltip" title="Joint first author"><a href="/cdsr/doi/10.1002/14651858.CD011964.pub2/information#CD011964-cr-0006">Pawana Sharma</a><sup>a</sup></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011964.pub2/information#CD011964-cr-0007">Jonathan J Deeks</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011964.pub2/information#CD011964-cr-0008">Sarah Berhane</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011964.pub2/information#CD011964-cr-0009">Sue Mallett</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011964.pub2/information#CD011964-cr-0010">Pratyusha Saha</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011964.pub2/information#CD011964-cr-0011">Rita Champaneria</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011964.pub2/information#CD011964-cr-0012">Susan E Bayliss</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011964.pub2/information#CD011964-cr-0013">Kym IE Snell</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD011964.pub2/information#CD011964-cr-0014">Sudha Sundar</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/information/en#CD011964-sec-0107">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 26 July 2022 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD011964.pub2">https://doi.org/10.1002/14651858.CD011964.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD011964-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011964-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011964-abs-0014">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011964-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011964-abs-0012">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011964-abs-0003">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD011964-abs-0001" lang="en"> <section id="CD011964-sec-0001"> <h3 class="title" id="CD011964-sec-0001">Background</h3> <p>Ovarian cancer (OC) has the highest case fatality rate of all gynaecological cancers. Diagnostic delays are caused by non‐specific symptoms. Existing systematic reviews have not comprehensively covered tests in current practice, not estimated accuracy separately in pre‐ and postmenopausal women, or used inappropriate meta‐analytic methods. </p> </section> <section id="CD011964-sec-0002"> <h3 class="title" id="CD011964-sec-0002">Objectives</h3> <p>To establish the accuracy of combinations of menopausal status, ultrasound scan (USS) and biomarkers for the diagnosis of ovarian cancer in pre‐ and postmenopausal women and compare the accuracy of different test combinations. </p> </section> <section id="CD011964-sec-0003"> <h3 class="title" id="CD011964-sec-0003">Search methods</h3> <p>We searched CENTRAL, MEDLINE (Ovid), Embase (Ovid), five other databases and three trial registries from 1991 to 2015 and MEDLINE (Ovid) and Embase (Ovid) from June 2015 to June 2019. We also searched conference proceedings from the European Society of Gynaecological Oncology, International Gynecologic Cancer Society, American Society of Clinical Oncology and Society of Gynecologic Oncology, ZETOC and Conference Proceedings Citation Index (Web of Knowledge). We searched reference lists of included studies and published systematic reviews. </p> </section> <section id="CD011964-sec-0004"> <h3 class="title" id="CD011964-sec-0004">Selection criteria</h3> <p>We included cross‐sectional diagnostic test accuracy studies evaluating single tests or comparing two or more tests, randomised trials comparing two or more tests, and studies validating multivariable models for the diagnosis of OC investigating test combinations, compared with a reference standard of histological confirmation or clinical follow‐up in women with a pelvic mass (detected clinically or through USS) suspicious for OC. </p> </section> <section id="CD011964-sec-0005"> <h3 class="title" id="CD011964-sec-0005">Data collection and analysis</h3> <p>Two review authors independently extracted data and assessed quality using QUADAS‐2. We used the bivariate hierarchical model to indirectly compare tests at commonly reported thresholds in pre‐ and postmenopausal women separately. We indirectly compared tests across all thresholds and estimated sensitivity at fixed specificities of 80% and 90% by fitting hierarchical summary receiver operating characteristic (HSROC) models in pre‐ and postmenopausal women separately. </p> </section> <section id="CD011964-sec-0006"> <h3 class="title" id="CD011964-sec-0006">Main results</h3> <p>We included 59 studies (32,059 women, 9545 cases of OC). Five studies evaluated the accuracy of a combination of menopausal status and USS findings (IOTA Logistic Regression Model 2 (LR2), four studies evaluated the Assessment of Different NEoplasias in the adneXa model (ADNEX)); 19 studies evaluated the accuracy of a combination of menopausal status, USS findings and serum biomarker CA125 (Risk of Malignancy Index (RMI)); and 42 studies evaluated the accuracy of a combination of menopausal status and two serum biomarkers (CA125 and HE4) (Risk of Ovarian Malignancy Algorithm (ROMA)). Most studies were at high or unclear risk of bias in participant, reference standard, and flow and timing domains. All studies were in hospital settings. Mean prevalence was 16% (RMI, ROMA), 22% (LR2) and 27% (ADNEX) in premenopausal women and 38% (RMI), 45% (ROMA), 52% (LR2) and 55% (ADNEX) in postmenopausal women. The prevalence of OC in the studies was considerably higher than would be expected in symptomatic women presenting in community‐based settings, or in women referred from the community to hospital with a suspicion of OC. Studies were at high or unclear applicability because presenting features were not reported, or USS was performed by experienced ultrasonographers for RMI, LR2 and ADNEX. </p> <p>The higher sensitivity and lower specificity observed in postmenopausal compared to premenopausal women across all index tests and at all thresholds may reflect highly selected patient cohorts in the included studies. </p> <p>In premenopausal women, ROMA at a threshold of 13.1 (± 2), LR2 at a threshold to achieve a post‐test probability of OC of 10% and ADNEX (post‐test probability 10%) demonstrated a higher sensitivity (ROMA: 77.4%, 95% CI 72.7% to 81.5%; LR2: 83.3%, 95% CI 74.7% to 89.5%; ADNEX: 95.5%, 95% CI 91.0% to 97.8%) compared to RMI (57.2%, 95% CI 50.3% to 63.8%). The specificity of ROMA and ADNEX were lower in premenopausal women (ROMA: 84.3%, 95% CI 81.2% to 87.0%; ADNEX: 77.8%, 95% CI 67.4% to 85.5%) compared to RMI 92.5% (95% CI 90.3% to 94.2%). The specificity of LR2 was comparable to RMI (90.4%, 95% CI 84.6% to 94.1%). </p> <p>In postmenopausal women, ROMA at a threshold of 27.7 (± 2), LR2 (post‐test probability 10%) and ADNEX (post‐test probability 10%) demonstrated a higher sensitivity (ROMA: 90.3%, 95% CI 87.5% to 92.6%; LR2: 94.8%, 95% CI 92.3% to 96.6%; ADNEX: 97.6%, 95% CI 95.6% to 98.7%) compared to RMI (78.4%, 95% CI 74.6% to 81.7%). Specificity of ROMA at a threshold of 27.7 (± 2) (81.5, 95% CI 76.5% to 85.5%) was comparable to RMI (85.4%, 95% CI 82.0% to 88.2%), whereas for LR2 (post‐test probability 10%) and ADNEX (post‐test probability 10%) specificity was lower (LR2: 60.6%, 95% CI 50.5% to 69.9%; ADNEX: 55.0%, 95% CI 42.8% to 66.6%). </p> </section> <section id="CD011964-sec-0007"> <h3 class="title" id="CD011964-sec-0007">Authors' conclusions</h3> <p>In specialist healthcare settings in both premenopausal and postmenopausal women, RMI has poor sensitivity. In premenopausal women, ROMA, LR2 and ADNEX offer better sensitivity (fewer missed cancers), but for ROMA and ADNEX this is off‐set by a decrease in specificity and increase in false positives. In postmenopausal women, ROMA demonstrates a higher sensitivity and comparable specificity to RMI. ADNEX has the highest sensitivity in postmenopausal women, but reduced specificity. The prevalence of OC in included studies is representative of a highly selected referred population, rather than a population in whom referral is being considered. The comparative accuracy of tests observed here may not be transferable to non‐specialist settings. Ultimately health systems need to balance accuracy and resource implications to identify the most suitable test. </p> </section> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD011964-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD011964-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD011964-abs-0015">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD011964-abs-0011">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD011964-abs-0013">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD011964-abs-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD011964-abs-0008">日本語</a> </li> <li class="section-language"> <a class="" href="full/ms#CD011964-abs-0007">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD011964-abs-0006">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD011964-abs-0004">简体中文</a> </li> <li class="section-language"> <a class="" href="full/zh_HANT#CD011964-abs-0005">繁體中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD011964-abs-0002" lang="en"> <h3>What is the accuracy of different combinations of ultrasound imaging and blood tests to diagnose ovarian cancer in women before and after the menopause? </h3> <p><b>Why is improving the diagnosis of ovarian cancer important?</b> </p> <p>Many women diagnosed with ovarian cancer (OC) die from the disease, because it has usually spread outside the tubes/ovaries at the time of diagnosis. Missing OC (a false‐negative result) may need major surgery and a lower chance of survival. An incorrect diagnosis of OC (a false‐positive result) may result in anxiety, unnecessary further tests and surgery. </p> <p><b>What did we aim to do?</b> </p> <p>We aimed to find out how accurate ultrasounds and blood tests are for diagnosing OC in premenopausal women and postmenopausal women. </p> <p><b>What did we study?</b> </p> <p>We included 59 studies that compared four tests: Risk of Malignancy Index (RMI) (ultrasound and CA125 blood test); Risk of Ovarian Malignancy Algorithm (ROMA) (CA125 and HE4 blood tests); the IOTA Logistic Regression model 2 (LR2) ultrasound and the Assessment of Different NEoplasias in the adneXa model (ADNEX) (CA125 blood test and ultrasound). </p> <p><b>What were the main results?</b> </p> <p>Premenopausal women </p> <p>The sensitivities (proportion of women <i>with</i> OC correctly identified) of ROMA (77.4%), LR2 (83.3%) and ADNEX (95.5%) are higher than RMI (57.2%). </p> <p>The specificities (proportion of women <i>without</i> OC correctly identified) of ROMA (84.3%) and ADNEX (77.8%) were lower than RMI (92.5%) and LR2 (90.4%). </p> <p>The results indicate that if these tests were to be used in hospital settings in a group of 1000 premenopausal women, of whom 30 (3%) actually have OC: </p> <p>– for RMI 13 women, for ROMA 7 women, for LR2 5 women and for ADNEX 1 woman would have their cancer missed by the test (false‐negative result); </p> <p>– for RMI 73 women, for ROMA 152 women, for LR2 93 women and for ADNEX 215 women would test positive when they do not have OC (false‐positive result). </p> <p>Postmenopausal women </p> <p>The sensitivities of ROMA (90.3%), LR2 (94.8%) and ADNEX (97.6%) are higher than RMI (78.4%). </p> <p>The specificities of ROMA (81.5%) and RMI (85.4%) are higher than LR2 (60.6%) and ADNEX (55.0%). </p> <p>The results of these studies indicate that if these tests were to be used in hospital settings in a group of 1000 postmenopausal women, of whom 30 (3%) actually have OC: </p> <p>– for RMI 6 women, for ROMA 3 women, for LR2 2 women and for ADNEX 1 woman would have their cancer missed by the test (false‐negative result); </p> <p>– for RMI 142 women, for ROMA 179 women, for LR2 382 women and for ADNEX 437 women would test positive when they do not have OC (false‐positive result). </p> <p><b>How reliable are the results?</b> </p> <p>OC was diagnosed by histology (looking at surgically removed specimens under a microscope) or following up women for one year to see if they remained free of OC. In some studies, women with negative test results were not followed up for long enough to be sure a cancer had not been missed, and some studies excluded women with types of OC that are harder to diagnose. This may make tests appear more accurate than they are in practice. </p> <p><b>Who do the results apply to?</b> </p> <p>Most studies were conducted in European hospitals in women with a confirmed pelvic mass. The occurrence of OC in included studies was much higher than seen in the community and so the accuracy of these tests may be different for women being tested in non‐specialist healthcare settings. </p> <p><b>What are the implications?</b> </p> <p>This review suggests that in both pre‐ and postmenopausal women referred to hospital with a pelvic mass, ADNEX appears to miss the fewest cases of OC and RMI misses the most cases of OC. RMI appears to result in the fewest incorrect diagnoses of OC and ADNEX results in the most incorrect diagnoses of OC. Incorrect diagnoses of OC, when no cancer is present (false‐positive test), may result in anxiety, unnecessary further tests and surgery. When choosing which test to use, the potential for missed cancers must be balanced against unnecessary testing and surgery. </p> <p><b>How up‐to‐date is this review?</b> </p> <p>The review includes studies published up to June 2019.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD011964-sec-0092" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD011964-sec-0092"></div> <h3 class="title" id="CD011964-sec-0093">Implications for practice</h3> <section id="CD011964-sec-0093"> <p>This review has demonstrated that menopausal status is associated with changes in disease spectrum, which is reflected in differences in test performance for women presenting with an adnexal mass. The implications of this finding for practice is that the utility of tests for diagnosing ovarian cancer (OC) should be considered separately in premenopausal and postmenopausal women. </p> <p>Furthermore, current guidelines recommending the Risk of Malignancy Index (RMI) as a diagnostic or triage test in pre‐ and postmenopausal women in secondary care settings should be reviewed. </p> <p>The Logistic Regression Model 2 (LR2) has been superseded by the Assessment of Different NEoplasias in the adneXa model (ADNEX) in clinical practice. The strength with which we can draw conclusions about the relative accuracy of Risk of Ovarian Malignancy Algorithm (ROMA) or ADNEX, as replacements to RMI, is undermined by the relatively small number of included ADNEX studies. However, our scoping for more‐recent ADNEX studies resulted in accuracy estimates within the range of present included studies. In spite of relatively wide confidence intervals for estimates of accuracy for ADNEX, we can still conclude that: </p> <p> <ul id="CD011964-list-0026"> <li> <p>for premenopausal women presenting to specialist settings with an adnexal mass suspicious for OC, ROMA and ADNEX both offer higher sensitivities compared to RMI, but at the expense of a decrease in specificity; </p> </li> <li> <p>for postmenopausal women, ROMA and ADNEX both offer higher sensitivities compared to RMI, but at the expense of a decrease in specificity for ADNEX. </p> </li> </ul> </p> <p>The decision about which test (ROMA or ADNEX) should replace RMI will depend in part on how healthcare systems view the trade‐off between sensitivity (false‐negative diagnoses) and specificity (false‐positive diagnoses). Inclusion of a larger number of ADNEX studies will improve precision and may reveal a distinction between the specificity of ADNEX and ROMA in premenopausal women. </p> <p>The choice of which combination test (ROMA or ADNEX) should replace RMI in practice in secondary care will also require consideration of the relative costs and the feasibility of introducing the test. ADNEX offers a polynomial probability of histology, which is valuable information for counselling patients on treatment options. However, implementing tests based on USS models will require training in specialist USS skills and quality assurance processes, similar to those introduced for nuchal scans in early pregnancy. Implementing USS through dedicated 'pelvic mass clinics' may represent a method for achieving this. Implementing testing with ROMA will require investment in laboratory processes. </p> <p>The implications of our findings for women presenting in generalist settings, and early in the diagnostic pathway in secondary care, is less clear. Participants in included studies had a confirmed adnexal mass and the presence of symptoms at the time of testing was mostly not reported. Prevalence of OC in premenopausal women in included studies was upwards of 9% and in postmenopausal women 40%. Included participants are therefore likely to represent a highly selected referred population, rather than a population in whom referral is being considered. The comparative accuracy of tests observed here may also not be stable when transferred to non‐specialist settings. </p> </section> <h3 class="title" id="CD011964-sec-0094">Implications for research</h3> <section id="CD011964-sec-0094"> <p>Most studies in this review were conducted in specialist centres and the prevalence of OC in both pre‐ and postmenopausal women was typical of tertiary healthcare settings, ranging from 8% to 81% across included studies. No studies were identified in populations with a prevalence of OC typical of that seen at the point of first referral to hospital (e.g. rapid access clinics) or in community settings. Clinical setting has significant implications for the performance of diagnostic tests and the cost‐benefit impact on a healthcare system. Research is urgently needed to evaluate tests for diagnosis of OC in community settings. Future studies performed earlier in the OC diagnostic pathway should also take care to report aspects of setting that will have a bearing on test performance such as healthcare setting (e.g. primary care or rapid access hospital clinic); presenting signs and symptoms and details of test conduct such as the skill of those eliciting symptoms; signs and conducting and interpreting imaging tests. In populations such as these that are more heterogeneous the use of rigorous clinical follow‐up as a reference standard in index test negative cases should be pursued. Importantly, higher reporting standards of diagnostic test accuracy studies are required. This is a common and major limitation to systematic review of diagnostic test accuracy studies, as previously noted (<a href="./references#CD011964-bbs2-0094" title="NagarH , WietekN , GoodallRJ , HughesW , Schmidt-HansenM , MorrisonJ . Sentinel node biopsy for diagnosis of lymph node involvement in endometrial cancer. Cochrane Database of Systematic Reviews2021, Issue 6. Art. No: CD013021. [DOI: 10.1002/14651858.CD013021.pub2]">Nagar 2021</a>). </p> <p>Primary studies should in future clearly report the occurrence of tumours found to be borderline at histology. Separate classification of these tumour types will ensure test accuracy research can be used flexibility, as knowledge advances about the malignant potential of such tumours and their most effective management. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD011964-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD011964-sec-0008"></div> <div class="table" id="CD011964-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings for menopausal status, ultrasound scan and biomarker tests in pre‐ and postmenopausal women in secondary care (prevalence ovarian cancer 3%)</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Review question</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Menopausal status, ultrasound scan and biomarker tests in combination for the diagnosis of ovarian cancer in women with symptoms suspicious for ovarian cancer </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Setting</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Secondary care</p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Reference standards</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Histology in women who have undergone surgery and clinical follow‐up (&gt; 6 months) in women with negative index tests results who do not undergo surgery </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Study limitations</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>For the participant selection domain, 44/59 (75%) studies were at high or unclear risk of bias because of concerns about selective recruitment of women. 58/59 (92%) studies were at high or unclear applicability concern for the participant selection domain because study participants were not symptomatic women. </p> <p>For the index test domain, 9/42 (21%) of ROMA studies, 11/20 (55%) of RMI studies, 2/4 (50%) of ADNEX studies, and 5/5 (100%) of LR2 studies were at high risk of bias because of lack of blinding of the index test or for ROMA studies because of no predefined threshold. Applicability concern was high or unclear for all RMI, ADNEX and LR2 studies because ultrasound was conducted by specialist sonographers or this was unclear. </p> <p>For the reference standard domain, 2/59 studies were at high risk of bias because the minimum length of follow‐up for index negatives was not reported or because of lack of blinding. Applicability concern was high or unclear in 50/59 (85%) studies because borderline tumours had been excluded from analysis or classification of borderline tumours for estimation of test accuracy was unclear. </p> <p>For the flow and timing domain, 45/59 (76%) studies were at unclear or high risk of bias because of no information about the interval between the index test and the reference standard or because not all participants receiving an index test received a reference standard. </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Population</b> </p> </th> <th align="center" class="headercell" colspan="6" rowspan="1" scope="col" valign="top"> <p><b>Premenopausal women</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Index test, threshold</b> </p> <p><b>Studies (participants)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Sensitivity (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Specificity</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Absolute sensitivity difference (95% CI) compared to RMI</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Absolute specificity difference (95% CI) compared to RMI</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Consequences in a hypothetical cohort of 1000 women assuming a prevalence of 3%*</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of women who would have their cancer missed (false‐negatives) (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of women who would test positive when they do not have ovarian cancer (false‐positives) (95% CI)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RMI 200</p> <p>17 (5233)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57.2 (50.3 to 63.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92.5 (90.3 to 94.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 (11 to 15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73 (56 to 94)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ROMA 13.1 (± 2)</p> <p>27 (4463)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77.4 (72.7 to 81.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84.3 (81.2 to 87.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.2 (12.2 to 28.3);</p> <p>P &lt; 0.0001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–8.2 (–11.7 to –4.7); P &lt; 0.0001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (6 to 8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152 (126 to 182)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LR2 post‐test probability ovarian cancer 10%</p> <p>4 (2843)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83.3 (74.7 to 89.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90.4 (84.6 to 94.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.2 (16.2 to 36.2); P &lt; 0.0001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–2.1 (–7.2 to 2.9); P = 0.404</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (3 to 8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93 (57 to 149)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADNEX post‐test probability ovarian cancer 10%</p> <p>4 (1696)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95.5 (91.0 to 97.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77.8 (67.4 to 85.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.3 (30.9 to 45.8); P &lt; 0.0001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–14.8 (–24.0 to –5.5);</p> <p>P = 0.002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (1 to 3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>215 (141 to 316)</p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Population</b> </p> </th> <th align="center" class="headercell" colspan="6" rowspan="1" scope="col" valign="top"> <p><b>Postmenopausal women</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Index test, threshold</b> </p> <p><b>Studies (participants)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Sensitivity (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Specificity</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Absolute sensitivity difference (95% CI) compared to RMI</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Absolute specificity difference (95% CI) compared to RMI</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Consequences in a hypothetical cohort of 1000 women assuming a prevalence of 3%*</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of women who would have their cancer missed (false‐negatives) (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of women who would test positive when they do not have ovarian cancer (false‐positives) (95% CI)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RMI 200</p> <p>17 (4369)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78.4 (74.6 to 81.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85.4 (82.0 to 88.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (5 to 8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142 (114 to 175)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ROMA (27.7 (± 2))</p> <p>13 (2002)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90.3 (87.5 to 92.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81.5 (76.5 to 85.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.9 (7.6 to 16.3);</p> <p>P &lt; 0.0001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–3.9 (–9.4 to 1.5);</p> <p>P = 0.157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (2 to 4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179 (141 to 228)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LR2 post‐test probability ovarian cancer 10%</p> <p>5 (2157)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94.8 (92.3 to 96.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60.6 (50.5 to 69.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.4 (12.3 to 20.5); P &lt; 0.0001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–24.8 (–35.1 to –14.5); P &lt; 0.0001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (1 to 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>382 (292 to 480)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADNEX post‐test probability ovarian cancer 10%</p> <p>4 (1365)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97.6 (95.6 to 98.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55.0 (42.8 to 66.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.2 (15.4 to 23.1); P &lt; 0.0001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–30.4 (–42.9 to –17.9); P &lt; 0.0001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (0 to 1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>437 (324 to 555)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>*Estimate of disease prevalence (pretest probability) reflecting the NICE threshold for cancer referral from generalist to specialist settings in the UK (<a href="./references#CD011964-bbs2-0097" title="National Institute for Health and Care Excellence. Suspected cancer: recognition and referral. www.nice.org.uk/guidance/ng12 (accessed 22 May 2019).">NICE 2017</a>). Note this is considerably lower (3%) compared to the prevalence of ovarian cancer in included studies in the review (16% to 55%). </p> <p>ADNEX: Assessment of Different NEoplasias in the adneXa model; CI: confidence interval; LR2: Logistic Regression model 2; RMI: Risk of Malignancy Index; ROMA: Risk of Ovarian Malignancy Algorithm. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD011964-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD011964-sec-0009"></div> <p>The estimated lifetime risk of being diagnosed with ovarian cancer (OC) is 1 in 50 (2%) for females born after 1960 in the UK Office for National Statistics (ONS) (<a href="./references#CD011964-bbs2-0099" title="Office for National Statistics. Office for National Statistics (ONS) 2016-based life expectancies and population projections. www.ons.gov.uk/releases/nationalpopulationprojections2016basedstatisticalbulletin (accessed December 2017).">Office for National Statistics 2016</a>; <a href="./references#CD011964-bbs2-0111" title="SmittenaarCR , PetersenKA , StewartK , MoittN . Cancer incidence and mortality projections in the UK until 2035. British Journal of Cancer2016;115(9):1147-55.">Smittenaar 2016</a>). Increasing age is a risk factor for OC; with incidence rates highest in females between 75 and 79 years of age (<a href="./references#CD011964-bbs2-0066" title="Cancer Research UK. Ovarian cancer statistics 2016–2018. www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/ovarian-cancer#heading-Zero (accessed prior to 29 June 2022).">Cancer Research UK 2017</a>). </p> <p>OC is the most common cause of mortality among all gynaecological cancers. In 2018, 295,414 women were diagnosed with OC and 184,799 women died worldwide (<a href="./references#CD011964-bbs2-0065" title="BrayF , FerlayJ , SoerjomataramI , SiegalRL , TorreLA , JemalA . Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a Cancer Journal for Clinicians2018;68:394-424.">Bray 2018</a>). The high case fatality rate is largely attributed to the advanced stage at diagnosis in most women with OC. Although overall survival is 35% at 10 years, one‐year survival is only 51% in stage 4 disease, in comparison to 99% in stage 1 disease (<a href="./references#CD011964-bbs2-0099" title="Office for National Statistics. Office for National Statistics (ONS) 2016-based life expectancies and population projections. www.ons.gov.uk/releases/nationalpopulationprojections2016basedstatisticalbulletin (accessed December 2017).">Office for National Statistics 2016</a>). Lack of awareness and recognition of pertinent symptoms and signs by patients and physicians is considered one of the main factors contributing to a delay in diagnosis. Diagnosis of OC is challenging because of variable presentation, the non‐specific nature of symptoms (<a href="./references#CD011964-bbs2-0079" title="FitchM , DeaneK , HowellD , GrayRE . Women's experiences with ovarian cancer: reflections on being diagnosed. Canadian Oncology Nursing Journal (Revue Canadienne de Nursing Oncologique)2002;12(3):152-68.">Fitch 2002</a>), and low prevalence. The prevalence of OC in primary care has been estimated as 0.023% (<a href="./references#CD011964-bbs2-0064" title="BankheadCR , KehoeST , AustokerJ . Symptoms associated with diagnosis of ovarian cancer: a systematic review. BJOG: an International Journal of Obstetrics and Gynaecology2005;112(7):857-65.">Bankhead 2005</a>; <a href="./references#CD011964-bbs2-0081" title="HamiltonW , PetersTJ , BankheadC , SharpD . Risk of ovarian cancer in women with symptoms in primary care: population based case-control study. BMJ2009;339:b2998.">Hamilton 2009</a>), whilst recent hospital audits suggest a prevalence of OC in secondary care of 10% (<a href="./references#CD011964-bbs2-0101" title="RaiN , NevinJ , DowneyG , AbedinP , BalogunM , KehoeS , et al. Outcomes following implementation of symptom triggered diagnostic testing for ovarian cancer. European Journal of Obstetrics, Gynecology and Reproductive Biology2015;187:64-9.">Rai 2015</a>). The prevalence of OC in women undergoing surgery for ovarian pathology in tertiary care settings is in the region of 30% (<a href="./references#CD011964-bbs2-0098" title="NunesN , AmblerG , FooX , NaftalinJ , WidschwendterM . Use of IOTA simple rules for diagnosis of ovarian cancer: meta-analysis. Ultrasound in Obstetrics &amp; Gynecology2014;44:503-14.">Nunes 2014</a>; <a href="./references#CD011964-bbs2-0051" title="TimmermanD , AmeyeL , FischerovaD , EpsteinE , MelisGB , GuerrieroS , et al. Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group. BMJ2010;341:c6839. ">Timmerman 2010</a>; <a href="./references#CD011964-bbs2-0116" title="TimmermanD , vanCalsterB , TestsA , SavelliL , FischerovaD , FroymanW , et al. Predicting the risk of malignancy in adnexal masses based on the simple rules from the International Ovarian Tumor Analysis group. American Journal of Obstetrics and Gynaecology2016;214(4):424-37.">Timmerman 2016</a>). </p> <p>Diagnosis of OC in premenopausal women poses additional challenges. Most ovarian tumours detected in premenopausal women tend to be benign; only 1 in 1000 symptomatic ovarian cysts are malignant, increasing to 3 in 1000 at age 50 years (<a href="./references#CD011964-bbs2-0102" title="Royal College of Obstetricians and Gynaecologists. Guideline no 62: management of suspected ovarian masses in premenopausal women. www.rcog.org.uk/globalassets/documents/guidelines/gtg_62.pdf (accessed prior to 29 June 2022).">RCOG 2011</a>). </p> <p>Advances in surgical practice and chemotherapy in recent years have slightly improved survival, but a diagnosis of OC continues to be associated with a high mortality, largely attributed to an advanced stage at diagnosis. </p> <section id="CD011964-sec-0010"> <h3 class="title" id="CD011964-sec-0010">Target condition being diagnosed</h3> <p>OC has various subtypes including, epithelial ovarian cancers (EOC), germ cell tumours, stromal cell tumours, metastatic cancers (from other primary sites) and tumours of low malignant potential (LMP) also known as borderline tumours. EOC are the most common type of OC in both pre‐ and postmenopausal women. More than 90% of OCs in postmenopausal women and 80% to 85% of OCs in premenopausal women are EOC; in premenopausal women, germ cell tumours account for 15% to 20% of OCs. Within the EOC group, high‐grade serous carcinoma (HGSC) is the most common histological type. Other common epithelial histological types are mucinous, clear cell and endometrioid (<a href="./references#CD011964-bbs2-0108" title="ShepherdJE . Current strategies for prevention, detection, and treatment of ovarian cancer. Journal of the American Pharmaceutical Association2000;40(3):392-401.">Shepherd 2000</a>). Morphological and genetic studies have helped to improve our understanding of ovarian carcinogenesis and tumour behaviour according to different histology types. The distal fallopian tube is the origin for serous ovarian carcinomas and ovarian clear cell cancers; the origin of endometrioid OCs has been linked to endometriosis (<a href="./references#CD011964-bbs2-0120" title="WiegandKC , ShahSP , Al-AghaOM , ZhaoY , TseK , ZengT , et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. New England Journal of Medicine2010;363(16):1532-43.">Wiegand 2010</a>). A dualistic model has been proposed based on the behaviour of tumours (<a href="./references#CD011964-bbs2-0109" title="ShihI , KurmanRJ . Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. American Journal of Pathology2004;164:1511-8.">Shih 2004</a>). Type 1 tumours are indolent and present at an early stage; a typical example is endometrioid cancer. Type 2 tumours are aggressive, high‐grade carcinomas, most often diagnosed at an advanced stage; a typical example is high‐grade serous OC. Type 1 and Type 2 tumours display markedly different and distinct genetic patterns (<a href="./references#CD011964-bbs2-0069" title="ChoKR , ShihI . Ovarian cancer. Annual Review of Pathology Mechanisms of Disease2009;4:287-313.">Cho 2009</a>). This advancement in understanding has major research implications, especially regarding the role of biomarkers, either alone, or as part of a composite index tests, in the management of OC. </p> <p>This review is concerned with primary OC of all histological types and stages, including borderline tumours. Metastatic disease (cancer found in the ovary, but originating in another organ) is outside the remit of this review. </p> </section> <section id="CD011964-sec-0011"> <h3 class="title" id="CD011964-sec-0011">Index test(s)</h3> <p>For the purpose of this review, combination tests are defined as tests which combine measures from more than one type of clinical information (e.g. age or menopausal status), biomarkers and ultrasound scan (USS) in any combination, and in any order. <a href="#CD011964-tbl-0002">Table 1</a> provides details of index tests considered eligible for inclusion in this review. </p> <div class="table" id="CD011964-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Details of included test combinations</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Index test combination</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Details</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Test positivity thresholds included</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RMI I</p> <p><i>U</i> × <i>M</i> × CA125 </p> <p><a href="./references#CD011964-bbs2-0085" title="JacobsI , OramD , FairbanksJ , TurnerJ , FrostC , GrudzinskasJG . A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. British Journal of Obstetrics and Gynaecology1990;97(10):922-9.">Jacobs 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ultrasound (U):</b> (1 point for each of multilocular cysts, solid areas, metastases, ascites and bilateral lesions) where a total ultrasound point score of 0 = 0, a point score of 1 = 1, and a point score of ≥ 2 = 3 </p> <p><b>Menopausal status (M):</b> premenopausal = 1 and postmenopausal = 3 </p> <p><b>Serum CA125:</b> CA125 U/mL applied directly to the calculation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200, 250</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ROMA</p> <p><a href="./references#CD011964-bbs2-0004" title="BandieraE , RomaniC , SpecchiaC , ZanottiL , GalliC , RuggeriG , et al. Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management. Cancer Epidemiology, Biomarkers &amp; Prevention2011;20(12):2496-506. ">Bandiera 2011</a> </p> <p><a href="./references#CD011964-bbs2-0029" title="MooreRG , McMeekinDS , BrownAK , DiSilvestroP , MillerMC , AllardWJ , et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecologic Oncology2009;112(1):40-6. ">Moore 2009</a> </p> <p><a href="./references#CD011964-bbs2-0054" title="vanGorpT , CadronI , DespierreE , DaemenA , LeunenK , AmantF , et al. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. British Journal of Cancer2011;104(5):863-70. ">van Gorp 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Premenopausal</b> PI = −12.0 + 2.38 × LN(HE4) + 0.0626 × LN(CA125) </p> <p><b>Postmenopausal</b> PI = −8.09 + 1.04 × LN(HE4) + 0.732 × LN(CA125) </p> <p><b>Predicted probability (ROMA score)</b> = exp(PI)/[1 + exp(PI)] × 100 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Premenopausal 7.4 and postmenopausal 25.3</p> <p>Premenopausal 12.5 and postmenopausal 14.4</p> <p>Premenopausal 13.1 and postmenopausal 27.7</p> <p>± 2% from common (above) thresholds</p> <p>Premenopausal: 7.4 (5.4 to 9.4%), 12.5 (10.5 to 14.5%), 14.4 (12.4 to 16.4%)</p> <p>Postmenopausal: 25.3 (23.3 to 27.3%), 27.7 (25.7 to 29.7%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LR2</p> <p><a href="./references#CD011964-bbs2-0051" title="TimmermanD , AmeyeL , FischerovaD , EpsteinE , MelisGB , GuerrieroS , et al. Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group. BMJ2010;341:c6839. ">Timmerman 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(3)</b> age of the woman (in years) </p> <p><b>(6)</b> presence of ascites (yes, 1; no, 0) </p> <p><b>(7)</b> presence of blood flow within a solid papillary projection (yes, 1; no, 0) </p> <p><b>(9)</b> maximum diameter of the solid component of the adnexal mass (expressed in millimetres, but with no increase 950 mm) </p> <p><b>(10)</b> irregular internal cyst walls (yes, 1; no, 0) </p> <p><b>(11)</b> presence of acoustic shadows (yes, 1; no, 0) </p> <p>The probability of malignancy is calculated using the formula y = 1/(1 + exp(jz)), where z = j5.3718 + 0.0354 <b>(3)</b> + 1.6159 <b>(6)</b> + 1.1768 <b>(7)</b> + 0.0697 <b>(9</b>) + </p> <p>0.9586 <b>(10)</b> j 2.9486 <b>(11</b>). The probability y is dichotomised at 0.1 to give a predictive diagnosis of cancer. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10% probability of ovarian cancer</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADNEX</p> <p><a href="./references#CD011964-bbs2-0052" title="vanCalsterB , vanHoordeK , ValentinL , TestaAC , FischerovaD , vanHolsbekeC , et al. Evaluating the risk of ovarian cancer before surgery using the ADNEX model to differentiate between benign, borderline, early and advanced stage invasive, and secondary metastatic tumours: prospective multicentre diagnostic study. BMJ2014;349:g5920. ">van Calster 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Age (years)</p> <p>Serum CA125 level (log transformed)</p> <p>Type of centre (oncology centres vs other hospitals)</p> <p>Maximum diameter of the lesion (log transformed)</p> <p>Proportion of solid tissue (with quadratic term)</p> <p>Number of papillary projections</p> <p>&gt; 10 cyst locules</p> <p>Acoustic shadows</p> <p>Ascites</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3%, 5%, 10% and 15% probability of ovarian cancer</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ADNEX: Assessment of Different NEoplasias in the adneXa model; LR2: Logistic Regression Model 2; RMI: Risk of Malignancy Index; ROMA: Risk of Ovarian Malignancy Algorithm. </p> </div> </div> <section id="CD011964-sec-0012"> <h4 class="title">Clinical information</h4> <p>The most important risk factor for OC is a family history of breast cancer or OC (<a href="./references#CD011964-bbs2-0061" title="American Cancer Society. Cancer facts and figures 2016. Atlanta (GA). www.cancer.org/acs/groups/content/@research/documents/document/acspc-047079.pdf (accessed prior to 29 June 2022).">American Cancer Society 2016</a>). Approximately 15% to 20% of OC is caused by an inherited genetic mutation in genes such as <i>BRCA1</i> and <i>BRCA2</i> (<a href="./references#CD011964-bbs2-0117" title="WalshT , CasadeiS , LeeMK , PennilCC , NordAS , ThorntonAM , et al. Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing. Proceedings of the National Academy of Sciences of the United States of America2011;108(44):18032-7.">Walsh 2011</a>). For women with a <i>BRCA1</i> or <i>BRCA2</i> genetic mutation, the lifetime risk of ovarian, fallopian tube or peritoneal cancer is approximately 41% to 46% for <i>BRCA1</i> and 10% to 27% for <i>BRCA2</i> by age 70 years (<a href="./references#CD011964-bbs2-0088" title="LancasterJM , PowellCB , ChenLM , RichardsonDL . Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. SGO Clinical Practice Committee [published erratum appears in Gynecol Oncol 2015;138:765]. Gynecologic Oncology2015;136:3-7.">Lancaster 2015</a>). The importance of menopausal status as a risk factor for OC is a function of the increased risk of cancer associated with increasing age (<a href="./references#CD011964-bbs2-0066" title="Cancer Research UK. Ovarian cancer statistics 2016–2018. www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/ovarian-cancer#heading-Zero (accessed prior to 29 June 2022).">Cancer Research UK 2017</a>). Although ovarian cysts are more common in premenopausal women, due to the physiological function of the ovary, most are benign functional cysts that resolve spontaneously. Some persistent benign cysts, caused by abnormal growth of cells such as endometriosis, fibromas and cystadenomas, may require intervention, but the risk of malignancy is low at 1/1000 women compared to 3/1000 women at age 50 years (<a href="./references#CD011964-bbs2-0102" title="Royal College of Obstetricians and Gynaecologists. Guideline no 62: management of suspected ovarian masses in premenopausal women. www.rcog.org.uk/globalassets/documents/guidelines/gtg_62.pdf (accessed prior to 29 June 2022).">RCOG 2011</a>). </p> </section> <section id="CD011964-sec-0013"> <h4 class="title">Biochemical markers</h4> <p>Biochemical markers, also known as biomarkers, are substances secreted or shed by tumours into surrounding blood and body fluids and expressed in abnormal tissues. Biomarkers may be uniquely specific for some tumour subtypes, or non‐specific. It has been noted that levels of some tumour markers may begin to rise as early as three years prior to diagnosis (<a href="./references#CD011964-bbs2-0062" title="AndersonGL , McIntoshM , WuL , BarnettM , GoodmanG , ThorpeJD , et al. Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study. Journal of the National Cancer Institute2010;102(1):26-38.">Anderson 2009</a>). </p> <p>The most commonly used biomarker for OC is CA125, which is raised in many benign and physiological conditions (<a href="./references#CD011964-bbs2-0093" title="MossEL , HollingworthJ , ReynoldsTM . The role of CA125 in clinical practice. Journal of Clinical Pathology2005;58(3):308-12.">Moss 2005</a>; <a href="./references#CD011964-bbs2-0100" title="PosadasEM , DavidsonB , KohnEC . Proteomics and ovarian cancer: implications for diagnosis and treatment: a critical review of the recent literature. Current Opinion in Oncology2004;16(5):478-84.">Posadas 2004</a>). CA125 operating at a threshold of 30 units/mL has a sensitivity of 81% and specificity of 75% for distinguishing benign from malignant tumours in mixed pre‐ and postmenopausal populations with adnexal masses (growths that occur in or near the uterus, ovaries, fallopian tubes and the connecting tissues) (<a href="./references#CD011964-bbs2-0085" title="JacobsI , OramD , FairbanksJ , TurnerJ , FrostC , GrudzinskasJG . A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. British Journal of Obstetrics and Gynaecology1990;97(10):922-9.">Jacobs 1990</a>). However, CA125 has a low sensitivity (50%) for early‐stage OC (<a href="./references#CD011964-bbs2-0084" title="JacobsI , Bast RC Jr. The CA 125 tumour-associated antigen: a review of the literature. Human Reproduction1989;4(1):1-12.">Jacobs 1989</a>), and reduced specificity in premenopausal women. </p> <p>The serum tumour marker Human Epididymis protein (HE4) is a glycoprotein belonging to the Whey acidic protein family (<a href="./references#CD011964-bbs2-0082" title="HellströmI , RaycraftJ , Hayden-LedbetterM , LedbetterJA , SchummerM , McIntoshM , et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Research2003;63(13):3695-700.">Hellstorm 2003</a>), and was approved as a biomarker for OC by the US Food and Drug Administration (FDA) in 2008. HE4 is elevated in 8% of benign conditions compared to 29% for CA125 and hence has the potential to improve specificity especially in premenopausal women (<a href="./references#CD011964-bbs2-0092" title="MooreRG , MillerMC , SteinhoffMM , SkatesSJ , LuKH , Lambert-MesserlianG , et al. Serum HE4 levels are less frequently elevated than CA-125 in women with benign gynecologic disorders. American Journal of Obstetrics and Gynecology2012;206(4):351 e1-8.">Moore 2012</a>). HE4 secretion increases with age (<a href="./references#CD011964-bbs2-0092" title="MooreRG , MillerMC , SteinhoffMM , SkatesSJ , LuKH , Lambert-MesserlianG , et al. Serum HE4 levels are less frequently elevated than CA-125 in women with benign gynecologic disorders. American Journal of Obstetrics and Gynecology2012;206(4):351 e1-8.">Moore 2012</a>), and is affected by different cellular types of OC, highest in endometrioid (100%), 93% of serous, 50% of clear cell and not elevated in mucinous types (<a href="./references#CD011964-bbs2-0074" title="DrapkinR , vonHorstenHH , LinY , MokSC , CrumCP , WelchWR , et al. Human Epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Research2005;65(6):2162-9.">Drapkin 2005</a>). HE4 has similar sensitivity, but improved specificity compared to CA125 for OC, particularly in premenopausal women (<a href="./references#CD011964-bbs2-0078" title="FerraroS , BragaF , LanzoniM , BoracchiP , BiganzoliEM , PanteghiniM . Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review. Journal of Clinical Pathology2013;66(4):273-81.">Ferraro 2013</a>; <a href="./references#CD011964-bbs2-0083" title="HolcombK , VuceticZ , MillerMC , KnappRC . Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women. American Journal of Obstetrics and Gynecology2011;205(4):358.e1-6.">Holcomb 2011</a>). </p> </section> <section id="CD011964-sec-0014"> <h4 class="title">Ultrasound scan</h4> <p>USS enables visualisation of morphological details of ovarian cysts. The diagnostic potential of USS has improved with advancing technology and the availability of transvaginal ultrasound (TVS), 3D ultrasound and Doppler techniques to characterise blood flow. However, the use of ultrasound to characterise lesions is influenced by interference from surrounding tissue, variability of the macroscopic features and the subjective nature of interpretation that is operator‐dependent. Various scores have been developed to make USS more objective (<a href="./references#CD011964-bbs2-0080" title="GeominiP , KruitwagenR , BremerGL , CnossenJ , MolBW . The accuracy of risk scores in predicting ovarian malignancy: a systematic review. Obstetrics and Gynecology2009;113(2 Pt 1):384-94.">Geomini 2009</a>). Morphological features, such as size, presence of bilateral lesions, presence and thickness of septum, presence of solid areas, excrescences and papillary structures within tumours, presence of metastases (spreading of a tumour to other parts of the body), presence of ascites (abnormal accumulation of fluid in the abdomen) and Doppler measurements of blood flow, have been combined in various ways. </p> <p>The 'U' score records the presence of bilateral lesions, multilocularity, solid areas, metastases or ascites, where U = 0 indicates the absence of any of these features; U = 1 indicates the presence of any one of these features and U = 3 indicates the presence of two or more of these features (<a href="./references#CD011964-bbs2-0102" title="Royal College of Obstetricians and Gynaecologists. Guideline no 62: management of suspected ovarian masses in premenopausal women. www.rcog.org.uk/globalassets/documents/guidelines/gtg_62.pdf (accessed prior to 29 June 2022).">RCOG 2011</a>). The U score is a component of the Risk of Malignancy Index (RMI) (see below). The International Ovarian Tumour Analysis (IOTA) proposed more‐recent USS‐based models as having better diagnostic accuracy in the preoperative evaluation of ovarian tumours than the U score, including the Logistic Regression model 2 (LR2) (<a href="./references#CD011964-bbs2-0086" title="KaijserJ , SayasnehA , vanHoordeK , Ghaem-MaghamiS , BourneT , TimmermanD , et al. Presurgical diagnosis of adnexal tumours using mathematical models and scoring systems: a systematic review and meta-analysis. Human Reproduction Update2014;20(3):449-62.">Kaijser 2014</a>). </p> </section> <section id="CD011964-sec-0015"> <h4 class="title">Test combinations</h4> <p>OC is a heterogeneous tumour and consequently it is likely that a combination of tests (clinical information, USS and biomarkers) has the potential to improve diagnostic accuracy over any single test (clinical assessment, biomarker or imaging) alone. Several composite tests have subsequently been developed. </p> <p>RMI is derived by multiplying the USS score (0 to 3) (1 point for each of the following characteristics: multilocular cysts, solid areas, metastases, ascites and bilateral lesions), menopausal status and CA125 in units per millilitre (RMI = U × M × CA125). RMI is the most widely used combination of tests. Four different versions of RMI (I to IV) have been developed, which differ in scores attributed to the result of each test component (<a href="./references#CD011964-bbs2-0063" title="AkturkE , KaracaRE , AlanbayI , DedeM , KarasahinE , YenenMC , et al. Comparison of four malignancy risk indices in the detection of malignant ovarian masses. Journal of Gynecologic Oncology2011;22(3):177-82.">Atkurk 2011</a>). In addition, RMI IV includes a score for the size of the tumour. RMI I is the version currently recommended by the National Institute for Health and Care Excellence (NICE) (<a href="./references#CD011964-bbs2-0096" title="National Institute for Health and Care Excellence. CG 122: ovarian cancer: the recognition and initial management of ovarian cancer. www.nice.org.uk/guidance/cg122/chapter/guidance (accessed prior to 29 June 2022).">NICE 2011</a>) and the Royal College of Obstetrics and Gynaecology (RCOG) (<a href="./references#CD011964-bbs2-0103" title="Royal College of Obstetricians and Gynaecologists. Guideline no 34: the management of ovarian cysts in post menopausal women. www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg34/ (accessed prior to 29 June 2022).">RCOG 2016</a>), in both pre‐ and postmenopausal women. In this review, we included only RMI version I and use the term RMI as synonymous with RMI I. </p> <p>Risk of Ovarian Malignancy Algorithm (ROMA) combines menopausal status and the biomarkers CA125 and HE4 in a multivariable model to estimate the probability (%) of malignancy in an adnexal mass. In subgroup analysis, the accuracy of ROMA was better for EOC compared to all OCs combined, in mixed populations compared to populations segregated by menopausal status (pre‐ or postmenopausal) and in late‐ compared to early‐stage disease (<a href="./references#CD011964-bbs2-0090" title="LiF , TieR , ChangK , WangF , DengS , LuW , et al. Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis. BMC Cancer2012;12:258.">Li 2012</a>). </p> <p>Two test combinations that integrate clinical information and USS findings to estimate the probability (%) of malignancy in an adnexal mass include the LR2 and (Assessment of Different NEoplasias in the adneXa model) ADNEX multivariable models. LR2 (superseding LR1) is a multivariable model to estimate the probability (%) of malignancy in an adnexal mass. The model combines clinical information (age) and USS findings (presence of ascites, presence of blood flow within a solid papillary projection, maximum diameter of the solid component of a mass, irregular cyst walls and the presence of acoustic shadows) (<a href="./references#CD011964-bbs2-0051" title="TimmermanD , AmeyeL , FischerovaD , EpsteinE , MelisGB , GuerrieroS , et al. Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group. BMJ2010;341:c6839. ">Timmerman 2010</a>). The ADNEX multivariable model has been developed to estimate the probability of malignancy in an adnexal mass. The model combines clinical information (age, healthcare setting), USS characteristics (maximum mass diameter, proportion of solid tissue, number of papillary projections, presence of more than 10 cyst locules (cavities within an organ), acoustic shadows, presence of ascites) and CA125 levels and shows promise in the preoperative discrimination of benign, borderline, early and advanced malignancies in ovarian masses (<a href="./references#CD011964-bbs2-0052" title="vanCalsterB , vanHoordeK , ValentinL , TestaAC , FischerovaD , vanHolsbekeC , et al. Evaluating the risk of ovarian cancer before surgery using the ADNEX model to differentiate between benign, borderline, early and advanced stage invasive, and secondary metastatic tumours: prospective multicentre diagnostic study. BMJ2014;349:g5920. ">van Calster 2014</a>). </p> </section> </section> <section id="CD011964-sec-0016"> <h3 class="title" id="CD011964-sec-0016">Clinical pathway</h3> <p>This review is concerned with women presenting with symptoms or signs (or both) in whom OC is being considered as a differential diagnosis. It is now recognised that women with OC may experience symptoms for a variable length of time prior to diagnosis (<a href="./references#CD011964-bbs2-0081" title="HamiltonW , PetersTJ , BankheadC , SharpD . Risk of ovarian cancer in women with symptoms in primary care: population based case-control study. BMJ2009;339:b2998.">Hamilton 2009</a>). Symptoms associated with OC include: abdominal bloating and distension; loss of appetite; early satiety; abdominal and pelvic pain; urinary urgency and frequency; vaginal and rectal bleeding; and change in bowel habit (constipation/diarrhoea). </p> <p>In the UK, women with symptoms suspicious for OC may present in a generalist setting (primary care/family practice), or to hospital settings (secondary care or tertiary care (specialist gynaecological oncology units)). Symptoms should prompt investigations including the serum biomarker CA125, an USS, or both to determine whether an adnexal mass is present and the degree of suspicion for OC. It is recommended that women with a high index of suspicion for OC (a positive index test result) are referred to a gynaecological oncologist (tertiary care) for further management whereas those with a low index of suspicion for OC (a negative index test result) are referred to a designated gynaecologist in secondary care. International guidelines differ on the types of test and test positivity thresholds to used. </p> <p>In the UK, NICE and RCOG recommend the following clinical pathway (<a href="./references#CD011964-bbs2-0096" title="National Institute for Health and Care Excellence. CG 122: ovarian cancer: the recognition and initial management of ovarian cancer. www.nice.org.uk/guidance/cg122/chapter/guidance (accessed prior to 29 June 2022).">NICE 2011</a>; <a href="#CD011964-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD011964-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="UK recommended clinical pathway based on NICE and RCOG guidance *'Suspicious' symptoms: persistent (&gt; 12 times per month) abdominal distension or bloating; early satiety/loss of appetite; urinary symptoms; abdominal or pelvic pain, weight loss; fatigue; change in bowel habit.**Ultrasound findings suggestive of ovarian cancer: laterality (any imbalance between masses observed in left compared to right ovary), multilocularity, solid areas, free fluid and distant metastasis.AFP: alpha fetoprotein; CT: computed tomography; hCG: human chorionic gonadotrophin; IOTA: International Ovarian Tumour Analysis; NICE: National Institute for Health and Care Excellence; RCOG: Royal College of Obstetrics and Gynaecology; RMI: Risk of Malignancy Index." data-id="CD011964-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p><b>UK recommended clinical pathway based on NICE and RCOG guidance</b> </p> <p>*'Suspicious' symptoms: persistent (&gt; 12 times per month) abdominal distension or bloating; early satiety/loss of appetite; urinary symptoms; abdominal or pelvic pain, weight loss; fatigue; change in bowel habit. </p> <p>**Ultrasound findings suggestive of ovarian cancer: laterality (any imbalance between masses observed in left compared to right ovary), multilocularity, solid areas, free fluid and distant metastasis. </p> <p>AFP: alpha fetoprotein; CT: computed tomography; hCG: human chorionic gonadotrophin; IOTA: International Ovarian Tumour Analysis; NICE: National Institute for Health and Care Excellence; RCOG: Royal College of Obstetrics and Gynaecology; RMI: Risk of Malignancy Index. </p> </div> </div> </div> <p> <ul id="CD011964-list-0001"> <li> <p>1. Women with suspicious findings on clinical examination:</p> </li> </ul> </p> <p> <ul class="plain" id="CD011964-list-0002"> <li> <ul id="CD011964-list-0003"> <li> <p>women with ascites and a pelvic mass that is not obviously fibroids on clinical examination in a primary care setting should be immediately referred to secondary care. </p> </li> </ul> </li> </ul> </p> <p> <ul id="CD011964-list-0004"> <li> <p>2a. Women with suspicious symptoms:</p> </li> </ul> </p> <p> <ul class="plain" id="CD011964-list-0005"> <li> <ul id="CD011964-list-0006"> <li> <p>women with persistent presence (more than 12 times per month) of abdominal distension or bloating, early satiety or loss of appetite, increased urinary urgency or frequency, and abdominal or pelvic pain, especially if aged over 50 years or women over 50 years presenting with unexplained weight loss, fatigue and change in bowel habit (symptoms suggestive of irritable bowel syndrome are rarely first diagnosed in women aged over 50 years). </p> </li> </ul> </li> </ul> </p> <p> <ul id="CD011964-list-0007"> <li> <p>2b. Women with suspicious symptoms should receive additional investigations: serum biomarker CA125 should be performed and, if 35 IU/mL or greater, a TVS scan should also be performed prior to referral to secondary care. Women with a high CA125 and presence of an adnexal mass on TVS scan should be urgently referred (within two weeks) to secondary care. </p> </li> <li> <p>3. Once in secondary care, an algorithm combining menopausal status, USS features of the pelvic mass (laterality, multilocularity, solid areas, free fluid and distant metastasis) and the CA125 level is used to calculate the RMI I score. Alternatively, following referral from primary care, women may undergo USS as per IOTA criteria (<a href="./references#CD011964-bbs2-0103" title="Royal College of Obstetricians and Gynaecologists. Guideline no 34: the management of ovarian cysts in post menopausal women. www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg34/ (accessed prior to 29 June 2022).">RCOG 2016</a>) TVS examination for a specific set of morphological features used to determine the malignant potential of a pelvic mass and, in the case of a mass which is indeterminate following IOTA assessment, a subjective assessment by an expert USS examiner (<a href="./references#CD011964-bbs2-0103" title="Royal College of Obstetricians and Gynaecologists. Guideline no 34: the management of ovarian cysts in post menopausal women. www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg34/ (accessed prior to 29 June 2022).">RCOG 2016</a>). </p> </li> <li> <p>4. Following either RMI or IOTA assessment and additional tests dictated by a woman's age (40 years or less: human chorionic gonadotrophin (hCG) and alpha fetoprotein (AFP) to detect germ cell tumours; or RMI score of 250 or greater: computed tomography (CT)), a multidisciplinary review team (MDT) is used to triage women for referral to a either a general gynaecologist (secondary care) or a gynaecological oncologist (tertiary care). </p> </li> </ul> </p> <p>In the UK, it is estimated that 28% of women are referred via the two‐week wait pathway (on the basis of symptoms and signs defined by guidelines as suspicious for cancer), 38% via general practitioner referral to gynaecologists, 26% via outpatients, 12% via other than gynaecology and 29% of women are diagnosed following an emergency presentation (<a href="./references#CD011964-bbs2-0076" title="Elliss-BrookesL , McPhailS , IvesA , GreensladeM , SheltonJ , HiomS , et al. Routes to diagnosis for cancer – determining the patient journey using multiple routine data sets. British Journal of Cancer2012;107:1220-6.">Ellis‐Brookes 2012</a>). One multicentre study in the UK demonstrated variable adherence to the recent NICE guidance regarding the tests used and the impact of results on patient management (<a href="./references#CD011964-bbs2-0101" title="RaiN , NevinJ , DowneyG , AbedinP , BalogunM , KehoeS , et al. Outcomes following implementation of symptom triggered diagnostic testing for ovarian cancer. European Journal of Obstetrics, Gynecology and Reproductive Biology2015;187:64-9.">Rai 2015</a>). </p> <p>The American College of Obstetrics and Gynaecology recommends TVS as the initial test of choice if physical examination suggests the presence of an adnexal mass (<a href="./references#CD011964-bbs2-0060" title="ACOG. Evaluation and management of adnexal masses. Obstetrics Gynecology2016;128(5):e210-26.">ACOG 2016</a>). Following TVS, referral to a gynaecological oncologist (tertiary care) is recommended in the presence of: </p> <p> <ul id="CD011964-list-0008"> <li> <p>elevated CA125 in combination with one or more of the following: a suspicious clinical history; suspicious TVS findings; elevation of other biomarkers; or </p> </li> <li> <p>an elevated risk score following assessment with LR2, RMI (OVA 1) or ROMA.</p> </li> </ul> </p> <p>Referral to tertiary care is recommended for women suspected of having a germ cell tumour: elevated inhibin A/B, beta hCG, AFP, or L‐lactate dehydrogenase. </p> <p>No pan‐European guideline for the investigation and management of suspected OC exists although variation in practice is recognised (<a href="./references#CD011964-bbs2-0089" title="LedermannJA , RajaFA , FotopoulouC , Gonzalez-MartinA , ColomboN , SessaC , on behalf of the ESMO Guidelines Working Group. Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology2013;24(Suppl 6):vi24-32.">Ledermann 2013</a>). </p> <section id="CD011964-sec-0017"> <h4 class="title">Prior test(s)</h4> <p>As a minimum, women who are being considered for testing with the index tests because of a suspicion of OC will present with self‐assessed symptoms. In addition, women may have had one or more clinical assessment (history and examination), biomarker tests and USS, depending on the point in the clinical pathway they present for testing with the index test. </p> </section> <section id="CD011964-sec-0018"> <h4 class="title">Role of index test(s)</h4> <p>The index tests are used to decide whether women presenting with symptoms or signs (or both) suspicious for OC should receive further investigation and management in secondary care or specialist gynaecological oncology units (tertiary care). </p> </section> <section id="CD011964-sec-0019"> <h4 class="title">Alternative test(s)</h4> <p>This review is concerned with initial investigations to diagnose OC that would be applicable in generalist and secondary‐care settings. Combination tests including CT, magnetic resonance imaging (MRI), positron emission tomography (PET) and other complex imaging techniques are therefore beyond the scope of this review. </p> <p>Four different versions of RMI (I to IV) have been developed (<a href="./references#CD011964-bbs2-0063" title="AkturkE , KaracaRE , AlanbayI , DedeM , KarasahinE , YenenMC , et al. Comparison of four malignancy risk indices in the detection of malignant ovarian masses. Journal of Gynecologic Oncology2011;22(3):177-82.">Atkurk 2011</a>), which differ in scores attributed to the result of each test component. In addition, RMI IV includes a score for the size of the tumour. RMI I is the version currently recommended by NICE and the RCOG in both pre‐ and postmenopausal women and is the version of RMI that will be evaluated by this review (<a href="./references#CD011964-bbs2-0096" title="National Institute for Health and Care Excellence. CG 122: ovarian cancer: the recognition and initial management of ovarian cancer. www.nice.org.uk/guidance/cg122/chapter/guidance (accessed prior to 29 June 2022).">NICE 2011</a>; <a href="./references#CD011964-bbs2-0103" title="Royal College of Obstetricians and Gynaecologists. Guideline no 34: the management of ovarian cysts in post menopausal women. www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg34/ (accessed prior to 29 June 2022).">RCOG 2016</a>). </p> </section> </section> <section id="CD011964-sec-0020"> <h3 class="title" id="CD011964-sec-0020">Rationale</h3> <p>The non‐specific nature of symptoms associated with OC and the high prevalence of ovarian cysts of uncertain significance (30% of females with regular menstruation, 50% of females with irregular menstruation and 6% of postmenopausal females) (<a href="./references#CD011964-bbs2-0075" title="DuklewskiK , AronsonA . Ovarian cysts. www.mdguidelines.com/ovarian-cyst-benign (accessed prior to 29 June 2022).">Duklewski 2009</a>), continues to pose problems for early and accurate diagnosis. Combining different test types has the potential to improve accuracy over one test type used alone, but the most accurate combination of tests has yet to be determined. There is also a need to understand how test accuracy is influenced by patient characteristics so that test combinations can be appropriately targeted. </p> <p>As part of a scoping review, 10 original systematic reviews were identified up to 2021 (<a href="./references#CD011964-bbs2-0067" title="ChacónE , DasíJ , CaballeroC , AlcázarJL . Risk of ovarian malignancy algorithm versus risk malignancy index-I for preoperative assessment of adnexal masses: a systematic review and meta-analysis. Gynecologic and Obstetric Investigation2019;84(6):591-8.">Chacon 2019</a>; <a href="./references#CD011964-bbs2-0073" title="DodgeJE , CovensAL , LacchettiC , ElitLM , LeT , Devries-AboudM , et al, and the Gynaecology Cancer Disease Site Group. Preoperative identification of a suspicious adnexal mass: a systematic review and meta-analysis. Gynecologic Oncology2012;126:157-66.">Dodge 2012</a>; <a href="./references#CD011964-bbs2-0077" title="FakharH , Rezaei TaviriniM , ZaliH , DarkhanehR , LeiliE , AghazadehM . Comparison of serum Human Epididymis protein (HE4), carbohydrate antigen 125 (CA125) and Risk of Ovarian Malignancy Algorithm (ROMA) as markers in ovarian cancer: a systematic review and a meta-analysis. Indian Journal of Gynecologic Oncology2018;16(10):174-5.">Fakhar 2018</a>; <a href="./references#CD011964-bbs2-0080" title="GeominiP , KruitwagenR , BremerGL , CnossenJ , MolBW . The accuracy of risk scores in predicting ovarian malignancy: a systematic review. Obstetrics and Gynecology2009;113(2 Pt 1):384-94.">Geomini 2009</a>; <a href="./references#CD011964-bbs2-0086" title="KaijserJ , SayasnehA , vanHoordeK , Ghaem-MaghamiS , BourneT , TimmermanD , et al. Presurgical diagnosis of adnexal tumours using mathematical models and scoring systems: a systematic review and meta-analysis. Human Reproduction Update2014;20(3):449-62.">Kaijser 2014</a>; <a href="./references#CD011964-bbs2-0090" title="LiF , TieR , ChangK , WangF , DengS , LuW , et al. Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and CA125 in predicting epithelial ovarian cancer: a meta-analysis. BMC Cancer2012;12:258.">Li 2012</a>; <a href="./references#CD011964-bbs2-0091" title="MeysEM , KaijserJ , KruitwagenRF , SlangenBF , vanCalsterB , AertgeertsB , et al. Subjective assessment versus ultrasound models to diagnose ovarian cancer: a systematic review and meta-analysis. European Journal of Cancer2016;58:17e29.">Meys 2016</a>; <a href="./references#CD011964-bbs2-0096" title="National Institute for Health and Care Excellence. CG 122: ovarian cancer: the recognition and initial management of ovarian cancer. www.nice.org.uk/guidance/cg122/chapter/guidance (accessed prior to 29 June 2022).">NICE 2011</a>; <a href="./references#CD011964-bbs2-0113" title="StukanM , DudziakM , RatajczakK , GrabowskiJP . Usefulness of diagnostic indices comprising clinical, sonographic, and biomarker data for discriminating benign from malignant ovarian masses. Ultrasound Medicine2015;34:207-17.">Stukan 2015</a>; <a href="./references#CD011964-bbs2-0118" title="WangJ , GaoJ , YaoH , WuZ , WangM , QiJ . Diagnostic accuracy of serum HE4, CA125 and ROMA in patients with ovarian cancer: a meta-analysis. Tumour Biology2014;35:6127-38.">Wang 2014</a>). Six of the 10 reviews included ROMA, seven RMI and four LR2. The search date of the most recent review was 2018 (<a href="./references#CD011964-bbs2-0067" title="ChacónE , DasíJ , CaballeroC , AlcázarJL . Risk of ovarian malignancy algorithm versus risk malignancy index-I for preoperative assessment of adnexal masses: a systematic review and meta-analysis. Gynecologic and Obstetric Investigation2019;84(6):591-8.">Chacon 2019</a>). None of the reviews included ADNEX. Two reviews compared ROMA and RMI (<a href="./references#CD011964-bbs2-0067" title="ChacónE , DasíJ , CaballeroC , AlcázarJL . Risk of ovarian malignancy algorithm versus risk malignancy index-I for preoperative assessment of adnexal masses: a systematic review and meta-analysis. Gynecologic and Obstetric Investigation2019;84(6):591-8.">Chacon 2019</a>; <a href="./references#CD011964-bbs2-0113" title="StukanM , DudziakM , RatajczakK , GrabowskiJP . Usefulness of diagnostic indices comprising clinical, sonographic, and biomarker data for discriminating benign from malignant ovarian masses. Ultrasound Medicine2015;34:207-17.">Stukan 2015</a>), and four compared RMI and LR2 (<a href="./references#CD011964-bbs2-0073" title="DodgeJE , CovensAL , LacchettiC , ElitLM , LeT , Devries-AboudM , et al, and the Gynaecology Cancer Disease Site Group. Preoperative identification of a suspicious adnexal mass: a systematic review and meta-analysis. Gynecologic Oncology2012;126:157-66.">Dodge 2012</a>; <a href="./references#CD011964-bbs2-0086" title="KaijserJ , SayasnehA , vanHoordeK , Ghaem-MaghamiS , BourneT , TimmermanD , et al. Presurgical diagnosis of adnexal tumours using mathematical models and scoring systems: a systematic review and meta-analysis. Human Reproduction Update2014;20(3):449-62.">Kaijser 2014</a>; <a href="./references#CD011964-bbs2-0091" title="MeysEM , KaijserJ , KruitwagenRF , SlangenBF , vanCalsterB , AertgeertsB , et al. Subjective assessment versus ultrasound models to diagnose ovarian cancer: a systematic review and meta-analysis. European Journal of Cancer2016;58:17e29.">Meys 2016</a>; <a href="./references#CD011964-bbs2-0113" title="StukanM , DudziakM , RatajczakK , GrabowskiJP . Usefulness of diagnostic indices comprising clinical, sonographic, and biomarker data for discriminating benign from malignant ovarian masses. Ultrasound Medicine2015;34:207-17.">Stukan 2015</a>), whilst six reviewed only single tests. Four of 10 reviews did not present results separately for pre‐ and postmenopausal women. Nine of 10 reviews undertook meta‐analysis, but only five used appropriate statistical methods. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD011964-sec-0021" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD011964-sec-0021"></div> <p>To establish the accuracy of combinations of menopausal status, ultrasound scan (USS) and biomarkers for the diagnosis of ovarian cancer in pre‐ and postmenopausal women and compare the accuracy of different test combinations. </p> <section id="CD011964-sec-0022"> <h3 class="title" id="CD011964-sec-0022">Secondary objectives</h3> <p>We planned to investigate the following sources of heterogeneity.</p> <section id="CD011964-sec-0023"> <h4 class="title">Population</h4> <p> <ul id="CD011964-list-0009"> <li> <p>Clinical setting (generalist/primary care/community/family practice) versus specialist setting (cancer unit/cancer centre/gynaecological oncology) </p> </li> <li> <p>Menopausal status (premenopausal versus postmenopausal)</p> </li> </ul> </p> </section> <section id="CD011964-sec-0024"> <h4 class="title">Index tests</h4> <p> <ul id="CD011964-list-0010"> <li> <p>Test positivity threshold</p> </li> <li> <p>Experience of the USS test operator (general sonographers versus specialist interest)</p> </li> </ul> </p> </section> <section id="CD011964-sec-0025"> <h4 class="title">Target condition</h4> <p> <ul id="CD011964-list-0011"> <li> <p>Histological subtype</p> </li> </ul> </p> </section> <section id="CD011964-sec-0026"> <h4 class="title">Study quality</h4> <p> <ul id="CD011964-list-0012"> <li> <p>For study participants not receiving surgery following a negative index test result (where clinical follow‐up rather than histology is used as a reference standard for index test negatives): 12 months' follow‐up versus less than 12 months' follow‐up </p> </li> </ul> </p> </section> </section> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD011964-sec-0027" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD011964-sec-0027"></div> <section id="CD011964-sec-0028"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD011964-sec-0029"> <h4 class="title">Types of studies</h4> <p>We included diagnostic case‐control studies (providing the control arm included women with benign ovarian pathology and these could be disaggregated from any healthy controls); diagnostic cross‐sectional studies (retrospective and prospective data collection). We anticipated that in view of the low prevalence of OC, the majority of cross‐sectional studies would recruit women who had already undergone the reference standard and index test results would be ascertained retrospectively. We also included studies externally validating multivariable models for the diagnosis of OC. We included comparative diagnostic test accuracy studies of any design (within‐person or between‐person comparisons). Studies were eligible if there were sufficient data to extract 2 × 2 tables on diagnostic test performance. We allowed inclusion of studies not providing verification of index test negatives where 2 × 2 tables could be constructed by imputation using setting‐specific prevalence estimates. However, we did not identify eligible studies where index test negatives were not verified. </p> </section> <section id="CD011964-sec-0030"> <h4 class="title">Participants</h4> <p>Women aged 18 years or older, irrespective of menopausal status. We excluded studies restricted exclusively to populations under 18. We excluded studies restricted to pregnant women, or women with a previous history of OC. </p> <section id="CD011964-sec-0031"> <h5 class="title">Prior tests</h5> <p>This review is concerned with women in whom a diagnosis of OC is suspected (i.e. women with symptoms or signs suggestive of OC). As a minimum, women should have self‐referred to a healthcare professional on the basis of the presence of symptoms. Individual components of the test combinations (index tests) included in this review may be used alone in both generalist and specialist settings and so at the time women receive an index test, in addition to presentation with symptoms and signs, they may have had prior testing with one or more testing with one or more biomarkers or imaging with USS. We excluded studies explicitly describing included participants as asymptomatic, for example where the index test was being applied as a screening test, or where studies explicitly included asymptomatic participants and these could not be disaggregated from participants who were symptomatic. Where the prior presence of symptoms or signs was unclear or not reported, studies were included and this was reflected as part of the quality assessment of included studies (QUADAS‐2) in the patient applicability domain. </p> </section> </section> <section id="CD011964-sec-0032"> <h4 class="title">Index tests</h4> <p>We included the following index tests in use in clinical practice at the time of undertaking our searches: any combination (two or more of the following test types): RMI (menopausal status, CA125 and USS examination); ROMA (menopausal status, CA125 and HE4), and the multivariable models LR2 and ADNEX (menopausal status and USS examination) (<a href="#CD011964-tbl-0002">Table 1</a>). We included studies where USS examination as part of RMI, LR2 and ADNEX was conducted by ultrasonographers with any experience: general sonographers or those with specialist training. </p> </section> <section id="CD011964-sec-0033"> <h4 class="title">Target conditions</h4> <p>OC, all stages and types. We excluded studies where only one type of ovarian pathology was reported with the exception of EOC, as this is the most common (greater than 90% in postmenopausal women) of the OCs and is associated with the highest mortality. We excluded studies concerned exclusively with recurrent OC, OC which was metastatic from another primary cancer site, and studies where it was not possible to disaggregate participants with primary OC from metastatic or recurrent disease. </p> </section> <section id="CD011964-sec-0034"> <h4 class="title">Reference standards</h4> <p>Histology in women who have undergone surgery and clinical follow‐up in women with negative index test results (suggestive of no OC) who do not undergo surgery. For studies using clinical follow‐up, the length of follow‐up was considered as part of quality assessment; a minimum of one year of follow‐up was considered of higher quality compared to less than one year of follow‐up. We planned to investigate length of follow‐up as a potential source of heterogeneity. </p> </section> </section> <section id="CD011964-sec-0035"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD011964-sec-0036"> <h4 class="title">Electronic searches</h4> <p>Original searches were conducted in 2015 to support a generic protocol for four separate reviews: USS, biomarkers, symptom scores and test combinations for the diagnosis of OC. With the exception of the symptom and symptom score search strategy, a date restriction was applied (1991 onwards) to ensure applicability to current technology. For the symptom search strategy a date restriction of 2009 was applied, reflecting the existence of a comprehensive review of symptoms for the diagnosis of OC (<a href="./references#CD011964-bbs2-0096" title="National Institute for Health and Care Excellence. CG 122: ovarian cancer: the recognition and initial management of ovarian cancer. www.nice.org.uk/guidance/cg122/chapter/guidance (accessed prior to 29 June 2022).">NICE 2011</a>). The 2015 strategies were designed to run across a range of databases: the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE and MEDLINE In Process (Ovid), Embase (Ovid), CINAHL (EBSCO), the <i>Cochrane Database of Systematic Reviews</i> (CDSR), Database of Abstracts of Reviews of Effects (DARE), Health Technology Assessment Database (HTA) and SCI Science Citation Index (ISI Web of Knowledge). </p> <p>We updated the search strategy in June 2019 specifically for this test combination review. The 2019 searches were a targeted update of evidence about RMI, ROMA, LR2 and ADNEX as these test combinations had emerged in the intervening period as the main contenders for use in clinical practice. For pragmatic reasons we restricted databases to MEDLINE and MEDLINE In Process (Ovid) and Embase (Ovid) for the 2019 update, combining terms for OC with terms to capture the index tests or their components (biochemical markers, symptom scores and USS) that were used in the original 2015 searches. The 2019 search was developed iteratively and evaluated for its performance in detecting key articles already deemed eligible for inclusion post‐2015. Specifically, the following changes were made between the 2015 and 2019 search strategies to reflect changes in the review scope: the 2019 search strategy additionally included terms for the index tests of current clinical interest: RMI, ROMA, LR2 and ADNEX; used a reduced range of terms used to describe symptoms and symptom scores (as symptoms are not a major component of the index tests of current interest), and used a reduced range of biomarker terms reflecting those contained in the index tests of current interest. Changes were also made to terms used to describe the target condition (OC) in line with changes in the description of OC as a disease of the adnexa, rather than being a disease of tubal or ovarian origin. The search strategy used for the original 2015 searches as well as the 2019 targeted updated search strategy are shown in <a href="./appendices#CD011964-sec-0098">Appendix 1</a> and <a href="./appendices#CD011964-sec-0099">Appendix 2</a>. </p> <p>No language restrictions were applied.</p> </section> <section id="CD011964-sec-0037"> <h4 class="title">Searching other resources</h4> <p>To identify ongoing and unpublished studies, we searched the following trials registers and conference abstracts and proceedings without date restrictions as part of the 2015 search strategy: ClinicalTrials.gov, UK Clinical Research Network Study Portfolio Database (UKCRN) and WHO International Clinical Trials Registry Platform (ICTRP). We searched conference proceedings from the European Society of Gynaecological Oncology (ESGO), International Gynecologic Cancer Society (IGCS), American Society of Clinical Oncology (ASCO) and Society of Gynecologic Oncology (SGO), supplemented by searches of the ZETOC and Conference Proceedings Citation Index (Web of Knowledge). For both the 2015 and 2019 search strategies, we drew on reference lists of existing systematic reviews and guidelines identified in the electronic searches as a source of primary studies. </p> </section> </section> <section id="CD011964-sec-0038"> <h3 class="title" id="CD011964-sec-0038">Data collection and analysis</h3> <p>Search results were managed in EndNote. After removal of duplicates, two review authors (from NR, RC, PSh, PSa) independently carried out study selection by reading the titles and abstracts and excluded obviously irrelevant studies at this stage. Two review authors (from NR, RC, PSh, PSa) independently read the full text of remaining studies. A third review author (CD, SS) resolved disagreements. Two review authors (NR, PSh, CD) independently extracted data into 2 × 2 tables and assessed quality. Another review author (RC or CD) double‐checked characteristics of 30% of the studies. We resolved disagreements by discussion. </p> <section id="CD011964-sec-0039"> <h4 class="title">Selection of studies</h4> <p>We reviewed unique titles and abstracts against predefined selection criteria to select potentially relevant studies for full‐text review. The results of the selection process and reasons for exclusion are documented and summarised using a PRISMA flow diagram (<a href="#CD011964-fig-0002">Figure 2</a>). </p> <div class="figure" id="CD011964-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="PRISMA study flow diagram.ADNEX: Assessment of Different NEoplasias in the adneXa model; LR2: Logistic Regression Model 2; RMI: Risk of Malignancy Index; ROMA: Risk of Ovarian Malignancy Algorithm." data-id="CD011964-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-FIG-02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>PRISMA study flow diagram.</p> <p>ADNEX: Assessment of Different NEoplasias in the adneXa model; LR2: Logistic Regression Model 2; RMI: Risk of Malignancy Index; ROMA: Risk of Ovarian Malignancy Algorithm. </p> </div> </div> </div> </section> <section id="CD011964-sec-0040"> <h4 class="title">Data extraction and management</h4> <p>We used a predefined data collection form to extract the following data into an Excel database prior to entry into Review Manager 5 (<a href="./references#CD011964-bbs2-0105" title="Review Manager (RevMan). Version 5.4. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>): study design; country; setting; single or multicentre; method of recruitment; reasons for exclusion; number of participants; number of women with a diagnosis of OC and borderline ovarian tumours; age; menopausal status (directly or using age over 50 years or history of previous hysterectomy as a proxy for postmenopausal status); prior tests; index tests and index test threshold(s); expertise of index test operator (for symptoms and USS); reference standard (including where relevant duration of follow‐up); stage, and histological subtype of OC. Either a clinician (NR) or review author (PSh, RC, CD) extracted data to derive a 2 × 2 table for each study; either a methodologist or statistician (CD, JD, SB) checked data. </p> </section> <section id="CD011964-sec-0041"> <h4 class="title">Assessment of methodological quality</h4> <p>Quality assessment was undertaken using the QUADAS‐2 checklist tailored according to the topic and detailed in <a href="./appendices#CD011964-sec-0100">Appendix 3</a> (<a href="./references#CD011964-bbs2-0119" title="WhitingPF , RutjesAW , WestwoodME , MallettS , DeeksJJ , ReitsmaJB , et al. QUADAS-2: A revised tool for the quality assessment of diagnostic accuracy studies. Annals of Internal Medicine2011;155(8):529-36.">Whiting 2011</a>). </p> <p>Tailoring of QUADAS‐2 to the clinical topic required consideration of the following.</p> <section id="CD011964-sec-0042"> <h5 class="title">Patient selection domain</h5> <p>Studies were considered at high risk of bias if they excluded certain types of malignant or benign pathology that is known to affect the accuracy of index tests specifically for detecting primary OC. Examples include endometriosis (which, for example, causes a raised serum CA125) and borderline ovarian tumours (which are managed surgically, similar to malignant tumours, but may result in a negative index test result). Additionally, restricting populations by age was considered to place studies at high risk of bias because an increase in age is associated with a change in disease spectrum. For example, EOC is more prevalent in older women and germ cell tumours are more prevalent in younger women. It has also been shown that index test performance differs in different histological subtypes of OC and at different stages of malignancy <a href="./references#CD011964-bbs2-0087" title="KobayashiE , UedaY , MatsuzakiS , YokoyamaT , KimuraT , YoshinoK , et al. Biomarkers for screening, diagnosis, and monitoring of ovarian cancer. Cancer Epidemiology, Biomarkers &amp; Prevention2012;21(11):1902-12.">Kobayashi 2012</a>). </p> <p>Menopausal status is a risk factor for OC. In addition the spectrum of disease (the type and severity of OC and the range of differential diagnoses) observed in postmenopausal women are different to those of premenopausal women. For example, in premenopausal women, the normal menstrual cycle and benign pathology, such as endometriosis, can result in false‐positive test results. Therefore, we considered distinguishing test performance in pre‐ and postmenopausal women an important feature of studies. For this reason, the quality of studies that stratified test results by menopausal status is presented separately. </p> <p>The target population for this review was symptomatic women receiving index tests because of a suspicion of OC on the basis of clinical history and examination. Therefore, studies were considered of high applicability concern if women were asymptomatic, and were selected for testing with index tests in secondary or tertiary care, following prior testing with one or more biomarker or USS. </p> </section> <section id="CD011964-sec-0043"> <h5 class="title">Index test domain</h5> <p>The review included composite index tests comprised at least two of three different test types: clinical information (menopausal status), biochemical testing and USS examination. Studies were considered at high risk of bias if the USS component of index tests was not conducted blind to the results of other index test components (biochemical markers and clinical assessment). Similarly, studies were considered at high risk of bias if the USS component of composite index tests was not conducted and interpreted blind to the disease status/reference standard result. Studies that did not prespecify the test positivity threshold were considered at high risk of bias because this usually results in over‐optimistic test accuracy estimates that are not replicable outside of the study sample. For quality assessment of index tests based on multivariable models (LR2 and ADNEX), QUADAS‐2 was tailored by adding items taken from the PROBAST risk of bias tool for prognostic studies (<a href="./references#CD011964-bbs2-0121" title="WolffRF , MoonsKG , RileyRD , WhitingPF , WestwoodM , CollinsGS , et al. PROBAST: a tool to assess the risk of bias and applicability of prediction model studies. Annals of Internal Medicine2019;170:51-8.">Wolf 2019</a>). These items were whether all model components and thresholds were prespecified and whether individual test components were assessed in a similar way (e.g. in similar healthcare settings or by individuals with similar levels of expertise). Assessment of applicability of index tests comprised consideration of whether the expertise of clinicians undertaking clinical assessment and USS examination was representative of a generalist setting. </p> </section> <section id="CD011964-sec-0044"> <h5 class="title">Reference standard and target condition domain</h5> <p>We considered histological diagnosis or clinical follow‐up for a minimum of 12 months as likely to classify correctly the target condition (therefore a low risk of bias). In studies using clinical follow‐up, risk of bias was considered high if follow‐up was less than six months. Concerning the applicability of the target condition, as defined by the reference standard; assessments were based on how authors had dealt with borderline tumours in their analysis and the implications this had for meta‐analysis. Within the constraints of a 2 × 2 table and reflecting current clinical practice, we considered that borderline tumours should be classified as malignant for the purposes of estimation of test accuracy. Thus studies reporting results allowing grouping of borderline tumours with malignant for the purpose of meta‐analysis were considered of low‐applicability concern. </p> </section> <section id="CD011964-sec-0045"> <h5 class="title">Flow and timing domain</h5> <p>We considered risk of bias high if the interval between index test and reference standard application was more than three months. </p> </section> </section> <section id="CD011964-sec-0046"> <h4 class="title">Statistical analysis and data synthesis</h4> <section id="CD011964-sec-0047"> <h5 class="title">Summary</h5> <p>Exploratory analyses included plotting estimates of sensitivity and specificity grouped by test threshold on Forest plots and in summary ROC (receiver operating characteristic) plots. </p> <p>Analyses were conducted in Stata version SE 17.0 (<a href="./references#CD011964-bbs2-0112" title="StataCorp. Version 16. College Station, TX, USA: StataCorp, 2019. Available at www.stata.com.">StataCorp 2019</a>) and SAS software (version 9.4) (<a href="./references#CD011964-bbs2-0107" title="SAS. Version 9.4. Cary (NC): SAS Institute Inc, 2015. Available at www.sas.com.">SAS 2015</a>). Where there were adequate data available and it was considered reasonable to pool results, we performed meta‐analyses using hierarchical models using the NLMIXED procedure in SAS (<a href="./references#CD011964-bbs2-0107" title="SAS. Version 9.4. Cary (NC): SAS Institute Inc, 2015. Available at www.sas.com.">SAS 2015</a>). Where meta‐analysis was not considered appropriate due to clinical or methodological heterogeneity, or in the case of fewer than three studies, we used narrative synthesis. </p> </section> <section id="CD011964-sec-0048"> <h5 class="title">Estimation of the accuracy of individual index tests</h5> <p>Since the characteristics measured by index tests could be extracted as 2 × 2 tables reported at common index test thresholds, we used the bivariate model including random effects (<a href="./references#CD011964-bbs2-0070" title="ChuH , ColeSR . Bivariate meta-analysis of sensitivity and specificity with sparse data: a generalized linear mixed model approach. Journal of Clinical Epidemiology2006;59(12):1331-2.">Chu 2006</a>; <a href="./references#CD011964-bbs2-0104" title="ReitsmaJB , GlasAS , RutjesAW , ScholtenRJ , BossuytPM , ZwindermanAH . Bivariate analysis of sensitivity and specificity produces informative summary measures in diagnostic reviews. Journal of Clinical Epidemiology2005;58(10):982-90.">Reitsma 2005</a>). To estimate average sensitivity and specificity at fixed thresholds, we performed the analysis of each index test version by first restricting to studies that reported thresholds recommended in guidelines or used in clinical practice (or both), and second to those thresholds most commonly reported across included studies. In addition, for ROMA, we included studies using thresholds ± 2 units around the most commonly reported thresholds. We excluded thresholds based on particular values of sensitivity and specificity where no threshold in terms of index test operation was reported for the values of sensitivity and specificity used. We used random‐effects univariate analyses (which ignore any correlation between sensitivity and specificity) where pooling was an appropriate approach but bivariate models failed to converge. </p> </section> <section id="CD011964-sec-0049"> <h5 class="title">Comparison of index tests</h5> <p>In order to maximise use of data across studies using different thresholds, we undertook indirect comparisons of index tests by fitting HSROC models and estimating sensitivity at fixed vales of specificity (80% and 90%), reflecting clinical consensus about an acceptable false‐positive rate (<a href="./references#CD011964-bbs2-0103" title="Royal College of Obstetricians and Gynaecologists. Guideline no 34: the management of ovarian cysts in post menopausal women. www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg34/ (accessed prior to 29 June 2022).">RCOG 2016</a>). To illustrate the comparative accuracy of index tests at specific test‐operating thresholds that could be applied in clinical practice, we also undertook indirect comparisons of index tests using bivariate hierarchical models. </p> <p>For the HSROC analysis (<a href="./references#CD011964-bbs2-0106" title="RutterCM , GatsonisCA . A hierarchical regression approach to meta-analysis of diagnostic test accuracy evaluations. Statistics in Medicine2001;20(19):2865-84.">Rutter 2001</a>), we used a covariate for test type and estimated a summary ROC curve for each index test across all included thresholds. Each included study contributed one threshold to the summary ROC curve. Where an individual study reported more than one threshold, we selected the most commonly reported threshold for that index test across all included studies for the meta‐analyses. The selection of one threshold per study was only necessary for ROMA studies where the threshold pairs 31.1 (± 2 units) and 27.2 (± 2 units) were the most commonly reported across studies. Summary ROC curves which have a common shape were fitted to the data. We performed estimation of differences in accuracy using the NLMIXED procedure in Statistical Analysis System (<a href="./references#CD011964-bbs2-0107" title="SAS. Version 9.4. Cary (NC): SAS Institute Inc, 2015. Available at www.sas.com.">SAS 2015</a>) and the metandi macro (<a href="./references#CD011964-bbs2-0114" title="MetaDAS: a SAS macro for metaanalysis of diagnostic accuracy studies. User Guide Version 1.3. TakwoingiY , DeeksJJ , Version 1.3. Available from: srdta.cochrane.org/, 2010.">Takwoingi 2010</a>). We computed P values for the difference in accuracy for each test compared to RMI (RMI being the test combination currently in routine use in the UK in both pre‐ and postmenopausal women) using Wald tests. We reported the difference in sensitivities at fixed specificities of 80% and 90% for each index test version compared to RMI with 95% confidence interval (CI). </p> <p>For the bivariate hierarchical analysis, we undertook a comparison of index tests at the single most commonly reported threshold across studies, including a covariate for test type. Absolute differences in sensitivity/specificity and the corresponding P values for each pair‐wise test comparison were reported from the model. Bivariate models were fitted using the <i>meqrlogit</i> command in Stata. Where appropriate, models were simplified by setting near‐zero variance estimates of the random effects to zero (<a href="./references#CD011964-bbs2-0115" title="TakwoingiY , GuoB , RileyRD , DeeksJJ . Performance of methods for meta-analysis of diagnostic test accuracy with few studies or sparse data. Statistical Methods in Medical Research2017;26(4):1896-911.">Takwoingi 2017</a>). In cases where both random effects were set to zero, a fixed‐effect logistic regression was fitted using the <i>blogit</i> command. Absolute differences in sensitivities/specificities and P values were derived from bivariate models using the <i>nlcom</i> command in Stata. This computes point estimates and standard errors using the delta method. We used random‐effects univariate analyses (which ignore any correlation between sensitivity and specificity) where pooling was considered an appropriate approach, but bivariate models failed to converge. </p> <p>We translated summary estimates of sensitivity and specificity into summary estimates of the absolute numbers of true‐positives, false‐negatives, false‐positives and true‐negatives using a hypothetical population of 1000 women using an estimate of disease prevalence (pretest probability) reflecting the NICE threshold for cancer referral from generalist to specialist settings in the UK of 3% (<a href="./references#CD011964-bbs2-0097" title="National Institute for Health and Care Excellence. Suspected cancer: recognition and referral. www.nice.org.uk/guidance/ng12 (accessed 22 May 2019).">NICE 2017</a>). </p> </section> </section> <section id="CD011964-sec-0050"> <h4 class="title">Investigations of heterogeneity</h4> <p>We investigated the effect on estimates of test accuracy of menopausal status (premenopausal or postmenopausal) and of classification of histologically borderline ovarian tumours as disease positive (grouped with histologically malignant ovarian tumours) or where classification of borderline ovarian tumours was unclear or these tumour types were excluded. Grouping of histologically borderline ovarian tumours with histologically malignant ovarian tumours was considered clinically appropriate (reflecting current clinical practice) whereas exclusion of histologically borderline ovarian tumours was considered methodologically inappropriate. </p> <p>We performed estimation of differences in accuracy using the NLMIXED procedure in Statistical Analysis System (<a href="./references#CD011964-bbs2-0107" title="SAS. Version 9.4. Cary (NC): SAS Institute Inc, 2015. Available at www.sas.com.">SAS 2015</a>) by including menopausal status or borderline grouping as covariates in the bivariate model. We reported differences in accuracy using the ratio of Diagnostic odds ratios with 95% CI and computed associated P values using Wald tests. </p> <p>We were unable to conduct separate meta‐analyses for the following planned investigations of heterogeneity because of a lack of data: </p> <p> <ul id="CD011964-list-0013"> <li> <p>healthcare setting: generalist setting (primary care, community care, family practice) versus specialist setting (secondary care, tertiary care (cancer unit, cancer centre)); </p> </li> <li> <p>target condition: histological subtype: EOC versus non‐EOC; high‐grade serous epithelial (type II) versus other epithelial (type I); early‐stage (stage I/II) versus late‐stage disease (stage III/IV). </p> </li> </ul> </p> </section> <section id="CD011964-sec-0051"> <h4 class="title">Sensitivity analyses</h4> <p>We did not undertake any sensitivity analyses.</p> </section> <section id="CD011964-sec-0052"> <h4 class="title">Assessment of reporting bias</h4> <p>We did not undertake any formal assessment of reporting bias in our review due to current uncertainty about how to assess reporting bias in diagnostic test accuracy reviews, especially in the presence of heterogeneity (<a href="./references#CD011964-bbs2-0071" title="DeeksJJ , MacaskillP , IrwigL . The performance of tests of publication bias and other sample size effects in systematic reviews of diagnostic test accuracy was assessed. Journal of Clinical Epidemiology2005;58(9):882-93.">Deeks 2005</a>). </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD011964-sec-0053" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD011964-sec-0053"></div> <section id="CD011964-sec-0054"> <h3 class="title" id="CD011964-sec-0054">Results of the search</h3> <p>The search identified 72,487 references. After removal of 20,388 duplicates, there remained 52,099 unique records. After reviewing titles and abstracts, we obtained and screened full‐text copies of 1215 potentially relevant reports, of which 59 studies reporting 71 data sets were deemed eligible for inclusion. Reasons for full‐text study exclusions are detailed in <a href="#CD011964-fig-0002">Figure 2</a> and studies are listed in <a href="./appendices#CD011964-sec-0101">Appendix 4</a>. Forty‐nine studies assessed the accuracy of a single test, whilst 10 studies included a within‐person comparison of two or more index tests (<a href="./references#CD011964-bbs2-0002" title="Al MusalhiK , Al KindiM , Al AisaryF , RamadhanF , Al RawahiT , Al HataliK , et al. Evaluation of HE4, CA-125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) in the preoperative assessment of patients with adnexal mass. Oman Medical Journal2016;31(5):336-44. ">Al Musalhi 2016</a>; <a href="./references#CD011964-bbs2-0003" title="AntonC , CarvalhoFM , OliveiraEI , MacielGA , BaracatEC , CarvalhoJP . A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses. Clinics (Sao Paulo, Brazil)2012;67(5):437-41. ">Anton 2012</a>; <a href="./references#CD011964-bbs2-0020" title="KrascsenitsG , BalazsB , DudnyikovaA , PurcsiK , OroszE , PeteI . Investigating the predictive value of RMI and ROMA indices in patients with ovarian tumors of uncertain dignity. Magyar Onkologia2016;60(4):320-7. ">Krascsenitis 2016</a>; <a href="./references#CD011964-bbs2-0022" title="LiestAL , OmranAS , MikiverR , RosenbergP , UppugunduriS . RMI and ROMA are equally effective in discriminating between benign and malignant gynecological tumors: a prospective population-based study. Acta Obstetricia et Gynecologica Scandinavica2019;98(1):24-33. ">Liest 2019</a>; <a href="./references#CD011964-bbs2-0023" title="LyckeM , KristjansdottirB , SundfeldtK . A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index. Gynecologic Oncology2018;151(1):159-65. ">Lycke 2018</a>; <a href="./references#CD011964-bbs2-0026" title="MeysEM , JeelofLS , AchtenNM , SlangenBF , LambrechtsS , KruitwagenRF , et al. Estimating risk of malignancy in adnexal masses: external validation of the ADNEX model and comparison with other frequently used ultrasound methods. Ultrasound in Obstetrics &amp; Gynecology2017;49(6):784-92. ">Meys 2017</a>; <a href="./references#CD011964-bbs2-0031" title="NiemiRJ , SaarelainenSK , LuukkaalaTH , MaenpaaJU . Reliability of preoperative evaluation of postmenopausal ovarian tumors. Journal of Ovarian Research2017;10(1):15. ">Niemi 2017</a>; <a href="./references#CD011964-bbs2-0039" title="RichardsA , HerbstU , PatherS , SaidiS , Tejada-BergesT , WilliamsP , et al. HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses – a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2015;55(5):493-7. ">Richards 2015</a>; <a href="./references#CD011964-bbs2-0042" title="SayasnehA , KaijserJ , PreislerJ , JohnsonS , StalderC , HusickaR , et al. A multicenter prospective external validation of the diagnostic performance of IOTA simple descriptors and rules to characterize ovarian masses. Gynecologic Oncology2013;130(1):140-6. [Sayasneh 2013]SayasnehA , WynantsL , PreislerJ , KaijserJ , JohnsonS , StalderC , et al. Multicentre external validation of IOTA prediction models and RMI by operators with varied training. British Journal of Cancer2013;108(12):2448-54. ">Sayasneh 2013a</a>; <a href="./references#CD011964-bbs2-0050" title="TestaA , KaijserJ , WynantsL , FischerovaD , vanHolsbekeC , FranchiD , et al. Strategies to diagnose ovarian cancer: new evidence from phase 3 of the multicentre international IOTA study. British Journal of Cancer2014;111(4):680-8. ">Testa 2014</a>). Test types and thresholds were too varied to permit separate meta‐analyses of direct comparison studies. </p> <section id="CD011964-sec-0055"> <h4 class="title">Index tests and thresholds</h4> <p>Of the 71 data sets (59 studies; 32,059 participants, 9545 cases of OC), 17 evaluated the accuracy of RMI at a threshold of 200 and two at a threshold of 250 (10,283 participants, 2654 cases of OC); 42 evaluated the accuracy of ROMA (13,715 unique participants, 3944 cases of OC) at threshold pairs for pre‐ and postmenopausal women of 7.4 (± 2) (N = 12) and 25.3 (± 2) (N = 15); 12.5 and 14.4 (N = 3), 13.1 (± 2) (N = 27) and 27.7 (± 2) (N = 13); 11.4 (N = 11) and 29.9 (N = 12); five studies evaluated the accuracy of LR2 (5000 participants, 1743 cases of OC to achieve a post‐test probability of OC of 10%); and four studies evaluated the accuracy of ADNEX (3061 participants, 1204 cases of OC) to achieve a post‐test probability of OC of 3%, 5%, 10% and 15% (<a href="#CD011964-tbl-0003">Table 2</a>). </p> <div class="table" id="CD011964-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary bivariate estimates of RMI I, ROMA, LR2 and ADNEX at all thresholds in pre‐ and postmenopausal women</span></div> <tbody> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign="bottom"> <p><b>Pooled sensitivity and specificity of RMI, ROMA, ADNEX, and LR2 at thresholds reported in included studies</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Score, threshold and menopause status</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Studies</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>OC cases</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Pooled sensitivity %</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Pooled specificity %</b> </p> <p><b>(95% CI)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign=""> <p><b>ROMA</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.4 (premenopausal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3051</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>342</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80.7 (69.6 to 88.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80.5 (73.8 to 85.9)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.3 (postmenopausal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>603</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86.8 (77.9 to 92.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87.6 (80.2 to 92.6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.4 (premenopausal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>445</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80.9 (71.0 to 88.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84.1 (81.2 to 86.7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29.9 (postmenopausal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1797</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>851</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91.6 (84.2 to 95.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86.3 (80.1 to 90.7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.5 (premenopausal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.5 (51.0 to 74.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89.3 (80.8 to 94.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.4 (postmenopausal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>299</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>177</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88.0 (80.6 to 92.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68.3 (57.4 to 77.4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.1 (premenopausal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1353</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75.2 (67.0 to 81.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84.0 (78.4 to 88.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27.7 (postmenopausal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>556</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90.5 (86.2 to 93.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81.1 (75.7 to 85.5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.4 ± 2 (premenopausal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>378</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80.6 (71.5 to 87.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81.7 (75.7 to 86.5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.3 ± 2 (postmenopausal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1049</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87.2 (81.7 to 91.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86.0 (80.3 to 90.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.1 ± 2 (premenopausal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4463</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>825</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77.8 (72.5 to 82.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84.3 (81.3 to 86.8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27.7 ± 2 (postmenopausal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>852</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90.4 (87.4 to 92.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81.3 (76.9 to 85.0)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign="top"> <p><b>RMI I</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200 (premenopausal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>851</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57.1 (50.6 to 63.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92.5 (90.0 to 94.4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200 (postmenopausal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1664</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78.7 (74.3 to 82.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85.5 (81.3 to 88.9)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p>Difference in sensitivity and specificity premenopausal vs postmenopausal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.6 (13.9 to 29.2); P &lt; 0.0001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–6.9 (–11.3 to –2.6); P = 0.002</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>250 (premenopausal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>461</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59.5 (44.3 to 73.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88.1 (84.6 to 90.8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>250 (postmenopausal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82.5 (73.6 to 88.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79.7 (71.6 to 85.9)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>Difference in sensitivity and specificity premenopausal vs postmenopausal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23.0 (6.3 to 39.6); P = 0.007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>–8.4 (–16.2 to –0.6); P = 0.034</p> </td> </tr> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign="top"> <p><b>LR2</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 (premenopausal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2843</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>619</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83.2 (78.6 to 87.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90.4 (84.6 to 94.1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 (postmenopausal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94.5 (92.8 to 95.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60.5 (49.3 to 70.7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p>Difference in sensitivity and specificity premenopausal vs postmenopausal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.2 (6.6 to 15.9); P &lt; 0.0001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–29.9 (–41.7 to –18.0); P &lt; 0.0001</p> </td> </tr> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign="top"> <p><b>ADNEX D+</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (premenopausal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1354</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>378</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97.9 (95.9 to 99.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56.6 (53.4 to 59.7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (postmenopausal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1049</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>602</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99.5 (98.6 to 99.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.1 (21.1 to 29.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (premenopausal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1354</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>378</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97.6 (95.5 to 98.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69.5 (66.5 to 72.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (postmenopausal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1049</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>602</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98.8 (97.6 to 99.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37.4 (32.9 to 42.0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 (premenopausal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1696</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>455</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94.9 (92.5 to 96.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78.2 (75.8 to 80.4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 (postmenopausal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1365</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>749</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97.6 (96.2 to 98.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55.2 (51.2 to 59.1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p>Difference in sensitivity and specificity premenopausal vs postmenopausal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.7 (0.4 to 4.9); P = 0.023</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–23.0 (–27.5 to –18.4); P &lt; 0.0001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 (premenopausal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1354</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>378</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90.5 (87.1 to 93.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83.4 (80.9 to 85.7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 (postmenopausal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1049</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>602</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96.5 (94.7 to 97.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.5 (58.9 to 68.0)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ADNEX: Assessment of Different NEoplasias in the adneXa model; CI: confidence interval; LR2: Logistic Regression model 2; OC: ovarian cancer; RMI: Risk of Malignancy Index; ROMA: Risk of Ovarian Malignancy Algorithm. </p> </div> </div> </section> <section id="CD011964-sec-0056"> <h4 class="title">Characteristics of included studies</h4> <p>In summary, 41 studies were conducted in Europe, 12 in the Asia‐Pacific region, five in North America and one in South America. Nineteen studies were multicentre. These tests can be carried out in primary care, by dedicated gynaecologists in hospital settings (secondary care), by gynaecological oncologists in specialist units (tertiary care), or across a mixture of healthcare settings. Forty‐nine studies were conducted in specialist settings (nine in mixed secondary and tertiary settings, 28 in tertiary care settings and 12 in secondary settings) and 10 studies did not report the healthcare setting. </p> <p>Menopausal status and age alter the spectrum of disease (the prevalence of OC, range of histological subtypes and the range of differential diagnoses). In postmenopausal women, the prevalence of OC is higher and certain histological subtypes (EOC) are more common. In premenopausal women the prevalence of germ cell tumours is higher and the normal menstrual cycle and benign pathology such as endometriosis can result in false‐positive test results. In the absence of information on menopausal status, 50 years can be used to stratify women for estimation of test accuracy to reflect this change in spectrum and risk. Across all studies reporting age (41/59 included studies), mean age varied between 37 and 65 years and age range varied between 11 and 94 years. One study restricted inclusion to premenopausal women and four studies restricted inclusion to postmenopausal women. </p> <p>Testing prior to surgical investigation in this patient group in current clinical practice will have included one or more of clinical history and examination, biomarker measurement and USS. None of the studies detailed the clinical pathway of participants from presentation to the decision to test and the role of the index tests. Only three ROMA studies (<a href="./references#CD011964-bbs2-0012" title="FarzanehF , HonarvarZ , YaraghiM , YaseriM , ArabM , HosseiniM , et al. Preoperative evaluation of risk of ovarian malignancy algorithm index in prediction of malignancy of adnexal masses. Iranian Red Crescent Medical Journal2014;16(6):e17185. ">Farzaneh 2014</a>; <a href="./references#CD011964-bbs2-0017" title="KarlsenMA , SandhuN , HogdallC , ChristensenIJ , NedergaardL , LundvallL , et al. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass. Gynecologic Oncology2012;127(2):379-83. ">Karlsen 2012</a>; <a href="./references#CD011964-bbs2-0034" title="Ortiz-MunozB , Aznar-OrovalE , Garcia GarciaA , Covisa PerisA , Perez BallesteroP , Sanchez YepesM , et al. HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer. Tumour Biology2014;35(7):7249-58. ">Ortiz‐Munoz 2014</a>), and one RMI study (<a href="./references#CD011964-bbs2-0017" title="KarlsenMA , SandhuN , HogdallC , ChristensenIJ , NedergaardL , LundvallL , et al. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass. Gynecologic Oncology2012;127(2):379-83. ">Karlsen 2012</a>) specified the presence of symptoms including 'gynaecological symptom's, pelvic pain and vaginal bleeding, pain, distension and weight loss', whilst 10 ROMA studies reported that an adnexal mass was identified following investigation with one of USS, MRI or CT. </p> <p>Excluding certain tumour types changes the population spectrum as index test performance differed in different histological subtypes and at different stages of malignancy. For example, CA125 is known to have a higher sensitivity in EOC compared to other types of ovarian tumour such as stromal and germ cell tumours (<a href="./references#CD011964-bbs2-0087" title="KobayashiE , UedaY , MatsuzakiS , YokoyamaT , KimuraT , YoshinoK , et al. Biomarkers for screening, diagnosis, and monitoring of ovarian cancer. Cancer Epidemiology, Biomarkers &amp; Prevention2012;21(11):1902-12.">Kobayashi 2012</a>). The range of ovarian pathology reported in included studies varied. Eighteen ROMA and four RMI studies explicitly restricted inclusion to EOC, and seven ROMA studies and one RMI study explicitly excluded borderline tumours. A further 18 ROMA and three RMI studies did not report the occurrence of borderline tumours. </p> <p>Characteristics of included studies are summarised in <a href="#CD011964-tbl-0004">Table 3</a> (RMI), <a href="#CD011964-tbl-0005">Table 4</a> (ROMA), <a href="#CD011964-tbl-0006">Table 5</a> (LR2) and <a href="#CD011964-tbl-0007">Table 6</a> (ADNEX). </p> <div class="table" id="CD011964-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Study characteristics: RMI I</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Author year</b> </p> <p><b>Country</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Setting</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Participants characteristics</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Index test threshold</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0001" title="AbdallaN , PiorkowskiR , PazuraM , CendrowskiK , SawickiW . Combined use of ultrasound and CA125 to predict malignancy in a patient with oviduct transitional carcinoma: case report. BJOG: an International Journal of Obstetrics and Gynaecology2017;124(Suppl 1):169. ">Abdalla 2017</a> </p> <p>Poland</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study criteria:</b> women scheduled to undergo surgery for adnexal tumours </p> <p><b>Clinical setting:</b> mixed </p> <p><b>Prior tests:</b> USS assessment of adnexal mass and measurement of tumour markers CA125 and HE4 within 5 days before surgical intervention </p> <p><b>Exclusions:</b> presence of fibroids &gt; 5 cm were excluded </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 312 </p> <p><b>Postmenopausal n (%):</b> 117 (37) </p> <p><b>Ovarian cancer n (%):</b> 45 (15) </p> <p><b>Borderline n (%):</b> 7 (2) </p> <p><b>Age:</b> range 18–85 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Threshold:</b> 200 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0002" title="Al MusalhiK , Al KindiM , Al AisaryF , RamadhanF , Al RawahiT , Al HataliK , et al. Evaluation of HE4, CA-125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) in the preoperative assessment of patients with adnexal mass. Oman Medical Journal2016;31(5):336-44. ">Al Musalhi 2016</a> </p> <p>Oman</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with an ovarian mass </p> <p><b>Clinical setting:</b> mixed </p> <p><b>Prior tests:</b> unclear but assume USS </p> <p><b>Exclusions:</b> none reported </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 213 </p> <p><b>Postmenopausal n (%):</b> 51 (24) </p> <p><b>Ovarian cancer n (%):</b> 48 (23) </p> <p><b>Borderline n (%):</b> 7 (3) </p> <p><b>Age:</b> not reported </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Threshold:</b> 200 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0003" title="AntonC , CarvalhoFM , OliveiraEI , MacielGA , BaracatEC , CarvalhoJP . A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses. Clinics (Sao Paulo, Brazil)2012;67(5):437-41. ">Anton 2012</a> </p> <p>Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women referred with pelvic mass diagnosed by USS, CT or MRI with signs of carcinomatosis undergoing surgery or image‐guided biopsy </p> <p><b>Clinical setting:</b> secondary care </p> <p><b>Prior tests:</b> unclear </p> <p><b>Exclusions:</b> none reported </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 120 </p> <p><b>Postmenopausal n (%):</b> 73 (60) </p> <p><b>Ovarian cancer n</b> <b>(%):</b> 30 (25) </p> <p><b>Borderline n (%):</b> 17 (14) </p> <p><b>Mean age:</b> malignant 54.7 years, borderline 56.4 years, benign 50.7 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Threshold:</b> 200 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0011" title="ErtasS , VuralF , VuralF , TufekciEC , ErtasAC , KoseG , et al. Predictive value of malignancy risk indices for ovarian masses in premenopausal and postmenopausal women. Asian Pacific Journal of Cancer Prevention2016;17(4):2177-83. ">Ertas 2016</a> </p> <p>Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with adnexal masses that underwent surgery </p> <p><b>Clinical setting:</b> tertiary </p> <p><b>Prior tests:</b> unclear </p> <p><b>Exclusions:</b> none reported </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n:</b> 408 </p> <p><b>Postmenopausal n (%):</b> 117 (71.4) </p> <p><b>Ovarian cancer n (%):</b> 55 (13) </p> <p><b>Borderline n (%):</b> 12 (3) </p> <p><b>Mean age:</b> benign 40.8 (SD 13.8) years, malignant 54.4 (SD 13.6) years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Threshold:</b> 200 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0015" title='IrshadF , IrshadM , NazM , Asim IkramM . Accuracy of "risk of malignancy index" in the preoperative diagnosis of ovarian malignancy in post menopausal women. Rawal Medical Journal2013;38(3):266-70. '>Irshad 2013</a> </p> <p>Pakistan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> unclear (ovarian masses) </p> <p><b>Clinical setting:</b> secondary </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> unclear </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 36 </p> <p><b>Postmenopausal n (%):</b> 36 (100) </p> <p><b>Ovarian cancer n (%)</b>: 24 (37) </p> <p><b>Borderline n (%):</b> not reported </p> <p><b>Mean age:</b> 58 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> 250 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0020" title="KrascsenitsG , BalazsB , DudnyikovaA , PurcsiK , OroszE , PeteI . Investigating the predictive value of RMI and ROMA indices in patients with ovarian tumors of uncertain dignity. Magyar Onkologia2016;60(4):320-7. ">Krascsenitis 2016</a> </p> <p>Hungary</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women diagnosed with an ovarian tumour of unknown significance admitted for surgery </p> <p><b>Clinical setting:</b> tertiary </p> <p><b>Prior tests:</b> not reported </p> <p><b>Exclusions:</b> none reported </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n:</b> 162 </p> <p><b>Postmenopausal n (%):</b> 102 (63) </p> <p><b>Ovarian cancer n (%):</b> 34 (21) </p> <p><b>Borderline n (%):</b> 11 (7) </p> <p><b>Mean age:</b> 55 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Threshold:</b> 200 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0022" title="LiestAL , OmranAS , MikiverR , RosenbergP , UppugunduriS . RMI and ROMA are equally effective in discriminating between benign and malignant gynecological tumors: a prospective population-based study. Acta Obstetricia et Gynecologica Scandinavica2019;98(1):24-33. ">Liest 2019</a> </p> <p>Sweden</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with a pelvic mass of probable ovarian origin and scheduled for surgery </p> <p><b>Clinical setting:</b> tertiary </p> <p><b>Prior tests:</b> preoperative USS </p> <p><b>Exclusions:</b> none reported </p> <p><b>Centre:</b> multicentre </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n:</b> 784 </p> <p><b>Postmenopausal n (%):</b> 117 (81) </p> <p><b>Ovarian cancer n (%):</b> 144 (18) (include borderline) </p> <p><b>Borderline n (%):</b> not reported </p> <p><b>Age:</b> not reported </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Threshold:</b> 200 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0023" title="LyckeM , KristjansdottirB , SundfeldtK . A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index. Gynecologic Oncology2018;151(1):159-65. ">Lycke 2018</a> </p> <p>Sweden</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women planned for a surgical procedure for a symptomatic/suspected malignant ovarian cyst or pelvic tumour </p> <p><b>Clinical setting:</b> mixed </p> <p><b>Prior tests:</b> unclear but assume history and examination, and USS from participant selection </p> <p><b>Exclusions:</b> none reported </p> <p><b>Centre:</b> multicentre </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n:</b> 638 </p> <p><b>Postmenopausal n (%):</b> 348 (55) </p> <p><b>Ovarian cancer n (%):</b> 162 (25) </p> <p><b>Borderline n (%):</b> 31 (5) </p> <p><b>Mean age:</b> benign 50.76 years, BOT 55.58 years, EOC 62.67 </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Threshold:</b> 200 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0024" title="Manegold-BrauerG , BuechelJ , Knipprath-MeszarosA , SchoetzauA , HackerNF , TercanliS , et al. Improved detection rate of ovarian cancer using a 2-step triage model of the risk of malignancy index and expert sonography in an outpatient screening setting. International Journal of Gynecological Cancer2016;26(6):1062-9. ">Manegold‐Brauer 2016</a> </p> <p>Switzerland</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women who had USS examination for an adnexal mass with histology and CA125 results available </p> <p><b>Clinical setting:</b> secondary </p> <p><b>Prior tests:</b> not reported </p> <p><b>Exclusions:</b> none reported </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 1108 </p> <p><b>Postmenopausal n (%):</b> 478 (43) </p> <p><b>Ovarian cancer n (%):</b> 118 (11) </p> <p><b>Borderline n (%):</b> 33 (3) </p> <p><b>Median age:</b> 48 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Threshold:</b> 200 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0026" title="MeysEM , JeelofLS , AchtenNM , SlangenBF , LambrechtsS , KruitwagenRF , et al. Estimating risk of malignancy in adnexal masses: external validation of the ADNEX model and comparison with other frequently used ultrasound methods. Ultrasound in Obstetrics &amp; Gynecology2017;49(6):784-92. ">Meys 2017</a> </p> <p>Netherlands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria</b>: women with adnexal pathology </p> <p><b>Clinical setting:</b> tertiary </p> <p><b>Prior tests:</b> not reported </p> <p><b>Exclusions:</b> none reported </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n:</b> 326 </p> <p><b>Postmenopausal n (%):</b> 198 (61) </p> <p><b>Ovarian cancer n (%):</b> 115 (35) </p> <p><b>Borderline n (%):</b> 27 (8) </p> <p><b>Median age:</b> benign 53.2 (IQR 16.1–87.2) years, malignant 67.7 (IQR 32.3–87) years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Threshold:</b> 200 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0031" title="NiemiRJ , SaarelainenSK , LuukkaalaTH , MaenpaaJU . Reliability of preoperative evaluation of postmenopausal ovarian tumors. Journal of Ovarian Research2017;10(1):15. ">Niemi 2017</a> </p> <p>Finland</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women aged &gt; 50 years presenting with an abnormal adnexal mass(es) </p> <p><b>Clinical setting:</b> tertiary </p> <p><b>Prior tests:</b> not reported </p> <p><b>Exclusions:</b> overtly benign or malignant‐appearing tumours such as unilocular simple ovarian cysts and tumours associated with marked ascites (depth of the greatest pool &gt; 10 cm) </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 98 </p> <p><b>Postmenopausal n (%):</b> 98 (100) </p> <p><b>Ovarian cancer n (%):</b> 23 (23) </p> <p><b>Borderline n (%):</b> 7 (7) </p> <p><b>Median age:</b> 61 (range 50–84) years </p> <p><b>Separated by menopausal status:</b> only postmenopausal included </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Threshold:</b> 200 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0032" title="NikolovaT , ZivadinovicR , EvtimovskaN , KlisarovskaV , StanojevicM , GeorgievskaJ , et al. Diagnostic performance of Human Epididymis protein4 compared to a combination of biophysical and biochemical markers to differentiate ovarian endometriosis from epithelial ovarian cancer in premenopausal women. Journal of Obstetrics and Gynaecology Research2017;43(12):1870-9. ">Nikolova 2016</a> </p> <p>Macedonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> premenopausal women with USS confirming an ovarian cyst/mass and undergoing surgery </p> <p><b>Clinical setting:</b> tertiary </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> postmenopausal women </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n:</b> 105 (analysed) </p> <p><b>Postmenopausal n (%):</b> 0 </p> <p><b>Ovarian cancer n (%):</b> 11 (10%) </p> <p><b>Borderline n (%):</b> not reported </p> <p><b>Mean age:</b> ovarian cancer 42.46 (SD 8.21) years, benign 36.90 (SD 10.12) years </p> <p><b>Separated by menopausal status:</b> only premenopausal women included </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Threshold:</b> 250 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0038" title="RadosaMP , CamaraO , VorwergkJ , DiebolderH , WinzerH , MothesA , et al. Preoperative multimodal strategies for risk assessment of adnexal masses: analysis of 1362 cases in a gynecologic cancer center. International Journal of Gynecological Cancer2011;21(6):1056-62. ">Radosa 2011</a> </p> <p>Germany</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with adnexal mass who subsequently underwent surgery were selected </p> <p><b>Clinical setting:</b> tertiary </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> none </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 442 </p> <p><b>Postmenopausal n (%):</b> 141 (32) </p> <p><b>Ovarian cancer n (%)</b>: 79 </p> <p><b>Borderline n (%):</b> 19 </p> <p><b>Mean age:</b> 43.3 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> 200 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0039" title="RichardsA , HerbstU , PatherS , SaidiS , Tejada-BergesT , WilliamsP , et al. HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses – a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2015;55(5):493-7. ">Richards 2015</a> </p> <p>Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women who were undergoing surgery for a complex pelvic mass, presumed to be arising from the ovary </p> <p><b>Clinical setting:</b> mixed </p> <p><b>Prior tests:</b> unclear </p> <p><b>Exclusions:</b> none reported </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n:</b> 50 </p> <p><b>Postmenopausal n (%):</b> 29 (58) </p> <p><b>Ovarian cancer n (%):</b> 16 (32) </p> <p><b>Borderline n (%):</b> 4 (8) </p> <p><b>Median age:</b> 60 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Threshold:</b> 200 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0042" title="SayasnehA , KaijserJ , PreislerJ , JohnsonS , StalderC , HusickaR , et al. A multicenter prospective external validation of the diagnostic performance of IOTA simple descriptors and rules to characterize ovarian masses. Gynecologic Oncology2013;130(1):140-6. [Sayasneh 2013]SayasnehA , WynantsL , PreislerJ , KaijserJ , JohnsonS , StalderC , et al. Multicentre external validation of IOTA prediction models and RMI by operators with varied training. British Journal of Cancer2013;108(12):2448-54. ">Sayasneh 2013a</a> </p> <p>UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women presenting with adnexal mass and undergoing surgery within 120 days after examination </p> <p><b>Clinical setting:</b> mixed </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> none </p> <p><b>Centre:</b> multicentre </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 255 </p> <p><b>Postmenopausal n (%):</b> 117 (46) </p> <p><b>Ovarian cancer n (%)</b>: 48 (19) </p> <p><b>Borderline n (%):</b> 18 (7) </p> <p><b>Mean age:</b> 46 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> 200 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0049" title="TerzicM , DotlicJ , LikicI , BrndusicN , PilicI , LadjevicN , et al. Risk of malignancy index validity assessment in premenopausal and postmenopausal women with adnexal tumors. Taiwanese Journal of Obstetrics &amp; Gynecology2013;52(2):253-7. ">Terzic 2013</a> </p> <p>Serbia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women treated for adnexal tumours </p> <p><b>Clinical setting:</b> secondary </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> none </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 689 </p> <p><b>Postmenopausal n (%):</b> 138 (20) </p> <p><b>Ovarian cancer n (%)</b>: 112 (16) </p> <p><b>Borderline n (%):</b> 33 (5) </p> <p><b>Mean age:</b> benign 42.8 years, borderline: 53.6 years, malignant 57.25 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> 250 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0050" title="TestaA , KaijserJ , WynantsL , FischerovaD , vanHolsbekeC , FranchiD , et al. Strategies to diagnose ovarian cancer: new evidence from phase 3 of the multicentre international IOTA study. British Journal of Cancer2014;111(4):680-8. ">Testa 2014</a> </p> <p>European countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women presenting with adnexal mass and undergoing TVS by 1 of the principal investigators and surgery within 120 days after examination </p> <p><b>Clinical setting:</b> mixed </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> none </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 2403 </p> <p><b>Postmenopausal n (%):</b> 1049 (44) </p> <p><b>Ovarian cancer n (%)</b>: 701 (29) </p> <p><b>Borderline n (%):</b> 153 (6) </p> <p><b>Age:</b> not reported </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> 200 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0053" title="vanden AkkerPA , ZusterzeelPL , AaldersAL , SnijdersMP , SamlalRA , VolleberghJH , et al. Use of risk of malignancy index to indicate frozen section analysis in the surgical care of women with ovarian tumors. International Journal of Gynaecology &amp; Obstetrics2016;133(3):355-8. ">van den Akker 2016</a> </p> <p>Netherlands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women admitted for surgical treatment of an ovarian mass with unknown histology </p> <p><b>Clinical setting:</b> mixed </p> <p><b>Prior tests:</b> not reported </p> <p><b>Exclusions:</b> women with clear evidence of malignancy found before or during the surgical procedure (e.g. pleural effusions and evidence of distal organ involvement) </p> <p><b>Centre:</b> multicentre </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 670 </p> <p><b>Postmenopausal n (%):</b> 390 (58) </p> <p><b>Ovarian cancer n (%):</b> 93 (14) </p> <p><b>Borderline n (%):</b> 46 (6) </p> <p><b>Median age:</b> 54 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Threshold:</b> 200 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0055" title="KaijserJ , vanGorpT , SmetME , vanHolsbekeC , SayasnehA , EpsteinE , et al. Are serum HE4 or ROMA scores useful to experienced examiners for improving characterization of adnexal masses after transvaginal ultrasonography?Ultrasound in Obstetrics &amp; Gynecology2014;43(1):89-97. [Secondary publication Kaijser 2014]vanGorpT , VeldmanJ , vanCalsterB , CadronI , LeunenK , AmantF , et al. Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses. European Journal of Cancer2012;48(11):1649-56. ">van Gorp 2012</a> </p> <p>Belgium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with a pelvic mass, scheduled for surgery </p> <p><b>Clinical setting:</b> secondary </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> none </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 374 </p> <p><b>Postmenopausal n (%):</b> 196 (52) </p> <p><b>Ovarian cancer n (%)</b>: 94 (25) </p> <p><b>Borderline n (%):</b> 31 (8) </p> <p><b>Mean age:</b> benign 46.2 years, malignant 57.7 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> 200 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0056" title="VuralF , AkaN , ErtasS , KoseG , TufekciEC . The ovarian cancers in geriatric population: the validity of inflammatory markers, malignancy risk indices 1, 2, 3, 4, and CA-125 levels in malignancy discrimination of adnexal masses. European Journal of Gynaecological Oncology2016;37(6):846-51. ">Vural 2016</a> </p> <p>Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria</b>: postmenopausal women with adnexal masses who underwent surgery </p> <p><b>Clinical setting:</b> tertiary </p> <p><b>Prior tests:</b> not reported </p> <p><b>Exclusions:</b> premenopausal women </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n:</b> 139 </p> <p><b>Postmenopausal n (%):</b> 139 (100) </p> <p><b>Ovarian cancer n (%):</b> 44 (32) </p> <p><b>Borderline n (%):</b> 8 (6) </p> <p><b>Mean age:</b> 61.1 (SD 8.9) years (range 42–87 years) </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Threshold:</b> 200 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*Thresholds extracted for RMI I: 200 and 250.</p> <p>BOT: borderline ovarian tumour; CT: computed tomography; EOC: epithelial ovarian cancer; HE4: Human Epididymis protein; IQR: interquartile range; MRI: magnetic resonance imaging; n: number of participants; RMI I: Risk of Malignancy Index I; SD: standard deviation; TVS: transvaginal ultrasound; USS: ultrasound scan. </p> </div> </div> <div class="table" id="CD011964-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Study characteristics: ROMA</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Author year</b> </p> <p><b>Country</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Setting</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Participant characteristics</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Index test threshold*</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0002" title="Al MusalhiK , Al KindiM , Al AisaryF , RamadhanF , Al RawahiT , Al HataliK , et al. Evaluation of HE4, CA-125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) in the preoperative assessment of patients with adnexal mass. Oman Medical Journal2016;31(5):336-44. ">Al Musalhi 2016</a> </p> <p>Oman</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with an ovarian mass </p> <p><b>Clinical setting:</b> mixed </p> <p><b>Prior tests:</b> unclear but assumed USS </p> <p><b>Exclusions:</b> none reported </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 213 </p> <p><b>Postmenopausal n (%):</b> 51 (24) </p> <p><b>Ovarian cancer n (%):</b> 48 (23) </p> <p><b>Borderline n (%):</b> 7 (3) </p> <p><b>Age:</b> not reported </p> <p><b>Separated by menopausal</b> </p> <p><b>status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Threshold:</b> premenopausal 13.1, postmenopausal 27.7 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0003" title="AntonC , CarvalhoFM , OliveiraEI , MacielGA , BaracatEC , CarvalhoJP . A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses. Clinics (Sao Paulo, Brazil)2012;67(5):437-41. ">Anton 2012</a> </p> <p>Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with signs of carcinomatosis with a pelvic mass diagnosed by US, CT or MRI undergoing surgery or image‐guided biopsy </p> <p><b>Clinical setting:</b> secondary care </p> <p><b>Prior tests:</b> not reported </p> <p><b>Exclusions</b>: none reported </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 120 </p> <p><b>Postmenopausal n (%):</b> 73 (60.8%) </p> <p><b>Ovarian cancer n (%):</b> 30 (25%) </p> <p><b>Borderline n (%):</b> 17 (14%) </p> <p><b>Mean age:</b> malignant 54.7 years, borderline 56.4 years, benign 50.73 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 13.1, postmenopausal 27.7 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0004" title="BandieraE , RomaniC , SpecchiaC , ZanottiL , GalliC , RuggeriG , et al. Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management. Cancer Epidemiology, Biomarkers &amp; Prevention2011;20(12):2496-506. ">Bandiera 2011</a> </p> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> not reported </p> <p><b>Clinical setting:</b> tertiary care </p> <p><b>Prior tests:</b> not reported </p> <p><b>Exclusions:</b> non‐EOC </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 278 </p> <p><b>Postmenopausal n (%):</b> 183 (65.8) </p> <p><b>Ovarian cancer n (%):</b> 113 (41) </p> <p><b>Borderline n (%):</b> not reported </p> <p><b>Mean age:</b> premenopausal: malignant 44.7 years, benign 41.5 years; postmenopausal: malignant 66.3 years, benign 64.0 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 7.4, postmenopausal 25.3 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0005" title="ChanKK , ChenCA , NamJH , OchiaiK , WilailakS , ChoonAT , et al. The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass. Gynecologic Oncology2013;128(2):239-44. WilailakS , ChanKK , ChenCA , NamJH , OchiaiK , AwTC , et al. Distinguishing benign from malignant pelvic mass utilizing an algorithm with HE4, menopausal status, and ultrasound findings. Journal of Gynecologic Oncology2015;26(1):46-53. [Secondary publication]">Chan 2013</a> </p> <p>Asia‐Pacific region</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women aged &gt; 18 years diagnosed with adnexal mass diagnosed by any imaging method (US, CT or MRI) </p> <p><b>Clinical setting:</b> unclear </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> none </p> <p><b>Centre:</b> multicentre </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 414 </p> <p><b>Postmenopausal n (%):</b> 26 (108) </p> <p><b>Ovarian cancer n (%):</b> 74 (18) </p> <p><b>Borderline n (%):</b> 16 (4) </p> <p><b>Age mean:</b> not reported </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 7.4, </p> <p>postmenopausal 25.3</p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0007" title="ChenX , ZhouH , ChenR , HeJ , WangY , HuangL , et al. Development of a multimarker assay for differential diagnosis of benign and malignant pelvic masses. Clinica Chimica Acta2015;440:57-63. ">Chen 2015</a> </p> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with pelvic masses scheduled for surgery </p> <p><b>Clinical setting:</b> unclear </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> none </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 130 </p> <p><b>Postmenopausal n (%):</b> 62 (48) </p> <p><b>Ovarian cancer n (%):</b> 60 (46) </p> <p><b>Borderline n (%):</b> not reported </p> <p><b>Median age:</b> benign 34 years, malignant 53 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 11.4, postmenopausal 29.9 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0006" title="ChenWT , GaoX , HanXD , ZhengH , GuoL , LuRQ . HE4 as a serum biomarker for ROMA prediction and prognosis of epithelial ovarian cancer. Asian Pacific Journal of Cancer Prevention2014;15(1):101-5. ">Chen 2014</a> </p> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with EOC and benign lesions </p> <p><b>Clinical setting:</b> tertiary </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> women with non‐EOC </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 192 </p> <p><b>Postmenopausal n (%):</b> 84 (44) </p> <p><b>Ovarian cancer n (%):</b> 123 (64) </p> <p><b>Borderline n (%):</b> not reported </p> <p><b>Age mean:</b> not reported </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 12.2, postmenopausal 25.8 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0008" title="Chudecka-GlazAM . ROMA, an algorithm for ovarian cancer. Clinica Chimica Acta2015;440:143-51. ">Chudecka‐Glaz 2015</a> </p> <p>Poland</p> <p>(ROMA and ROMA‐P)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> consecutive women who attended the hospital presenting with suspected ovarian cancer (ovarian tumour, ovarian cyst, or ascites) </p> <p><b>Clinical setting:</b> tertiary </p> <p><b>Prior test:</b> not reported </p> <p><b>Exclusions:</b> none reported </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 413 </p> <p><b>Postmenopausal (%):</b> 251 (61) </p> <p><b>Ovarian cancer n (%):</b> 162 (39%) </p> <p><b>Borderline n (%):</b> not reported </p> <p><b>Age median:</b> benign 35 years, malignant 59.7 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>a) ROMA</b> </p> <p><b>Thresholds:</b> premenopausal 14.1, postmenopausal 25 </p> <p><b>Prespecified:</b> yes </p> <p><b>b) ROMA‐P</b> </p> <p><b>Thresholds:</b> determined by age group in both pre‐ and postmenopausal; age group included: &lt; 20 years, 21–30 years, 31–40 years, 41–50 years, 51–60 years, 61–70 years, 71–80 years, and &gt; 80 years </p> <p><b>Prespecified:</b> no </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0009" title="CradicKW , LashoMA , Algeciras-SchimnichA . Validation of the cut-points recommended for ROMA using the Roche Elecsys CA125 and HE4 assays. Annals of Clinical &amp; Laboratory Science2018;48(1):90-3. ">Cradic 2018</a> </p> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with EOC or benign ovarian lesions </p> <p><b>Clinical setting:</b> tertiary </p> <p><b>Prior test:</b> not reported </p> <p><b>Exclusions:</b> not reported </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 207 </p> <p><b>Postmenopausal n (%):</b> 93 (45) </p> <p><b>Ovarian cancer n (%):</b> 76 (37) (EOC) </p> <p><b>Borderline n (%):</b> not reported </p> <p><b>Age mean:</b> not reported </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 11.4, postmenopausal 29.9 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0010" title="DikmenZG , ColakA , DoganP , TuncerS , AkbiyikF . Diagnostic performances of CA125, HE4, and ROMA index in ovarian cancer. European Journal of Gynaecological Oncology2015;36(4):457-62. ">Dikmen 2015</a> </p> <p>Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women were 'preoperative' </p> <p><b>Clinical setting:</b> unclear </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> none reported </p> <p><b>Centre:</b> unclear </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n:</b> 143 </p> <p><b>Postmenopausal n (%):</b> 46 (32%) </p> <p><b>Ovarian cancer n (%):</b> 47 (33%) </p> <p><b>Borderline n (%):</b> not reported </p> <p><b>Age mean:</b> benign 42 (SD 10) years, malignant 56 (SD 14) years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 13.1, postmenopausal 27.7 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0012" title="FarzanehF , HonarvarZ , YaraghiM , YaseriM , ArabM , HosseiniM , et al. Preoperative evaluation of risk of ovarian malignancy algorithm index in prediction of malignancy of adnexal masses. Iranian Red Crescent Medical Journal2014;16(6):e17185. ">Farzaneh 2014</a> </p> <p>Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with adnexal mass undergoing surgery and having attained menarche 12 months before presenting with adnexal mass </p> <p><b>Clinical setting:</b> secondary </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> non‐EOC </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 99 </p> <p><b>Postmenopausal n (%):</b> 31 (31) </p> <p><b>Ovarian cancer n (%):</b> 43 (43) (EOC) </p> <p><b>Borderline n (%):</b> not reported </p> <p><b>Mean age:</b> benign 39 years, malignant 51 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 11.5, postmenopausal 25.5 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0013" title="GrenacheDG , HeichmanKA , WernerTL , VuceticZ . Clinical performance of two multi-marker blood tests for predicting malignancy in women with an adnexal mass. Clinica Chimica Acta2015;438:358-63. ">Grenache 2015</a> </p> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with abnormal adnexal mass detected on physical examination and imaging Included USS, CT or MRI) followed by surgery </p> <p><b>Clinical setting:</b> unclear </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> unclear </p> <p><b>Centre:</b> multicentre </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 146 </p> <p><b>Postmenopausal n (%):</b> 76 (52) </p> <p><b>Ovarian cancer n (%):</b> 19 (13) </p> <p><b>Borderline n (%):</b> 7 (5) </p> <p><b>Mean age:</b> 52 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 8.6 and 13.1, postmenopausal 27.7 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0014" title="HuyNV , vanKhoaV , TamLM , VinhTQ , TungNS , ThanhCN , et al. Standard and optimal cut-off values of serum ca-125, HE4 and ROMA in preoperative prediction of ovarian cancer in Vietnam. Gynecologic Oncology Reports2018;25:110-4. ">Huy 2018</a> </p> <p>Vietnam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study criteria:</b> women with sufficient personal information, clinical symptoms, data on serum CA125 and serum HE4 levels, and postoperative pathologic findings </p> <p><b>Clinical setting:</b> mixed </p> <p><b>Prior test:</b> not reported </p> <p><b>Exclusions:</b> unclear borderline cases </p> <p><b>Centre:</b> single </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 277 </p> <p><b>Postmenopausal n (%):</b> 47 (17) </p> <p><b>Ovarian cancer n (%):</b> 30 (11) (EOC only) </p> <p><b>Borderline n (%):</b> not reported </p> <p><b>Age:</b> not reported </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 7.4, postmenopausal 25.3 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0017" title="KarlsenMA , SandhuN , HogdallC , ChristensenIJ , NedergaardL , LundvallL , et al. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass. Gynecologic Oncology2012;127(2):379-83. ">Karlsen 2012</a> </p> <p>Denmark</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women admitted to surgery for pelvic mass or pelvic pain potentially caused by malignant disease or endometriosis </p> <p><b>Clinical setting:</b> secondary </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> none </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 1218 </p> <p><b>Postmenopausal n (%):</b> 621 (51) </p> <p><b>Ovarian cancer n (%):</b> 261 (21) </p> <p><b>Borderline n (%):</b> 79 (6) </p> <p><b>Age mean:</b> not reported </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 7.4, postmenopausal 25.3 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0016" title="KadijaS , StefanovicA , JeremicK , RadojevicMM , NikolicL , MarkovicI , et al. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis. International Journal of Gynecological Cancer2012;22(2):238-44. ">Kadija 2012</a> </p> <p>Serbia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women diagnosed with adnexal mass scheduled to undergo surgery </p> <p><b>Clinical setting:</b> secondary </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> none </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 108 </p> <p><b>Postmenopausal n (%):</b> 41 (38) </p> <p><b>Ovarian cancer n (%):</b> 24 (22) </p> <p><b>Borderline n (%):</b> 5 (5) </p> <p><b>Age:</b> not reported </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 12.5, postmenopausal 14.4 </p> <p><b>Prespecified:</b> no </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0018" title="KimYM , WhangDH , ParkJ , KimSH , LeeSW , ParkHA , et al. Evaluation of the accuracy of serum Human Epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case-control study in a Korean population. Clinical Chemistry &amp; Laboratory Medicine2011;49(3):527-34. ">Kim 2011</a> </p> <p>South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women diagnosed with adnexal mass on the first visit to the gynaecological oncology clinic and underwent surgery </p> <p><b>Clinical setting:</b> tertiary </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> only EOC included </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 159 </p> <p><b>Postmenopausal n (%):</b> 108 (68) </p> <p><b>Ovarian cancer n (%):</b> 68 (43) </p> <p><b>Borderline n (%):</b> 10 (6) </p> <p><b>Mean age:</b> benign 35.7, malignant 51.7 </p> <p><b>Separated by menopausal status:</b> **yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Threshold:</b> premenopausal 7.6 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0019" title="KimB , ParkY , AhnHJ , LeeKA , ChungJE , HanSW . Diagnostic performance of CA 125, HE4, and risk of Ovarian Malignancy Algorithm for ovarian cancer. Journal of Clinical Laboratory Analysis2019;33(1):e22624. ">Kim 2019</a> </p> <p>Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with suspected gynaecological disease </p> <p><b>Clinical setting:</b> tertiary </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> unclear; presume BOT excluded as retrospective </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 832 </p> <p><b>Postmenopausal n (%):</b> 251 (30) </p> <p><b>Ovarian cancer n (%):</b> 70 (8) </p> <p><b>Borderline n (%):</b> not reported </p> <p><b>Median age:</b> benign 45.0 (IQR 36.0–51.0) years, malignant 64.0 (IQR 50.9–77.0) years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 11.4, postmenopausal 29.9 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0020" title="KrascsenitsG , BalazsB , DudnyikovaA , PurcsiK , OroszE , PeteI . Investigating the predictive value of RMI and ROMA indices in patients with ovarian tumors of uncertain dignity. Magyar Onkologia2016;60(4):320-7. ">Krascsenitis 2016</a> </p> <p>Hungary</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women diagnosed with an ovarian tumour of unknown significance admitted for surgery </p> <p><b>Clinical setting:</b> tertiary </p> <p><b>Prior tests:</b> not reported </p> <p><b>Exclusions:</b> none reported </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 162 </p> <p><b>Postmenopausal n (%):</b> 102 (63) </p> <p><b>Ovarian cancer n (%):</b> 34 (21) </p> <p><b>Borderline n (%):</b> 11 (7) </p> <p><b>Mean age:</b> 55 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 11.4, postmenopausal 29.9 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0021" title="LiL , WanJ , CaiG , YuanL , LiangJ , SongJ , et al. Value of serum human epididymis secretory protein 4 as a marker for differential diagnosis of malignant and benign gynecological diseases of patients in southern China. Clinica Chimica Acta2016;459:170-6. ">Li 2016</a> </p> <p><b>China</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women diagnosed with gynaecological diseases by US, CT scan, PET‐CT scan or MRI </p> <p><b>Clinical setting:</b> unclear </p> <p><b>Prior test:</b> not reported </p> <p><b>Exclusions:</b> none </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 916 </p> <p><b>Postmenopausal n (%):</b> 172 (19) </p> <p><b>Ovarian cancer n (%):</b> 190 </p> <p><b>Borderline n (%):</b> not reported </p> <p><b>Median age:</b> 50 years (range 18–82 years) </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 7.4, postmenopausal 25.3 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0022" title="LiestAL , OmranAS , MikiverR , RosenbergP , UppugunduriS . RMI and ROMA are equally effective in discriminating between benign and malignant gynecological tumors: a prospective population-based study. Acta Obstetricia et Gynecologica Scandinavica2019;98(1):24-33. ">Liest 2019</a> </p> <p>Sweden</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with a pelvic mass of probable ovarian origin and scheduled for surgery </p> <p><b>Clinical setting:</b> tertiary </p> <p><b>Prior tests:</b> preoperative US </p> <p><b>Exclusions:</b> none reported </p> <p><b>Centre:</b> multicentre </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 784 </p> <p><b>Postmenopausal n (%):</b> 117 (81) </p> <p><b>Ovarian cancer n (%):</b> 144 (18) (EOC + borderline) </p> <p><b>Borderline n (%):</b> not reported </p> <p><b>Mean age:</b> not reported </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 11, postmenopausal 25 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0023" title="LyckeM , KristjansdottirB , SundfeldtK . A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index. Gynecologic Oncology2018;151(1):159-65. ">Lycke 2018</a> </p> <p>Sweden</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women planned for a surgical procedure for a symptomatic/suspected malignant ovarian cyst or pelvic </p> <p>tumour</p> <p><b>Clinical setting:</b> mixed </p> <p><b>Prior tests:</b> unclear but assume history and examination, and US from patient selection </p> <p><b>Exclusions:</b> none </p> <p><b>Centre:</b> multicentre </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 638 </p> <p><b>Postmenopausal n (%):</b> 348 (55) </p> <p><b>Ovarian cancer n (%):</b> 162 (25) (EOC only) </p> <p><b>Borderline n (%):</b> 31 (5) </p> <p><b>Mean age:</b> benign 50.76 years, BOT 55.58 years, EOC 62.67 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 11.4, postmenopausal 29.9 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0025" title="MeloA , VerissimoR , FarinhaM , MartinsNN , MartinsFN . Discriminative value of CA-125, HE4, risk of Malignancy Index II (RMI-II) and risk of malignancy algorithm (ROMA) in the differential diagnosis of pelvic masses: conclusions from a referral centre in Portugal. Journal of Obstetrics &amp; Gynaecology2018;38(8):1140-5. ">Melo 2018</a> </p> <p>Portugal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with adnexal neoplasia submitted to surgical treatment, with a histological diagnosis and in which ROMA had been determined </p> <p><b>Clinical setting:</b> tertiary </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> none reported but age group unclear </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 247 </p> <p><b>Postmenopausal n (%):</b> 92 (37) </p> <p><b>Ovarian cancer n (%):</b> 34 (14) </p> <p><b>Borderline n (%):</b> 7 (3) </p> <p><b>Age:</b> not reported </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 7.4, postmenopausal 25.3 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0027" title="MolinaR , EscuderoJM , AugeJM , FilellaX , FojL , TorneA , et al. HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. Tumour Biology2011;32(6):1087-95. [1010-4283]">Molina 2011</a> </p> <p>Spain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> not reported </p> <p><b>Clinical setting:</b> unclear </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> none </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 396 </p> <p><b>Postmenopausal n (%):</b> 143 (36) </p> <p><b>Ovarian cancer n (%):</b> 111 (28) </p> <p><b>Borderline n (%):</b> not reported </p> <p><b>Age:</b> not reported </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 13.1, postmenopausal 27.7 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0028" title="MontagnanaM , DaneseE , RuzzenenteO , BrescianiV , NuzzoT , GelatiM , et al. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?Clinical Chemistry &amp; Laboratory Medicine2011;49(3):521-5. ">Montagnana 2011</a> </p> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with pelvic mass scheduled to have radical surgery </p> <p><b>Clinical setting:</b> secondary </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> only EOC included </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 104 </p> <p><b>Postmenopausal n (%):</b> 53 (51) </p> <p><b>Ovarian cancer n (%):</b> 55 (53) </p> <p><b>Borderline n (%): e</b>xcluded </p> <p><b>Mean age:</b> malignant 56.9 years, benign 42 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 12.5, postmenopausal 14.4 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0029" title="MooreRG , McMeekinDS , BrownAK , DiSilvestroP , MillerMC , AllardWJ , et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecologic Oncology2009;112(1):40-6. ">Moore 2009</a> </p> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with ovarian cyst scheduled to undergo surgery </p> <p><b>Clinical setting:</b> unclear </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> none </p> <p><b>Centre:</b> multicentre </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 513 </p> <p><b>Postmenopausal n (%):</b> 150 (29) </p> <p><b>Ovarian cancer n (%):</b> 143 (28) </p> <p><b>Borderline n (%):</b> 22 (4) </p> <p><b>Mean age:</b> 54 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 13.1, postmenopausal 27.7 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0030" title="MooreRG , MillerMC , DisilvestroP , LandrumLM , GajewskiW , BallJJ , et al. Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. Obstetrics &amp; Gynecology2011;118(2 Pt 1):280-8. ">Moore 2011</a> </p> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with ovarian cyst scheduled to undergo surgery </p> <p><b>Clinical setting:</b> mixed </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> none </p> <p><b>Centre:</b> multicentre </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 472 </p> <p><b>Postmenopausal n (%):</b> 217 (46) </p> <p><b>Ovarian cancer n (%):</b> 68 (14) </p> <p><b>Borderline n (%):</b> 19 (4) </p> <p><b>Mean age:</b> 50.3 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 13.1, postmenopausal 27.7 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0032" title="NikolovaT , ZivadinovicR , EvtimovskaN , KlisarovskaV , StanojevicM , GeorgievskaJ , et al. Diagnostic performance of Human Epididymis protein4 compared to a combination of biophysical and biochemical markers to differentiate ovarian endometriosis from epithelial ovarian cancer in premenopausal women. Journal of Obstetrics and Gynaecology Research2017;43(12):1870-9. ">Nikolova 2016</a> </p> <p>Macedonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> premenopausal women to have an USS confirming an ovarian cyst/mass and to undergo surgery </p> <p><b>Clinical setting:</b> tertiary </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> postmenopausal women </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 105 (analysed) </p> <p><b>Postmenopausal n (%):</b> 0 </p> <p><b>Ovarian cancer n (%):</b> 11 (10%) (EOC only) </p> <p><b>Borderline n (%):</b> not reported </p> <p><b>Mean age:</b> malignant 42.46 (SD 8.21) years, benign 36.90 (SD 10.12) years </p> <p><b>Separated by menopausal status:</b> only premenopausal women included </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 7.4 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0033" title="NovotnyZ , PreslJ , KuceraR , TopolcanO , VrzalovaJ , FuchsovaR , et al. HE4 and ROMA index in Czech postmenopausal women. Anticancer Research2012;32(9):4137-40. ">Novotny 2012</a> </p> <p>Czech Republic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with pelvic abnormalities </p> <p><b>Clinical setting:</b> secondary </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> premenopausal women </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 256 </p> <p><b>Postmenopausal n (%):</b> 256 (100) </p> <p><b>Ovarian cancer n (%):</b> 21 (8) </p> <p><b>Borderline n (%):</b> not reported </p> <p><b>Mean age:</b> benign 65.28 years, malignant 64.37 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> postmenopausal 26.3 </p> <p><b>Prespecified:</b> no </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0034" title="Ortiz-MunozB , Aznar-OrovalE , Garcia GarciaA , Covisa PerisA , Perez BallesteroP , Sanchez YepesM , et al. HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer. Tumour Biology2014;35(7):7249-58. ">Ortiz‐Munoz 2014</a> </p> <p>Spain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with gynaecological symptoms, diagnosed with primary ovarian cancer </p> <p><b>Clinical setting:</b> tertiary </p> <p><b>Prior test:</b> symptoms </p> <p><b>Exclusions:</b> none </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 148 </p> <p><b>Postmenopausal n (%):</b> 104 (70) </p> <p><b>Ovarian cancer n (%):</b> 29 (20) </p> <p><b>Borderline n (%):</b> not reported </p> <p><b>Age:</b> not reported </p> <p><b>Separated by menopausal status:</b> **yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 11.4, postmenopausal 29.9 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0035" title="ParkH , ShinJ , LeeDW , KimMJ , LeeHN . Diagnostic accuracy of the risk of Ovarian Malignancy Algorithm in clinical practice at a single hospital in Korea. Annals of Laboratory Medicine2019;39(3):252-62. ">Park 2019</a> </p> <p>Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women for whom gynaecologists had requested HE4, CA125 and ROMA tests to evaluate a pelvic mass </p> <p><b>Clinical setting:</b> secondary </p> <p><b>Prior test:</b> USS, CT or MRI </p> <p><b>Exclusions:</b> 2 cases of non‐EOC excluded from analysis </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 433 (biopsy 309; follow‐up 134) </p> <p><b>Postmenopausal n (%):</b> biopsy: 81 (26), follow‐up: 37 (28) </p> <p><b>Ovarian cancer n (%):</b> 18 (4) </p> <p><b>Borderline n (%):</b> 15 (3) </p> <p><b>Median age:</b> benign 43.0 (SD 21.0) years, malignant 52.3 (SD 6.1) years, BOT 47.8 (SD 12.9) years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 7.4, postmenopausal 25.3 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0036" title="PartheenK , KristjansdottirB , SundfeldtK . Evaluation of ovarian cancer biomarkers HE4 and CA-125 in women presenting with a suspicious cystic ovarian mass. Journal of Gynecologic Oncology2011;22(4):244-52. ">Partheen 2011a</a> </p> <p>Sweden</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with complex cystic mass and suspicious of malignancy undergoing surgery </p> <p><b>Clinical setting:</b> tertiary </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> solid and unilocular mass </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 374 </p> <p><b>Postmenopausal n (%):</b> 276 (74) </p> <p><b>Ovarian cancer n (%):</b> 108 (29) </p> <p><b>Borderline n (%):</b> 45 (12) </p> <p><b>Age:</b> not reported </p> <p><b>Separated by menopausal status:</b> **yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 17.3, postmenopausal 26.0 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0037" title="PrskaloZS , GaceM , DobrijevicS , MayerL . Benefits human epidydimis protein (HE4) compared to traditional used tumor markers in gynecological oncology. Libri Oncologici2015;43(1-3):9-14. ">Prskalo 2015</a> </p> <p>Croatia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with suspected adnexal mass on a TVS scheduled for elective surgery </p> <p><b>Clinical setting:</b> mixed </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> none </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 159 </p> <p><b>Postmenopausal n (%):</b> 102 (64) </p> <p><b>Ovarian cancer n (%):</b> 43 (27) </p> <p><b>Borderline n (%):</b> 11 (7) </p> <p><b>Mean age:</b> premenopausal 36.9 (SD 8.9) years; postmenopausal 60.2 (SD 9.6) years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 11.7, postmenopausal 29.9 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0039" title="RichardsA , HerbstU , PatherS , SaidiS , Tejada-BergesT , WilliamsP , et al. HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses – a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2015;55(5):493-7. ">Richards 2015</a> </p> <p>Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women who were undergoing surgery for a complex pelvic mass, presumed to be arising from the ovary </p> <p><b>Clinical setting:</b> mixed </p> <p><b>Prior tests:</b> unclear </p> <p><b>Exclusions:</b> none reported </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 50 </p> <p><b>Postmenopausal n (%):</b> 29 (58) </p> <p><b>Ovarian cancer n (%):</b> 16 (32) (EOC only) </p> <p><b>Borderline n (%):</b> 4 (8) </p> <p><b>Median age:</b> 60 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 7.4, postmenopausal 25.3 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0040" title="RomagnoloC , LeonA , FabricioAS , TaborelliM , PoleselJ , Del PupL , et al. HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: an Italian multicenter study. Gynecologic Oncology2016;141(2):303-11. ">Romagnolo 2016</a> </p> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women referred to gynaecological oncologist with a suspicious pelvic mass requiring surgery </p> <p><b>Clinical setting:</b> tertiary </p> <p><b>Prior test:</b> pelvic masses confirmed by USS prior to inclusion </p> <p><b>Exclusions:</b> non‐EOC </p> <p><b>Centre:</b> multicentre </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 387 </p> <p><b>Postmenopausal n (%):</b> 148 (38) </p> <p><b>Ovarian cancer n (%):</b> 73 (19) (EOC only) </p> <p><b>Borderline n (%):</b> 15 (3.9) </p> <p><b>Mean age:</b> premenopausal 37.6 (SD 8.6) years, postmenopausal 63 (SD 9.5) years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 13.1, postmenopausal 27.7 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0041" title="SalimE , ZubairiAM , DanishSH , AliU . Diagnostic accuracy of Risk of Ovarian Malignancy Algorithm (ROMA) in post-menopausal patients with ovarian mass. Journal of the College of Physicians and Surgeons Pakistan2018;28(6):440-4. ">Salim 2018</a> </p> <p>Pakistan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> postmenopausal women with ovarian mass (&gt; 2 cm) on pelvic ultrasound examination, attending gynaecology clinics, planned for surgical intervention </p> <p><b>Clinical setting:</b> secondary </p> <p><b>Prior test:</b> not reported </p> <p><b>Exclusions:</b> only postmenopausal women included </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 260 </p> <p><b>Postmenopausal n (%):</b> 260 (100) </p> <p><b>Ovarian cancer n (%):</b> 122 (47) </p> <p><b>Borderline n (%):</b> NR </p> <p><b>Mean age:</b> 49.28 (SD 6.26) years </p> <p><b>Separated by menopausal status:</b> only postmenopausal women included </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> postmenopausal 27.7 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0043" title="ShenF , LuS , PengY , YangF , ChenY , LinY , et al. Performance of ROMA based on Architect CA 125 II and HE4 values in Chinese women presenting with a pelvic mass: a multicenter prospective study. Clinica Chimica Acta2017;471:119-25. ">Shen 2017</a> </p> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women referred to a participating centre with a pelvic mass or an ovarian cyst and planning to undergo surgery </p> <p><b>Clinical setting:</b> mixed </p> <p><b>Prior test:</b> pelvic USS, CT, MRI and the medical history (the diagnosis and treatment of pelvic mass and history of renal disease) </p> <p><b>Exclusions:</b> none </p> <p><b>Centre:</b> multicentre </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 684 </p> <p><b>Postmenopausal n (%):</b> 174 (25) </p> <p><b>Ovarian cancer n (%):</b> 169 (25) (EOC + BOT) </p> <p><b>Borderline n (%):</b> 18 (3) </p> <p><b>Mean age:</b> 58.8 (SD 8.6) years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 7.4, postmenopausal 25.3 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0044" title="StiekemaA , LokCA , KenterGG , vanDrielWJ , VincentAD , KorseCM . A predictive model combining human epididymal protein 4 and radiologic features for the diagnosis of ovarian cancer. Gynecologic Oncology2014;132(3):573-7. ">Stiekma 2014</a> </p> <p>Netherlands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> histologically confirmed EOC or benign ovarian disease referred to the institute </p> <p><b>Clinical setting:</b> tertiary </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> BOT </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 181 </p> <p><b>Postmenopausal n (%):</b> 143 (79) </p> <p><b>Ovarian cancer n (%):</b> 147 (81) </p> <p><b>Borderline n (%):</b> excluded </p> <p><b>Mean age:</b> benign 47 years, malignant 57 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 12.9, postmenopausal 27.8 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0047" title="TehBH , YongSL , SimW , LauKB , SuharjonoHN . Evaluation in the predictive value of serum human epididymal protein 4 (HE4), cancer antigen 125 (CA 125) and a combination of both in detecting ovarian malignancy. Hormone Molecular Biology and Clinical Investigation2018;35:1. ">Teh 2018</a> </p> <p>Malaysia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with pelvic mass(es) suspected of originating in the ovary who had been scheduled for surgery or radiological‐guided biopsy </p> <p><b>Clinical setting:</b> tertiary </p> <p><b>Prior test:</b> not reported </p> <p><b>Exclusions:</b> unclear; low malignant potential tumours were included in the benign tumour group for analysis </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 129 </p> <p><b>Postmenopausal n (%):</b> 27 (21) </p> <p><b>Ovarian cancer n (%):</b> 27 (21) </p> <p><b>Borderline n (%):</b> 10 (8) </p> <p><b>Median age:</b> 37 (IQR 27.5–48.5) years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 11.4, postmenopausal 29.9 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0048" title="TerlikowskaKM , DobrzyckaB , WitkowskaAM , Mackowiak-MatejczykB , SledziewskiTK , KinalskiM , et al. Preoperative HE4, CA125 and ROMA in the differential diagnosis of benign and malignant adnexal masses. Journal of Ovarian Research2016;9(1):43. ">Terlikowska 2016</a> </p> <p>Poland</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> Caucasian women surgically treated on account of benign ovarian disease and epithelial cancer according to international treatment guidelines </p> <p><b>Clinical setting:</b> mixed </p> <p><b>Prior test:</b> not reported </p> <p><b>Exclusions:</b> non‐EOC </p> <p><b>Centre:</b> multicentre </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 224 </p> <p><b>Postmenopausal n (%):</b> 104 (46) </p> <p><b>Ovarian cancer n (%):</b> 96 (43) (EOC only) </p> <p><b>Borderline n (%):</b> not reported </p> <p><b>Median age:</b> premenopausal 36, postmenopausal 63 </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 11.4, postmenopausal 29.9 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0054" title="vanGorpT , CadronI , DespierreE , DaemenA , LeunenK , AmantF , et al. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. British Journal of Cancer2011;104(5):863-70. ">van Gorp 2011</a> </p> <p>(<a href="./references#CD011964-bbs2-0055" title="KaijserJ , vanGorpT , SmetME , vanHolsbekeC , SayasnehA , EpsteinE , et al. Are serum HE4 or ROMA scores useful to experienced examiners for improving characterization of adnexal masses after transvaginal ultrasonography?Ultrasound in Obstetrics &amp; Gynecology2014;43(1):89-97. [Secondary publication Kaijser 2014]vanGorpT , VeldmanJ , vanCalsterB , CadronI , LeunenK , AmantF , et al. Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses. European Journal of Cancer2012;48(11):1649-56. ">van Gorp 2012</a> secondary publication; smaller cohort) </p> <p>Belgium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women diagnosed with pelvic mass undergoing surgery </p> <p><b>Clinical setting:</b> unclear </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> none </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n<b>:</b> 389 </p> <p><b>Postmenopausal n (%):</b> 161 (41) </p> <p><b>Ovarian cancer n (%):</b> 161 (41) </p> <p><b>Borderline n (%):</b> not reported </p> <p><b>Mean age:</b> benign 46.3 years, malignant 57.8 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 12.5, postmenopausal 14.4 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0057" title="XuY , ZhongR , HeJ , DingR , LinH , DengY , et al. Modification of cut-off values for HE4, CA125 and the ROMA algorithm for early-stage epithelial ovarian cancer detection: results from 1021 cases in South China. Clinical Biochemistry2016;49(1-2):32-40. ">Xu 2016</a> </p> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with a pelvic mass (defined as a simple, complex or solid ovarian cyst/pelvic mass) and healthy women from the Physical Examination Center </p> <p><b>Clinical setting:</b> mixed </p> <p><b>Prior test:</b> not reported </p> <p><b>Exclusions:</b> non‐EOC </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 566 </p> <p><b>Postmenopausal n (%):</b> 159 (28) </p> <p><b>Ovarian cancer n (%):</b> 210 (37) (EOC only) </p> <p><b>Borderline n (%):</b> 45 (8) </p> <p><b>Mean age:</b> benign 42 years, malignant 57 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 11.4, postmenopausal 29.9 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0058" title="ZhangP , WangC , ChengL , ZhangP , GuoL , LiuW , et al. Comparison of HE4, CA125, and ROMA diagnostic accuracy: a prospective and multicenter study for Chinese women with epithelial ovarian cancer. Medicine2015;94(52):e2402. ">Zhang 2015</a> </p> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> all women scheduled for surgery, with and without pelvic mass on USS </p> <p><b>Clinical setting:</b> unclear </p> <p><b>Prior test:</b> USS; adnexal lesions reported according to IOTA </p> <p><b>Exclusions:</b> non‐EOC excluded </p> <p><b>Centre:</b> multicentre </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 612 </p> <p><b>Postmenopausal n (%):</b> 232 (37) </p> <p><b>Ovarian cancer n (%):</b> 264 (43) (EOC only) </p> <p><b>Borderline n (%):</b> not reported </p> <p><b>Median age (25th centile, 75th centile):</b> benign: premenopausal 41 (35, 46), postmenopausal 57 (54, 68); malignant premenopausal 43 (38, 47), postmenopausal 59 (54, 65) </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 11.4, postmenopausal 29.9 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0059" title="ZhangL , ChenY , WangK . Comparison of CA125, HE4, and ROMA index for ovarian cancer diagnosis. Current Problems in Cancer2019;43(2):135-44. ">Zhang 2019</a> </p> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with ovarian tumour </p> <p><b>Clinical setting:</b> tertiary </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> borderline excluded from analysis </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 373 </p> <p><b>Postmenopausal n (%):</b> 185 (50) </p> <p><b>Ovarian cancer n (%):</b> 181 (48) </p> <p><b>Borderline n (%):</b> 17 (5) </p> <p><b>Mean age:</b> 51 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 11.4, postmenopausal 29.9 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*ROMA thresholds most commonly reported and included: <b>premenopausal</b> 7.4 (± 2); 12.5; 13.1 (± 2); <b>postmenopausal</b> 25.3 (± 2); 14.4; 27.7 (± 2) </p> <p>**Threshold for premenopausal women OR postmenopausal women reported in the study not included in analysis. </p> <p>BOT: borderline ovarian tumour; CT: computed tomography; EOC: epithelial ovarian cancer; HE4: Human Epididymis protein; IQR: interquartile range; IOTA: International Ovarian Tumour Analysis; MRI: magnetic resonance imaging; n: number of participants; PET‐CT: positron emission tomography–computed tomography; ROMA: Risk of Ovarian Malignancy Algorithm; ROMA‐P: a modified ROMA; TVS: transvaginal ultrasound; USS: ultrasound scan. </p> </div> </div> <div class="table" id="CD011964-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Study characteristics: LR2</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Author year country</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Setting*</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Participant characteristics</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Index test threshold</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0026" title="MeysEM , JeelofLS , AchtenNM , SlangenBF , LambrechtsS , KruitwagenRF , et al. Estimating risk of malignancy in adnexal masses: external validation of the ADNEX model and comparison with other frequently used ultrasound methods. Ultrasound in Obstetrics &amp; Gynecology2017;49(6):784-92. ">Meys 2017</a> </p> <p><b>Netherlands</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria</b>: women with adnexal pathology </p> <p><b>Clinical setting:</b> tertiary </p> <p><b>Prior tests:</b> not reported </p> <p><b>Exclusions:</b> none reported </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 326 </p> <p><b>Postmenopausal n (%):</b> 198 (61) </p> <p><b>Ovarian cancer n (%):</b> 115 (35) </p> <p><b>Borderline n (%):</b> 27 (8) </p> <p><b>Median age:</b> malignant 67.7 (IQR 32.3–87) years, borderline 53.2 (016.1–87.2) years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Threshold:</b> 10% post‐test probability of malignancy </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0031" title="NiemiRJ , SaarelainenSK , LuukkaalaTH , MaenpaaJU . Reliability of preoperative evaluation of postmenopausal ovarian tumors. Journal of Ovarian Research2017;10(1):15. ">Niemi 2017</a> </p> <p><b>Finland</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria</b>: women aged &gt; 50 years presenting with an abnormal adnexal mass(es) </p> <p><b>Clinical setting:</b> tertiary </p> <p><b>Prior tests:</b> not reported </p> <p><b>Exclusions:</b> overtly benign or malignant‐appearing tumours such as unilocular simple ovarian cysts and tumours associated with marked ascites (depth of the greatest pool &gt; 10 cm) </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 98 </p> <p><b>Postmenopausal n (%):</b> 98 (100) </p> <p><b>Ovarian cancer n (%):</b> 23 (23) </p> <p><b>Borderline n (%):</b> 7 (7) </p> <p><b>Median age:</b> 61 (range 50–84) years </p> <p><b>Separated by menopausal status:</b> only postmenopausal included </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Threshold:</b> 10%, 25% and 43% of post‐test probability of malignancy </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0042" title="SayasnehA , KaijserJ , PreislerJ , JohnsonS , StalderC , HusickaR , et al. A multicenter prospective external validation of the diagnostic performance of IOTA simple descriptors and rules to characterize ovarian masses. Gynecologic Oncology2013;130(1):140-6. [Sayasneh 2013]SayasnehA , WynantsL , PreislerJ , KaijserJ , JohnsonS , StalderC , et al. Multicentre external validation of IOTA prediction models and RMI by operators with varied training. British Journal of Cancer2013;108(12):2448-54. ">Sayasneh 2013a</a> </p> <p><b>Secondary study:</b> </p> <p>Sayasneh 2013 (see under <a href="./references#CD011964-bbs2-0042" title="SayasnehA , KaijserJ , PreislerJ , JohnsonS , StalderC , HusickaR , et al. A multicenter prospective external validation of the diagnostic performance of IOTA simple descriptors and rules to characterize ovarian masses. Gynecologic Oncology2013;130(1):140-6. [Sayasneh 2013]SayasnehA , WynantsL , PreislerJ , KaijserJ , JohnsonS , StalderC , et al. Multicentre external validation of IOTA prediction models and RMI by operators with varied training. British Journal of Cancer2013;108(12):2448-54. ">Sayasneh 2013a</a>) </p> <p><b>UK</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women presenting with adnexal mass and undergoing surgery within 120 days after examination </p> <p><b>Clinical setting:</b> mixed secondary and tertiary care </p> <p><b>Prior tests:</b> not reported </p> <p><b>Exclusions:</b> none reported </p> <p><b>Centre:</b> multicentre </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 255 </p> <p><b>Postmenopausal n (%):</b> 117 (45.9) </p> <p><b>Malignant n (%):</b> 48 (18.8) </p> <p><b>Borderline n (%):</b> 18 (7.1) </p> <p><b>Mean age:</b> 46 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Threshold:</b> 10% post‐test probability of malignancy </p> <p><b>Prespecified threshold:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0050" title="TestaA , KaijserJ , WynantsL , FischerovaD , vanHolsbekeC , FranchiD , et al. Strategies to diagnose ovarian cancer: new evidence from phase 3 of the multicentre international IOTA study. British Journal of Cancer2014;111(4):680-8. ">Testa 2014</a> </p> <p><b>Europe</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women presenting with adnexal mass on TVS and undergoing surgery within 120 days. </p> <p><b>Clinical setting:</b> mixed secondary and tertiary care </p> <p><b>Prior tests:</b> not reported </p> <p><b>Exclusions:</b> none reported </p> <p><b>Centre:</b> multicentre </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 2403 </p> <p><b>Postmenopausal n (%):</b> 1049 (43.7) </p> <p><b>Malignant n (%):</b> 701(18.8) </p> <p><b>Borderline n (%):</b> 153 (6.4) </p> <p><b>Median age:</b> malignant 57 (range 33–66) years; benign 44 (range not reported) years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Threshold:</b> 10% post‐test probability of malignancy </p> <p><b>Prespecified threshold:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0051" title="TimmermanD , AmeyeL , FischerovaD , EpsteinE , MelisGB , GuerrieroS , et al. Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group. BMJ2010;341:c6839. ">Timmerman 2010</a> </p> <p>Secondary study:</p> <p><a href="./references#CD011964-bbs2-0072" title="Di LeggeA , TestaAC , AmeyeL , vanCalsterB , LissoniAA , LeoneFP , et al. Lesion size affects diagnostic performance of IOTA logistic regression models, IOTA simple rules and risk of malignancy index in discriminating between benign and malignant adnexal masses. Ultrasound in Obstetrics &amp; Gynecology2012;40:345-54. [DOI: org/10.1002/uog.11167]">Di Legge 2012</a> </p> <p><b>Europe</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with persistent adnexal mass undergoing surgery within 120 days </p> <p><b>Clinical setting:</b> mixed secondary and tertiary </p> <p><b>Prior tests:</b> not reported </p> <p><b>Exclusions:</b> none reported </p> <p><b>Centre:</b> multicentre </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 1938 </p> <p><b>Postmenopausal n (%):</b> 742 (38.0) </p> <p><b>Malignant n (%):</b> 373 (19.2) </p> <p><b>Borderline n (%):</b> 111 (5.7) </p> <p><b>Mean age:</b> 46 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Threshold:</b> 10% post‐test probability of malignancy </p> <p><b>Prespecified threshold:</b> yes </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*Setting: secondary care: dedicated gynaecologist in a general hospital; tertiary care: gynaecological oncology centre. </p> <p>IQR: interquartile range; n: number of participants; TVS: transvaginal ultrasound.</p> </div> </div> <div class="table" id="CD011964-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Study characteristics: ADNEX</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Author year country</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Setting*</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Participants characteristics</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Index test threshold</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0026" title="MeysEM , JeelofLS , AchtenNM , SlangenBF , LambrechtsS , KruitwagenRF , et al. Estimating risk of malignancy in adnexal masses: external validation of the ADNEX model and comparison with other frequently used ultrasound methods. Ultrasound in Obstetrics &amp; Gynecology2017;49(6):784-92. ">Meys 2017</a> </p> <p><b>Netherlands</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria</b>: women with adnexal pathology </p> <p><b>Clinical setting:</b> tertiary </p> <p><b>Prior tests:</b> not reported </p> <p><b>Exclusions:</b> none reported </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 326 </p> <p><b>Postmenopausal n (%):</b> 198 (61) </p> <p><b>Ovarian cancer n (%):</b> 115 (35) </p> <p><b>Borderline n (%):</b> 27 (8) </p> <p><b>Median age:</b> benign 53.2 (IQR 16.1–87.2) years, malignant 67.7 (IQR 32.3–87) years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Threshold:</b> 10% post‐test probability of malignancy </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0045" title="SzubertS , WojtowiczA , MoszynskiR , ZywicaP , DyczkowskiK , StachowiakA , et al. External validation of the IOTA ADNEX model performed by two independent gynecologic centers. Gynecologic Oncology2016;142(3):490-5. ">Szubert 2016a</a> </p> <p><b>Poland</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with a 'need for surgery due to an ovarian tumour' </p> <p><b>Clinical setting:</b> unclear, probably tertiary </p> <p><b>Prior test:</b> not reported </p> <p><b>Exclusions:</b> none reported </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 204 </p> <p><b>Postmenopausal n (%):</b> 66 (54) </p> <p><b>Ovarian cancer n (%):</b> 58 (28) </p> <p><b>Borderline n (%):</b> 12 (6) </p> <p><b>Median age:</b> 46 </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> 2000 IOTA criteria 10% </p> <p><b>Prespecified: y</b>es </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0046" title="SzubertS , WojtowiczA , MoszynskiR , ZywicaP , DyczkowskiK , StachowiakA , et al. External validation of the IOTA ADNEX model performed by two independent gynecologic centers. Gynecologic Oncology2016;142(3):490-5. ">Szubert 2016b</a> </p> <p><b>Spain</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with a 'need for surgery due to an ovarian tumour' </p> <p><b>Clinical setting:</b> unclear, probably tertiary </p> <p><b>Prior test:</b> not reported </p> <p><b>Exclusions:</b> none reported </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 128 </p> <p><b>Postmenopausal n (%):</b> 52 (42) </p> <p><b>Ovarian cancer n (%):</b> 35 (27) </p> <p><b>Borderline n (%):</b> 4 (3) </p> <p><b>Median age:</b> 47 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> 2000 IOTA criteria 10% </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0052" title="vanCalsterB , vanHoordeK , ValentinL , TestaAC , FischerovaD , vanHolsbekeC , et al. Evaluating the risk of ovarian cancer before surgery using the ADNEX model to differentiate between benign, borderline, early and advanced stage invasive, and secondary metastatic tumours: prospective multicentre diagnostic study. BMJ2014;349:g5920. ">van Calster 2014</a> </p> <p><b>Europe</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women presenting with adnexal mass on US and selected for surgery </p> <p><b>Clinical setting:</b> mixed secondary and tertiary care </p> <p><b>Prior tests:</b> not reported </p> <p><b>Exclusions:</b> none reported </p> <p><b>Centre:</b> multicentre </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 2403 </p> <p><b>Postmenopausal n (%):</b> 1049 (43.7)** </p> <p><b>Malignant n (%):</b> 827 (34.4) </p> <p><b>Borderline n (%):</b> 153 (6.4) </p> <p><b>Age:</b> not reported </p> <p><b>Separated by menopausal status:</b> yes** </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Threshold:</b> 3, 5, 10 and 15% post‐test probability of malignancy </p> <p><b>Prespecified threshold:</b> yes </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*Setting: secondary care: dedicated gynaecologist in a general hospital; tertiary care: gynaecological oncology centre. </p> <p>**Contact with authors</p> <p>IOTA: International Ovarian Tumour Analysis; IQR: interquartile range; n: number of participants. </p> </div> </div> </section> </section> <section id="CD011964-sec-0057"> <h3 class="title">Methodological quality of included studies</h3> <p>The methodological quality of all 59 included studies (71 data sets) evaluating one or more of RMI, ROMA, LR2 and ADNEX studies is summarised in <a href="#CD011964-fig-0003">Figure 3</a> and <a href="#CD011964-fig-0004">Figure 4</a>. Separate figures summarise study quality by index test: RMI, ROMA, LR2 and ADNEX (<a href="./appendices#CD011964-sec-0102">Appendix 5</a>). </p> <div class="figure" id="CD011964-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Risk of bias and applicability concerns graph for 59 individual included studies for index tests. Review authors' judgements about each domain presented as percentages across included studies.ADNEX: Assessment of Different NEoplasias in the adneXa model; LR2: Logistic Regression 2 model; RMI I: Risk of Malignancy Index I; ROMA: Risk of Ovarian Malignancy Algorithm." data-id="CD011964-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-FIG-03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias and applicability concerns graph for 59 individual included studies for index tests. Review authors' judgements about each domain presented as percentages across included studies. </p> <p>ADNEX: Assessment of Different NEoplasias in the adneXa model; LR2: Logistic Regression 2 model; RMI I: Risk of Malignancy Index I; ROMA: Risk of Ovarian Malignancy Algorithm. </p> </div> </div> </div> <div class="figure" id="CD011964-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Risk of bias and applicability concerns figure for 59 individual included studies for index tests. Review authors' judgements about each domain for each included study. Empty cells indicate that an index test was not evaluated by a study.ADNEX: Assessment of Different NEoplasias in the adneXa model; LR2: Logistic Regression 2 model; RMI I: Risk of Malignancy Index I; ROMA: Risk of Ovarian Malignancy Algorithm." data-id="CD011964-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-FIG-04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias and applicability concerns figure for 59 individual included studies for index tests. Review authors' judgements about each domain for each included study. Empty cells indicate that an index test was not evaluated by a study. </p> <p>ADNEX: Assessment of Different NEoplasias in the adneXa model; LR2: Logistic Regression 2 model; RMI I: Risk of Malignancy Index I; ROMA: Risk of Ovarian Malignancy Algorithm. </p> </div> </div> </div> <section id="CD011964-sec-0058"> <h4 class="title">Participant selection domain</h4> <p>Across all included studies for the participant selection domain (<a href="#CD011964-fig-0003">Figure 3</a>), 16/59 (27%) studies were at high risk of bias and 38/59 (64%) at unclear risk of bias. Only five studies were at low risk of bias on the basis that authors explicitly reported consecutive sampling and comprehensively listed tumour pathology identified at histology allowing a judgement to be made about selection of tumour types that might affect estimates of accuracy such as EOC and borderline tumours (<a href="./references#CD011964-bbs2-0023" title="LyckeM , KristjansdottirB , SundfeldtK . A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index. Gynecologic Oncology2018;151(1):159-65. ">Lycke 2018</a>; <a href="./references#CD011964-bbs2-0026" title="MeysEM , JeelofLS , AchtenNM , SlangenBF , LambrechtsS , KruitwagenRF , et al. Estimating risk of malignancy in adnexal masses: external validation of the ADNEX model and comparison with other frequently used ultrasound methods. Ultrasound in Obstetrics &amp; Gynecology2017;49(6):784-92. ">Meys 2017</a>; <a href="./references#CD011964-bbs2-0032" title="NikolovaT , ZivadinovicR , EvtimovskaN , KlisarovskaV , StanojevicM , GeorgievskaJ , et al. Diagnostic performance of Human Epididymis protein4 compared to a combination of biophysical and biochemical markers to differentiate ovarian endometriosis from epithelial ovarian cancer in premenopausal women. Journal of Obstetrics and Gynaecology Research2017;43(12):1870-9. ">Nikolova 2016</a>; <a href="./references#CD011964-bbs2-0040" title="RomagnoloC , LeonA , FabricioAS , TaborelliM , PoleselJ , Del PupL , et al. HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: an Italian multicenter study. Gynecologic Oncology2016;141(2):303-11. ">Romagnolo 2016</a>; <a href="./references#CD011964-bbs2-0052" title="vanCalsterB , vanHoordeK , ValentinL , TestaAC , FischerovaD , vanHolsbekeC , et al. Evaluating the risk of ovarian cancer before surgery using the ADNEX model to differentiate between benign, borderline, early and advanced stage invasive, and secondary metastatic tumours: prospective multicentre diagnostic study. BMJ2014;349:g5920. ">van Calster 2014</a>). Fifty‐four of 59 (92%) studies were at high or unclear applicability concern for the participant selection domain because study participants did not obviously represent symptomatic women. </p> </section> <section id="CD011964-sec-0059"> <h4 class="title">Index test domain</h4> <p>For the index test domain, 33/42 (79%) ROMA studies, 2/4 (50%) ADNEX studies and 9/20 (45%) RMI studies were at low risk of bias either because of the prospective nature of studies, or in the case of ROMA, the objective nature of the index test. One retrospective RMI study was at high risk of bias because RMI test results were interpreted with knowledge of the reference standard result (presence of absence of OC) (<a href="./references#CD011964-bbs2-0015" title='IrshadF , IrshadM , NazM , Asim IkramM . Accuracy of "risk of malignancy index" in the preoperative diagnosis of ovarian malignancy in post menopausal women. Rawal Medical Journal2013;38(3):266-70. '>Irshad 2013</a>). Four ROMA studies were at high risk of bias because they did not predefine the definition of the cut‐off point for a positive test result (<a href="./references#CD011964-bbs2-0006" title="ChenWT , GaoX , HanXD , ZhengH , GuoL , LuRQ . HE4 as a serum biomarker for ROMA prediction and prognosis of epithelial ovarian cancer. Asian Pacific Journal of Cancer Prevention2014;15(1):101-5. ">Chen 2014</a>; <a href="./references#CD011964-bbs2-0012" title="FarzanehF , HonarvarZ , YaraghiM , YaseriM , ArabM , HosseiniM , et al. Preoperative evaluation of risk of ovarian malignancy algorithm index in prediction of malignancy of adnexal masses. Iranian Red Crescent Medical Journal2014;16(6):e17185. ">Farzaneh 2014</a>; <a href="./references#CD011964-bbs2-0016" title="KadijaS , StefanovicA , JeremicK , RadojevicMM , NikolicL , MarkovicI , et al. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis. International Journal of Gynecological Cancer2012;22(2):238-44. ">Kadija 2012</a>; <a href="./references#CD011964-bbs2-0018" title="KimYM , WhangDH , ParkJ , KimSH , LeeSW , ParkHA , et al. Evaluation of the accuracy of serum Human Epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case-control study in a Korean population. Clinical Chemistry &amp; Laboratory Medicine2011;49(3):527-34. ">Kim 2011</a>). For the index test domain, applicability concern was high or unclear for all RMI, ADNEX and LR2 studies because USS was conducted by specialist sonographers or their level of specialisation was unclear. </p> </section> <section id="CD011964-sec-0060"> <h4 class="title">Reference standard and target condition domain</h4> <p>For the reference standard domain, 30/59 (51%) studies were at low risk of bias. Twenty‐seven of 59 (46%) studies were at unclear risk of bias, and two were at high risk of bias (<a href="./references#CD011964-bbs2-0014" title="HuyNV , vanKhoaV , TamLM , VinhTQ , TungNS , ThanhCN , et al. Standard and optimal cut-off values of serum ca-125, HE4 and ROMA in preoperative prediction of ovarian cancer in Vietnam. Gynecologic Oncology Reports2018;25:110-4. ">Huy 2018</a>; <a href="./references#CD011964-bbs2-0035" title="ParkH , ShinJ , LeeDW , KimMJ , LeeHN . Diagnostic accuracy of the risk of Ovarian Malignancy Algorithm in clinical practice at a single hospital in Korea. Annals of Laboratory Medicine2019;39(3):252-62. ">Park 2019</a>), either because the minimum length of follow‐up for index negatives was not reported at six months, or because there was concern that the reference standard outcome was ascertained with knowledge of the index test result. For the reference standard and target condition domain, applicability concern was as high or unclear in 50/59 (85%) studies because borderline tumours had been excluded from analysis or classification of borderline tumours for estimation of test accuracy was unclear. </p> </section> <section id="CD011964-sec-0061"> <h4 class="title">Flow and timing domain</h4> <p>For the flow and timing domain, 32/59 (54%) studies were at unclear risk of bias most commonly because of no information about the interval between the index test and the reference standard. Thirteen of 59 (22%) studies were at high risk of bias because not all participants receiving an index test received a reference standard. </p> </section> </section> <section id="CD011964-sec-0062"> <h3 class="title" id="CD011964-sec-0062">Findings</h3> <section id="CD011964-sec-0063"> <h4 class="title">Comparison of accuracy in premenopausal and postmenopausal women</h4> <p><a href="#CD011964-tbl-0003">Table 2</a>, <a href="#CD011964-fig-0005">Figure 5</a> (RMI), <a href="#CD011964-fig-0006">Figure 6</a> (ROMA), <a href="#CD011964-fig-0007">Figure 7</a> (LR2) and <a href="#CD011964-fig-0008">Figure 8</a> (ADNEX) present the accuracy of the 59 unique included studies and 71 data sets in pre‐ and postmenopausal women. There was a consistent difference in sensitivity (higher in postmenopausal women) and specificity (lower in postmenopausal women) across all versions of all index tests at all thresholds analysed. Subsequently, we estimated sensitivity and specificity in pre‐ and postmenopausal women separately. </p> <div class="figure" id="CD011964-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Forest plot of tests: Risk of Malignancy Index I (RMI I) at thresholds of 200 and 250, separately for pre‐menopausal and post‐menopausal women.FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive." data-id="CD011964-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-FIG-09.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of tests: Risk of Malignancy Index I (RMI I) at thresholds of 200 and 250, separately for pre‐menopausal and post‐menopausal women. </p> <p>FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive.</p> </div> </div> </div> <div class="figure" id="CD011964-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Forest plot of tests: Risk of Ovarian Malignancy Algorithm (ROMA) in at thresholds of 7.4 (± 2), 12.5, 13.1 (± 2), 7.4, 13.1 and 11.4 in premenopausal women, and at thresholds of 25.3 (± 2), 14.4, 27.7 (± 2), 25.3, 27.7 and 29.9 in postmenopausal women.FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive." data-id="CD011964-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-FIG-10.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of tests: Risk of Ovarian Malignancy Algorithm (ROMA) in at thresholds of 7.4 (± 2), 12.5, 13.1 (± 2), 7.4, 13.1 and 11.4 in premenopausal women, and at thresholds of 25.3 (± 2), 14.4, 27.7 (± 2), 25.3, 27.7 and 29.9 in postmenopausal women. </p> <p>FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive.</p> </div> </div> </div> <div class="figure" id="CD011964-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Forest plot of tests: Logistic Regression 2 model (LR2) separately for premenopausal and postmenopausal women.FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive." data-id="CD011964-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-FIG-11.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of tests: Logistic Regression 2 model (LR2) separately for premenopausal and postmenopausal women. </p> <p>FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive.</p> </div> </div> </div> <div class="figure" id="CD011964-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Forest plot of tests: Assessment of Different NEoplasias in the adneXa model (ADNEX) at thresholds of 3%, 5%, 10% and 15% disease probability separately for premenopausal and postmenopausal women.FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive." data-id="CD011964-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-FIG-12.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Forest plot of tests: Assessment of Different NEoplasias in the adneXa model (ADNEX) at thresholds of 3%, 5%, 10% and 15% disease probability separately for premenopausal and postmenopausal women. </p> <p>FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive.</p> </div> </div> </div> </section> <section id="CD011964-sec-0064"> <h4 class="title">Test positivity threshold</h4> <p>ROMA and ADNEX included studies reporting accuracy across a range of test positivity thresholds. The expected trade‐off between sensitivity and specificity with changes in threshold was observed; as test positivity threshold increased, sensitivity increased and specificity decreased. For ROMA, there was no evidence of a difference in accuracy at thresholds reported by included studies. </p> <p>It is of note that this pattern of test performance suggests a population selected on the basis of prior testing (i.e. representative of specialist settings). At earlier points in the testing pathway for OC, it would be expected that specificity would be lower in premenopausal women compared to postmenopausal women as a result of false‐positives caused by benign conditions common in premenopausal women (ovarian cysts, endometriosis) and the normal menstrual cycle. </p> </section> <section id="CD011964-sec-0065"> <h4 class="title">Accuracy of RMI, ROMA, LR2 and ADNEX in premenopausal women</h4> <section id="CD011964-sec-0066"> <h5 class="title">RMI at a threshold of 200</h5> <p>Based on 17 studies, including 5233 premenopausal women, of whom 851 had a diagnosis of OC, the sensitivity of RMI at a threshold of 200 was 57.1% (95% CI 50.6% to 63.4%) and the specificity was 92.5% (95% CI 90.0% to 94.4%). </p> </section> <section id="CD011964-sec-0067"> <h5 class="title">RMI at a threshold of 250</h5> <p>Based on two studies, including 461 premenopausal women, of whom 42 had a diagnosis of OC, the sensitivity of RMI at a threshold of 250 was 59.5% (95% CI 44.3% to 73.1%) and the specificity was 88.1% (84.6% to 90.8%) </p> </section> <section id="CD011964-sec-0068"> <h5 class="title">LR2 to achieve a post‐test probability of ovarian cancer of 10%</h5> <p>Based on four studies, including 2843 premenopausal women, of whom 619 had a diagnosis of OC, the sensitivity of LR2 was 83.2% (95% CI 78.6% to 87.0%) and the specificity was 90.4% (95% CI 84.6% to 94.1%). </p> </section> <section id="CD011964-sec-0069"> <h5 class="title">ROMA</h5> <p>For ROMA, there was no evidence of a difference in accuracy at thresholds reported by included studies. Based on the threshold pair reported by the most studies: based on 27 studies, 4463 premenopausal women, of whom 825 had a diagnosis of OC, the sensitivity of ROMA at a threshold of 13.1 ± 2 was 77.8% (95% CI 72.5% to 82.4%) and the specificity was 84.3% (95% CI 81.3% to 86.8%). </p> </section> <section id="CD011964-sec-0070"> <h5 class="title">ADNEX to achieve a post‐test probability of ovarian cancer of 10%</h5> <p>For ADNEX, accuracy was reported at a threshold to achieve a post‐test probability of OC of 3% (one study), 5% (one study), 10% (four studies) and 15% (one study). Based on four studies, including 1696 premenopausal women, of whom 455 had a diagnosis of OC, the sensitivity of ADNEX to achieve a post‐test probability of OC of 10% was 94.9% (95% CI 92.5% to 96.6%) and the specificity was 78.2% (95% CI 75.8% to 80.4%). </p> </section> </section> <section id="CD011964-sec-0071"> <h4 class="title">Accuracy of RMI, ROMA, LR2 and ADNEX in postmenopausal women</h4> <section id="CD011964-sec-0072"> <h5 class="title">RMI at a threshold of 200</h5> <p>Based on 17 studies, including 4369 postmenopausal women, of whom 1664 had a diagnosis of OC, the sensitivity of RMI at a threshold of 200 was 78.7% (95% CI 74.3% to 82.5%) and the specificity was 85.5% (95% CI 81.3% to 88.9%). </p> </section> <section id="CD011964-sec-0073"> <h5 class="title">RMI at a threshold of 250</h5> <p>Based on two studies, including 220 postmenopausal women, of whom 97 had a diagnosis of OC, the sensitivity of RMI at a threshold of 250 was 82.5% (95% CI 73.6% to 88.8%) and the specificity was 79.7% (95% CI 71.6% to 85.9%). </p> </section> <section id="CD011964-sec-0074"> <h5 class="title">LR2 to achieve a post‐test probability of ovarian cancer of 10%</h5> <p>Based on five studies, including 2157 postmenopausal women, of whom 1124 had a diagnosis of OC, the sensitivity of LR2 was 94.5% (95% CI 92.8% to 95.7%) and the specificity was 60.5% (95% CI 49.3% to 70.7%). </p> </section> <section id="CD011964-sec-0075"> <h5 class="title">ROMA</h5> <p>For ROMA, there was no evidence of a difference in accuracy at thresholds reported by the included studies. Based on the threshold pair reported by the most studies: based on 13 studies, including 2002 postmenopausal women, of whom 852 had a diagnosis of OC, the sensitivity of ROMA at a threshold of 27.7 ± 2 was 90.4% (95% CI 87.4% to 92.7%) and the specificity was 81.3% (95% CI 76.9% to 85.0%). </p> </section> <section id="CD011964-sec-0076"> <h5 class="title">ADNEX to achieve a post‐test probability of ovarian cancer of 10%</h5> <p>For ADNEX, accuracy was reported at a threshold to achieve a post‐test probability of OC of 3% (one study), 5% (one study), 10% (four studies) and 15% (one study). Based on four studies, including 1365 postmenopausal women, of whom 749 had a diagnosis of OC, the sensitivity of ADNEX to achieve a post‐test probability of OC of 10% was 97.6% (95% CI 96.2% to 98.5%) and the specificity was 55.2% (95% CI 51.2% to 59.1%). </p> </section> </section> <section id="CD011964-sec-0077"> <h4 class="title">HSROC (between study) comparison of RMI, ROMA, LR2 and ADNEX</h4> <p>To maximise data for comparison, studies were included regardless of the test positivity threshold used and we undertook an indirect comparison of index (<a href="#CD011964-tbl-0008">Table 7</a>) tests by fitting HSROC curves for premenopausal women (<a href="#CD011964-fig-0009">Figure 9</a>) and postmenopausal women (<a href="#CD011964-fig-0010">Figure 10</a>) separately. RMI was chosen as the baseline comparator as this is the test combination currently in routine clinical use in the UK. In premenopausal women, ADNEX and LR2 but not ROMA demonstrated superior accuracy compared to RMI (relative Diagnostic Odds Ratio (rDOR): ADNEX: 4.70, 95% CI 1.45 to 15.20; P = 0.014; LR2: 2.19, 95% CI 1.18 to 4.06; P = 0.0108; ROMA: 1.19, 95% CI 0.69 to 2.07; P = 0.5202). In postmenopausal women only ROMA demonstrated superior overall accuracy compared to RMI (rDOR 1.75, 95% CI 1.23 to 2.5; P = 0.0024) (<a href="#CD011964-tbl-0008">Table 7</a>). </p> <div class="table" id="CD011964-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">HSROC analysis: comparison of sensitivity at a fixed specificity of 80% and 90%: all studies, all thresholds, pre‐ and postmenopausal women separately</span></div> <tbody> <tr> <th align="" class="headercell" colspan="10" rowspan="1" scope="col" valign=""> <p><b>HSROC analysis: comparison of ROMA, LR2 and ADNEX compared to RMI I. Mixed test positivity threshold analysis at fixed specificities of 80% and 90%</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Test</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Studies</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Participants (OC cases)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Diagnostic odds ratio (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative diagnostic odds ratio (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Sensitivity at fixed specificity of 80%</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Sensitivity at fixed specificity of 90%</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sensitivity (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Difference from RMI I (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sensitivity (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Difference from RMI I (95% CI)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="10" rowspan="1" scope="col" valign=""> <p><b>Pr</b> emen<b>opausal</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RMI I 200/250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5694</p> <p>(893)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.5 (9.0 to 26.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79.4 (69.5 to 86.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65.1 (57.2 to 72.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ROMA mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7616</p> <p>(1198)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.5 (14.3 to 23.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.19 (0.69 to 2.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82.0 (77.9 to 85.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.6 (–5.5 to 10.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68.8 (61.8 to 75.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.7 (–7.3 to 14.7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LR2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2843</p> <p>(619)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.9 (21.5 to 53.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.19 (1.18 to 4.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89.0 (83.8 to 92.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.6 (2.2, 17.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79.7 (71.3 to 86.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.6 (5.6 to 23.6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADNEX 10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1696</p> <p>(455)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72.6 (29.4 to 179.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.70 (1.45 to 15.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94.4 (88.3 to 7.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.9 (5.4 to 24.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89.0 (77.6 to 95.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.9 (12.0 to 35.8)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="10" rowspan="1" scope="col" valign="top"> <p><b>Po</b> stmen<b>opausal</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RMI I 200/250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4589</p> <p>(1761)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.8 (17.3 to 30.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85.1 (80.9 to 88.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.8 (65.4 to 77.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ROMA mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6099</p> <p>(2746)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.0 (31.5 to 50.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.75 (1.23 to 2.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0024</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90.9 (88.8 to 92.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.8 (2.1 to 9.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81.7 (76.8 to 85.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.9 (4.0 to 15.8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LR2 10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2157</p> <p>(1124)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.5 (22.6 to 69.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.73 (0.97 to 3.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0622</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90.8 (85.9 to 94.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.7 (0.7 to 10.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81.5 (70.0 to 89.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.7 (2.0 to 17.4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADNEX 10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1365</p> <p>(749)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.7 (21.9 to 146.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.48 (0.90 to 6.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0776</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93.4 (85.9 to 97.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.3 (1.5 to 15.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86.3 (70.2 to 94.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.6 (3.4 to 25.7)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Notes to table: ADNEX 10% &amp; LR2 10%: threshold to achieve a post‐test probability of ovarian cancer of 10%. ADNEX and LR2 studies reported a range of thresholds but all included a threshold of 10%. For RMI I and ROMA studies, each included study contributed a different test positivity threshold. </p> <p>ADNEX: Assessment of Different NEoplasias in the adneXa model; CI: confidence interval; HSROC: hierarchical summary receiver operating characteristic; LR2: Logistic Regression Model 2; OC: ovarian cancer; RMI I: Risk of Malignancy Index I; ROMA: Risk of Ovarian Malignancy Algorithm. </p> </div> </div> <div class="figure" id="CD011964-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Summary ROC plot of tests (pre‐menopausal women): RMI I, ROMA, LR2 and ADNEX 10% D+ probability.ADNEX: Assessment of Different NEoplasias in the adneXa model; LR2: Logistic Regression 2 model; RMI I: Risk of Malignancy Index I; ROC: receiver operating characteristic; ROMA: Risk of Ovarian Malignancy Algorithm." data-id="CD011964-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-FIG-13.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Summary ROC plot of tests (pre‐menopausal women): RMI I, ROMA, LR2 and ADNEX 10% D+ probability. </p> <p>ADNEX: Assessment of Different NEoplasias in the adneXa model; LR2: Logistic Regression 2 model; RMI I: Risk of Malignancy Index I; ROC: receiver operating characteristic; ROMA: Risk of Ovarian Malignancy Algorithm. </p> </div> </div> </div> <div class="figure" id="CD011964-fig-0010"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 10</div> </div> <hr class="top"/><img alt="Summary ROC plot of tests (post‐menopausal women): RMI I, ROMA, LR2 and ADNEX 10% D+ probability.ADNEX: Assessment of Different NEoplasias in the adneXa model; LR2: Logistic Regression 2 model; RMI I: Risk of Malignancy Index I; ROC: receiver operating characteristic; ROMA: Risk of Ovarian Malignancy Algorithm." data-id="CD011964-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-FIG-14.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Summary ROC plot of tests (post‐menopausal women): RMI I, ROMA, LR2 and ADNEX 10% D+ probability. </p> <p>ADNEX: Assessment of Different NEoplasias in the adneXa model; LR2: Logistic Regression 2 model; RMI I: Risk of Malignancy Index I; ROC: receiver operating characteristic; ROMA: Risk of Ovarian Malignancy Algorithm. </p> </div> </div> </div> <p>Differences in sensitivity between tests was estimated at fixed specificities of 80% and 90% (<a href="#CD011964-tbl-0008">Table 7</a>). These specificity thresholds were chosen in keeping with clinical consensus about an acceptable false‐positive rate which is reflected in previous research and RCOG guidelines (<a href="./references#CD011964-bbs2-0103" title="Royal College of Obstetricians and Gynaecologists. Guideline no 34: the management of ovarian cysts in post menopausal women. www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg34/ (accessed prior to 29 June 2022).">RCOG 2016</a>). It should be noted that the estimate of sensitivity for ADNEX in pre‐ and postmenopausal women at a fixed specificity of 90% is extrapolating beyond the data contributed by included ADNEX studies. </p> <p>In premenopausal women at a fixed specificity of 80%, RMI has an estimated average sensitivity of 79.4% (95% CI 69.5% to 86.7%). The average difference in sensitivity of ROMA compared to RMI at a fixed specificity of 80% is compatible with chance (2.6% percentage points, 95% CI –5.5 to 10.7), but there was an increase in average sensitivity with LR2 and ADNEX (LR2: 9.6 percentage points higher, 95% CI 2.2 to 17.0; ADNEX: 14.9 percentage points higher, 95% CI 5.4 to 24.5). </p> <p>In postmenopausal women at a fixed specificity of 80%, RMI has an average sensitivity of 85.1% (95% CI 80.9% to 88.5%). ROMA, LR2 and ADNEX demonstrated an increase in average sensitivity compared to RMI (ROMA: 5.8 percentage points, 95% CI 21.1 to 9.6; LR2: 5.7 percentage points, 95% CI 0.7 to 10.7; ADNEX: 8.3 percentage points, 95% CI 1.5 to 15.1). </p> </section> <section id="CD011964-sec-0078"> <h4 class="title">Bivariate (between study) comparison of RMI, ROMA, LR2 and ADNEX</h4> <p>For decision‐making purposes, the consequences of false‐negatives (driven by sensitivity) and false‐positives (driven by specificity) will not necessarily be considered equivalent and expressing accuracy in terms of overall discrimination misses this important distinction. In making recommendations for practice it is therefore useful to present test performance illustrating the trade‐off between sensitivity and specificity at specific operating thresholds<i>.</i><a href="#CD011964-tbl-0009">Table 8</a> illustrates a comparison of tests at fixed thresholds in premenopausal women and <a href="#CD011964-tbl-0010">Table 9</a> presents a comparison of tests at fixed thresholds in postmenopausal women: ROMA at a threshold of 13.1 (± 2) in premenopausal women (27/42 ROMA studies) and at a threshold of 27.7(± 2) in postmenopausal women (13/42 ROMA studies); LR2 at a post‐test probability of 10% (4/4 studies in premenopausal women and 5/5 studies in postmenopausal women) and ADNEX at a post‐test probability of 10% (4/4 studies in pre‐ and postmenopausal women) compared to RMI at a threshold of 200 (17/19 studies in pre‐ and postmenopausal women). For ROMA and ADNEX, the threshold pair reported by the most studies was chosen for this analysis. </p> <div class="table" id="CD011964-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Bivariate comparisons of ROMA, LR2 and ADNEX compared to RMI I in premenopausal women</span></div> <tbody> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign="top"> <p><b>Bivariate model‐pairwise comparisons: premenopausal women</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Absolute sensitivity difference (95% CI); P value for comparison</b> </p> <p><b>Absolute specificity difference (95% CI); P value for comparison</b> </p> </th> <td align="" class="headercell" colspan="1" rowspan="1" valign="bottom"></td> <td align="" class="headercell" colspan="1" rowspan="1" valign="bottom"></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>RMI I</b> </p> <p><b>(200)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>ROMA</b> </p> <p><b>(13.1 ± 2)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>LR2</b> </p> <p><b>(10)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Studies (participants)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17 (5233)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27 (4463)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (2843)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Sensitivity % (95% CI)</b> </p> <p><b>Specificity % (95% CI)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57.2 (50.3 to 63.8)</p> <p>92.5 (90.3 to 94.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77.4 (72.7 to 81.5)</p> <p>84.3 (81.2 to 87.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83.3 (74.7 to 89.5)</p> <p>90.4 (84.6 to 94.1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Studies (participants)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ROMA</b> (13.1 ± 2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 (4463)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77.4 (95% CI 72.7 to 81.5)</p> <p>84.3 (95% CI 81.2 to 87.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.2 (12.2 to 28.3); P &lt; 0.0001</p> <p>–8.2 (–11.7 to –4.7); P &lt; 0.0001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LR2</b> (10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (2843)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83.3 (95% CI 74.7 to 89.5)</p> <p>90.4 (95% CI 84.6 to 94.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.2 (16.2 to 36.2); P &lt; 0.0001</p> <p>–2.1 (–7.2 to 2.9); P = 0.404</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.0 (–2.6 to 14.5); P = 0.170</p> <p>6.1 (0.6 to 11.5); P = 0.029</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ADNEX</b> (10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (1696)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95.5 (95% CI 91.0 to 97.8)</p> <p>77.8 (95% CI 67.4 to 85.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.3 (30.9 to 45.8); P &lt; 0.0001</p> <p>–14.8 (–24.0 to –5.5); P = 0.002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.1 (12.7 to 23.5); P = 0.0001</p> <p>–6.5 (–16.0 to 3.0); P = 0.178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.1 (4.2 to 20.1); P = 0.003</p> <p>–12.6 (–22.8 to –2.4); P = 0.015</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ADNEX: Assessment of Different NEoplasias in the adneXa model; CI: confidence interval; LR2: Logistic Regression Model 2; OC: ovarian cancer; RMI I: Risk of Malignancy Index I; ROMA: Risk of Ovarian Malignancy Algorithm. </p> </div> </div> <div class="table" id="CD011964-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Bivariate comparisons of ROMA, LR2 and ADNEX compared to RMI I in postmenopausal women</span></div> <tbody> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign="bottom"> <p><b>Bivariate model‐pairwise comparisons: po</b> stmen<b>opausal women</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Absolute sensitivity difference (95% CI)</b> ; P<b>value for comparison</b> </p> <p><b>Absolute specificity difference (95% CI)</b> ; P<b>value for comparison</b> </p> </th> <td align="" class="headercell" colspan="1" rowspan="1" valign="bottom"></td> <td align="" class="headercell" colspan="1" rowspan="1" valign="bottom"></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>RMI I</b> </p> <p><b>(200)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>ROMA</b> </p> <p><b>(27.7 ± 2)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>LR2</b> </p> <p><b>(10)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Studies (participants)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17 (4369)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 (2002)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (2157)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Sensitivity % (95% CI)</b> </p> <p><b>Specificity % (95% CI)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78.4 (74.6 to 81.7)</p> <p>85.4 (82.0 to 88.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90.3 (87.5 to 92.6)</p> <p>81.5 (76.5 to 85.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94.8 (92.3 to 96.6)</p> <p>60.6 (50.5 to 69.9)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Studies (participants)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ROMA</b> (27.7 ± 2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 (2002)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90.3 (87.5 to 92.6)</p> <p>81.5 (76.5 to 85.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.9 (7.6 to 16.3); P &lt; 0.0001</p> <p>–3.9 (–9.4 to 1.5); P = 0.157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LR2</b> (10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (2157)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94.8 (92.3 to 96.6)</p> <p>60.6 (50.5 to 69.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.4 (12.3 to 20.5); P &lt; 0.0001</p> <p>–24.8 (–35.1 to –14.5); P &lt; 0.0001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.5 (1.2 to 7.8); P = 0.008</p> <p>–20.9 (–31.7 to –10.1); P &lt; 0.0001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ADNEX</b> (10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (1365)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97.6 (95.6 to 98.7)</p> <p>55.0 (42.8 to 66.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.2 (15.4 to 23.1); P &lt; 0.0001</p> <p>–30.4 (–42.9 to –17.9); P &lt; 0.0001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.3 (4.3 to 10.2); P &lt; 0.0001</p> <p>–26.5 (–39.4 to –13.6); P &lt; 0.0001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8 (0.2 to 5.3); P = 0.034</p> <p>–5.6 (–21.2 to 10.0); P = 0.480</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>ADNEX: Assessment of Different NEoplasias in the adneXa model; CI: confidence interval; LR2: Logistic Regression Model 2; OC: ovarian cancer; RMI I: Risk of Malignancy Index I; ROMA: Risk of Ovarian Malignancy Algorithm. </p> </div> </div> <section id="CD011964-sec-0079"> <h5 class="title">Premenopausal women</h5> <p>In premenopausal women, RMI at a threshold of 200 (17 studies, 5233 participants, 851 cases of OC) had a sensitivity of 57.2% (95% CI 50.3 to 63.8) and a specificity of 92.5 (95% CI 90.3 to 94.2). Compared to RMI: ROMA at a threshold of 13.1 (± 2) (27 studies, 4463 participants, 825 cases of OC), demonstrated an increase in sensitivity of 20.2 percentage points (95% CI 12.2 to 28.3) but a decrease in specificity of –8.2 percentage points (95% CI –11.7 to –4.7), LR2 at a threshold to achieve a post‐test probability of OC of 10% (4 studies, 2843 participants, 619 cases of OC), demonstrated an increase in sensitivity of 26.2 percentage points (95% CI 16.2 to 36.2) but with comparable specificity –2.1 percentage points (95% CI –7.2 to +2.9), ADNEX at a threshold to achieve a post‐test probability of OC of 10% (4 studies, 1696 participants, 455 cases of OC), demonstrated an increase in sensitivity of 38.3 percentage points (95% CI 30.9 to 45.8) but a decrease in specificity of –14.8 percentage points (95% CI –24.0 to –5.5). In summary, in premenopausal women, ROMA, ADNEX and LR2 all demonstrated a higher sensitivity compared to RMI at a threshold of 200. In addition ADNEX appeared to demonstrate a marginally higher sensitivity compared to ROMA. LR2 had comparable specificity to RMI at a threshold of 200 whilst for ROMA and ADNEX specificity was lower. </p> </section> <section id="CD011964-sec-0080"> <h5 class="title">Postmenopausal women</h5> <p>In postmenopausal women, RMI at a threshold of 200 (17 studies, 4369 participants, 1664 cases of OC) had a sensitivity of 78.4% (95% CI 74.6 to 81.7) and a specificity of 85.4% (95% CI 82.0 to 88.2). Compared to RMI: ROMA at a threshold of 27.7 (± 2) (13 studies, 2002 participants, 852 cases of OC), demonstrated an increase in sensitivity of 11.9 percentage points (95% CI 7.6 to 16.3) but a comparable specificity of –3.9 percentage points (95% CI –9.4 to 1.5), LR2 at a threshold to achieve a post‐test probability of OC of 10% (5 studies, 2157 participants, 1124 cases of OC), demonstrated an increase in sensitivity of 16.4 percentage points (95% CI 12.3 to 20.5) but a decrease in specificity of –24.8 percentage points (95% CI –35.1 to –14.5), ADNEX at a threshold to achieve a post‐test probability of OC of 10% (4 studies, 1365 participants, 749 cases of OC), demonstrated an increase in sensitivity of 19.2 percentage points (95% CI 15.4 to 23.1) but a decrease in specificity of –30.4 percentage points (95% CI –42.9 to –17.9). In summary, in postmenopausal women, ROMA, ADNEX and LR2 all demonstrated a higher sensitivity compared to RMI I at a threshold of 200. ROMA demonstrated a comparable specificity to RMI whilst for LR2 and ADNEX specificity was lower compared to RMI. </p> </section> </section> <section id="CD011964-sec-0081"> <h4 class="title">Investigation of the effect of classification of borderline tumours on estimates of test accuracy </h4> <p>In current clinical practice borderline ovarian tumours undergo similar surgical management to invasive malignant tumours. Included studies did not consistently include borderline ovarian tumours with malignant tumours for the purposes of estimating test accuracy. Exclusion of borderline tumours when estimating test accuracy in primary studies would be expected to result in overestimation of sensitivity, as they are a source of false‐negative test results. In premenopausal women (38 ROMA studies; 19 RMI studies) and postmenopausal women (40 ROMA studies), there were sufficient data, when utilising all test positivity thresholds at a fixed specificity of 80%, to allow comparison of sensitivity estimated by studies where borderline tumours were classified as positive (grouped with malignant tumours) with studies excluding borderline tumours from analysis or where the classification of borderline tumours for analysis was unclear. </p> <p>In postmenopausal women, for ROMA, there was a decrease in sensitivity of 6.4 percentage points (95% CI 1.2 to 11.5) for studies grouping borderline tumours with malignant compared to studies that excluded borderline tumours or where categorisation of borderline tumours for analysis was unclear (<a href="#CD011964-tbl-0011">Table 10</a>). </p> <div class="table" id="CD011964-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Sensitivity analysis: borderline ovarian tumours</span></div> <tbody> <tr> <th align="" class="headercell" colspan="11" rowspan="1" scope="col" valign=""> <p><b>Sensitivity analysis </b> :<b>sensitivity at fixed specificities of 80% and 90% for RMI I and ROMA (all thresholds) for studies grouping borderline ovarian tumours with malignant for the estimation of test accuracy (BOT=1) compared to studies that excluded borderline tumours or where their management for the estimation of test accuracy was unclear (BOT=2/3)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Test</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Studies</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>OC Cases</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>DOR (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative DOR</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Sensitivity at fixed specificity of 80%</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Sensitivity at fixed specificity of 90%</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sensitivity (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Difference from</b> </p> <p><b>BOT=1 (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sensitivity</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Difference from</b> </p> <p><b>BOT=1 (95% CI)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="11" rowspan="1" scope="col" valign=""> <p><b>Pr</b> emen<b>opausal</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign=""> <p>RMI I 200/250</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>BOT=1</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4861</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>801</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.7 (5.3 to 25.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74.9 (59.6 to 85.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.2 (53.1 to 70.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>BOT=2/3</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>833</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.5 (4.2 to 31.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.98 (0.37 to 2.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.9699</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74.6 (55.0 to 87.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–0.3 (–16.1 to 15.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.8 (43.3 to 77.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–0.4 (–20.1 to 19.4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign=""> <p>ROMA mixed thresholds</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>BOT=1</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2737</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>363</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.9 (9.0 to 21.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77.6 (69.1 to 84.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59.2 (47.0 to 70.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>BOT=2/3</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4879</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>835</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.3 (15.9 to 31.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.60 (0.94 to 2.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84.9 (79.7 to 89.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.4 (–1.2 to 15.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70.2 (60.3 to 78.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.1 (–1.3 to 23.5)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="11" rowspan="1" scope="col" valign=""> <p><b>Po</b> stmen<b>opausal</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign=""> <p>ROMA mixed thresholds</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>BOT=1</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>882</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27.4 (18.6 to 40.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87.7 (82.3 to 91.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72.4 (59.6 to 82.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>BOT=2/3</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3810</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1864</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.3 (40.5 to 78.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.06 (1.24 to 3.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0062</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94.1 (91.3 to 96.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.4 (1.2, 11.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85.4 (79.6 to 89.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.0 (1.9 to 24.0)</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>BOT=1: borderline tumours grouped with malignant ovarian tumours for estimation of test accuracy; BOT=2/3: borderline tumours excluded, grouped with benign or management unclear for estimation of test accuracy; CI: confidence interval; DOR: diagnostic odds ratio; OC: ovarian cancer; RMI: Risk of Malignancy Index; ROMA: Risk of Ovarian Malignancy Algorithm. </p> </div> </div> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD011964-sec-0082" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD011964-sec-0082"></div> <section id="CD011964-sec-0083"> <h3 class="title" id="CD011964-sec-0083">Summary of main results</h3> <p>To our knowledge, our systematic review is the first to compare the accuracy of ROMA, RMI and ADNEX in separately in premenopausal and postmenopausal women. Previous reviews have mostly evaluated combination tests (ROMA, RMI or LR2) in isolation and none have evaluated ADNEX. The most recent systematic review undertaking meta‐analysis using hierarchical models was based on searches up to 2015 (<a href="./references#CD011964-bbs2-0091" title="MeysEM , KaijserJ , KruitwagenRF , SlangenBF , vanCalsterB , AertgeertsB , et al. Subjective assessment versus ultrasound models to diagnose ovarian cancer: a systematic review and meta-analysis. European Journal of Cancer2016;58:17e29.">Meys 2016</a>). Estimates of sensitivity and specificity in premenopausal women (sensitivity 63%, specificity 93%) and postmenopausal women (sensitivity 79%, specificity 86%) were higher, but of a similar magnitude to those in this review. </p> <section id="CD011964-sec-0084"> <h4 class="title">Accuracy in premenopausal compared to postmenopausal women</h4> <p>We observed a consistent difference in sensitivity (higher in postmenopausal women) and specificity (lower in postmenopausal women) across all versions of all index tests at all thresholds analysed greater than could be expected by chance. This finding has important implications for research and practice: the utility of tests for diagnosing OC should be considered separately in premenopausal and postmenopausal women. </p> </section> <section id="CD011964-sec-0085"> <h4 class="title">Comparison of the accuracy of RMI, ROMA, LR2 and ADNEX</h4> <p>In the UK, women with a suspected adnexal mass and with either an abnormal CA125 or USS are referred for investigation to secondary care where RMI is performed. Therefore, we investigated the performance of ROMA, LR2 and ADNEX relative to RMI. In pre‐ and postmenopausal women, RMI has lower sensitivity compared to ROMA, LR2 and ADNEX. </p> <section id="CD011964-sec-0086"> <h5 class="title">Premenopausal women</h5> <p>In premenopausal women, ROMA at a threshold of 13.1 (± 2), LR2 at a threshold to achieve a post‐test probability of OC of 10% (post‐test probability 10%) and ADNEX (post‐test probability 10%) demonstrated a higher sensitivity compared to RMI (ROMA: 77.4%, 95% CI 72.7% to 81.5%; LR2: 83.3%, 95% CI 74.7% to 89.5%; ADNEX: 95.5%, 95% CI 91.0% to 97.8%; RMI: 57.2%, 95% CI 50.3% to 63.8%). The specificity of ROMA and ADNEX were lower in premenopausal women compared to RMI (ROMA: 84.3%, 95% CI 81.2% to 87.0%; ADNEX: 77.8%, 95% CI 67.4% to 85.5%; RMI: 92.5%, 95% CI 90.3% to 94.2%); the specificity of LR2 was comparable to RMI (90.4%, 95% CI 84.6% to 94.1%). </p> <p>Based on our analysis, in a clinical setting with a pretest probability of OC of 3% (<a href="./references#CD011964-bbs2-0097" title="National Institute for Health and Care Excellence. Suspected cancer: recognition and referral. www.nice.org.uk/guidance/ng12 (accessed 22 May 2019).">NICE 2017</a>) in premenopausal women, for every 1000 premenopausal women tested: </p> <p> <ul id="CD011964-list-0014"> <li> <p>consequences of a positive test result: </p> </li> </ul> </p> <p> <ul class="plain" id="CD011964-list-0015"> <li> <ul id="CD011964-list-0016"> <li> <p>an estimated 90 will have an RMI result indicating OC is present and of these 73 (81%) will not have OC; </p> </li> <li> <p>an estimated 176 will have a ROMA result indicating OC is present and of these 152 (86%) will not have OC; </p> </li> <li> <p>an estimated 118 will have an LR2 result indicating OC is present and of these 93 (79%) will not have OC; </p> </li> <li> <p>an estimated 245 will have an ADNEX result indicating OC is present and of these 216 (88%) will not have OC; </p> </li> </ul> </li> </ul> </p> <p> <ul id="CD011964-list-0017"> <li> <p>consequences of a negative test result: </p> </li> </ul> </p> <p> <ul class="plain" id="CD011964-list-0018"> <li> <ul id="CD011964-list-0019"> <li> <p>of the 910 people with an RMI result indicating that OC is not present, 13 (1%) will actually have OC; </p> </li> <li> <p>of the 824 people with a ROMA result indicating that OC is not present, 7 (0.8%) will actually have OC; </p> </li> <li> <p>of the 882 people with an LR2 result indicating that OC is not present, 5 (0.6%) will actually have OC; </p> </li> <li> <p>of the 755 people with an ADNEX result indicating that OC is not present, 1 (0.1%) will actually have OC. </p> </li> </ul> </li> </ul> </p> <p>See <a href="#CD011964-fig-0011">Figure 11</a>. </p> <div class="figure" id="CD011964-fig-0011"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 11</div> </div> <hr class="top"/><img alt="Illustration of the consequences of testing a hypothetical cohort of premenopausal women referred from primary care (estimated prevalence of ovarian cancer 3%).ADNEX: Assessment of Different NEoplasias in the adneXa model; LR2: Logistic Regression 2 model; RMI I: Risk of Malignancy Index I; ROC: receiver operating characteristic; ROMA: Risk of Ovarian Malignancy Algorithm." data-id="CD011964-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-FIG-15.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Illustration of the consequences of testing a hypothetical cohort of premenopausal women referred from primary care (estimated prevalence of ovarian cancer 3%). </p> <p>ADNEX: Assessment of Different NEoplasias in the adneXa model; LR2: Logistic Regression 2 model; RMI I: Risk of Malignancy Index I; ROC: receiver operating characteristic; ROMA: Risk of Ovarian Malignancy Algorithm. </p> </div> </div> </div> </section> <section id="CD011964-sec-0087"> <h5 class="title">Postmenopausal women</h5> <p>In postmenopausal women, ROMA at a threshold of 27.7 (± 2), LR2 (post‐test probability 10%) and ADNEX (post‐test probability 10%) demonstrated a higher sensitivity compared to RMI (ROMA: 90.3%, 95% CI 87.5% to 92.6%; LR2: 94.8%, 95% CI 92.3% to 96.6%; ADNEX: 97.6%, 95% CI 95.6% to 98.7%; RMI 78.4%, 95% CI 74.6% to 81.7%). Specificity of ROMA at a threshold of 27.7 (± 2) was comparable to RMI (ROMA: 81.5%, 95% CI 76.5% to 85.5%; RMI: 85.4%, 95% CI 82.0% to 88.2%), whereas for LR2 (post‐test probability 10%) and ADNEX (post‐test probability 10%), specificity was lower (LR2: 60.6%, 95% CI 50.5% to 69.9%; ADNEX: 55.0%, 95% CI 42.8% to 66.6%). </p> <p>Based on our analysis, in a clinical setting with a pretest probability of OC of 3% in postmenopausal women, for every 1000 postmenopausal women tested: </p> <p> <ul id="CD011964-list-0020"> <li> <p>consequences of a positive test result: </p> </li> </ul> </p> <p> <ul class="plain" id="CD011964-list-0021"> <li> <ul id="CD011964-list-0022"> <li> <p>an estimated 165 will have an RMI result indicating OC is present and of these 142 (86%) will not have OC; </p> </li> <li> <p>an estimated 207 will have a ROMA result indicating OC is present and of these 179 (86%) will not have OC; </p> </li> <li> <p>an estimated 411 will have an LR2 result indicating OC is present and of these 382 (93%) will not have OC; </p> </li> <li> <p>an estimated 466 will have an ADNEX result indicating OC and of these 437 (94%) will not have OC; </p> </li> </ul> </li> </ul> </p> <p> <ul id="CD011964-list-0023"> <li> <p>consequences of a negative test result: </p> </li> </ul> </p> <p> <ul class="plain" id="CD011964-list-0024"> <li> <ul id="CD011964-list-0025"> <li> <p>of the 835 people with an RMI result indicating that OC is not present, 6 (0.7%) will actually have OC; </p> </li> <li> <p>of the 793 people with a ROMA result indicating that OC is not present, 3 (0.4%) will actually have OC; </p> </li> <li> <p>of the 492 people with an LR2 result indicating that OC is not present, 2 (0.4 %) will actually have OC; </p> </li> <li> <p>of the 534 people with an ADNEX result indicating that OC is not present, 1 (0.1%) will actually have OC. </p> </li> </ul> </li> </ul> </p> <p>See <a href="#CD011964-fig-0012">Figure 12</a>. </p> <div class="figure" id="CD011964-fig-0012"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 12</div> </div> <hr class="top"/><img alt="Illustration of the consequences of testing a hypothetical cohort of postmenopausal women referred from primary care (estimated prevalence of ovarian cancer 3%).ADNEX: Assessment of Different NEoplasias in the adneXa model; LR2: Logistic Regression 2 model; RMI I: Risk of Malignancy Index I; ROC: receiver operating characteristic; ROMA: Risk of Ovarian Malignancy Algorithm." data-id="CD011964-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-FIG-16.jpg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Illustration of the consequences of testing a hypothetical cohort of postmenopausal women referred from primary care (estimated prevalence of ovarian cancer 3%). </p> <p>ADNEX: Assessment of Different NEoplasias in the adneXa model; LR2: Logistic Regression 2 model; RMI I: Risk of Malignancy Index I; ROC: receiver operating characteristic; ROMA: Risk of Ovarian Malignancy Algorithm. </p> </div> </div> </div> <p>Considerations other than accuracy when deciding on ROMA, LR2 or ADNEX as alternative tests to RMI will include the relative costs and the feasibility of introducing ROMA or ADNEX. The adoption of ROMA does not rely on availability of expertise in USS, but would require investment in laboratory facilities for processing of HE4 tests. In addition, a decision is likely to be influenced by factors such as baseline risk (prevalence) of OC, which will be dependent on healthcare setting and menopausal status, and the adverse consequences of unnecessary investigation and treatment, for example, loss of fertility. </p> </section> </section> </section> <section id="CD011964-sec-0088"> <h3 class="title" id="CD011964-sec-0088">Strengths and weaknesses of the review</h3> <section id="CD011964-sec-0089"> <h4 class="title">Strengths</h4> <p>This is the first review of test combinations for the diagnosis of OC to include and compare all tests currently used in clinical practice. Although literature searches were completed in 2019, this review remains the most up‐to‐date comprehensive review to our knowledge. We used sensitive search strategies to capture relevant literature regardless of country of publication, publication status (published or unpublished), language or clinical setting (primary care or specialist care (secondary and tertiary). Novel features of this review include systematic investigation of the effects of menopausal status and classification of borderline tumours on estimates of test accuracy and statistical comparison of tests relevant to clinical practice at the time of writing. We attempted to mitigate against heterogeneity by attempting to restrict our analysis to primary tumours of adnexal origin and where this was not possible or unclear in studies reporting mixed primary, recurrent and metastatic disease, this was reflected in downgrading of quality assessment. </p> </section> <section id="CD011964-sec-0090"> <h4 class="title">Weaknesses</h4> <p>Due to time and resource constraints, we were unable to consider including non‐English Language studies. The impact of this omission on study findings is unknown. We acknowledge a major limitation of this review is the search date, which at the time of writing is 2.5 years old. We cannot rule out the possibility that inclusion of more‐recent studies will have changed our summary estimates of accuracy for each of the four included index tests. The potential impact on estimates of test accuracy of not including more recently published studies is likely to be less for RMI (19 included studies) and ROMA (40 included studies) compared to ADNEX (four included studies) and LR2 (five included studies). LR2 has been superseded by ADNEX as the multivariable USS model of choice in clinical practice; this clinical situation is reflected by the fact that in the intervening period between our 2015 and 2019 searches, only an additional two LR2 studies were identified for inclusion in this review. In recognition of the relatively small number of ADNEX studies included in our review, we performed a scoping search for primary studies published since our search cut‐off date of June 2019. The search found three studies, two single‐centre studies (<a href="./references#CD011964-bbs2-0068" title="ChenH , QianL , JiangM , DuQ , YuanF , FengW . Performance of IOTA ADNEX model in evaluating adnexal masses in a gynecological oncology center in China. Ultrasound in Obstetrics and Gynaecology2019;54(6):815-22.">Chen 2019</a>; <a href="./references#CD011964-bbs2-0095" title="NamG , LeeSR , JeongK , MoonHS , ChaeHD . Assessment of different NEoplasias in the adneXa model for differentiation of benign and malignant adnexal masses in Korean women. Obstetrics and Gynaecology Science2021;64(3):293-9.">Nam 2021</a>), and one multicentre study (<a href="./references#CD011964-bbs2-0052" title="vanCalsterB , vanHoordeK , ValentinL , TestaAC , FischerovaD , vanHolsbekeC , et al. Evaluating the risk of ovarian cancer before surgery using the ADNEX model to differentiate between benign, borderline, early and advanced stage invasive, and secondary metastatic tumours: prospective multicentre diagnostic study. BMJ2014;349:g5920. ">van Calster 2014</a>). Only one study reported sensitivity and specificity separately in pre‐ and postmenopausal women (<a href="./references#CD011964-bbs2-0095" title="NamG , LeeSR , JeongK , MoonHS , ChaeHD . Assessment of different NEoplasias in the adneXa model for differentiation of benign and malignant adnexal masses in Korean women. Obstetrics and Gynaecology Science2021;64(3):293-9.">Nam 2021</a>). Sensitivity and specificity were both 83% in premenopausal women and sensitivity was 100% and specificity was 76% in postmenopausal women at a threshold to achieve a post‐test probability of OC of 10%. These estimates are in line with those from studies included in this review and we consider it unlikely that inclusion of this single eligible additional ADNEX study would alter the overall conclusions of this review regarding the relative performance of tests. </p> <p>We also recognise the limitation on our review methods of the pragmatic decision to reduce the number of bibliographic databases searched for the review update (between 2015 and 2019). Although we developed the 2019 search strategy iteratively, testing the sensitivity of the search strategy using articles we had already identified as potentially eligible, we cannot rule out the possibility that eligible studies may have been missed. </p> <p>The major limitation of our review is deficiencies in included studies. Lack of data and poor reporting in included studies precluded quality assessment and investigation of potential important sources of heterogeneity in test accuracy estimates. These included clinical setting (primary versus specialist), target condition (primary versus recurrent and metastatic disease), and cancer histological subtype and stage. Included studies varied with respect to the range of ovarian pathology included with some restricting inclusion to EOC whilst in others metastatic disease to the ovaries could not be disaggregated from primary OC for the purposes of analysis. A lack of distinction between pre‐ and postmenopausal women when evaluating test accuracy continues to be a major limitation of research in this area. Thirty‐seven of 59 included studies were conducted in specialist gynaecological oncology centres in women scheduled for surgery. The method of presentation of these women was documented in only four included studies. </p> </section> </section> <section id="CD011964-sec-0091"> <h3 class="title" id="CD011964-sec-0091">Applicability of findings to the review question</h3> <p>This review aimed to answer the question of the accuracy of imaging and biomarkers for women <i>with symptoms suspicious for</i> OC. In the UK, NICE and the RCOG recommend women with suspicious symptoms presenting in primary care should receive additional investigations with biomarkers and USS to determine further management (<a href="./references#CD011964-bbs2-0096" title="National Institute for Health and Care Excellence. CG 122: ovarian cancer: the recognition and initial management of ovarian cancer. www.nice.org.uk/guidance/cg122/chapter/guidance (accessed prior to 29 June 2022).">NICE 2011</a>; <a href="./references#CD011964-bbs2-0103" title="Royal College of Obstetricians and Gynaecologists. Guideline no 34: the management of ovarian cysts in post menopausal women. www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg34/ (accessed prior to 29 June 2022).">RCOG 2016</a>). The American College of Obstetrics and Gynaecology recommends TVS as the initial test of choice <i>if physical examination suggests the presence of an adnexal mass</i> (<a href="./references#CD011964-bbs2-0060" title="ACOG. Evaluation and management of adnexal masses. Obstetrics Gynecology2016;128(5):e210-26.">ACOG 2016</a>). </p> <p>The presence of suspicious symptoms is therefore a trigger for further investigation. Most included studies were at high or unclear applicability to the review question on the basis that women were either asymptomatic, or it was unclear if they were symptomatic, at the point of index test use. Further, we did not identify any studies of the accuracy of test combinations to diagnose OC in a generalist setting. Most included studies had a prevalence of OC that was in keeping with tertiary hospitals. Test accuracy estimates from this review are therefore unlikely to be applicable to generalist settings, where the prevalence of OC is lower and the spectrum of the tested population more heterogeneous. </p> <p>With the exception of one study (<a href="./references#CD011964-bbs2-0017" title="KarlsenMA , SandhuN , HogdallC , ChristensenIJ , NedergaardL , LundvallL , et al. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass. Gynecologic Oncology2012;127(2):379-83. ">Karlsen 2012</a>), all included women had a confirmed adnexal mass at the point of testing. <a href="./references#CD011964-bbs2-0017" title="KarlsenMA , SandhuN , HogdallC , ChristensenIJ , NedergaardL , LundvallL , et al. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass. Gynecologic Oncology2012;127(2):379-83. ">Karlsen 2012</a> had the lowest estimated specificity (53%) and one of the highest estimates of sensitivity (94%) (<a href="#CD011964-fig-0006">Figure 6</a>). Early in the OC testing pathway it would be expected that test specificity would be lower, particularly in premenopausal women, reflecting a more diverse population in terms of comorbidity (e.g. endometriosis and functional benign tumours), and normal physiological processes such as the menstrual cycle, which are causes of false‐positive test results and a lower test specificity. Thus in generalist settings, the relationship between sensitivity and specificity and menopausal status observed in this review may be reversed. The implication is that estimates of the accuracy of index tests in this review are likely to be applicable to women selected on the basis of prior tests in specialist settings (secondary and tertiary care), but are unlikely to be applicable to women without a confirmed adnexal mass (i.e. in primary care settings). </p> <p>All studies of index tests with an USS component (RMI, LR2 and ADNEX) were at high or unclear risk of bias in the index test domain on the basis that sonographers were specialists or their level of skill was not reported. Therefore, we cannot assume that the performance of RMI, LR2 or ADNEX could be replicated by non‐specialist sonographers as would be the case for investigations initiated in primary care or secondary care settings. </p> <p>A further concern regarding the applicability of this review's findings is that in most studies, borderline tumours were either excluded or it was unclear how they were classified for estimation of test accuracy (excluded, classified as malignant or classified as benign). Borderline ovarian tumours account for an estimated 15% of ovarian tumours (<a href="./references#CD011964-bbs2-0110" title="SkírnisdóttirI , GarmoH , WilanderE , HolmbergL . Borderline ovarian tumors in Sweden 1960-2005: trends in incidence and age at diagnosis compared to ovarian cancer. International Journal of Cancer2008;123(8):1897-901.">Skirnisdottir 2008</a>). In current clinical practice, borderline ovarian tumours undergo similar surgical management to invasive malignant tumours. We observed a decrease in sensitivity of 6.4 percentage points (95% CI 1.2 to 11.5) in ROMA studies of postmenopausal women grouping borderline tumours with malignant compared to studies where borderline tumours were excluded, or where categorisation of borderline tumours for analysis was unclear (<a href="#CD011964-tbl-0011">Table 10</a>). Exclusion of borderline tumours in studies in this review is therefore likely to have resulted in overestimation of sensitivity. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD011964-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-FIG-01" target="_blank"><b></b></a></p> </div><img alt="UK recommended clinical pathway based on NICE and RCOG guidance *'Suspicious' symptoms: persistent (&gt; 12 times per month) abdominal distension or bloating; early satiety/loss of appetite; urinary symptoms; abdominal or pelvic pain, weight loss; fatigue; change in bowel habit.**Ultrasound findings suggestive of ovarian cancer: laterality (any imbalance between masses observed in left compared to right ovary), multilocularity, solid areas, free fluid and distant metastasis.AFP: alpha fetoprotein; CT: computed tomography; hCG: human chorionic gonadotrophin; IOTA: International Ovarian Tumour Analysis; NICE: National Institute for Health and Care Excellence; RCOG: Royal College of Obstetrics and Gynaecology; RMI: Risk of Malignancy Index." data-id="CD011964-fig-0001" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p><b>UK recommended clinical pathway based on NICE and RCOG guidance</b> </p> <p>*'Suspicious' symptoms: persistent (&gt; 12 times per month) abdominal distension or bloating; early satiety/loss of appetite; urinary symptoms; abdominal or pelvic pain, weight loss; fatigue; change in bowel habit. </p> <p>**Ultrasound findings suggestive of ovarian cancer: laterality (any imbalance between masses observed in left compared to right ovary), multilocularity, solid areas, free fluid and distant metastasis. </p> <p>AFP: alpha fetoprotein; CT: computed tomography; hCG: human chorionic gonadotrophin; IOTA: International Ovarian Tumour Analysis; NICE: National Institute for Health and Care Excellence; RCOG: Royal College of Obstetrics and Gynaecology; RMI: Risk of Malignancy Index. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/full#CD011964-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-FIG-02" target="_blank"><b></b></a></p> </div><img alt="PRISMA study flow diagram.ADNEX: Assessment of Different NEoplasias in the adneXa model; LR2: Logistic Regression Model 2; RMI: Risk of Malignancy Index; ROMA: Risk of Ovarian Malignancy Algorithm." data-id="CD011964-fig-0002" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-FIG-02.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>PRISMA study flow diagram.</p> <p>ADNEX: Assessment of Different NEoplasias in the adneXa model; LR2: Logistic Regression Model 2; RMI: Risk of Malignancy Index; ROMA: Risk of Ovarian Malignancy Algorithm. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/full#CD011964-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-FIG-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-FIG-03" target="_blank"><b></b></a></p> </div><img alt="Risk of bias and applicability concerns graph for 59 individual included studies for index tests. Review authors' judgements about each domain presented as percentages across included studies.ADNEX: Assessment of Different NEoplasias in the adneXa model; LR2: Logistic Regression 2 model; RMI I: Risk of Malignancy Index I; ROMA: Risk of Ovarian Malignancy Algorithm." data-id="CD011964-fig-0003" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-FIG-03.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-FIG-03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Risk of bias and applicability concerns graph for 59 individual included studies for index tests. Review authors' judgements about each domain presented as percentages across included studies. </p> <p>ADNEX: Assessment of Different NEoplasias in the adneXa model; LR2: Logistic Regression 2 model; RMI I: Risk of Malignancy Index I; ROMA: Risk of Ovarian Malignancy Algorithm. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/full#CD011964-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-FIG-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-FIG-04" target="_blank"><b></b></a></p> </div><img alt="Risk of bias and applicability concerns figure for 59 individual included studies for index tests. Review authors' judgements about each domain for each included study. Empty cells indicate that an index test was not evaluated by a study.ADNEX: Assessment of Different NEoplasias in the adneXa model; LR2: Logistic Regression 2 model; RMI I: Risk of Malignancy Index I; ROMA: Risk of Ovarian Malignancy Algorithm." data-id="CD011964-fig-0004" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-FIG-04.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-FIG-04.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Risk of bias and applicability concerns figure for 59 individual included studies for index tests. Review authors' judgements about each domain for each included study. Empty cells indicate that an index test was not evaluated by a study. </p> <p>ADNEX: Assessment of Different NEoplasias in the adneXa model; LR2: Logistic Regression 2 model; RMI I: Risk of Malignancy Index I; ROMA: Risk of Ovarian Malignancy Algorithm. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/full#CD011964-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-FIG-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-FIG-09" target="_blank"><b></b></a></p> </div><img alt="Forest plot of tests: Risk of Malignancy Index I (RMI I) at thresholds of 200 and 250, separately for pre‐menopausal and post‐menopausal women.FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive." data-id="CD011964-fig-0005" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-FIG-09.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-FIG-09.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Forest plot of tests: Risk of Malignancy Index I (RMI I) at thresholds of 200 and 250, separately for pre‐menopausal and post‐menopausal women. </p> <p>FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/full#CD011964-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-FIG-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-FIG-10" target="_blank"><b></b></a></p> </div><img alt="Forest plot of tests: Risk of Ovarian Malignancy Algorithm (ROMA) in at thresholds of 7.4 (± 2), 12.5, 13.1 (± 2), 7.4, 13.1 and 11.4 in premenopausal women, and at thresholds of 25.3 (± 2), 14.4, 27.7 (± 2), 25.3, 27.7 and 29.9 in postmenopausal women.FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive." data-id="CD011964-fig-0006" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-FIG-10.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-FIG-10.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Forest plot of tests: Risk of Ovarian Malignancy Algorithm (ROMA) in at thresholds of 7.4 (± 2), 12.5, 13.1 (± 2), 7.4, 13.1 and 11.4 in premenopausal women, and at thresholds of 25.3 (± 2), 14.4, 27.7 (± 2), 25.3, 27.7 and 29.9 in postmenopausal women. </p> <p>FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/full#CD011964-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-FIG-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-FIG-11" target="_blank"><b></b></a></p> </div><img alt="Forest plot of tests: Logistic Regression 2 model (LR2) separately for premenopausal and postmenopausal women.FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive." data-id="CD011964-fig-0007" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-FIG-11.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-FIG-11.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Forest plot of tests: Logistic Regression 2 model (LR2) separately for premenopausal and postmenopausal women. </p> <p>FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/full#CD011964-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-FIG-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-FIG-12" target="_blank"><b></b></a></p> </div><img alt="Forest plot of tests: Assessment of Different NEoplasias in the adneXa model (ADNEX) at thresholds of 3%, 5%, 10% and 15% disease probability separately for premenopausal and postmenopausal women.FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive." data-id="CD011964-fig-0008" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-FIG-12.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-FIG-12.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Forest plot of tests: Assessment of Different NEoplasias in the adneXa model (ADNEX) at thresholds of 3%, 5%, 10% and 15% disease probability separately for premenopausal and postmenopausal women. </p> <p>FN: false‐negative; FP: false‐positive; TN: true‐negative; TP: true‐positive.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/full#CD011964-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-FIG-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-FIG-13" target="_blank"><b></b></a></p> </div><img alt="Summary ROC plot of tests (pre‐menopausal women): RMI I, ROMA, LR2 and ADNEX 10% D+ probability.ADNEX: Assessment of Different NEoplasias in the adneXa model; LR2: Logistic Regression 2 model; RMI I: Risk of Malignancy Index I; ROC: receiver operating characteristic; ROMA: Risk of Ovarian Malignancy Algorithm." data-id="CD011964-fig-0009" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-FIG-13.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-FIG-13.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Summary ROC plot of tests (pre‐menopausal women): RMI I, ROMA, LR2 and ADNEX 10% D+ probability. </p> <p>ADNEX: Assessment of Different NEoplasias in the adneXa model; LR2: Logistic Regression 2 model; RMI I: Risk of Malignancy Index I; ROC: receiver operating characteristic; ROMA: Risk of Ovarian Malignancy Algorithm. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/full#CD011964-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-FIG-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-FIG-14" target="_blank"><b></b></a></p> </div><img alt="Summary ROC plot of tests (post‐menopausal women): RMI I, ROMA, LR2 and ADNEX 10% D+ probability.ADNEX: Assessment of Different NEoplasias in the adneXa model; LR2: Logistic Regression 2 model; RMI I: Risk of Malignancy Index I; ROC: receiver operating characteristic; ROMA: Risk of Ovarian Malignancy Algorithm." data-id="CD011964-fig-0010" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-FIG-14.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-FIG-14.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 10</div> <div class="figure-caption"> <p>Summary ROC plot of tests (post‐menopausal women): RMI I, ROMA, LR2 and ADNEX 10% D+ probability. </p> <p>ADNEX: Assessment of Different NEoplasias in the adneXa model; LR2: Logistic Regression 2 model; RMI I: Risk of Malignancy Index I; ROC: receiver operating characteristic; ROMA: Risk of Ovarian Malignancy Algorithm. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/full#CD011964-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-FIG-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-FIG-15" target="_blank"><b></b></a></p> </div><img alt="Illustration of the consequences of testing a hypothetical cohort of premenopausal women referred from primary care (estimated prevalence of ovarian cancer 3%).ADNEX: Assessment of Different NEoplasias in the adneXa model; LR2: Logistic Regression 2 model; RMI I: Risk of Malignancy Index I; ROC: receiver operating characteristic; ROMA: Risk of Ovarian Malignancy Algorithm." data-id="CD011964-fig-0011" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-FIG-15.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 11</div> <div class="figure-caption"> <p>Illustration of the consequences of testing a hypothetical cohort of premenopausal women referred from primary care (estimated prevalence of ovarian cancer 3%). </p> <p>ADNEX: Assessment of Different NEoplasias in the adneXa model; LR2: Logistic Regression 2 model; RMI I: Risk of Malignancy Index I; ROC: receiver operating characteristic; ROMA: Risk of Ovarian Malignancy Algorithm. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/full#CD011964-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-FIG-15.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-FIG-16" target="_blank"><b></b></a></p> </div><img alt="Illustration of the consequences of testing a hypothetical cohort of postmenopausal women referred from primary care (estimated prevalence of ovarian cancer 3%).ADNEX: Assessment of Different NEoplasias in the adneXa model; LR2: Logistic Regression 2 model; RMI I: Risk of Malignancy Index I; ROC: receiver operating characteristic; ROMA: Risk of Ovarian Malignancy Algorithm." data-id="CD011964-fig-0012" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-FIG-16.jpg"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 12</div> <div class="figure-caption"> <p>Illustration of the consequences of testing a hypothetical cohort of postmenopausal women referred from primary care (estimated prevalence of ovarian cancer 3%). </p> <p>ADNEX: Assessment of Different NEoplasias in the adneXa model; LR2: Logistic Regression 2 model; RMI I: Risk of Malignancy Index I; ROC: receiver operating characteristic; ROMA: Risk of Ovarian Malignancy Algorithm. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/full#CD011964-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-FIG-16.jpg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0057"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-FIG-05" target="_blank"><b></b></a></p> </div><img alt="Risk of bias and applicability concerns summary: Risk of Malignancy Index I. Review authors' judgements about each domain for each included study." data-id="CD011964-fig-0057" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-FIG-05.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-FIG-05.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 13</div> <div class="figure-caption"> <p>Risk of bias and applicability concerns summary: Risk of Malignancy Index I. Review authors' judgements about each domain for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/appendices#CD011964-fig-0057">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-FIG-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0058"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-FIG-06" target="_blank"><b></b></a></p> </div><img alt="Risk of bias and applicability concerns summary: Risk of Ovarian Malignancy Algorithm. Review authors' judgements about each domain for each included study." data-id="CD011964-fig-0058" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-FIG-06.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-FIG-06.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 14</div> <div class="figure-caption"> <p>Risk of bias and applicability concerns summary: Risk of Ovarian Malignancy Algorithm. Review authors' judgements about each domain for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/appendices#CD011964-fig-0058">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-FIG-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0059"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-FIG-07" target="_blank"><b></b></a></p> </div><img alt="Risk of bias and applicability concerns summary: Logistic Regression 2 model. Review authors' judgements about each domain for each included study." data-id="CD011964-fig-0059" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-FIG-07.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-FIG-07.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 15</div> <div class="figure-caption"> <p>Risk of bias and applicability concerns summary: Logistic Regression 2 model. Review authors' judgements about each domain for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/appendices#CD011964-fig-0059">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-FIG-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0060"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-FIG-08" target="_blank"><b></b></a></p> </div><img alt="Risk of bias and applicability concerns summary: Assessment of Different NEoplasias in the adneXa model. Review authors' judgements about each domain for each included study." data-id="CD011964-fig-0060" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-FIG-08.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-FIG-08.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 16</div> <div class="figure-caption"> <p>Risk of bias and applicability concerns summary: Assessment of Different NEoplasias in the adneXa model. Review authors' judgements about each domain for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/appendices#CD011964-fig-0060">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-FIG-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-TST-001" target="_blank"><b></b></a></p> </div><img alt="ROMA 7.4 (± 2) premenopausal" data-id="CD011964-fig-0013" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-001.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-TST-001.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 1</div> <div class="figure-caption"> <p>ROMA 7.4 (± 2) premenopausal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/references#CD011964-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-001.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-TST-002" target="_blank"><b></b></a></p> </div><img alt="ROMA 25.3 (± 2) postmenopausal" data-id="CD011964-fig-0014" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-002.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-TST-002.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 2</div> <div class="figure-caption"> <p>ROMA 25.3 (± 2) postmenopausal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/references#CD011964-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-002.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-TST-003" target="_blank"><b></b></a></p> </div><img alt="ROMA 12.5 premenopausal" data-id="CD011964-fig-0015" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-003.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-TST-003.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 3</div> <div class="figure-caption"> <p>ROMA 12.5 premenopausal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/references#CD011964-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-003.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-TST-004" target="_blank"><b></b></a></p> </div><img alt="ROMA 14.4 postmenopausal" data-id="CD011964-fig-0016" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-004.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-TST-004.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 4</div> <div class="figure-caption"> <p>ROMA 14.4 postmenopausal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/references#CD011964-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-004.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-TST-005" target="_blank"><b></b></a></p> </div><img alt="ROMA 13.1 (± 2) premenopausal" data-id="CD011964-fig-0017" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-005.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-TST-005.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 5</div> <div class="figure-caption"> <p>ROMA 13.1 (± 2) premenopausal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/references#CD011964-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-005.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-TST-006" target="_blank"><b></b></a></p> </div><img alt="ROMA 27.7 (± 2) postmenopausal" data-id="CD011964-fig-0018" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-006.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-TST-006.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 6</div> <div class="figure-caption"> <p>ROMA 27.7 (± 2) postmenopausal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/references#CD011964-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-006.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-TST-007" target="_blank"><b></b></a></p> </div><img alt="ROMA 7.4 premenopausal" data-id="CD011964-fig-0019" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-007.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-TST-007.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 7</div> <div class="figure-caption"> <p>ROMA 7.4 premenopausal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/references#CD011964-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-007.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-TST-008" target="_blank"><b></b></a></p> </div><img alt="ROMA 25.3 postmenopausal" data-id="CD011964-fig-0020" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-008.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-TST-008.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 8</div> <div class="figure-caption"> <p>ROMA 25.3 postmenopausal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/references#CD011964-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-008.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-TST-009" target="_blank"><b></b></a></p> </div><img alt="ROMA 7.4/25.3 all" data-id="CD011964-fig-0021" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-009.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-TST-009.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 9</div> <div class="figure-caption"> <p>ROMA 7.4/25.3 all</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/references#CD011964-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-009.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-TST-010" target="_blank"><b></b></a></p> </div><img alt="ROMA 12.5/14.4 all" data-id="CD011964-fig-0022" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-010.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-TST-010.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 10</div> <div class="figure-caption"> <p>ROMA 12.5/14.4 all</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/references#CD011964-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-010.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-TST-011" target="_blank"><b></b></a></p> </div><img alt="ROMA 13.1 premenopausal" data-id="CD011964-fig-0023" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-011.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-TST-011.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 11</div> <div class="figure-caption"> <p>ROMA 13.1 premenopausal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/references#CD011964-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-011.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-TST-012" target="_blank"><b></b></a></p> </div><img alt="ROMA 27.7 postmenopausal" data-id="CD011964-fig-0024" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-012.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-TST-012.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 12</div> <div class="figure-caption"> <p>ROMA 27.7 postmenopausal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/references#CD011964-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-012.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-TST-013" target="_blank"><b></b></a></p> </div><img alt="ROMA 13.1/27.7 all" data-id="CD011964-fig-0025" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-013.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-TST-013.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 13</div> <div class="figure-caption"> <p>ROMA 13.1/27.7 all</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/references#CD011964-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-013.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-TST-014" target="_blank"><b></b></a></p> </div><img alt="ROMA 11.4 premenopausal" data-id="CD011964-fig-0026" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-014.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-TST-014.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 14</div> <div class="figure-caption"> <p>ROMA 11.4 premenopausal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/references#CD011964-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-014.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-TST-015" target="_blank"><b></b></a></p> </div><img alt="ROMA 29.9 postmenopausal" data-id="CD011964-fig-0027" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-015.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-TST-015.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 15</div> <div class="figure-caption"> <p>ROMA 29.9 postmenopausal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/references#CD011964-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-015.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-TST-018" target="_blank"><b></b></a></p> </div><img alt="ROMA mixed premenopausal" data-id="CD011964-fig-0028" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-018.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-TST-018.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 18</div> <div class="figure-caption"> <p>ROMA mixed premenopausal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/references#CD011964-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-018.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-TST-019" target="_blank"><b></b></a></p> </div><img alt="ROMA mixed postmenopausal" data-id="CD011964-fig-0029" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-019.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-TST-019.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 19</div> <div class="figure-caption"> <p>ROMA mixed postmenopausal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/references#CD011964-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-019.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-TST-020" target="_blank"><b></b></a></p> </div><img alt="ROMA mixed all" data-id="CD011964-fig-0030" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-020.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-TST-020.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 20</div> <div class="figure-caption"> <p>ROMA mixed all</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/references#CD011964-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-020.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-TST-021" target="_blank"><b></b></a></p> </div><img alt="RMI I 200 premenopausal" data-id="CD011964-fig-0031" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-021.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-TST-021.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 21</div> <div class="figure-caption"> <p>RMI I 200 premenopausal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/references#CD011964-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-021.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0032"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-TST-022" target="_blank"><b></b></a></p> </div><img alt="RMI I 200 postmenopausal" data-id="CD011964-fig-0032" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-022.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-TST-022.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 22</div> <div class="figure-caption"> <p>RMI I 200 postmenopausal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/references#CD011964-fig-0032">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-022.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0033"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-TST-023" target="_blank"><b></b></a></p> </div><img alt="RMI I 200 all" data-id="CD011964-fig-0033" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-023.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-TST-023.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 23</div> <div class="figure-caption"> <p>RMI I 200 all</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/references#CD011964-fig-0033">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-023.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0034"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-TST-024" target="_blank"><b></b></a></p> </div><img alt="RMI I 250 premenopausal" data-id="CD011964-fig-0034" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-024.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-TST-024.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 24</div> <div class="figure-caption"> <p>RMI I 250 premenopausal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/references#CD011964-fig-0034">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-024.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0035"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-TST-025" target="_blank"><b></b></a></p> </div><img alt="RMI I 250 postmenopausal" data-id="CD011964-fig-0035" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-025.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-TST-025.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 25</div> <div class="figure-caption"> <p>RMI I 250 postmenopausal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/references#CD011964-fig-0035">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-025.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0036"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-TST-026" target="_blank"><b></b></a></p> </div><img alt="RMI I 250 all" data-id="CD011964-fig-0036" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-026.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-TST-026.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 26</div> <div class="figure-caption"> <p>RMI I 250 all</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/references#CD011964-fig-0036">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-026.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0037"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-TST-035" target="_blank"><b></b></a></p> </div><img alt="RMI mixed premenopausal" data-id="CD011964-fig-0037" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-035.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-TST-035.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 35</div> <div class="figure-caption"> <p>RMI mixed premenopausal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/references#CD011964-fig-0037">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-035.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0038"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-TST-036" target="_blank"><b></b></a></p> </div><img alt="RMI mixed postmenopausal" data-id="CD011964-fig-0038" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-036.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-TST-036.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 36</div> <div class="figure-caption"> <p>RMI mixed postmenopausal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/references#CD011964-fig-0038">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-036.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0039"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-TST-037" target="_blank"><b></b></a></p> </div><img alt="RMI mixed all" data-id="CD011964-fig-0039" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-037.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-TST-037.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 37</div> <div class="figure-caption"> <p>RMI mixed all</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/references#CD011964-fig-0039">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-037.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0040"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-TST-038" target="_blank"><b></b></a></p> </div><img alt="LR2 premenopausal" data-id="CD011964-fig-0040" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-038.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-TST-038.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 38</div> <div class="figure-caption"> <p>LR2 premenopausal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/references#CD011964-fig-0040">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-038.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0041"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-TST-039" target="_blank"><b></b></a></p> </div><img alt="LR2 postmenopausal" data-id="CD011964-fig-0041" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-039.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-TST-039.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 39</div> <div class="figure-caption"> <p>LR2 postmenopausal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/references#CD011964-fig-0041">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-039.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0042"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-TST-040" target="_blank"><b></b></a></p> </div><img alt="LR2 all" data-id="CD011964-fig-0042" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-040.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-TST-040.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 40</div> <div class="figure-caption"> <p>LR2 all</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/references#CD011964-fig-0042">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-040.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0043"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-TST-041" target="_blank"><b></b></a></p> </div><img alt="ADNEX 3% D+ probability all" data-id="CD011964-fig-0043" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-041.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-TST-041.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 41</div> <div class="figure-caption"> <p>ADNEX 3% D+ probability all</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/references#CD011964-fig-0043">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-041.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0044"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-TST-042" target="_blank"><b></b></a></p> </div><img alt="ADNEX 3% D+ probability premenopausal" data-id="CD011964-fig-0044" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-042.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-TST-042.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 42</div> <div class="figure-caption"> <p>ADNEX 3% D+ probability premenopausal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/references#CD011964-fig-0044">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-042.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0045"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-TST-043" target="_blank"><b></b></a></p> </div><img alt="ADNEX 3% D+ probability postmenopausal" data-id="CD011964-fig-0045" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-043.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-TST-043.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 43</div> <div class="figure-caption"> <p>ADNEX 3% D+ probability postmenopausal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/references#CD011964-fig-0045">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-043.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0046"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-TST-044" target="_blank"><b></b></a></p> </div><img alt="ADNEX 5% D+ probability all" data-id="CD011964-fig-0046" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-044.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-TST-044.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 44</div> <div class="figure-caption"> <p>ADNEX 5% D+ probability all</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/references#CD011964-fig-0046">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-044.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0047"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-TST-045" target="_blank"><b></b></a></p> </div><img alt="ADNEX 5% D+ probability premenopausal" data-id="CD011964-fig-0047" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-045.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-TST-045.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 45</div> <div class="figure-caption"> <p>ADNEX 5% D+ probability premenopausal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/references#CD011964-fig-0047">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-045.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0048"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-TST-046" target="_blank"><b></b></a></p> </div><img alt="ADNEX 5% D+ probability postmenopausal" data-id="CD011964-fig-0048" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-046.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-TST-046.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 46</div> <div class="figure-caption"> <p>ADNEX 5% D+ probability postmenopausal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/references#CD011964-fig-0048">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-046.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0049"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-TST-047" target="_blank"><b></b></a></p> </div><img alt="ADNEX 10% D+ probability all" data-id="CD011964-fig-0049" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-047.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-TST-047.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 47</div> <div class="figure-caption"> <p>ADNEX 10% D+ probability all</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/references#CD011964-fig-0049">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-047.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0050"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-TST-048" target="_blank"><b></b></a></p> </div><img alt="ADNEX 10% D+ probability premenopausal" data-id="CD011964-fig-0050" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-048.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-TST-048.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 48</div> <div class="figure-caption"> <p>ADNEX 10% D+ probability premenopausal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/references#CD011964-fig-0050">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-048.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0051"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-TST-049" target="_blank"><b></b></a></p> </div><img alt="ADNEX 10% D+ probability postmenopausal" data-id="CD011964-fig-0051" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-049.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-TST-049.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 49</div> <div class="figure-caption"> <p>ADNEX 10% D+ probability postmenopausal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/references#CD011964-fig-0051">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-049.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0052"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-TST-050" target="_blank"><b></b></a></p> </div><img alt="ADNEX 15% D+ probability all" data-id="CD011964-fig-0052" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-050.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-TST-050.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 50</div> <div class="figure-caption"> <p>ADNEX 15% D+ probability all</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/references#CD011964-fig-0052">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-050.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0053"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-TST-051" target="_blank"><b></b></a></p> </div><img alt="ADNEX 15% D+ probability premenopausal" data-id="CD011964-fig-0053" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-051.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-TST-051.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 51</div> <div class="figure-caption"> <p>ADNEX 15% D+ probability premenopausal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/references#CD011964-fig-0053">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-051.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0054"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-TST-052" target="_blank"><b></b></a></p> </div><img alt="ADNEX 15% D+ probability postmenopausal" data-id="CD011964-fig-0054" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-052.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-TST-052.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 52</div> <div class="figure-caption"> <p>ADNEX 15% D+ probability postmenopausal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/references#CD011964-fig-0054">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-052.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0055"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-TST-067" target="_blank"><b></b></a></p> </div><img alt="RMI I mixed premenopausal" data-id="CD011964-fig-0055" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-067.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-TST-067.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 67</div> <div class="figure-caption"> <p>RMI I mixed premenopausal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/references#CD011964-fig-0055">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-067.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD011964-fig-0056"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/urn:x-wiley:14651858:media:CD011964:CD011964-TST-068" target="_blank"><b></b></a></p> </div><img alt="RMI I mixed postmenopausal" data-id="CD011964-fig-0056" src="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-068.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_t/tCD011964-TST-068.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Test 68</div> <div class="figure-caption"> <p>RMI I mixed postmenopausal</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/references#CD011964-fig-0056">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/media/CDSR/CD011964/image_n/nCD011964-TST-068.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD011964-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings for menopausal status, ultrasound scan and biomarker tests in pre‐ and postmenopausal women in secondary care (prevalence ovarian cancer 3%)</span></div> <tbody> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Review question</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Menopausal status, ultrasound scan and biomarker tests in combination for the diagnosis of ovarian cancer in women with symptoms suspicious for ovarian cancer </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Setting</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Secondary care</p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Reference standards</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>Histology in women who have undergone surgery and clinical follow‐up (&gt; 6 months) in women with negative index tests results who do not undergo surgery </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Study limitations</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign="top"> <p>For the participant selection domain, 44/59 (75%) studies were at high or unclear risk of bias because of concerns about selective recruitment of women. 58/59 (92%) studies were at high or unclear applicability concern for the participant selection domain because study participants were not symptomatic women. </p> <p>For the index test domain, 9/42 (21%) of ROMA studies, 11/20 (55%) of RMI studies, 2/4 (50%) of ADNEX studies, and 5/5 (100%) of LR2 studies were at high risk of bias because of lack of blinding of the index test or for ROMA studies because of no predefined threshold. Applicability concern was high or unclear for all RMI, ADNEX and LR2 studies because ultrasound was conducted by specialist sonographers or this was unclear. </p> <p>For the reference standard domain, 2/59 studies were at high risk of bias because the minimum length of follow‐up for index negatives was not reported or because of lack of blinding. Applicability concern was high or unclear in 50/59 (85%) studies because borderline tumours had been excluded from analysis or classification of borderline tumours for estimation of test accuracy was unclear. </p> <p>For the flow and timing domain, 45/59 (76%) studies were at unclear or high risk of bias because of no information about the interval between the index test and the reference standard or because not all participants receiving an index test received a reference standard. </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Population</b> </p> </th> <th align="center" class="headercell" colspan="6" rowspan="1" scope="col" valign="top"> <p><b>Premenopausal women</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Index test, threshold</b> </p> <p><b>Studies (participants)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Sensitivity (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Specificity</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Absolute sensitivity difference (95% CI) compared to RMI</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Absolute specificity difference (95% CI) compared to RMI</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Consequences in a hypothetical cohort of 1000 women assuming a prevalence of 3%*</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of women who would have their cancer missed (false‐negatives) (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of women who would test positive when they do not have ovarian cancer (false‐positives) (95% CI)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RMI 200</p> <p>17 (5233)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57.2 (50.3 to 63.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92.5 (90.3 to 94.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 (11 to 15)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73 (56 to 94)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ROMA 13.1 (± 2)</p> <p>27 (4463)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77.4 (72.7 to 81.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84.3 (81.2 to 87.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.2 (12.2 to 28.3);</p> <p>P &lt; 0.0001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–8.2 (–11.7 to –4.7); P &lt; 0.0001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7 (6 to 8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152 (126 to 182)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LR2 post‐test probability ovarian cancer 10%</p> <p>4 (2843)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83.3 (74.7 to 89.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90.4 (84.6 to 94.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.2 (16.2 to 36.2); P &lt; 0.0001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–2.1 (–7.2 to 2.9); P = 0.404</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (3 to 8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93 (57 to 149)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADNEX post‐test probability ovarian cancer 10%</p> <p>4 (1696)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95.5 (91.0 to 97.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77.8 (67.4 to 85.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.3 (30.9 to 45.8); P &lt; 0.0001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–14.8 (–24.0 to –5.5);</p> <p>P = 0.002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (1 to 3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>215 (141 to 316)</p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Population</b> </p> </th> <th align="center" class="headercell" colspan="6" rowspan="1" scope="col" valign="top"> <p><b>Postmenopausal women</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Index test, threshold</b> </p> <p><b>Studies (participants)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Sensitivity (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Specificity</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Absolute sensitivity difference (95% CI) compared to RMI</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Absolute specificity difference (95% CI) compared to RMI</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign=""> <p><b>Consequences in a hypothetical cohort of 1000 women assuming a prevalence of 3%*</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of women who would have their cancer missed (false‐negatives) (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Number of women who would test positive when they do not have ovarian cancer (false‐positives) (95% CI)</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RMI 200</p> <p>17 (4369)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78.4 (74.6 to 81.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85.4 (82.0 to 88.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6 (5 to 8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142 (114 to 175)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ROMA (27.7 (± 2))</p> <p>13 (2002)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90.3 (87.5 to 92.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81.5 (76.5 to 85.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.9 (7.6 to 16.3);</p> <p>P &lt; 0.0001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–3.9 (–9.4 to 1.5);</p> <p>P = 0.157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (2 to 4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179 (141 to 228)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LR2 post‐test probability ovarian cancer 10%</p> <p>5 (2157)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94.8 (92.3 to 96.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60.6 (50.5 to 69.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.4 (12.3 to 20.5); P &lt; 0.0001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–24.8 (–35.1 to –14.5); P &lt; 0.0001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (1 to 2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>382 (292 to 480)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADNEX post‐test probability ovarian cancer 10%</p> <p>4 (1365)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97.6 (95.6 to 98.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55.0 (42.8 to 66.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.2 (15.4 to 23.1); P &lt; 0.0001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–30.4 (–42.9 to –17.9); P &lt; 0.0001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 (0 to 1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>437 (324 to 555)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>*Estimate of disease prevalence (pretest probability) reflecting the NICE threshold for cancer referral from generalist to specialist settings in the UK (<a href="./references#CD011964-bbs2-0097" title="National Institute for Health and Care Excellence. Suspected cancer: recognition and referral. www.nice.org.uk/guidance/ng12 (accessed 22 May 2019).">NICE 2017</a>). Note this is considerably lower (3%) compared to the prevalence of ovarian cancer in included studies in the review (16% to 55%). </p> <p>ADNEX: Assessment of Different NEoplasias in the adneXa model; CI: confidence interval; LR2: Logistic Regression model 2; RMI: Risk of Malignancy Index; ROMA: Risk of Ovarian Malignancy Algorithm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Summary of findings for menopausal status, ultrasound scan and biomarker tests in pre‐ and postmenopausal women in secondary care (prevalence ovarian cancer 3%)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/full#CD011964-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011964-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Details of included test combinations</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Index test combination</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Details</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Test positivity thresholds included</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RMI I</p> <p><i>U</i> × <i>M</i> × CA125 </p> <p><a href="./references#CD011964-bbs2-0085" title="JacobsI , OramD , FairbanksJ , TurnerJ , FrostC , GrudzinskasJG . A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. British Journal of Obstetrics and Gynaecology1990;97(10):922-9.">Jacobs 1990</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ultrasound (U):</b> (1 point for each of multilocular cysts, solid areas, metastases, ascites and bilateral lesions) where a total ultrasound point score of 0 = 0, a point score of 1 = 1, and a point score of ≥ 2 = 3 </p> <p><b>Menopausal status (M):</b> premenopausal = 1 and postmenopausal = 3 </p> <p><b>Serum CA125:</b> CA125 U/mL applied directly to the calculation </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200, 250</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ROMA</p> <p><a href="./references#CD011964-bbs2-0004" title="BandieraE , RomaniC , SpecchiaC , ZanottiL , GalliC , RuggeriG , et al. Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management. Cancer Epidemiology, Biomarkers &amp; Prevention2011;20(12):2496-506. ">Bandiera 2011</a> </p> <p><a href="./references#CD011964-bbs2-0029" title="MooreRG , McMeekinDS , BrownAK , DiSilvestroP , MillerMC , AllardWJ , et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecologic Oncology2009;112(1):40-6. ">Moore 2009</a> </p> <p><a href="./references#CD011964-bbs2-0054" title="vanGorpT , CadronI , DespierreE , DaemenA , LeunenK , AmantF , et al. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. British Journal of Cancer2011;104(5):863-70. ">van Gorp 2011</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Premenopausal</b> PI = −12.0 + 2.38 × LN(HE4) + 0.0626 × LN(CA125) </p> <p><b>Postmenopausal</b> PI = −8.09 + 1.04 × LN(HE4) + 0.732 × LN(CA125) </p> <p><b>Predicted probability (ROMA score)</b> = exp(PI)/[1 + exp(PI)] × 100 </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Premenopausal 7.4 and postmenopausal 25.3</p> <p>Premenopausal 12.5 and postmenopausal 14.4</p> <p>Premenopausal 13.1 and postmenopausal 27.7</p> <p>± 2% from common (above) thresholds</p> <p>Premenopausal: 7.4 (5.4 to 9.4%), 12.5 (10.5 to 14.5%), 14.4 (12.4 to 16.4%)</p> <p>Postmenopausal: 25.3 (23.3 to 27.3%), 27.7 (25.7 to 29.7%)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LR2</p> <p><a href="./references#CD011964-bbs2-0051" title="TimmermanD , AmeyeL , FischerovaD , EpsteinE , MelisGB , GuerrieroS , et al. Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group. BMJ2010;341:c6839. ">Timmerman 2010</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>(3)</b> age of the woman (in years) </p> <p><b>(6)</b> presence of ascites (yes, 1; no, 0) </p> <p><b>(7)</b> presence of blood flow within a solid papillary projection (yes, 1; no, 0) </p> <p><b>(9)</b> maximum diameter of the solid component of the adnexal mass (expressed in millimetres, but with no increase 950 mm) </p> <p><b>(10)</b> irregular internal cyst walls (yes, 1; no, 0) </p> <p><b>(11)</b> presence of acoustic shadows (yes, 1; no, 0) </p> <p>The probability of malignancy is calculated using the formula y = 1/(1 + exp(jz)), where z = j5.3718 + 0.0354 <b>(3)</b> + 1.6159 <b>(6)</b> + 1.1768 <b>(7)</b> + 0.0697 <b>(9</b>) + </p> <p>0.9586 <b>(10)</b> j 2.9486 <b>(11</b>). The probability y is dichotomised at 0.1 to give a predictive diagnosis of cancer. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10% probability of ovarian cancer</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADNEX</p> <p><a href="./references#CD011964-bbs2-0052" title="vanCalsterB , vanHoordeK , ValentinL , TestaAC , FischerovaD , vanHolsbekeC , et al. Evaluating the risk of ovarian cancer before surgery using the ADNEX model to differentiate between benign, borderline, early and advanced stage invasive, and secondary metastatic tumours: prospective multicentre diagnostic study. BMJ2014;349:g5920. ">van Calster 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Age (years)</p> <p>Serum CA125 level (log transformed)</p> <p>Type of centre (oncology centres vs other hospitals)</p> <p>Maximum diameter of the lesion (log transformed)</p> <p>Proportion of solid tissue (with quadratic term)</p> <p>Number of papillary projections</p> <p>&gt; 10 cyst locules</p> <p>Acoustic shadows</p> <p>Ascites</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3%, 5%, 10% and 15% probability of ovarian cancer</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="3"> <div class="table-footnote"> <p>ADNEX: Assessment of Different NEoplasias in the adneXa model; LR2: Logistic Regression Model 2; RMI: Risk of Malignancy Index; ROMA: Risk of Ovarian Malignancy Algorithm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Details of included test combinations</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/full#CD011964-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011964-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary bivariate estimates of RMI I, ROMA, LR2 and ADNEX at all thresholds in pre‐ and postmenopausal women</span></div> <tbody> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign="bottom"> <p><b>Pooled sensitivity and specificity of RMI, ROMA, ADNEX, and LR2 at thresholds reported in included studies</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Score, threshold and menopause status</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Studies</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>OC cases</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Pooled sensitivity %</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Pooled specificity %</b> </p> <p><b>(95% CI)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign=""> <p><b>ROMA</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.4 (premenopausal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3051</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>342</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80.7 (69.6 to 88.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80.5 (73.8 to 85.9)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.3 (postmenopausal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1386</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>603</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86.8 (77.9 to 92.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87.6 (80.2 to 92.6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11.4 (premenopausal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2281</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>445</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80.9 (71.0 to 88.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84.1 (81.2 to 86.7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29.9 (postmenopausal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1797</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>851</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91.6 (84.2 to 95.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86.3 (80.1 to 90.7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12.5 (premenopausal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>302</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.5 (51.0 to 74.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>89.3 (80.8 to 94.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14.4 (postmenopausal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>299</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>177</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88.0 (80.6 to 92.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>68.3 (57.4 to 77.4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.1 (premenopausal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1353</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>158</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75.2 (67.0 to 81.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84.0 (78.4 to 88.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27.7 (postmenopausal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1265</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>556</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90.5 (86.2 to 93.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81.1 (75.7 to 85.5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7.4 ± 2 (premenopausal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3223</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>378</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>80.6 (71.5 to 87.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81.7 (75.7 to 86.5)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.3 ± 2 (postmenopausal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2599</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1049</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87.2 (81.7 to 91.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86.0 (80.3 to 90.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13.1 ± 2 (premenopausal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4463</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>825</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77.8 (72.5 to 82.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>84.3 (81.3 to 86.8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27.7 ± 2 (postmenopausal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>852</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90.4 (87.4 to 92.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81.3 (76.9 to 85.0)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign="top"> <p><b>RMI I</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200 (premenopausal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5233</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>851</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57.1 (50.6 to 63.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92.5 (90.0 to 94.4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200 (postmenopausal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4369</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1664</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78.7 (74.3 to 82.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85.5 (81.3 to 88.9)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p>Difference in sensitivity and specificity premenopausal vs postmenopausal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21.6 (13.9 to 29.2); P &lt; 0.0001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–6.9 (–11.3 to –2.6); P = 0.002</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>250 (premenopausal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>461</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59.5 (44.3 to 73.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>88.1 (84.6 to 90.8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>250 (postmenopausal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>220</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>82.5 (73.6 to 88.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79.7 (71.6 to 85.9)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>Difference in sensitivity and specificity premenopausal vs postmenopausal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23.0 (6.3 to 39.6); P = 0.007</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>–8.4 (–16.2 to –0.6); P = 0.034</p> </td> </tr> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign="top"> <p><b>LR2</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 (premenopausal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2843</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>619</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83.2 (78.6 to 87.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90.4 (84.6 to 94.1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 (postmenopausal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1124</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94.5 (92.8 to 95.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60.5 (49.3 to 70.7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p>Difference in sensitivity and specificity premenopausal vs postmenopausal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.2 (6.6 to 15.9); P &lt; 0.0001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–29.9 (–41.7 to –18.0); P &lt; 0.0001</p> </td> </tr> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign="top"> <p><b>ADNEX D+</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (premenopausal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1354</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>378</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97.9 (95.9 to 99.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56.6 (53.4 to 59.7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 (postmenopausal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1049</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>602</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99.5 (98.6 to 99.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.1 (21.1 to 29.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (premenopausal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1354</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>378</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97.6 (95.5 to 98.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69.5 (66.5 to 72.3)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (postmenopausal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1049</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>602</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98.8 (97.6 to 99.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37.4 (32.9 to 42.0)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 (premenopausal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1696</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>455</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94.9 (92.5 to 96.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78.2 (75.8 to 80.4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10 (postmenopausal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1365</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>749</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97.6 (96.2 to 98.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55.2 (51.2 to 59.1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p>Difference in sensitivity and specificity premenopausal vs postmenopausal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.7 (0.4 to 4.9); P = 0.023</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–23.0 (–27.5 to –18.4); P &lt; 0.0001</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 (premenopausal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1354</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>378</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90.5 (87.1 to 93.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83.4 (80.9 to 85.7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15 (postmenopausal)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1049</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>602</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96.5 (94.7 to 97.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63.5 (58.9 to 68.0)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>ADNEX: Assessment of Different NEoplasias in the adneXa model; CI: confidence interval; LR2: Logistic Regression model 2; OC: ovarian cancer; RMI: Risk of Malignancy Index; ROMA: Risk of Ovarian Malignancy Algorithm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Summary bivariate estimates of RMI I, ROMA, LR2 and ADNEX at all thresholds in pre‐ and postmenopausal women</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/full#CD011964-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011964-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Study characteristics: RMI I</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Author year</b> </p> <p><b>Country</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Setting</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Participants characteristics</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Index test threshold</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0001" title="AbdallaN , PiorkowskiR , PazuraM , CendrowskiK , SawickiW . Combined use of ultrasound and CA125 to predict malignancy in a patient with oviduct transitional carcinoma: case report. BJOG: an International Journal of Obstetrics and Gynaecology2017;124(Suppl 1):169. ">Abdalla 2017</a> </p> <p>Poland</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study criteria:</b> women scheduled to undergo surgery for adnexal tumours </p> <p><b>Clinical setting:</b> mixed </p> <p><b>Prior tests:</b> USS assessment of adnexal mass and measurement of tumour markers CA125 and HE4 within 5 days before surgical intervention </p> <p><b>Exclusions:</b> presence of fibroids &gt; 5 cm were excluded </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 312 </p> <p><b>Postmenopausal n (%):</b> 117 (37) </p> <p><b>Ovarian cancer n (%):</b> 45 (15) </p> <p><b>Borderline n (%):</b> 7 (2) </p> <p><b>Age:</b> range 18–85 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Threshold:</b> 200 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0002" title="Al MusalhiK , Al KindiM , Al AisaryF , RamadhanF , Al RawahiT , Al HataliK , et al. Evaluation of HE4, CA-125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) in the preoperative assessment of patients with adnexal mass. Oman Medical Journal2016;31(5):336-44. ">Al Musalhi 2016</a> </p> <p>Oman</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with an ovarian mass </p> <p><b>Clinical setting:</b> mixed </p> <p><b>Prior tests:</b> unclear but assume USS </p> <p><b>Exclusions:</b> none reported </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 213 </p> <p><b>Postmenopausal n (%):</b> 51 (24) </p> <p><b>Ovarian cancer n (%):</b> 48 (23) </p> <p><b>Borderline n (%):</b> 7 (3) </p> <p><b>Age:</b> not reported </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Threshold:</b> 200 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0003" title="AntonC , CarvalhoFM , OliveiraEI , MacielGA , BaracatEC , CarvalhoJP . A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses. Clinics (Sao Paulo, Brazil)2012;67(5):437-41. ">Anton 2012</a> </p> <p>Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women referred with pelvic mass diagnosed by USS, CT or MRI with signs of carcinomatosis undergoing surgery or image‐guided biopsy </p> <p><b>Clinical setting:</b> secondary care </p> <p><b>Prior tests:</b> unclear </p> <p><b>Exclusions:</b> none reported </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 120 </p> <p><b>Postmenopausal n (%):</b> 73 (60) </p> <p><b>Ovarian cancer n</b> <b>(%):</b> 30 (25) </p> <p><b>Borderline n (%):</b> 17 (14) </p> <p><b>Mean age:</b> malignant 54.7 years, borderline 56.4 years, benign 50.7 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Threshold:</b> 200 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0011" title="ErtasS , VuralF , VuralF , TufekciEC , ErtasAC , KoseG , et al. Predictive value of malignancy risk indices for ovarian masses in premenopausal and postmenopausal women. Asian Pacific Journal of Cancer Prevention2016;17(4):2177-83. ">Ertas 2016</a> </p> <p>Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with adnexal masses that underwent surgery </p> <p><b>Clinical setting:</b> tertiary </p> <p><b>Prior tests:</b> unclear </p> <p><b>Exclusions:</b> none reported </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n:</b> 408 </p> <p><b>Postmenopausal n (%):</b> 117 (71.4) </p> <p><b>Ovarian cancer n (%):</b> 55 (13) </p> <p><b>Borderline n (%):</b> 12 (3) </p> <p><b>Mean age:</b> benign 40.8 (SD 13.8) years, malignant 54.4 (SD 13.6) years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Threshold:</b> 200 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0015" title='IrshadF , IrshadM , NazM , Asim IkramM . Accuracy of "risk of malignancy index" in the preoperative diagnosis of ovarian malignancy in post menopausal women. Rawal Medical Journal2013;38(3):266-70. '>Irshad 2013</a> </p> <p>Pakistan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> unclear (ovarian masses) </p> <p><b>Clinical setting:</b> secondary </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> unclear </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 36 </p> <p><b>Postmenopausal n (%):</b> 36 (100) </p> <p><b>Ovarian cancer n (%)</b>: 24 (37) </p> <p><b>Borderline n (%):</b> not reported </p> <p><b>Mean age:</b> 58 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> 250 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0020" title="KrascsenitsG , BalazsB , DudnyikovaA , PurcsiK , OroszE , PeteI . Investigating the predictive value of RMI and ROMA indices in patients with ovarian tumors of uncertain dignity. Magyar Onkologia2016;60(4):320-7. ">Krascsenitis 2016</a> </p> <p>Hungary</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women diagnosed with an ovarian tumour of unknown significance admitted for surgery </p> <p><b>Clinical setting:</b> tertiary </p> <p><b>Prior tests:</b> not reported </p> <p><b>Exclusions:</b> none reported </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n:</b> 162 </p> <p><b>Postmenopausal n (%):</b> 102 (63) </p> <p><b>Ovarian cancer n (%):</b> 34 (21) </p> <p><b>Borderline n (%):</b> 11 (7) </p> <p><b>Mean age:</b> 55 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Threshold:</b> 200 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0022" title="LiestAL , OmranAS , MikiverR , RosenbergP , UppugunduriS . RMI and ROMA are equally effective in discriminating between benign and malignant gynecological tumors: a prospective population-based study. Acta Obstetricia et Gynecologica Scandinavica2019;98(1):24-33. ">Liest 2019</a> </p> <p>Sweden</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with a pelvic mass of probable ovarian origin and scheduled for surgery </p> <p><b>Clinical setting:</b> tertiary </p> <p><b>Prior tests:</b> preoperative USS </p> <p><b>Exclusions:</b> none reported </p> <p><b>Centre:</b> multicentre </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n:</b> 784 </p> <p><b>Postmenopausal n (%):</b> 117 (81) </p> <p><b>Ovarian cancer n (%):</b> 144 (18) (include borderline) </p> <p><b>Borderline n (%):</b> not reported </p> <p><b>Age:</b> not reported </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Threshold:</b> 200 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0023" title="LyckeM , KristjansdottirB , SundfeldtK . A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index. Gynecologic Oncology2018;151(1):159-65. ">Lycke 2018</a> </p> <p>Sweden</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women planned for a surgical procedure for a symptomatic/suspected malignant ovarian cyst or pelvic tumour </p> <p><b>Clinical setting:</b> mixed </p> <p><b>Prior tests:</b> unclear but assume history and examination, and USS from participant selection </p> <p><b>Exclusions:</b> none reported </p> <p><b>Centre:</b> multicentre </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n:</b> 638 </p> <p><b>Postmenopausal n (%):</b> 348 (55) </p> <p><b>Ovarian cancer n (%):</b> 162 (25) </p> <p><b>Borderline n (%):</b> 31 (5) </p> <p><b>Mean age:</b> benign 50.76 years, BOT 55.58 years, EOC 62.67 </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Threshold:</b> 200 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0024" title="Manegold-BrauerG , BuechelJ , Knipprath-MeszarosA , SchoetzauA , HackerNF , TercanliS , et al. Improved detection rate of ovarian cancer using a 2-step triage model of the risk of malignancy index and expert sonography in an outpatient screening setting. International Journal of Gynecological Cancer2016;26(6):1062-9. ">Manegold‐Brauer 2016</a> </p> <p>Switzerland</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women who had USS examination for an adnexal mass with histology and CA125 results available </p> <p><b>Clinical setting:</b> secondary </p> <p><b>Prior tests:</b> not reported </p> <p><b>Exclusions:</b> none reported </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 1108 </p> <p><b>Postmenopausal n (%):</b> 478 (43) </p> <p><b>Ovarian cancer n (%):</b> 118 (11) </p> <p><b>Borderline n (%):</b> 33 (3) </p> <p><b>Median age:</b> 48 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Threshold:</b> 200 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0026" title="MeysEM , JeelofLS , AchtenNM , SlangenBF , LambrechtsS , KruitwagenRF , et al. Estimating risk of malignancy in adnexal masses: external validation of the ADNEX model and comparison with other frequently used ultrasound methods. Ultrasound in Obstetrics &amp; Gynecology2017;49(6):784-92. ">Meys 2017</a> </p> <p>Netherlands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria</b>: women with adnexal pathology </p> <p><b>Clinical setting:</b> tertiary </p> <p><b>Prior tests:</b> not reported </p> <p><b>Exclusions:</b> none reported </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n:</b> 326 </p> <p><b>Postmenopausal n (%):</b> 198 (61) </p> <p><b>Ovarian cancer n (%):</b> 115 (35) </p> <p><b>Borderline n (%):</b> 27 (8) </p> <p><b>Median age:</b> benign 53.2 (IQR 16.1–87.2) years, malignant 67.7 (IQR 32.3–87) years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Threshold:</b> 200 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0031" title="NiemiRJ , SaarelainenSK , LuukkaalaTH , MaenpaaJU . Reliability of preoperative evaluation of postmenopausal ovarian tumors. Journal of Ovarian Research2017;10(1):15. ">Niemi 2017</a> </p> <p>Finland</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women aged &gt; 50 years presenting with an abnormal adnexal mass(es) </p> <p><b>Clinical setting:</b> tertiary </p> <p><b>Prior tests:</b> not reported </p> <p><b>Exclusions:</b> overtly benign or malignant‐appearing tumours such as unilocular simple ovarian cysts and tumours associated with marked ascites (depth of the greatest pool &gt; 10 cm) </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 98 </p> <p><b>Postmenopausal n (%):</b> 98 (100) </p> <p><b>Ovarian cancer n (%):</b> 23 (23) </p> <p><b>Borderline n (%):</b> 7 (7) </p> <p><b>Median age:</b> 61 (range 50–84) years </p> <p><b>Separated by menopausal status:</b> only postmenopausal included </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Threshold:</b> 200 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0032" title="NikolovaT , ZivadinovicR , EvtimovskaN , KlisarovskaV , StanojevicM , GeorgievskaJ , et al. Diagnostic performance of Human Epididymis protein4 compared to a combination of biophysical and biochemical markers to differentiate ovarian endometriosis from epithelial ovarian cancer in premenopausal women. Journal of Obstetrics and Gynaecology Research2017;43(12):1870-9. ">Nikolova 2016</a> </p> <p>Macedonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> premenopausal women with USS confirming an ovarian cyst/mass and undergoing surgery </p> <p><b>Clinical setting:</b> tertiary </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> postmenopausal women </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n:</b> 105 (analysed) </p> <p><b>Postmenopausal n (%):</b> 0 </p> <p><b>Ovarian cancer n (%):</b> 11 (10%) </p> <p><b>Borderline n (%):</b> not reported </p> <p><b>Mean age:</b> ovarian cancer 42.46 (SD 8.21) years, benign 36.90 (SD 10.12) years </p> <p><b>Separated by menopausal status:</b> only premenopausal women included </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Threshold:</b> 250 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0038" title="RadosaMP , CamaraO , VorwergkJ , DiebolderH , WinzerH , MothesA , et al. Preoperative multimodal strategies for risk assessment of adnexal masses: analysis of 1362 cases in a gynecologic cancer center. International Journal of Gynecological Cancer2011;21(6):1056-62. ">Radosa 2011</a> </p> <p>Germany</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with adnexal mass who subsequently underwent surgery were selected </p> <p><b>Clinical setting:</b> tertiary </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> none </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 442 </p> <p><b>Postmenopausal n (%):</b> 141 (32) </p> <p><b>Ovarian cancer n (%)</b>: 79 </p> <p><b>Borderline n (%):</b> 19 </p> <p><b>Mean age:</b> 43.3 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> 200 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0039" title="RichardsA , HerbstU , PatherS , SaidiS , Tejada-BergesT , WilliamsP , et al. HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses – a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2015;55(5):493-7. ">Richards 2015</a> </p> <p>Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women who were undergoing surgery for a complex pelvic mass, presumed to be arising from the ovary </p> <p><b>Clinical setting:</b> mixed </p> <p><b>Prior tests:</b> unclear </p> <p><b>Exclusions:</b> none reported </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n:</b> 50 </p> <p><b>Postmenopausal n (%):</b> 29 (58) </p> <p><b>Ovarian cancer n (%):</b> 16 (32) </p> <p><b>Borderline n (%):</b> 4 (8) </p> <p><b>Median age:</b> 60 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Threshold:</b> 200 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0042" title="SayasnehA , KaijserJ , PreislerJ , JohnsonS , StalderC , HusickaR , et al. A multicenter prospective external validation of the diagnostic performance of IOTA simple descriptors and rules to characterize ovarian masses. Gynecologic Oncology2013;130(1):140-6. [Sayasneh 2013]SayasnehA , WynantsL , PreislerJ , KaijserJ , JohnsonS , StalderC , et al. Multicentre external validation of IOTA prediction models and RMI by operators with varied training. British Journal of Cancer2013;108(12):2448-54. ">Sayasneh 2013a</a> </p> <p>UK</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women presenting with adnexal mass and undergoing surgery within 120 days after examination </p> <p><b>Clinical setting:</b> mixed </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> none </p> <p><b>Centre:</b> multicentre </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 255 </p> <p><b>Postmenopausal n (%):</b> 117 (46) </p> <p><b>Ovarian cancer n (%)</b>: 48 (19) </p> <p><b>Borderline n (%):</b> 18 (7) </p> <p><b>Mean age:</b> 46 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> 200 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0049" title="TerzicM , DotlicJ , LikicI , BrndusicN , PilicI , LadjevicN , et al. Risk of malignancy index validity assessment in premenopausal and postmenopausal women with adnexal tumors. Taiwanese Journal of Obstetrics &amp; Gynecology2013;52(2):253-7. ">Terzic 2013</a> </p> <p>Serbia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women treated for adnexal tumours </p> <p><b>Clinical setting:</b> secondary </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> none </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 689 </p> <p><b>Postmenopausal n (%):</b> 138 (20) </p> <p><b>Ovarian cancer n (%)</b>: 112 (16) </p> <p><b>Borderline n (%):</b> 33 (5) </p> <p><b>Mean age:</b> benign 42.8 years, borderline: 53.6 years, malignant 57.25 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> 250 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0050" title="TestaA , KaijserJ , WynantsL , FischerovaD , vanHolsbekeC , FranchiD , et al. Strategies to diagnose ovarian cancer: new evidence from phase 3 of the multicentre international IOTA study. British Journal of Cancer2014;111(4):680-8. ">Testa 2014</a> </p> <p>European countries</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women presenting with adnexal mass and undergoing TVS by 1 of the principal investigators and surgery within 120 days after examination </p> <p><b>Clinical setting:</b> mixed </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> none </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 2403 </p> <p><b>Postmenopausal n (%):</b> 1049 (44) </p> <p><b>Ovarian cancer n (%)</b>: 701 (29) </p> <p><b>Borderline n (%):</b> 153 (6) </p> <p><b>Age:</b> not reported </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> 200 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0053" title="vanden AkkerPA , ZusterzeelPL , AaldersAL , SnijdersMP , SamlalRA , VolleberghJH , et al. Use of risk of malignancy index to indicate frozen section analysis in the surgical care of women with ovarian tumors. International Journal of Gynaecology &amp; Obstetrics2016;133(3):355-8. ">van den Akker 2016</a> </p> <p>Netherlands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women admitted for surgical treatment of an ovarian mass with unknown histology </p> <p><b>Clinical setting:</b> mixed </p> <p><b>Prior tests:</b> not reported </p> <p><b>Exclusions:</b> women with clear evidence of malignancy found before or during the surgical procedure (e.g. pleural effusions and evidence of distal organ involvement) </p> <p><b>Centre:</b> multicentre </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 670 </p> <p><b>Postmenopausal n (%):</b> 390 (58) </p> <p><b>Ovarian cancer n (%):</b> 93 (14) </p> <p><b>Borderline n (%):</b> 46 (6) </p> <p><b>Median age:</b> 54 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Threshold:</b> 200 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0055" title="KaijserJ , vanGorpT , SmetME , vanHolsbekeC , SayasnehA , EpsteinE , et al. Are serum HE4 or ROMA scores useful to experienced examiners for improving characterization of adnexal masses after transvaginal ultrasonography?Ultrasound in Obstetrics &amp; Gynecology2014;43(1):89-97. [Secondary publication Kaijser 2014]vanGorpT , VeldmanJ , vanCalsterB , CadronI , LeunenK , AmantF , et al. Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses. European Journal of Cancer2012;48(11):1649-56. ">van Gorp 2012</a> </p> <p>Belgium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with a pelvic mass, scheduled for surgery </p> <p><b>Clinical setting:</b> secondary </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> none </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 374 </p> <p><b>Postmenopausal n (%):</b> 196 (52) </p> <p><b>Ovarian cancer n (%)</b>: 94 (25) </p> <p><b>Borderline n (%):</b> 31 (8) </p> <p><b>Mean age:</b> benign 46.2 years, malignant 57.7 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> 200 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0056" title="VuralF , AkaN , ErtasS , KoseG , TufekciEC . The ovarian cancers in geriatric population: the validity of inflammatory markers, malignancy risk indices 1, 2, 3, 4, and CA-125 levels in malignancy discrimination of adnexal masses. European Journal of Gynaecological Oncology2016;37(6):846-51. ">Vural 2016</a> </p> <p>Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria</b>: postmenopausal women with adnexal masses who underwent surgery </p> <p><b>Clinical setting:</b> tertiary </p> <p><b>Prior tests:</b> not reported </p> <p><b>Exclusions:</b> premenopausal women </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n:</b> 139 </p> <p><b>Postmenopausal n (%):</b> 139 (100) </p> <p><b>Ovarian cancer n (%):</b> 44 (32) </p> <p><b>Borderline n (%):</b> 8 (6) </p> <p><b>Mean age:</b> 61.1 (SD 8.9) years (range 42–87 years) </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Threshold:</b> 200 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>*Thresholds extracted for RMI I: 200 and 250.</p> <p>BOT: borderline ovarian tumour; CT: computed tomography; EOC: epithelial ovarian cancer; HE4: Human Epididymis protein; IQR: interquartile range; MRI: magnetic resonance imaging; n: number of participants; RMI I: Risk of Malignancy Index I; SD: standard deviation; TVS: transvaginal ultrasound; USS: ultrasound scan. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Study characteristics: RMI I</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/full#CD011964-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011964-tbl-0005"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Study characteristics: ROMA</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Author year</b> </p> <p><b>Country</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Setting</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Participant characteristics</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Index test threshold*</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0002" title="Al MusalhiK , Al KindiM , Al AisaryF , RamadhanF , Al RawahiT , Al HataliK , et al. Evaluation of HE4, CA-125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) in the preoperative assessment of patients with adnexal mass. Oman Medical Journal2016;31(5):336-44. ">Al Musalhi 2016</a> </p> <p>Oman</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with an ovarian mass </p> <p><b>Clinical setting:</b> mixed </p> <p><b>Prior tests:</b> unclear but assumed USS </p> <p><b>Exclusions:</b> none reported </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 213 </p> <p><b>Postmenopausal n (%):</b> 51 (24) </p> <p><b>Ovarian cancer n (%):</b> 48 (23) </p> <p><b>Borderline n (%):</b> 7 (3) </p> <p><b>Age:</b> not reported </p> <p><b>Separated by menopausal</b> </p> <p><b>status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Threshold:</b> premenopausal 13.1, postmenopausal 27.7 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0003" title="AntonC , CarvalhoFM , OliveiraEI , MacielGA , BaracatEC , CarvalhoJP . A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses. Clinics (Sao Paulo, Brazil)2012;67(5):437-41. ">Anton 2012</a> </p> <p>Brazil</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with signs of carcinomatosis with a pelvic mass diagnosed by US, CT or MRI undergoing surgery or image‐guided biopsy </p> <p><b>Clinical setting:</b> secondary care </p> <p><b>Prior tests:</b> not reported </p> <p><b>Exclusions</b>: none reported </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 120 </p> <p><b>Postmenopausal n (%):</b> 73 (60.8%) </p> <p><b>Ovarian cancer n (%):</b> 30 (25%) </p> <p><b>Borderline n (%):</b> 17 (14%) </p> <p><b>Mean age:</b> malignant 54.7 years, borderline 56.4 years, benign 50.73 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 13.1, postmenopausal 27.7 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0004" title="BandieraE , RomaniC , SpecchiaC , ZanottiL , GalliC , RuggeriG , et al. Serum human epididymis protein 4 and risk for ovarian malignancy algorithm as new diagnostic and prognostic tools for epithelial ovarian cancer management. Cancer Epidemiology, Biomarkers &amp; Prevention2011;20(12):2496-506. ">Bandiera 2011</a> </p> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> not reported </p> <p><b>Clinical setting:</b> tertiary care </p> <p><b>Prior tests:</b> not reported </p> <p><b>Exclusions:</b> non‐EOC </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 278 </p> <p><b>Postmenopausal n (%):</b> 183 (65.8) </p> <p><b>Ovarian cancer n (%):</b> 113 (41) </p> <p><b>Borderline n (%):</b> not reported </p> <p><b>Mean age:</b> premenopausal: malignant 44.7 years, benign 41.5 years; postmenopausal: malignant 66.3 years, benign 64.0 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 7.4, postmenopausal 25.3 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0005" title="ChanKK , ChenCA , NamJH , OchiaiK , WilailakS , ChoonAT , et al. The use of HE4 in the prediction of ovarian cancer in Asian women with a pelvic mass. Gynecologic Oncology2013;128(2):239-44. WilailakS , ChanKK , ChenCA , NamJH , OchiaiK , AwTC , et al. Distinguishing benign from malignant pelvic mass utilizing an algorithm with HE4, menopausal status, and ultrasound findings. Journal of Gynecologic Oncology2015;26(1):46-53. [Secondary publication]">Chan 2013</a> </p> <p>Asia‐Pacific region</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women aged &gt; 18 years diagnosed with adnexal mass diagnosed by any imaging method (US, CT or MRI) </p> <p><b>Clinical setting:</b> unclear </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> none </p> <p><b>Centre:</b> multicentre </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 414 </p> <p><b>Postmenopausal n (%):</b> 26 (108) </p> <p><b>Ovarian cancer n (%):</b> 74 (18) </p> <p><b>Borderline n (%):</b> 16 (4) </p> <p><b>Age mean:</b> not reported </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 7.4, </p> <p>postmenopausal 25.3</p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0007" title="ChenX , ZhouH , ChenR , HeJ , WangY , HuangL , et al. Development of a multimarker assay for differential diagnosis of benign and malignant pelvic masses. Clinica Chimica Acta2015;440:57-63. ">Chen 2015</a> </p> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with pelvic masses scheduled for surgery </p> <p><b>Clinical setting:</b> unclear </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> none </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 130 </p> <p><b>Postmenopausal n (%):</b> 62 (48) </p> <p><b>Ovarian cancer n (%):</b> 60 (46) </p> <p><b>Borderline n (%):</b> not reported </p> <p><b>Median age:</b> benign 34 years, malignant 53 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 11.4, postmenopausal 29.9 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0006" title="ChenWT , GaoX , HanXD , ZhengH , GuoL , LuRQ . HE4 as a serum biomarker for ROMA prediction and prognosis of epithelial ovarian cancer. Asian Pacific Journal of Cancer Prevention2014;15(1):101-5. ">Chen 2014</a> </p> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with EOC and benign lesions </p> <p><b>Clinical setting:</b> tertiary </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> women with non‐EOC </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 192 </p> <p><b>Postmenopausal n (%):</b> 84 (44) </p> <p><b>Ovarian cancer n (%):</b> 123 (64) </p> <p><b>Borderline n (%):</b> not reported </p> <p><b>Age mean:</b> not reported </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 12.2, postmenopausal 25.8 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0008" title="Chudecka-GlazAM . ROMA, an algorithm for ovarian cancer. Clinica Chimica Acta2015;440:143-51. ">Chudecka‐Glaz 2015</a> </p> <p>Poland</p> <p>(ROMA and ROMA‐P)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> consecutive women who attended the hospital presenting with suspected ovarian cancer (ovarian tumour, ovarian cyst, or ascites) </p> <p><b>Clinical setting:</b> tertiary </p> <p><b>Prior test:</b> not reported </p> <p><b>Exclusions:</b> none reported </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 413 </p> <p><b>Postmenopausal (%):</b> 251 (61) </p> <p><b>Ovarian cancer n (%):</b> 162 (39%) </p> <p><b>Borderline n (%):</b> not reported </p> <p><b>Age median:</b> benign 35 years, malignant 59.7 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>a) ROMA</b> </p> <p><b>Thresholds:</b> premenopausal 14.1, postmenopausal 25 </p> <p><b>Prespecified:</b> yes </p> <p><b>b) ROMA‐P</b> </p> <p><b>Thresholds:</b> determined by age group in both pre‐ and postmenopausal; age group included: &lt; 20 years, 21–30 years, 31–40 years, 41–50 years, 51–60 years, 61–70 years, 71–80 years, and &gt; 80 years </p> <p><b>Prespecified:</b> no </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0009" title="CradicKW , LashoMA , Algeciras-SchimnichA . Validation of the cut-points recommended for ROMA using the Roche Elecsys CA125 and HE4 assays. Annals of Clinical &amp; Laboratory Science2018;48(1):90-3. ">Cradic 2018</a> </p> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with EOC or benign ovarian lesions </p> <p><b>Clinical setting:</b> tertiary </p> <p><b>Prior test:</b> not reported </p> <p><b>Exclusions:</b> not reported </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 207 </p> <p><b>Postmenopausal n (%):</b> 93 (45) </p> <p><b>Ovarian cancer n (%):</b> 76 (37) (EOC) </p> <p><b>Borderline n (%):</b> not reported </p> <p><b>Age mean:</b> not reported </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 11.4, postmenopausal 29.9 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0010" title="DikmenZG , ColakA , DoganP , TuncerS , AkbiyikF . Diagnostic performances of CA125, HE4, and ROMA index in ovarian cancer. European Journal of Gynaecological Oncology2015;36(4):457-62. ">Dikmen 2015</a> </p> <p>Turkey</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women were 'preoperative' </p> <p><b>Clinical setting:</b> unclear </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> none reported </p> <p><b>Centre:</b> unclear </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>n:</b> 143 </p> <p><b>Postmenopausal n (%):</b> 46 (32%) </p> <p><b>Ovarian cancer n (%):</b> 47 (33%) </p> <p><b>Borderline n (%):</b> not reported </p> <p><b>Age mean:</b> benign 42 (SD 10) years, malignant 56 (SD 14) years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 13.1, postmenopausal 27.7 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0012" title="FarzanehF , HonarvarZ , YaraghiM , YaseriM , ArabM , HosseiniM , et al. Preoperative evaluation of risk of ovarian malignancy algorithm index in prediction of malignancy of adnexal masses. Iranian Red Crescent Medical Journal2014;16(6):e17185. ">Farzaneh 2014</a> </p> <p>Iran</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with adnexal mass undergoing surgery and having attained menarche 12 months before presenting with adnexal mass </p> <p><b>Clinical setting:</b> secondary </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> non‐EOC </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 99 </p> <p><b>Postmenopausal n (%):</b> 31 (31) </p> <p><b>Ovarian cancer n (%):</b> 43 (43) (EOC) </p> <p><b>Borderline n (%):</b> not reported </p> <p><b>Mean age:</b> benign 39 years, malignant 51 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 11.5, postmenopausal 25.5 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0013" title="GrenacheDG , HeichmanKA , WernerTL , VuceticZ . Clinical performance of two multi-marker blood tests for predicting malignancy in women with an adnexal mass. Clinica Chimica Acta2015;438:358-63. ">Grenache 2015</a> </p> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with abnormal adnexal mass detected on physical examination and imaging Included USS, CT or MRI) followed by surgery </p> <p><b>Clinical setting:</b> unclear </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> unclear </p> <p><b>Centre:</b> multicentre </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 146 </p> <p><b>Postmenopausal n (%):</b> 76 (52) </p> <p><b>Ovarian cancer n (%):</b> 19 (13) </p> <p><b>Borderline n (%):</b> 7 (5) </p> <p><b>Mean age:</b> 52 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 8.6 and 13.1, postmenopausal 27.7 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0014" title="HuyNV , vanKhoaV , TamLM , VinhTQ , TungNS , ThanhCN , et al. Standard and optimal cut-off values of serum ca-125, HE4 and ROMA in preoperative prediction of ovarian cancer in Vietnam. Gynecologic Oncology Reports2018;25:110-4. ">Huy 2018</a> </p> <p>Vietnam</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Study criteria:</b> women with sufficient personal information, clinical symptoms, data on serum CA125 and serum HE4 levels, and postoperative pathologic findings </p> <p><b>Clinical setting:</b> mixed </p> <p><b>Prior test:</b> not reported </p> <p><b>Exclusions:</b> unclear borderline cases </p> <p><b>Centre:</b> single </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 277 </p> <p><b>Postmenopausal n (%):</b> 47 (17) </p> <p><b>Ovarian cancer n (%):</b> 30 (11) (EOC only) </p> <p><b>Borderline n (%):</b> not reported </p> <p><b>Age:</b> not reported </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 7.4, postmenopausal 25.3 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0017" title="KarlsenMA , SandhuN , HogdallC , ChristensenIJ , NedergaardL , LundvallL , et al. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass. Gynecologic Oncology2012;127(2):379-83. ">Karlsen 2012</a> </p> <p>Denmark</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women admitted to surgery for pelvic mass or pelvic pain potentially caused by malignant disease or endometriosis </p> <p><b>Clinical setting:</b> secondary </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> none </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 1218 </p> <p><b>Postmenopausal n (%):</b> 621 (51) </p> <p><b>Ovarian cancer n (%):</b> 261 (21) </p> <p><b>Borderline n (%):</b> 79 (6) </p> <p><b>Age mean:</b> not reported </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 7.4, postmenopausal 25.3 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0016" title="KadijaS , StefanovicA , JeremicK , RadojevicMM , NikolicL , MarkovicI , et al. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis. International Journal of Gynecological Cancer2012;22(2):238-44. ">Kadija 2012</a> </p> <p>Serbia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women diagnosed with adnexal mass scheduled to undergo surgery </p> <p><b>Clinical setting:</b> secondary </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> none </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 108 </p> <p><b>Postmenopausal n (%):</b> 41 (38) </p> <p><b>Ovarian cancer n (%):</b> 24 (22) </p> <p><b>Borderline n (%):</b> 5 (5) </p> <p><b>Age:</b> not reported </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 12.5, postmenopausal 14.4 </p> <p><b>Prespecified:</b> no </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0018" title="KimYM , WhangDH , ParkJ , KimSH , LeeSW , ParkHA , et al. Evaluation of the accuracy of serum Human Epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case-control study in a Korean population. Clinical Chemistry &amp; Laboratory Medicine2011;49(3):527-34. ">Kim 2011</a> </p> <p>South Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women diagnosed with adnexal mass on the first visit to the gynaecological oncology clinic and underwent surgery </p> <p><b>Clinical setting:</b> tertiary </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> only EOC included </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 159 </p> <p><b>Postmenopausal n (%):</b> 108 (68) </p> <p><b>Ovarian cancer n (%):</b> 68 (43) </p> <p><b>Borderline n (%):</b> 10 (6) </p> <p><b>Mean age:</b> benign 35.7, malignant 51.7 </p> <p><b>Separated by menopausal status:</b> **yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Threshold:</b> premenopausal 7.6 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0019" title="KimB , ParkY , AhnHJ , LeeKA , ChungJE , HanSW . Diagnostic performance of CA 125, HE4, and risk of Ovarian Malignancy Algorithm for ovarian cancer. Journal of Clinical Laboratory Analysis2019;33(1):e22624. ">Kim 2019</a> </p> <p>Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with suspected gynaecological disease </p> <p><b>Clinical setting:</b> tertiary </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> unclear; presume BOT excluded as retrospective </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 832 </p> <p><b>Postmenopausal n (%):</b> 251 (30) </p> <p><b>Ovarian cancer n (%):</b> 70 (8) </p> <p><b>Borderline n (%):</b> not reported </p> <p><b>Median age:</b> benign 45.0 (IQR 36.0–51.0) years, malignant 64.0 (IQR 50.9–77.0) years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 11.4, postmenopausal 29.9 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0020" title="KrascsenitsG , BalazsB , DudnyikovaA , PurcsiK , OroszE , PeteI . Investigating the predictive value of RMI and ROMA indices in patients with ovarian tumors of uncertain dignity. Magyar Onkologia2016;60(4):320-7. ">Krascsenitis 2016</a> </p> <p>Hungary</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women diagnosed with an ovarian tumour of unknown significance admitted for surgery </p> <p><b>Clinical setting:</b> tertiary </p> <p><b>Prior tests:</b> not reported </p> <p><b>Exclusions:</b> none reported </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 162 </p> <p><b>Postmenopausal n (%):</b> 102 (63) </p> <p><b>Ovarian cancer n (%):</b> 34 (21) </p> <p><b>Borderline n (%):</b> 11 (7) </p> <p><b>Mean age:</b> 55 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 11.4, postmenopausal 29.9 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0021" title="LiL , WanJ , CaiG , YuanL , LiangJ , SongJ , et al. Value of serum human epididymis secretory protein 4 as a marker for differential diagnosis of malignant and benign gynecological diseases of patients in southern China. Clinica Chimica Acta2016;459:170-6. ">Li 2016</a> </p> <p><b>China</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women diagnosed with gynaecological diseases by US, CT scan, PET‐CT scan or MRI </p> <p><b>Clinical setting:</b> unclear </p> <p><b>Prior test:</b> not reported </p> <p><b>Exclusions:</b> none </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 916 </p> <p><b>Postmenopausal n (%):</b> 172 (19) </p> <p><b>Ovarian cancer n (%):</b> 190 </p> <p><b>Borderline n (%):</b> not reported </p> <p><b>Median age:</b> 50 years (range 18–82 years) </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 7.4, postmenopausal 25.3 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0022" title="LiestAL , OmranAS , MikiverR , RosenbergP , UppugunduriS . RMI and ROMA are equally effective in discriminating between benign and malignant gynecological tumors: a prospective population-based study. Acta Obstetricia et Gynecologica Scandinavica2019;98(1):24-33. ">Liest 2019</a> </p> <p>Sweden</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with a pelvic mass of probable ovarian origin and scheduled for surgery </p> <p><b>Clinical setting:</b> tertiary </p> <p><b>Prior tests:</b> preoperative US </p> <p><b>Exclusions:</b> none reported </p> <p><b>Centre:</b> multicentre </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 784 </p> <p><b>Postmenopausal n (%):</b> 117 (81) </p> <p><b>Ovarian cancer n (%):</b> 144 (18) (EOC + borderline) </p> <p><b>Borderline n (%):</b> not reported </p> <p><b>Mean age:</b> not reported </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 11, postmenopausal 25 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0023" title="LyckeM , KristjansdottirB , SundfeldtK . A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index. Gynecologic Oncology2018;151(1):159-65. ">Lycke 2018</a> </p> <p>Sweden</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women planned for a surgical procedure for a symptomatic/suspected malignant ovarian cyst or pelvic </p> <p>tumour</p> <p><b>Clinical setting:</b> mixed </p> <p><b>Prior tests:</b> unclear but assume history and examination, and US from patient selection </p> <p><b>Exclusions:</b> none </p> <p><b>Centre:</b> multicentre </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 638 </p> <p><b>Postmenopausal n (%):</b> 348 (55) </p> <p><b>Ovarian cancer n (%):</b> 162 (25) (EOC only) </p> <p><b>Borderline n (%):</b> 31 (5) </p> <p><b>Mean age:</b> benign 50.76 years, BOT 55.58 years, EOC 62.67 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 11.4, postmenopausal 29.9 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0025" title="MeloA , VerissimoR , FarinhaM , MartinsNN , MartinsFN . Discriminative value of CA-125, HE4, risk of Malignancy Index II (RMI-II) and risk of malignancy algorithm (ROMA) in the differential diagnosis of pelvic masses: conclusions from a referral centre in Portugal. Journal of Obstetrics &amp; Gynaecology2018;38(8):1140-5. ">Melo 2018</a> </p> <p>Portugal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with adnexal neoplasia submitted to surgical treatment, with a histological diagnosis and in which ROMA had been determined </p> <p><b>Clinical setting:</b> tertiary </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> none reported but age group unclear </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 247 </p> <p><b>Postmenopausal n (%):</b> 92 (37) </p> <p><b>Ovarian cancer n (%):</b> 34 (14) </p> <p><b>Borderline n (%):</b> 7 (3) </p> <p><b>Age:</b> not reported </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 7.4, postmenopausal 25.3 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0027" title="MolinaR , EscuderoJM , AugeJM , FilellaX , FojL , TorneA , et al. HE4 a novel tumour marker for ovarian cancer: comparison with CA 125 and ROMA algorithm in patients with gynaecological diseases. Tumour Biology2011;32(6):1087-95. [1010-4283]">Molina 2011</a> </p> <p>Spain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> not reported </p> <p><b>Clinical setting:</b> unclear </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> none </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 396 </p> <p><b>Postmenopausal n (%):</b> 143 (36) </p> <p><b>Ovarian cancer n (%):</b> 111 (28) </p> <p><b>Borderline n (%):</b> not reported </p> <p><b>Age:</b> not reported </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 13.1, postmenopausal 27.7 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0028" title="MontagnanaM , DaneseE , RuzzenenteO , BrescianiV , NuzzoT , GelatiM , et al. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?Clinical Chemistry &amp; Laboratory Medicine2011;49(3):521-5. ">Montagnana 2011</a> </p> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with pelvic mass scheduled to have radical surgery </p> <p><b>Clinical setting:</b> secondary </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> only EOC included </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 104 </p> <p><b>Postmenopausal n (%):</b> 53 (51) </p> <p><b>Ovarian cancer n (%):</b> 55 (53) </p> <p><b>Borderline n (%): e</b>xcluded </p> <p><b>Mean age:</b> malignant 56.9 years, benign 42 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 12.5, postmenopausal 14.4 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0029" title="MooreRG , McMeekinDS , BrownAK , DiSilvestroP , MillerMC , AllardWJ , et al. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass. Gynecologic Oncology2009;112(1):40-6. ">Moore 2009</a> </p> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with ovarian cyst scheduled to undergo surgery </p> <p><b>Clinical setting:</b> unclear </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> none </p> <p><b>Centre:</b> multicentre </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 513 </p> <p><b>Postmenopausal n (%):</b> 150 (29) </p> <p><b>Ovarian cancer n (%):</b> 143 (28) </p> <p><b>Borderline n (%):</b> 22 (4) </p> <p><b>Mean age:</b> 54 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 13.1, postmenopausal 27.7 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0030" title="MooreRG , MillerMC , DisilvestroP , LandrumLM , GajewskiW , BallJJ , et al. Evaluation of the diagnostic accuracy of the risk of ovarian malignancy algorithm in women with a pelvic mass. Obstetrics &amp; Gynecology2011;118(2 Pt 1):280-8. ">Moore 2011</a> </p> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with ovarian cyst scheduled to undergo surgery </p> <p><b>Clinical setting:</b> mixed </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> none </p> <p><b>Centre:</b> multicentre </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 472 </p> <p><b>Postmenopausal n (%):</b> 217 (46) </p> <p><b>Ovarian cancer n (%):</b> 68 (14) </p> <p><b>Borderline n (%):</b> 19 (4) </p> <p><b>Mean age:</b> 50.3 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 13.1, postmenopausal 27.7 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0032" title="NikolovaT , ZivadinovicR , EvtimovskaN , KlisarovskaV , StanojevicM , GeorgievskaJ , et al. Diagnostic performance of Human Epididymis protein4 compared to a combination of biophysical and biochemical markers to differentiate ovarian endometriosis from epithelial ovarian cancer in premenopausal women. Journal of Obstetrics and Gynaecology Research2017;43(12):1870-9. ">Nikolova 2016</a> </p> <p>Macedonia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> premenopausal women to have an USS confirming an ovarian cyst/mass and to undergo surgery </p> <p><b>Clinical setting:</b> tertiary </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> postmenopausal women </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 105 (analysed) </p> <p><b>Postmenopausal n (%):</b> 0 </p> <p><b>Ovarian cancer n (%):</b> 11 (10%) (EOC only) </p> <p><b>Borderline n (%):</b> not reported </p> <p><b>Mean age:</b> malignant 42.46 (SD 8.21) years, benign 36.90 (SD 10.12) years </p> <p><b>Separated by menopausal status:</b> only premenopausal women included </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 7.4 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0033" title="NovotnyZ , PreslJ , KuceraR , TopolcanO , VrzalovaJ , FuchsovaR , et al. HE4 and ROMA index in Czech postmenopausal women. Anticancer Research2012;32(9):4137-40. ">Novotny 2012</a> </p> <p>Czech Republic</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with pelvic abnormalities </p> <p><b>Clinical setting:</b> secondary </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> premenopausal women </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 256 </p> <p><b>Postmenopausal n (%):</b> 256 (100) </p> <p><b>Ovarian cancer n (%):</b> 21 (8) </p> <p><b>Borderline n (%):</b> not reported </p> <p><b>Mean age:</b> benign 65.28 years, malignant 64.37 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> postmenopausal 26.3 </p> <p><b>Prespecified:</b> no </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0034" title="Ortiz-MunozB , Aznar-OrovalE , Garcia GarciaA , Covisa PerisA , Perez BallesteroP , Sanchez YepesM , et al. HE4, Ca125 and ROMA algorithm for differential diagnosis between benign gynaecological diseases and ovarian cancer. Tumour Biology2014;35(7):7249-58. ">Ortiz‐Munoz 2014</a> </p> <p>Spain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with gynaecological symptoms, diagnosed with primary ovarian cancer </p> <p><b>Clinical setting:</b> tertiary </p> <p><b>Prior test:</b> symptoms </p> <p><b>Exclusions:</b> none </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 148 </p> <p><b>Postmenopausal n (%):</b> 104 (70) </p> <p><b>Ovarian cancer n (%):</b> 29 (20) </p> <p><b>Borderline n (%):</b> not reported </p> <p><b>Age:</b> not reported </p> <p><b>Separated by menopausal status:</b> **yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 11.4, postmenopausal 29.9 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0035" title="ParkH , ShinJ , LeeDW , KimMJ , LeeHN . Diagnostic accuracy of the risk of Ovarian Malignancy Algorithm in clinical practice at a single hospital in Korea. Annals of Laboratory Medicine2019;39(3):252-62. ">Park 2019</a> </p> <p>Korea</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women for whom gynaecologists had requested HE4, CA125 and ROMA tests to evaluate a pelvic mass </p> <p><b>Clinical setting:</b> secondary </p> <p><b>Prior test:</b> USS, CT or MRI </p> <p><b>Exclusions:</b> 2 cases of non‐EOC excluded from analysis </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 433 (biopsy 309; follow‐up 134) </p> <p><b>Postmenopausal n (%):</b> biopsy: 81 (26), follow‐up: 37 (28) </p> <p><b>Ovarian cancer n (%):</b> 18 (4) </p> <p><b>Borderline n (%):</b> 15 (3) </p> <p><b>Median age:</b> benign 43.0 (SD 21.0) years, malignant 52.3 (SD 6.1) years, BOT 47.8 (SD 12.9) years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 7.4, postmenopausal 25.3 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0036" title="PartheenK , KristjansdottirB , SundfeldtK . Evaluation of ovarian cancer biomarkers HE4 and CA-125 in women presenting with a suspicious cystic ovarian mass. Journal of Gynecologic Oncology2011;22(4):244-52. ">Partheen 2011a</a> </p> <p>Sweden</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with complex cystic mass and suspicious of malignancy undergoing surgery </p> <p><b>Clinical setting:</b> tertiary </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> solid and unilocular mass </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 374 </p> <p><b>Postmenopausal n (%):</b> 276 (74) </p> <p><b>Ovarian cancer n (%):</b> 108 (29) </p> <p><b>Borderline n (%):</b> 45 (12) </p> <p><b>Age:</b> not reported </p> <p><b>Separated by menopausal status:</b> **yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 17.3, postmenopausal 26.0 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0037" title="PrskaloZS , GaceM , DobrijevicS , MayerL . Benefits human epidydimis protein (HE4) compared to traditional used tumor markers in gynecological oncology. Libri Oncologici2015;43(1-3):9-14. ">Prskalo 2015</a> </p> <p>Croatia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with suspected adnexal mass on a TVS scheduled for elective surgery </p> <p><b>Clinical setting:</b> mixed </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> none </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 159 </p> <p><b>Postmenopausal n (%):</b> 102 (64) </p> <p><b>Ovarian cancer n (%):</b> 43 (27) </p> <p><b>Borderline n (%):</b> 11 (7) </p> <p><b>Mean age:</b> premenopausal 36.9 (SD 8.9) years; postmenopausal 60.2 (SD 9.6) years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 11.7, postmenopausal 29.9 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0039" title="RichardsA , HerbstU , PatherS , SaidiS , Tejada-BergesT , WilliamsP , et al. HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses – a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology2015;55(5):493-7. ">Richards 2015</a> </p> <p>Australia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women who were undergoing surgery for a complex pelvic mass, presumed to be arising from the ovary </p> <p><b>Clinical setting:</b> mixed </p> <p><b>Prior tests:</b> unclear </p> <p><b>Exclusions:</b> none reported </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 50 </p> <p><b>Postmenopausal n (%):</b> 29 (58) </p> <p><b>Ovarian cancer n (%):</b> 16 (32) (EOC only) </p> <p><b>Borderline n (%):</b> 4 (8) </p> <p><b>Median age:</b> 60 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 7.4, postmenopausal 25.3 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0040" title="RomagnoloC , LeonA , FabricioAS , TaborelliM , PoleselJ , Del PupL , et al. HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: an Italian multicenter study. Gynecologic Oncology2016;141(2):303-11. ">Romagnolo 2016</a> </p> <p>Italy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women referred to gynaecological oncologist with a suspicious pelvic mass requiring surgery </p> <p><b>Clinical setting:</b> tertiary </p> <p><b>Prior test:</b> pelvic masses confirmed by USS prior to inclusion </p> <p><b>Exclusions:</b> non‐EOC </p> <p><b>Centre:</b> multicentre </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 387 </p> <p><b>Postmenopausal n (%):</b> 148 (38) </p> <p><b>Ovarian cancer n (%):</b> 73 (19) (EOC only) </p> <p><b>Borderline n (%):</b> 15 (3.9) </p> <p><b>Mean age:</b> premenopausal 37.6 (SD 8.6) years, postmenopausal 63 (SD 9.5) years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 13.1, postmenopausal 27.7 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0041" title="SalimE , ZubairiAM , DanishSH , AliU . Diagnostic accuracy of Risk of Ovarian Malignancy Algorithm (ROMA) in post-menopausal patients with ovarian mass. Journal of the College of Physicians and Surgeons Pakistan2018;28(6):440-4. ">Salim 2018</a> </p> <p>Pakistan</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> postmenopausal women with ovarian mass (&gt; 2 cm) on pelvic ultrasound examination, attending gynaecology clinics, planned for surgical intervention </p> <p><b>Clinical setting:</b> secondary </p> <p><b>Prior test:</b> not reported </p> <p><b>Exclusions:</b> only postmenopausal women included </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 260 </p> <p><b>Postmenopausal n (%):</b> 260 (100) </p> <p><b>Ovarian cancer n (%):</b> 122 (47) </p> <p><b>Borderline n (%):</b> NR </p> <p><b>Mean age:</b> 49.28 (SD 6.26) years </p> <p><b>Separated by menopausal status:</b> only postmenopausal women included </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> postmenopausal 27.7 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0043" title="ShenF , LuS , PengY , YangF , ChenY , LinY , et al. Performance of ROMA based on Architect CA 125 II and HE4 values in Chinese women presenting with a pelvic mass: a multicenter prospective study. Clinica Chimica Acta2017;471:119-25. ">Shen 2017</a> </p> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women referred to a participating centre with a pelvic mass or an ovarian cyst and planning to undergo surgery </p> <p><b>Clinical setting:</b> mixed </p> <p><b>Prior test:</b> pelvic USS, CT, MRI and the medical history (the diagnosis and treatment of pelvic mass and history of renal disease) </p> <p><b>Exclusions:</b> none </p> <p><b>Centre:</b> multicentre </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 684 </p> <p><b>Postmenopausal n (%):</b> 174 (25) </p> <p><b>Ovarian cancer n (%):</b> 169 (25) (EOC + BOT) </p> <p><b>Borderline n (%):</b> 18 (3) </p> <p><b>Mean age:</b> 58.8 (SD 8.6) years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 7.4, postmenopausal 25.3 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0044" title="StiekemaA , LokCA , KenterGG , vanDrielWJ , VincentAD , KorseCM . A predictive model combining human epididymal protein 4 and radiologic features for the diagnosis of ovarian cancer. Gynecologic Oncology2014;132(3):573-7. ">Stiekma 2014</a> </p> <p>Netherlands</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> histologically confirmed EOC or benign ovarian disease referred to the institute </p> <p><b>Clinical setting:</b> tertiary </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> BOT </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 181 </p> <p><b>Postmenopausal n (%):</b> 143 (79) </p> <p><b>Ovarian cancer n (%):</b> 147 (81) </p> <p><b>Borderline n (%):</b> excluded </p> <p><b>Mean age:</b> benign 47 years, malignant 57 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 12.9, postmenopausal 27.8 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0047" title="TehBH , YongSL , SimW , LauKB , SuharjonoHN . Evaluation in the predictive value of serum human epididymal protein 4 (HE4), cancer antigen 125 (CA 125) and a combination of both in detecting ovarian malignancy. Hormone Molecular Biology and Clinical Investigation2018;35:1. ">Teh 2018</a> </p> <p>Malaysia</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with pelvic mass(es) suspected of originating in the ovary who had been scheduled for surgery or radiological‐guided biopsy </p> <p><b>Clinical setting:</b> tertiary </p> <p><b>Prior test:</b> not reported </p> <p><b>Exclusions:</b> unclear; low malignant potential tumours were included in the benign tumour group for analysis </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 129 </p> <p><b>Postmenopausal n (%):</b> 27 (21) </p> <p><b>Ovarian cancer n (%):</b> 27 (21) </p> <p><b>Borderline n (%):</b> 10 (8) </p> <p><b>Median age:</b> 37 (IQR 27.5–48.5) years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 11.4, postmenopausal 29.9 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0048" title="TerlikowskaKM , DobrzyckaB , WitkowskaAM , Mackowiak-MatejczykB , SledziewskiTK , KinalskiM , et al. Preoperative HE4, CA125 and ROMA in the differential diagnosis of benign and malignant adnexal masses. Journal of Ovarian Research2016;9(1):43. ">Terlikowska 2016</a> </p> <p>Poland</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> Caucasian women surgically treated on account of benign ovarian disease and epithelial cancer according to international treatment guidelines </p> <p><b>Clinical setting:</b> mixed </p> <p><b>Prior test:</b> not reported </p> <p><b>Exclusions:</b> non‐EOC </p> <p><b>Centre:</b> multicentre </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 224 </p> <p><b>Postmenopausal n (%):</b> 104 (46) </p> <p><b>Ovarian cancer n (%):</b> 96 (43) (EOC only) </p> <p><b>Borderline n (%):</b> not reported </p> <p><b>Median age:</b> premenopausal 36, postmenopausal 63 </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 11.4, postmenopausal 29.9 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0054" title="vanGorpT , CadronI , DespierreE , DaemenA , LeunenK , AmantF , et al. HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm. British Journal of Cancer2011;104(5):863-70. ">van Gorp 2011</a> </p> <p>(<a href="./references#CD011964-bbs2-0055" title="KaijserJ , vanGorpT , SmetME , vanHolsbekeC , SayasnehA , EpsteinE , et al. Are serum HE4 or ROMA scores useful to experienced examiners for improving characterization of adnexal masses after transvaginal ultrasonography?Ultrasound in Obstetrics &amp; Gynecology2014;43(1):89-97. [Secondary publication Kaijser 2014]vanGorpT , VeldmanJ , vanCalsterB , CadronI , LeunenK , AmantF , et al. Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses. European Journal of Cancer2012;48(11):1649-56. ">van Gorp 2012</a> secondary publication; smaller cohort) </p> <p>Belgium</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women diagnosed with pelvic mass undergoing surgery </p> <p><b>Clinical setting:</b> unclear </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> none </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>n<b>:</b> 389 </p> <p><b>Postmenopausal n (%):</b> 161 (41) </p> <p><b>Ovarian cancer n (%):</b> 161 (41) </p> <p><b>Borderline n (%):</b> not reported </p> <p><b>Mean age:</b> benign 46.3 years, malignant 57.8 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 12.5, postmenopausal 14.4 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0057" title="XuY , ZhongR , HeJ , DingR , LinH , DengY , et al. Modification of cut-off values for HE4, CA125 and the ROMA algorithm for early-stage epithelial ovarian cancer detection: results from 1021 cases in South China. Clinical Biochemistry2016;49(1-2):32-40. ">Xu 2016</a> </p> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with a pelvic mass (defined as a simple, complex or solid ovarian cyst/pelvic mass) and healthy women from the Physical Examination Center </p> <p><b>Clinical setting:</b> mixed </p> <p><b>Prior test:</b> not reported </p> <p><b>Exclusions:</b> non‐EOC </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 566 </p> <p><b>Postmenopausal n (%):</b> 159 (28) </p> <p><b>Ovarian cancer n (%):</b> 210 (37) (EOC only) </p> <p><b>Borderline n (%):</b> 45 (8) </p> <p><b>Mean age:</b> benign 42 years, malignant 57 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 11.4, postmenopausal 29.9 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0058" title="ZhangP , WangC , ChengL , ZhangP , GuoL , LiuW , et al. Comparison of HE4, CA125, and ROMA diagnostic accuracy: a prospective and multicenter study for Chinese women with epithelial ovarian cancer. Medicine2015;94(52):e2402. ">Zhang 2015</a> </p> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> all women scheduled for surgery, with and without pelvic mass on USS </p> <p><b>Clinical setting:</b> unclear </p> <p><b>Prior test:</b> USS; adnexal lesions reported according to IOTA </p> <p><b>Exclusions:</b> non‐EOC excluded </p> <p><b>Centre:</b> multicentre </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 612 </p> <p><b>Postmenopausal n (%):</b> 232 (37) </p> <p><b>Ovarian cancer n (%):</b> 264 (43) (EOC only) </p> <p><b>Borderline n (%):</b> not reported </p> <p><b>Median age (25th centile, 75th centile):</b> benign: premenopausal 41 (35, 46), postmenopausal 57 (54, 68); malignant premenopausal 43 (38, 47), postmenopausal 59 (54, 65) </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 11.4, postmenopausal 29.9 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0059" title="ZhangL , ChenY , WangK . Comparison of CA125, HE4, and ROMA index for ovarian cancer diagnosis. Current Problems in Cancer2019;43(2):135-44. ">Zhang 2019</a> </p> <p>China</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with ovarian tumour </p> <p><b>Clinical setting:</b> tertiary </p> <p><b>Prior test:</b> unclear </p> <p><b>Exclusions:</b> borderline excluded from analysis </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 373 </p> <p><b>Postmenopausal n (%):</b> 185 (50) </p> <p><b>Ovarian cancer n (%):</b> 181 (48) </p> <p><b>Borderline n (%):</b> 17 (5) </p> <p><b>Mean age:</b> 51 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> premenopausal 11.4, postmenopausal 29.9 </p> <p><b>Prespecified:</b> yes </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>*ROMA thresholds most commonly reported and included: <b>premenopausal</b> 7.4 (± 2); 12.5; 13.1 (± 2); <b>postmenopausal</b> 25.3 (± 2); 14.4; 27.7 (± 2) </p> <p>**Threshold for premenopausal women OR postmenopausal women reported in the study not included in analysis. </p> <p>BOT: borderline ovarian tumour; CT: computed tomography; EOC: epithelial ovarian cancer; HE4: Human Epididymis protein; IQR: interquartile range; IOTA: International Ovarian Tumour Analysis; MRI: magnetic resonance imaging; n: number of participants; PET‐CT: positron emission tomography–computed tomography; ROMA: Risk of Ovarian Malignancy Algorithm; ROMA‐P: a modified ROMA; TVS: transvaginal ultrasound; USS: ultrasound scan. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Study characteristics: ROMA</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/full#CD011964-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011964-tbl-0006"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Study characteristics: LR2</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Author year country</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Setting*</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Participant characteristics</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Index test threshold</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0026" title="MeysEM , JeelofLS , AchtenNM , SlangenBF , LambrechtsS , KruitwagenRF , et al. Estimating risk of malignancy in adnexal masses: external validation of the ADNEX model and comparison with other frequently used ultrasound methods. Ultrasound in Obstetrics &amp; Gynecology2017;49(6):784-92. ">Meys 2017</a> </p> <p><b>Netherlands</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria</b>: women with adnexal pathology </p> <p><b>Clinical setting:</b> tertiary </p> <p><b>Prior tests:</b> not reported </p> <p><b>Exclusions:</b> none reported </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 326 </p> <p><b>Postmenopausal n (%):</b> 198 (61) </p> <p><b>Ovarian cancer n (%):</b> 115 (35) </p> <p><b>Borderline n (%):</b> 27 (8) </p> <p><b>Median age:</b> malignant 67.7 (IQR 32.3–87) years, borderline 53.2 (016.1–87.2) years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Threshold:</b> 10% post‐test probability of malignancy </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0031" title="NiemiRJ , SaarelainenSK , LuukkaalaTH , MaenpaaJU . Reliability of preoperative evaluation of postmenopausal ovarian tumors. Journal of Ovarian Research2017;10(1):15. ">Niemi 2017</a> </p> <p><b>Finland</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria</b>: women aged &gt; 50 years presenting with an abnormal adnexal mass(es) </p> <p><b>Clinical setting:</b> tertiary </p> <p><b>Prior tests:</b> not reported </p> <p><b>Exclusions:</b> overtly benign or malignant‐appearing tumours such as unilocular simple ovarian cysts and tumours associated with marked ascites (depth of the greatest pool &gt; 10 cm) </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 98 </p> <p><b>Postmenopausal n (%):</b> 98 (100) </p> <p><b>Ovarian cancer n (%):</b> 23 (23) </p> <p><b>Borderline n (%):</b> 7 (7) </p> <p><b>Median age:</b> 61 (range 50–84) years </p> <p><b>Separated by menopausal status:</b> only postmenopausal included </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Threshold:</b> 10%, 25% and 43% of post‐test probability of malignancy </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0042" title="SayasnehA , KaijserJ , PreislerJ , JohnsonS , StalderC , HusickaR , et al. A multicenter prospective external validation of the diagnostic performance of IOTA simple descriptors and rules to characterize ovarian masses. Gynecologic Oncology2013;130(1):140-6. [Sayasneh 2013]SayasnehA , WynantsL , PreislerJ , KaijserJ , JohnsonS , StalderC , et al. Multicentre external validation of IOTA prediction models and RMI by operators with varied training. British Journal of Cancer2013;108(12):2448-54. ">Sayasneh 2013a</a> </p> <p><b>Secondary study:</b> </p> <p>Sayasneh 2013 (see under <a href="./references#CD011964-bbs2-0042" title="SayasnehA , KaijserJ , PreislerJ , JohnsonS , StalderC , HusickaR , et al. A multicenter prospective external validation of the diagnostic performance of IOTA simple descriptors and rules to characterize ovarian masses. Gynecologic Oncology2013;130(1):140-6. [Sayasneh 2013]SayasnehA , WynantsL , PreislerJ , KaijserJ , JohnsonS , StalderC , et al. Multicentre external validation of IOTA prediction models and RMI by operators with varied training. British Journal of Cancer2013;108(12):2448-54. ">Sayasneh 2013a</a>) </p> <p><b>UK</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women presenting with adnexal mass and undergoing surgery within 120 days after examination </p> <p><b>Clinical setting:</b> mixed secondary and tertiary care </p> <p><b>Prior tests:</b> not reported </p> <p><b>Exclusions:</b> none reported </p> <p><b>Centre:</b> multicentre </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 255 </p> <p><b>Postmenopausal n (%):</b> 117 (45.9) </p> <p><b>Malignant n (%):</b> 48 (18.8) </p> <p><b>Borderline n (%):</b> 18 (7.1) </p> <p><b>Mean age:</b> 46 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Threshold:</b> 10% post‐test probability of malignancy </p> <p><b>Prespecified threshold:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0050" title="TestaA , KaijserJ , WynantsL , FischerovaD , vanHolsbekeC , FranchiD , et al. Strategies to diagnose ovarian cancer: new evidence from phase 3 of the multicentre international IOTA study. British Journal of Cancer2014;111(4):680-8. ">Testa 2014</a> </p> <p><b>Europe</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women presenting with adnexal mass on TVS and undergoing surgery within 120 days. </p> <p><b>Clinical setting:</b> mixed secondary and tertiary care </p> <p><b>Prior tests:</b> not reported </p> <p><b>Exclusions:</b> none reported </p> <p><b>Centre:</b> multicentre </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 2403 </p> <p><b>Postmenopausal n (%):</b> 1049 (43.7) </p> <p><b>Malignant n (%):</b> 701(18.8) </p> <p><b>Borderline n (%):</b> 153 (6.4) </p> <p><b>Median age:</b> malignant 57 (range 33–66) years; benign 44 (range not reported) years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Threshold:</b> 10% post‐test probability of malignancy </p> <p><b>Prespecified threshold:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0051" title="TimmermanD , AmeyeL , FischerovaD , EpsteinE , MelisGB , GuerrieroS , et al. Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group. BMJ2010;341:c6839. ">Timmerman 2010</a> </p> <p>Secondary study:</p> <p><a href="./references#CD011964-bbs2-0072" title="Di LeggeA , TestaAC , AmeyeL , vanCalsterB , LissoniAA , LeoneFP , et al. Lesion size affects diagnostic performance of IOTA logistic regression models, IOTA simple rules and risk of malignancy index in discriminating between benign and malignant adnexal masses. Ultrasound in Obstetrics &amp; Gynecology2012;40:345-54. [DOI: org/10.1002/uog.11167]">Di Legge 2012</a> </p> <p><b>Europe</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with persistent adnexal mass undergoing surgery within 120 days </p> <p><b>Clinical setting:</b> mixed secondary and tertiary </p> <p><b>Prior tests:</b> not reported </p> <p><b>Exclusions:</b> none reported </p> <p><b>Centre:</b> multicentre </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 1938 </p> <p><b>Postmenopausal n (%):</b> 742 (38.0) </p> <p><b>Malignant n (%):</b> 373 (19.2) </p> <p><b>Borderline n (%):</b> 111 (5.7) </p> <p><b>Mean age:</b> 46 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Threshold:</b> 10% post‐test probability of malignancy </p> <p><b>Prespecified threshold:</b> yes </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>*Setting: secondary care: dedicated gynaecologist in a general hospital; tertiary care: gynaecological oncology centre. </p> <p>IQR: interquartile range; n: number of participants; TVS: transvaginal ultrasound.</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Study characteristics: LR2</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/full#CD011964-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011964-tbl-0007"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Study characteristics: ADNEX</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Author year country</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Setting*</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Participants characteristics</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Index test threshold</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0026" title="MeysEM , JeelofLS , AchtenNM , SlangenBF , LambrechtsS , KruitwagenRF , et al. Estimating risk of malignancy in adnexal masses: external validation of the ADNEX model and comparison with other frequently used ultrasound methods. Ultrasound in Obstetrics &amp; Gynecology2017;49(6):784-92. ">Meys 2017</a> </p> <p><b>Netherlands</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria</b>: women with adnexal pathology </p> <p><b>Clinical setting:</b> tertiary </p> <p><b>Prior tests:</b> not reported </p> <p><b>Exclusions:</b> none reported </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 326 </p> <p><b>Postmenopausal n (%):</b> 198 (61) </p> <p><b>Ovarian cancer n (%):</b> 115 (35) </p> <p><b>Borderline n (%):</b> 27 (8) </p> <p><b>Median age:</b> benign 53.2 (IQR 16.1–87.2) years, malignant 67.7 (IQR 32.3–87) years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Threshold:</b> 10% post‐test probability of malignancy </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0045" title="SzubertS , WojtowiczA , MoszynskiR , ZywicaP , DyczkowskiK , StachowiakA , et al. External validation of the IOTA ADNEX model performed by two independent gynecologic centers. Gynecologic Oncology2016;142(3):490-5. ">Szubert 2016a</a> </p> <p><b>Poland</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with a 'need for surgery due to an ovarian tumour' </p> <p><b>Clinical setting:</b> unclear, probably tertiary </p> <p><b>Prior test:</b> not reported </p> <p><b>Exclusions:</b> none reported </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 204 </p> <p><b>Postmenopausal n (%):</b> 66 (54) </p> <p><b>Ovarian cancer n (%):</b> 58 (28) </p> <p><b>Borderline n (%):</b> 12 (6) </p> <p><b>Median age:</b> 46 </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> 2000 IOTA criteria 10% </p> <p><b>Prespecified: y</b>es </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0046" title="SzubertS , WojtowiczA , MoszynskiR , ZywicaP , DyczkowskiK , StachowiakA , et al. External validation of the IOTA ADNEX model performed by two independent gynecologic centers. Gynecologic Oncology2016;142(3):490-5. ">Szubert 2016b</a> </p> <p><b>Spain</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women with a 'need for surgery due to an ovarian tumour' </p> <p><b>Clinical setting:</b> unclear, probably tertiary </p> <p><b>Prior test:</b> not reported </p> <p><b>Exclusions:</b> none reported </p> <p><b>Centre:</b> single </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 128 </p> <p><b>Postmenopausal n (%):</b> 52 (42) </p> <p><b>Ovarian cancer n (%):</b> 35 (27) </p> <p><b>Borderline n (%):</b> 4 (3) </p> <p><b>Median age:</b> 47 years </p> <p><b>Separated by menopausal status:</b> yes </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Thresholds:</b> 2000 IOTA criteria 10% </p> <p><b>Prespecified:</b> yes </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD011964-bbs2-0052" title="vanCalsterB , vanHoordeK , ValentinL , TestaAC , FischerovaD , vanHolsbekeC , et al. Evaluating the risk of ovarian cancer before surgery using the ADNEX model to differentiate between benign, borderline, early and advanced stage invasive, and secondary metastatic tumours: prospective multicentre diagnostic study. BMJ2014;349:g5920. ">van Calster 2014</a> </p> <p><b>Europe</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study criteria:</b> women presenting with adnexal mass on US and selected for surgery </p> <p><b>Clinical setting:</b> mixed secondary and tertiary care </p> <p><b>Prior tests:</b> not reported </p> <p><b>Exclusions:</b> none reported </p> <p><b>Centre:</b> multicentre </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>n:</b> 2403 </p> <p><b>Postmenopausal n (%):</b> 1049 (43.7)** </p> <p><b>Malignant n (%):</b> 827 (34.4) </p> <p><b>Borderline n (%):</b> 153 (6.4) </p> <p><b>Age:</b> not reported </p> <p><b>Separated by menopausal status:</b> yes** </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Threshold:</b> 3, 5, 10 and 15% post‐test probability of malignancy </p> <p><b>Prespecified threshold:</b> yes </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>*Setting: secondary care: dedicated gynaecologist in a general hospital; tertiary care: gynaecological oncology centre. </p> <p>**Contact with authors</p> <p>IOTA: International Ovarian Tumour Analysis; IQR: interquartile range; n: number of participants. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Study characteristics: ADNEX</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/full#CD011964-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011964-tbl-0008"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">HSROC analysis: comparison of sensitivity at a fixed specificity of 80% and 90%: all studies, all thresholds, pre‐ and postmenopausal women separately</span></div> <tbody> <tr> <th align="" class="headercell" colspan="10" rowspan="1" scope="col" valign=""> <p><b>HSROC analysis: comparison of ROMA, LR2 and ADNEX compared to RMI I. Mixed test positivity threshold analysis at fixed specificities of 80% and 90%</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Test</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Studies</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Participants (OC cases)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Diagnostic odds ratio (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative diagnostic odds ratio (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Sensitivity at fixed specificity of 80%</b> </p> </th> <th align="center" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Sensitivity at fixed specificity of 90%</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sensitivity (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Difference from RMI I (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sensitivity (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Difference from RMI I (95% CI)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="10" rowspan="1" scope="col" valign=""> <p><b>Pr</b> emen<b>opausal</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RMI I 200/250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5694</p> <p>(893)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15.5 (9.0 to 26.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79.4 (69.5 to 86.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65.1 (57.2 to 72.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ROMA mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7616</p> <p>(1198)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.5 (14.3 to 23.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.19 (0.69 to 2.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5202</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82.0 (77.9 to 85.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.6 (–5.5 to 10.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68.8 (61.8 to 75.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3.7 (–7.3 to 14.7)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LR2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2843</p> <p>(619)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.9 (21.5 to 53.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.19 (1.18 to 4.06)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.014</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89.0 (83.8 to 92.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.6 (2.2, 17.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79.7 (71.3 to 86.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.6 (5.6 to 23.6)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADNEX 10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1696</p> <p>(455)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72.6 (29.4 to 179.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.70 (1.45 to 15.20)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0108</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94.4 (88.3 to 7.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.9 (5.4 to 24.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89.0 (77.6 to 95.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23.9 (12.0 to 35.8)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="10" rowspan="1" scope="col" valign="top"> <p><b>Po</b> stmen<b>opausal</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RMI I 200/250</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4589</p> <p>(1761)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.8 (17.3 to 30.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85.1 (80.9 to 88.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.8 (65.4 to 77.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ROMA mixed</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6099</p> <p>(2746)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40.0 (31.5 to 50.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.75 (1.23 to 2.50)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0024</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90.9 (88.8 to 92.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.8 (2.1 to 9.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81.7 (76.8 to 85.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.9 (4.0 to 15.8)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LR2 10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2157</p> <p>(1124)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.5 (22.6 to 69.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.73 (0.97 to 3.09)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0622</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90.8 (85.9 to 94.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5.7 (0.7 to 10.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81.5 (70.0 to 89.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.7 (2.0 to 17.4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ADNEX 10%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1365</p> <p>(749)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.7 (21.9 to 146.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.48 (0.90 to 6.85)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0776</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93.4 (85.9 to 97.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.3 (1.5 to 15.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86.3 (70.2 to 94.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14.6 (3.4 to 25.7)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>Notes to table: ADNEX 10% &amp; LR2 10%: threshold to achieve a post‐test probability of ovarian cancer of 10%. ADNEX and LR2 studies reported a range of thresholds but all included a threshold of 10%. For RMI I and ROMA studies, each included study contributed a different test positivity threshold. </p> <p>ADNEX: Assessment of Different NEoplasias in the adneXa model; CI: confidence interval; HSROC: hierarchical summary receiver operating characteristic; LR2: Logistic Regression Model 2; OC: ovarian cancer; RMI I: Risk of Malignancy Index I; ROMA: Risk of Ovarian Malignancy Algorithm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">HSROC analysis: comparison of sensitivity at a fixed specificity of 80% and 90%: all studies, all thresholds, pre‐ and postmenopausal women separately</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/full#CD011964-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011964-tbl-0009"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Bivariate comparisons of ROMA, LR2 and ADNEX compared to RMI I in premenopausal women</span></div> <tbody> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign="top"> <p><b>Bivariate model‐pairwise comparisons: premenopausal women</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Absolute sensitivity difference (95% CI); P value for comparison</b> </p> <p><b>Absolute specificity difference (95% CI); P value for comparison</b> </p> </th> <td align="" class="headercell" colspan="1" rowspan="1" valign="bottom"></td> <td align="" class="headercell" colspan="1" rowspan="1" valign="bottom"></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>RMI I</b> </p> <p><b>(200)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>ROMA</b> </p> <p><b>(13.1 ± 2)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>LR2</b> </p> <p><b>(10)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Studies (participants)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17 (5233)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27 (4463)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4 (2843)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Sensitivity % (95% CI)</b> </p> <p><b>Specificity % (95% CI)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57.2 (50.3 to 63.8)</p> <p>92.5 (90.3 to 94.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77.4 (72.7 to 81.5)</p> <p>84.3 (81.2 to 87.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83.3 (74.7 to 89.5)</p> <p>90.4 (84.6 to 94.1)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Studies (participants)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ROMA</b> (13.1 ± 2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 (4463)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>77.4 (95% CI 72.7 to 81.5)</p> <p>84.3 (95% CI 81.2 to 87.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20.2 (12.2 to 28.3); P &lt; 0.0001</p> <p>–8.2 (–11.7 to –4.7); P &lt; 0.0001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LR2</b> (10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (2843)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83.3 (95% CI 74.7 to 89.5)</p> <p>90.4 (95% CI 84.6 to 94.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26.2 (16.2 to 36.2); P &lt; 0.0001</p> <p>–2.1 (–7.2 to 2.9); P = 0.404</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.0 (–2.6 to 14.5); P = 0.170</p> <p>6.1 (0.6 to 11.5); P = 0.029</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ADNEX</b> (10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (1696)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95.5 (95% CI 91.0 to 97.8)</p> <p>77.8 (95% CI 67.4 to 85.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.3 (30.9 to 45.8); P &lt; 0.0001</p> <p>–14.8 (–24.0 to –5.5); P = 0.002</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18.1 (12.7 to 23.5); P = 0.0001</p> <p>–6.5 (–16.0 to 3.0); P = 0.178</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12.1 (4.2 to 20.1); P = 0.003</p> <p>–12.6 (–22.8 to –2.4); P = 0.015</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>ADNEX: Assessment of Different NEoplasias in the adneXa model; CI: confidence interval; LR2: Logistic Regression Model 2; OC: ovarian cancer; RMI I: Risk of Malignancy Index I; ROMA: Risk of Ovarian Malignancy Algorithm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Bivariate comparisons of ROMA, LR2 and ADNEX compared to RMI I in premenopausal women</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/full#CD011964-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011964-tbl-0010"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Bivariate comparisons of ROMA, LR2 and ADNEX compared to RMI I in postmenopausal women</span></div> <tbody> <tr> <th align="" class="headercell" colspan="6" rowspan="1" scope="col" valign="bottom"> <p><b>Bivariate model‐pairwise comparisons: po</b> stmen<b>opausal women</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Absolute sensitivity difference (95% CI)</b> ; P<b>value for comparison</b> </p> <p><b>Absolute specificity difference (95% CI)</b> ; P<b>value for comparison</b> </p> </th> <td align="" class="headercell" colspan="1" rowspan="1" valign="bottom"></td> <td align="" class="headercell" colspan="1" rowspan="1" valign="bottom"></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>RMI I</b> </p> <p><b>(200)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>ROMA</b> </p> <p><b>(27.7 ± 2)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>LR2</b> </p> <p><b>(10)</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Studies (participants)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17 (4369)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13 (2002)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5 (2157)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Sensitivity % (95% CI)</b> </p> <p><b>Specificity % (95% CI)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78.4 (74.6 to 81.7)</p> <p>85.4 (82.0 to 88.2)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90.3 (87.5 to 92.6)</p> <p>81.5 (76.5 to 85.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94.8 (92.3 to 96.6)</p> <p>60.6 (50.5 to 69.9)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="top"> <p><b>Studies (participants)</b> </p> </th> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ROMA</b> (27.7 ± 2) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13 (2002)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90.3 (87.5 to 92.6)</p> <p>81.5 (76.5 to 85.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.9 (7.6 to 16.3); P &lt; 0.0001</p> <p>–3.9 (–9.4 to 1.5); P = 0.157</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LR2</b> (10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (2157)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94.8 (92.3 to 96.6)</p> <p>60.6 (50.5 to 69.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16.4 (12.3 to 20.5); P &lt; 0.0001</p> <p>–24.8 (–35.1 to –14.5); P &lt; 0.0001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.5 (1.2 to 7.8); P = 0.008</p> <p>–20.9 (–31.7 to –10.1); P &lt; 0.0001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>ADNEX</b> (10) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (1365)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97.6 (95.6 to 98.7)</p> <p>55.0 (42.8 to 66.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19.2 (15.4 to 23.1); P &lt; 0.0001</p> <p>–30.4 (–42.9 to –17.9); P &lt; 0.0001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.3 (4.3 to 10.2); P &lt; 0.0001</p> <p>–26.5 (–39.4 to –13.6); P &lt; 0.0001</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.8 (0.2 to 5.3); P = 0.034</p> <p>–5.6 (–21.2 to 10.0); P = 0.480</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="6"> <div class="table-footnote"> <p>ADNEX: Assessment of Different NEoplasias in the adneXa model; CI: confidence interval; LR2: Logistic Regression Model 2; OC: ovarian cancer; RMI I: Risk of Malignancy Index I; ROMA: Risk of Ovarian Malignancy Algorithm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Bivariate comparisons of ROMA, LR2 and ADNEX compared to RMI I in postmenopausal women</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/full#CD011964-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011964-tbl-0011"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Sensitivity analysis: borderline ovarian tumours</span></div> <tbody> <tr> <th align="" class="headercell" colspan="11" rowspan="1" scope="col" valign=""> <p><b>Sensitivity analysis </b> :<b>sensitivity at fixed specificities of 80% and 90% for RMI I and ROMA (all thresholds) for studies grouping borderline ovarian tumours with malignant for the estimation of test accuracy (BOT=1) compared to studies that excluded borderline tumours or where their management for the estimation of test accuracy was unclear (BOT=2/3)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Test</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Studies</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>OC Cases</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>DOR (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>Relative DOR</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="2" scope="col" valign="bottom"> <p><b>P value</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Sensitivity at fixed specificity of 80%</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Sensitivity at fixed specificity of 90%</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sensitivity (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Difference from</b> </p> <p><b>BOT=1 (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Sensitivity</b> </p> <p><b>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Difference from</b> </p> <p><b>BOT=1 (95% CI)</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="11" rowspan="1" scope="col" valign=""> <p><b>Pr</b> emen<b>opausal</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign=""> <p>RMI I 200/250</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>BOT=1</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4861</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>801</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.7 (5.3 to 25.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74.9 (59.6 to 85.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62.2 (53.1 to 70.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>BOT=2/3</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>833</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.5 (4.2 to 31.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.98 (0.37 to 2.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.9699</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74.6 (55.0 to 87.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–0.3 (–16.1 to 15.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61.8 (43.3 to 77.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>–0.4 (–20.1 to 19.4)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign=""> <p>ROMA mixed thresholds</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>BOT=1</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2737</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>363</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.9 (9.0 to 21.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77.6 (69.1 to 84.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59.2 (47.0 to 70.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>BOT=2/3</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4879</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>835</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22.3 (15.9 to 31.3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.60 (0.94 to 2.74)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0837</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84.9 (79.7 to 89.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7.4 (–1.2 to 15.9)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70.2 (60.3 to 78.6)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11.1 (–1.3 to 23.5)</p> </td> </tr> <tr> <th align="" class="headercell" colspan="11" rowspan="1" scope="col" valign=""> <p><b>Po</b> stmen<b>opausal</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="11" rowspan="1" valign=""> <p>ROMA mixed thresholds</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>BOT=1</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>882</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27.4 (18.6 to 40.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87.7 (82.3 to 91.7)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72.4 (59.6 to 82.4)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i>BOT=2/3</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3810</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1864</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56.3 (40.5 to 78.1)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.06 (1.24 to 3.40)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.0062</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94.1 (91.3 to 96.0)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6.4 (1.2, 11.5)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85.4 (79.6 to 89.8)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13.0 (1.9 to 24.0)</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="11"> <div class="table-footnote"> <p>BOT=1: borderline tumours grouped with malignant ovarian tumours for estimation of test accuracy; BOT=2/3: borderline tumours excluded, grouped with benign or management unclear for estimation of test accuracy; CI: confidence interval; DOR: diagnostic odds ratio; OC: ovarian cancer; RMI: Risk of Malignancy Index; ROMA: Risk of Ovarian Malignancy Algorithm. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 10.</span> <span class="table-title">Sensitivity analysis: borderline ovarian tumours</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/full#CD011964-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011964-tbl-0013"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Excluded studies: no 2 × 2 table</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>No 2</b> × <b>2 table</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Ovarian cancer: screening, treatment, and follow up. NIH Consensus Statement. 1994;12(3):1‐30.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2. Ovarian cancer. Journal of Practical Nursing. 2009;59(3):12‐4.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3. CA125 remains best predictor of ovarian cancer. Contemporary OB/GYN. 2011;56(5):16.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4. Clinical use of tumor markers in China. Tumor Biology. 2014;35:S11.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5. A.N AL‐N, Ahmed M, Petersen CB. Epithelial ovarian cancer. Obstetrics and Gynecology Clinics of North America. 2012;39(2):269‐83. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6. Abbas AM. A new scoring model for characterization of adnexal masses based on two‐dimensional gray‐scale and colour Doppler sonographic features. Facts Views &amp; Vision in Obgyn. 2014;6(2):68‐74. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7. Abdalla N, Bachanek M, Kowalska J, Cendrowski K, Sawicki W. Role of HE4 and simple ultrasound rules proposed by iota group in preoperative evaluation of adnexal masses: A prospective study. International Journal of Gynecological Cancer. 2013;1):835. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8. Abdalla YN, Bachanek M, Kowalska J, Cendrowski K, Sawicki W. The role of risk of malignancy algorithm in the presurgical assessment of adnexal tumors: A prospective study. International Journal of Gynecological Cancer. 2013;1):441. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9. Abdulrahman GO, Jr, McKnight L, Lutchman Singh K. The risk of malignancy index (RMI) in women with adnexal masses in Wales. Taiwanese Journal of Obstetrics &amp; Gynecology. 2014;53(3):376‐81. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10. Aggarwal P, Kehoe S. Serum tumour markers in gynaecological cancers. Maturitas. 2010;67(1):46‐53. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11. Aguado Romeo MJ, Llanos Mendez A. Serum biomarkers panel for detecting early stage ovarian cancer (Structured abstract). Health Technology Assessment Database [Internet]. 2010 [cited HTA N]; (1). Available from: http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA‐32011001516/frame.html. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12. Aiken C, Deakin N, Mehasseb M, Baldwin P. Surgical management of ovarian cysts in premenopausal women. Gynecological Surgery. 2012;1):S24. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13. Akdeniz N, Kuyumcuoglu U, Kale A, Erdemoglu M, Caca F. Risk of malignancy index for adnexal masses. European Journal of Gynaecological Oncology. 2009;30(2):178‐80. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14. Alborzi S, Keramati P, Younesi M, Samsami A, Dadras N. The impact of laparoscopic cystectomy on ovarian reserve in patients with unilateral and bilateral endometriomas. Fertility &amp; Sterility. 2014;101(2):427‐34. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15. Alcazar JL. Three‐dimensional static ultrasound and 3D power doppler in gynecologic pelvic tumors. Donald School Journal of Ultrasound in Obstetrics and Gynecology. 2013;7(2):187‐99. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16. Alcazar JL, Errasti T, Laparte C, Jurado M, Lopez‐Garcia G. Assessment of a new logistic model in the preoperative evaluation of adnexal masses. Journal of Ultrasound in Medicine. 2001;20(8):841‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17. Alcazar JL, Guerriero S, Laparte C, Ajossa S, Jurado M. Contribution of power Doppler blood flow mapping to gray‐scale ultrasound for predicting malignancy of adnexal masses in symptomatic and asymptomatic women. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology. 2011;155(1):99‐105. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18. Alcazar JL, Utrilla‐Layna J, Minguez JA, Jurado M. Clinical and ultrasound features of type I and type II epithelial ovarian cancer. International Journal of Gynecological Cancer. 2013;23(4):680‐4. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19. Amayo AA, Kuria JG. Clinical application of tumour markers: a review. East African Medical Journal. 2009;86(12 Suppl):S76‐83. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20. Amor F, Vaccaro H, Alcazar JL, Leon M, Craig JM, Martinez J. Gynecologic imaging reporting and data system: a new proposal for classifying adnexal masses on the basis of sonographic findings. Journal of Ultrasound in Medicine. 2009;28(3):285‐91. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21. Anthoulakis C, Nikoloudis N. Pelvic MRI as the "gold standard" in the subsequent evaluation of ultrasound‐indeterminate adnexal lesions: a systematic review. Gynecologic Oncology. 2014;132(3):661‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22. Arab M, Honarvar Z, Hosseini‐Zijoud S‐M. Ovarian Malignancy Probability Score (OMPS) for appropriate referral of adnexal masses. Asian Pacific Journal of Cancer Prevention: Apjcp. 2014;15(20):8647‐50. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23. Arab M, Yaseri M, Farzaneh M, Moridi A, Tehranian A, Sheibani K. The construction and validation of a new ovarian malignancy probability score (omps) for prediction of ovarian malignancy. Iranian Journal of Cancer Prevention. 2010;3(3):132‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24. Aslam N, Banerjee S, Carr JV, Savvas M, Hooper R, Jurkovic D. Prospective evaluation of logistic regression models for the diagnosis of ovarian cancer. Obstetrics &amp; Gynecology. 2000;96(1):75‐80. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25. Autelitano DJ, Raineri L, Knight K, Bannister K, Rice GE. Performance of a multianalyte test as an aid for the diagnosis of ovarian cancer in symptomatic women. Journal of Translational Medicine. 2012;10:45. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26. Azzam AZ, Hashad DI, Kamel NAF. Evaluation of HE4 as an extrabiomarker to CA125 to improve detection of ovarian carcinoma: is it time for a step forward? Archives of Gynecology &amp; Obstetrics. 2013;288(1):167‐72. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27. Bandiera E, Ragnoli M, Zanotti L, Bignotti E, Romani C, Tassi R, et al. Clinical role of human epididymis protein 4 (HE4) in epithelial ovarian cancer. European Journal of Cancer, Supplement. 2009;7 (2‐3):143. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28. Bankhead CR, Kehoe ST, Austoker J. Symptoms associated with diagnosis of ovarian cancer: a systematic review. BJOG: An International Journal of Obstetrics &amp; Gynaecology. 2005;112(7):857‐65. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29. Bast RC, Jr. Biomarkers for ovarian cancer: new technologies and targets to address persistently unmet needs. Cancer Biomarkers: Section A of Disease Markers. 2010;8(4‐5):161‐6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30. Bast RC, Jr, Skates S, Lokshin A, Moore RG. Differential diagnosis of a pelvic mass: improved algorithms and novel biomarkers. International Journal of Gynecological Cancer. 2012;22 Suppl 1:S5‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31. Behtash N, Rahmani M, Ghotbizadeh F, Karimi Zarchi M, Mousavi A. Ultrasonography and computed tomography for management of adnexal masses in Iranian patients with suspected ovarian cancer: results of a prospective study. Asian Pacific Journal of Cancer Prevention: Apjcp. 2009;10(2):201‐4. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32. Berlanda N, Ferrari MM, Mezzopane R, Boero V, Grijuela B, Ferrazzi E, et al. Impact of a multiparameter, ultrasound‐based triage on surgical management of adnexal masses. Ultrasound in Obstetrics &amp; Gynecology. 2002;20(2):181‐5. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33. Bharwani N, Reznek RH, Rockall AG. Ovarian Cancer Management: The role of imaging and diagnostic challenges. European Journal of Radiology. 2011;78(1):41‐51. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34. Bhoola S, Hoskins WJ. Diagnosis and management of epithelial ovarian cancer. Obstetrics and gynecology. 2006;107(6):1399‐410. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35. Braicu E, Mecke H, Hellmeyer L, Mueller B, Nohe G, Rodekamp E, et al. HE4 and its value for the gynecologic oncologist‐first results from the berlin‐roma study. Tumor Biology. 2014;35:S6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36. Braicu EI, Pietzner K, Henrich W, Sehouli J. Possibilities and limits of diagnostic tests in ovarian cancer. Onkologe. 2014;20(7):650‐+. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37. Braicu EI, Van Gorp T, Nassir M, Richter R, Chekerov R, Gasimli K, et al. Preoperative HE4 and ROMA values do not improve the CA125 diagnostic value for borderline tumors of the ovary (BOT) ‐ a study of the TOC Consortium. Journal of ovarian research. 2014;7:49. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38. Brown DL, Dudiak KM, Laing FC. Adnexal masses: US characterization and reporting. Radiology. 2010;254(2):342‐54. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39. Bruchim I, Aviram R, Halevy RS, Beyth Y, Tepper R. Contribution of Sonographic Measurement of Ovarian Volume to Diagnosing Ovarian Tumors in Postmenopausal Women. Journal of Clinical Ultrasound. 2004;32(3):107‐14. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40. Burges A, Schmalfeldt B. Ovarian cancer: diagnosis and treatment. Deutsches Arzteblatt International. 2011;108(38):635‐41. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41. Buy JN, Ghossain MA, Hugol D, Hassen K, Sciot C, Truc JB, et al. Characterization of adnexal masses: combination of color Doppler and conventional sonography compared with spectral Doppler analysis alone and conventional sonography alone. AJR American Journal of Roentgenology. 1996;166(2):385‐93. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42. Candido Dos Reis FJ, De Andrade JM, Bighetti S. CA 125 and vascular endothelial growth factor in the differential diagnosis of epithelial ovarian tumors. Gynecologic and Obstetric Investigation. 2002;54(3):132‐6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43. Cardillo G, Di Biase I, Biscotti U. The bayes theorem for the evidence based ovarian cancer diagnosis. International Journal of Gynecological Cancer. 2014;2. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44. Cesario S. Advances in the early detection of ovarian cancer. Nursing for Women's Health. 2010;14(3):222‐34. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45. Chauhan SC, Singh AP, Ruiz F, Johansson SL, Jain M, Smith LM, et al. Aberrant expression of MUC4 in ovarian carcinoma: Diagnostic significance alone and in combination with MUC1 and MUC16 (CA125). Modern Pathology. 2006;19(10):1386‐94. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46. Chia YN, Marsden DE, Robertson G, Hacker NF. Triage of ovarian masses. The Australian &amp; New Zealand journal of obstetrics &amp; gynaecology. 2008;48(3):322‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47. Choudhury S, Mohiuddin ASM, Ahmed AU, Ahsan S. Preoperative discrimination of benign and malignant ovarian tumors using color Doppler sonography and its correlation with histopathology. Bangladesh Medical Research Council Bulletin. 2005;31(1):21‐6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48. Chu MM, Fishman D. Risk assessment for epithelial ovarian cancer: proposing a new approach to a deadly problem. Scandinavian Journal of Clinical and Laboratory Investigation Supplement. 2014;244:63‐7; discussion 6‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49. Chudecka‐Glaz AM. ROMA, an algorithm for ovarian cancer. Clinica Chimica Acta. 2015;440:143‐51. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50. Coccia ME, Rizzello F, Romanelli C, Capezzuoli T. Adnexal masses: what is the role of ultrasonographic imaging? Archives of Gynecology &amp; Obstetrics. 2014;290(5):843‐54. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51. Cohen J, Yu X, Deshmukh H, Zhang R, Shin JY, Osann K, et al. The association of serial ultrasounds and CA‐125 prior to diagnosis of ovarian cancer: Do they improve early detection? Gynecologic Oncology. 2009;112(2):S65‐S. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52. Colak A, Dikmen ZG, Basaran D, Tuncer S, Akbiyik F. Human epididymis protein 4 (HE4) as a new tumour marker for diagnosis of ovarian carcinoma. FEBS Journal. 2012;279:117. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53. Coleman RL. Two‐step Ovarian Cancer Screening: A 'Scissor‐step' Forward? Clinical Oncology Alert. 2013;29(10):78‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54. Collins GS, Altman DG. Identifying women with undetected ovarian cancer: independent and external validation of QCancer() (Ovarian) prediction model. European Journal of Cancer Care. 2013;22(4):423‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55. Cramer DW, Bast RC, Jr, Berg CD, Diamandis EP, Godwin AK, Hartge P, et al. Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prevention Research. 2011;4(3):365‐74. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56. Cramer DW, Vitonis AF. Thoughts on the prevention and early detection of postmenopausal ovarian cancer. Sexuality, Reproduction and Menopause. 2011;9(1):1‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57. Cui H, Li D, Chang X, Ye X, Cheng H. The values of serum human epididymis secretory protein 4 and CA125 assay in the diagnosis of ovarian malignance. International Journal of Gynecology and Obstetrics. 2009;107:S240. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58. Daponte A, Stergioti E, Messinis IE. Risk scoring for adnexal masses and endoscopic management. International Journal of Gynecology and Obstetrics.96(1):42‐3. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59. de Gauna BR, Sanchez P, Pineda L, Utrilla‐Layna J, Juez L, Alcazar JL. Interobserver agreement in describing adnexal masses using the International Ovarian Tumor Analysis simple rules in a real‐time setting and using three‐dimensional ultrasound volumes and digital clips. Ultrasound in Obstetrics &amp; Gynecology. 2014;44(1):95‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60. del Carmen MG, Birrer M, Schorge JO. Clear cell carcinoma of the ovary: a review of the literature. Gynecologic Oncology. 2012;126(3):481‐90. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61. del Carmen MG, Birrer M, Schorge JO. Carcinosarcoma of the ovary: a review of the literature. Gynecologic Oncology. 2012;125(1):271‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62. Diaz E, Burky RE, Hummel CS, Farias‐Eisner R. Early detection of ovarian cancer. Expert Review of Obstetrics and Gynecology. 2013;8(2):169‐79. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63. Diaz‐Padilla I, Razak ARA, Minig L, Bernardini MQ, Maria Del Campo J. Prognostic and predictive value of CA‐125 in the primary treatment of epithelial ovarian cancer: potentials and pitfalls. Clinical &amp; Translational Oncology: Official Publication of the Federation of Spanish Oncology Societes &amp; of the National Cancer Institute of Mexico. 2012;14(1):15‐20. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64. Dilks P, Narayanan P, Reznek R, Sahdev A, Rockall A. Can quantitative dynamic contrastenhanced MRI independently characterize an ovarian mass? European Radiology. 2010;20(9):2176‐83. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65. Djordjevic B, Stojanovic S, Conic I, Jankovic‐Velickovic L, Vukomanovic P, Zivadinovic R, et al. Current approach to epithelial ovarian cancer based on the concept of cancer stem cells. Journal of BUOn. 2012;17(4):627‐36. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66. Dochez V, Randet M, Renaudeau C, Dimet J, Le Thuaut A, Caillon H, et al. Diagnostic performances of HE4, CA125, RMI and ROMA for the detection of ovarian cancer in presumed benign ovarian tumours. BJOG: An International Journal of Obstetrics and Gynaecology. 2017;124 (Supplement 1):77. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67. Domali E, Ficherova D, Kyriakopoulos K, Papamanolis V, Rodolakis A, Chaidopoulos D, et al. Endometrial and ovarian malignancies: Diagnostic involvement of ultrasound and CT scans. International Journal of Gynecological Cancer. 2011;3):S400. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68. Donach M, Yu Y, Artioli G, Banna G, Feng W, Bast Jr RC, et al. Combined use of biomarkers for detection of ovarian cancer in high‐risk women. Tumor Biology. 2010;31(3):209‐15. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69. Dorigo O, Berek JS. Personalizing CA125 levels for ovarian cancer screening. Cancer Prevention Research. 2011;4(9):1356‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70. Dotlic J, Terzic M, Likic I, Brndusic N, Milenkovic S, Maricic S, et al. New models for preoperative triage of women with benignant and malignant adnexal tumours. BJOG: An International Journal of Obstetrics and Gynaecology. 2013;120:236. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71. Drake J. Diagnosis and management of the adnexal mass. American Family Physician. 1998;57(10):2471‐6, 9‐80. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72. Durno CA, Aronson M, Tabori U, Malkin D, Chan H, Gallinger S. Oncologic surveillance for subjects with biallelic mismatch repair gene mutations‐10 year follow‐up in a kindred. Hereditary Cancer in Clinical Practice. 2011;9:9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73. Dutta S, Wang F‐q, Fleischer AC, Fishman DA. New frontiers for ovarian cancer risk evaluation: proteomics and contrast‐enhanced ultrasound. AJR American Journal of Roentgenology. 2010;194(2):349‐54. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74. Dutta S, Wang F‐q, Phalen A, Fishman DA. Biomarkers for ovarian cancer detection and therapy. Cancer Biology &amp; Therapy. 2010;9(9):668‐77. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75. Escudero JM, Auge JM, Filella X, Torne A, Pahisa J, Molina R. Comparison of serum human epididymis protein 4 with cancer antigen 125 as a tumor marker in patients with malignant and nonmalignant diseases. Clinical Chemistry. 2011;57(11):1534‐44. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76. Farghaly SA. Current diagnosis and management of ovarian cysts. Clinical &amp; Experimental Obstetrics &amp; Gynecology. 2014;41(6):609‐12. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77. Farnaz, Hassan L. Serum CA‐125 versus ultrasound examination in differentiating between benign and malignant ovarian masses. JPMI ‐ Journal of Postgraduate Medical Institute. 2012;26(3):291‐5. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78. Faschingbauer F, Benz M, Haberle L, Goecke TW, Beckmann MW, Renner S, et al. Subjective assessment of ovarian masses using pattern recognition: the impact of experience on diagnostic performance and interobserver variability. Archives of Gynecology &amp; Obstetrics. 2012;285(6):1663‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79. Fischerova D, Burgetova A. Imaging techniques for the evaluation of ovarian cancer. Best Practice &amp; Research in Clinical Obstetrics &amp; Gynaecology. 2014;28(5):697‐720. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80. Fischerova D, Zikan M, Dundr P, Cibula D. Diagnosis, treatment, and follow‐up of borderline ovarian tumors. Oncologist. 2012;17(12):1515‐33. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81. Fischerova D, Zikan M, Pinkavova I, Slama S, Fruhauf F, Freitag P, et al. [The rational preoperative diagnosis of ovarian tumors ‐ imaging techniques and tumor biomarkers (review)]. Ceska Gynekologie. 2012;77(4):272‐87. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82. Fleischer AC, Lyshchik A, Andreotti RF, Hwang M, Jones HW, 3rd, Fishman DA. Advances in sonographic detection of ovarian cancer: depiction of tumor neovascularity with microbubbles. AJR American Journal of Roentgenology. 2010;194(2):343‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83. Fleischer AC, Lyshchik AP, Jones IHW, Fishman DA. Early detection of ovarian cancer with contrast enhanced transvaginal sonography. MedicaMundi. 2009;53(1):49‐54+7+9+60+1. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84. Fleischer AC, Rodgers WH, Kepple DM, Williams LL, Jones HW, 3rd. Color Doppler sonography of ovarian masses: a multiparameter analysis. Journal of ultrasound in medicine: official journal of the American Institute of Ultrasound in Medicine. 1993;12(1):41‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85. Florinas S, Kim J, Nam K, Janat‐Amsbury MM, Kim SW. Ultrasound‐assisted siRNA delivery via arginine‐grafted bioreducible polymer and microbubbles targeting VEGF for ovarian cancer treatment. Journal of Controlled Release. 2014;183:1‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86. Franchi D, Sandri M, Boveri S, Peiretti M, Radice D, Preti E, et al. Ultrasound imaging compared to a multivariate predictive algorithm combining HE4 and CA 125 (roma) in patients with adnexal masses. International Journal of Gynecological Cancer. 2011;3):S364. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87. Fuste P. HE‐4 in the diagnosis of abdominal masses. Comparison with ultrasonography and RMI. Tumor Biology. 2014;35:S9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88. Gasiorowska E, Michalak M, Warchol W, Lemanska A, Jasinski P, Spaczynski M, et al. Clinical application of HE4 and CA125 in ovarian cancer type I and type II detection and differential diagnosis. Ginekologia Polska. 2015;86(2):88‐93. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89. Geetha P, Nair MK. Granulosa cell tumours of the ovary. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology. 2010;50(3):216‐20. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90. Geomini P, Coppus S, Kluivers KB, Bremer GL, Kruitwagen R, Mol BWJ. Is three‐dimensional ultrasonography of additional value in the assessment of adnexal masses? Gynecologic Oncology. 2007;106(1):153‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91. Gilbert L, Basso O, Sampalis J, Karp I, Martins C, Feng J, et al. Assessment of symptomatic women for early diagnosis of ovarian cancer: results from the prospective DOvE pilot project. Lancet Oncology. 2012;13(3):285‐91. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92. Givens V, Mitchell GE, Harraway‐Smith C, Reddy A, Maness DL. Diagnosis and management of adnexal masses. American Family Physician. 2009;80(8):815‐20. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93. Goff B. Symptoms Associated With Ovarian Cancer. Clinical Obstetrics and Gynecology. 2012;55(1):36‐42. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94. Gotlieb WH, Soriano D, Achiron R, Zalel Y, Davidson B, Kopolovic J, et al. CA 125 measurement and ultrasonography in borderline tumors of the ovary. American journal of obstetrics and gynecology. 2000;183(3):541‐6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95. Goyal S. Assessment of adnexal masses by color Doppler study and serum CA125 assay. BJOG: An International Journal of Obstetrics and Gynaecology. 2014;121:49. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96. Grasso M, Blanco S, Grasso AAC, Nespoli L. Inguinal polypropylene plug: A cause of unusual testicular tumor pelvic metastasis. Archivio Italiano di Urologia e Andrologia. 2013;85(1):47‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97. Grewal K, Hamilton W, Sharp D. Ovarian cancer: A scoring system for primary care. BJOG: An International Journal of Obstetrics and Gynaecology. 2012;119:158. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98. Griffin N, Grant LA, Sala E. Adnexal masses: characterization and imaging strategies. Seminars in Ultrasound, CT &amp; MR. 2010;31(5):330‐46. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99. Gubbels JA, Claussen N, Kapur AK, Connor JP, Patankar MS. The detection, treatment, and biology of epithelial ovarian cancer. Journal of ovarian research. 2010;3:8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100. Guerriero S, Ajossa S, Garau N, Piras B, Paoletti AM, Melis GB. Ultrasonography and color Doppler‐based triage for adnexal masses to provide the most appropriate surgical approach. American journal of obstetrics and gynecology. 2005;192(2):401‐6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100. Guerriero S, Ajossa S, Lai MP, Alcazar JL, Paoletti AM, Marisa O, et al. The diagnosis of functional ovarian cysts using transvaginal ultrasound combined with clinical parameters, CA125 determinations, and color Doppler. European Journal of Obstetrics &amp; Gynecology and Reproductive Biology. 2003;110(1):83‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101. Guerriero S, Mallarini G, Ajossa S, Risalvato A, Satta R, Mais V, et al. Transvaginal ultrasound and computed tomography combined with clinical parameters and CA‐125 determinations in the differential diagnosis of persistent ovarian cysts in premenopausal women. Ultrasound in Obstetrics &amp; Gynecology. 1997;9(5):339‐43. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102. Guerriero S, Saba L, Ajossa S, Peddes C, Sedda F, Piras A, et al. Assessing the reproducibility of the IOTA simple ultrasound rules for classifying adnexal masses as benign or malignant using stored 3D volumes. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology. 2013;171(1):157‐60. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103. Haiyan H, Min D. Ultrasound operators' confidence influences diagnosis of ovarian tumors ‐ a study in China. Asian Pacific Journal of Cancer Prevention: Apjcp. 2011;12(5):1275‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104. Hamilton W, Roobottom C. Early diagnosis of cancer by imaging: The primary care perspective. Radiography. 2012;18(1):5‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>105. Hamper UM, Sheth S, Abbas FM, Rosenshein NB, Aronson D, Kurman RJ. Transvaginal color Doppler sonography of adnexal masses: differences in blood flow impedance in benign and malignant lesions. AJR American Journal of Roentgenology. 1993;160(6):1225‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106. Haoula Z, Deshpande R, Jayaprakasan K, Raine‐Fenning N. Doppler imaging in the diagnosis of ovarian disease. Expert Opinion on Medical Diagnostics. 2012;6(1):59‐73. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107. Hartman CA, Juliato CRT, Sarian LO, Toledo MC, Jales RM, Morais SS, et al. Ultrasound criteria and CA 125 as predictive variables of ovarian cancer in women with adnexal tumors. Ultrasound in Obstetrics &amp; Gynecology. 2012;40(3):360‐6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108. Hata K, Akiba S, Hata T, Miyazaki K. A multivariate logistic regression analysis in predicting malignancy for patients with ovarian tumors. Gynecologic Oncology. 1998;68(3):256‐62. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109. Hata T, Hata K, Noguchi J, Kanenishi K, Shiota A. Ultrasound for evaluation of adnexal malignancy: from 2D to 3D ultrasound. Journal of Obstetrics &amp; Gynaecology Research. 2011;37(10):1255‐68. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110. Hellstrom I, Heagerty PJ, Swisher EM, Liu P, Jaffar J, Agnew K, et al. Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms. Cancer Letters. 2010;296(1):43‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111. Hellstrom I, Hellstrom KE. Two new biomarkers, mesothelin and HE4, for diagnosis of ovarian carcinoma. Expert Opinion on Medical Diagnostics. 2011;5(3):227‐40. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112. Hertlein L, Stieber P, Kirschenhofer A, Krocker K, Nagel D, Lenhard M, et al. Human epididymis protein 4 (HE4) in benign and malignant diseases. Clinical Chemistry &amp; Laboratory Medicine. 2012;50(12):2181‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113. Hodeib M, Bristow RE, Smith A, Zhang Z, Chan DW, Fung ET, et al. Impact of a multivariate index assay on referral patterns for surgical management of an adnexal mass. Gynecologic Oncology. 2013;131 (1):258. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114. Hogdall E, Aarnstrup Rasmussen M, Christensen IJ, Lundvall L, Engelholm SA, Nedergaard L, et al. Diagnostic value of he4, CA125 and the roma index in ovarian cancer patients from a tertiary center. International Journal of Gynecological Cancer. 2011;3):S607. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115. Holdenrieder S, Molina R, Gion M, Gressner A, Troalen F, Maria Auge J, et al. Alternative antibody for the detection of CA125 antigen: A European multicenter study for the evaluation of the analytical and clinical performance of the Access OV Monitor assay on the UniCel DxI 800 Immunoassay System. Clinical Chemistry and Laboratory Medicine. 2008;46(5):588‐99. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>116. Horala A, Swiatly A, Lorek J, Kokot ZJ, Matysiak J and Nowak‐Markwitz E. Assessment of diagnostic utility of multivariate diagnostic models in differential diagnosis of ovarian tumors. Ginekologia Polska 2018;89(10): 568‐572 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117. Hossain F, Khan N, Hussain R. Preoperative detection of ovarian cancer by colour Doppler ultrasonography and CA125. BJOG: An International Journal of Obstetrics and Gynaecology. 2012;119:160. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>118. Ibrahim M, Bahaa A, Ibrahim A, El Hakem AA, Abo‐El Noor A, El Tohamy U. Evaluation of serum mesothelin in malignant and benign ovarian masses. Archives of Gynecology &amp; Obstetrics. 2014;290(1):107‐13. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119. Jacobs I, Menon U. The sine qua non of discovering novel biomarkers for early detection of ovarian cancer: carefully selected preclinical samples. Cancer Prevention Research. 2011;4(3):299‐302. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120. Jayde V, White K, Blomfield P. Symptoms and diagnostic delay in ovarian cancer: a summary of the literature. Contemporary Nurse. 2009;34(1):55‐65. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121. Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA: a Cancer Journal for Clinicians. 2011;61(3):183‐203. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122. Kaijser J, Bourne T, Valentin L, Sayasneh A, Van Holsbeke C, Vergote I, et al. Improving strategies for diagnosing ovarian cancer: a summary of the International Ovarian Tumor Analysis (IOTA) studies. Ultrasound in Obstetrics &amp; Gynecology. 2013;41(1):9‐20. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123. Kaijser J, Van Gorp T, Van Holsbeke C, Sayasneh A, Vergote I, Bourne T, et al. Diagnostic test performance of CA125, HE4, ROMA and IOTA's LR2 in adnexal tumours of different size. BJOG: An International Journal of Obstetrics and Gynaecology. 2013;120:360‐1. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124. Kaijser J, Vandecaveye V, Deroose CM, Rockall A, Thomassin‐Naggara I, Bourne T, et al. Imaging techniques for the pre‐surgical diagnosis of adnexal tumours. Best Practice &amp; Research in Clinical Obstetrics &amp; Gynaecology. 2014;28(5):683‐95. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125. Kalmantis K, Papageorgiou T, Rodolakis A, Lymberopoulos E, Daskalakis G, Voulgaris Z, et al. The role of three‐dimensional (3D) sonography and 3D power Doppler in the preoperative assessment of borderline ovarian tumors. European Journal of Gynaecological Oncology. 2007;28(5):381‐5. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126. Kazantseva M, Porhanova N, Syrota E, Potemin S. Sensitivity of the serum HE4 and CA‐125 combination in the ovarian cancer diagnosis. International Journal of Gynecological Cancer. 2011;3):S415. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127. Kesterson J, Chan JK, Tian C, Monk BJ, Bell JG. Symptoms of women with high‐risk early‐stage ovarian cancer: A Gynecologic Oncology Group study. Gynecologic Oncology. 2009;112(2):S36‐S7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>128. Khan A, Sultana K. Presenting signs and symptoms of ovarian cancer at a tertiary care hospital. JPMA The Journal of the Pakistan Medical Association. 2010;60(4):260‐2. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>129. Kim J, Lee HN, Park H, Lee DW, Kim MJ, Shin JE. Diagnostic accuracy of risk of ovarian malignancy algorithm (ROMA) experienced in the clinical practice at a single hospital. International Journal of Gynecological Cancer. 2018;28 (Supplement 3):58 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130. Kim KH, Alvarez RD. Using a multivariate index assay to assess malignancy in a pelvic mass. Obstetrics &amp; Gynecology. 2012;119(2 Pt 1):365‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131. Kim PS, Djazayeri S, Zeineldin R. Novel nanotechnology approaches to diagnosis and therapy of ovarian cancer. Gynecologic Oncology. 2011;120(3):393‐403. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>132. Kirschenhofer A, Lenhard M, Hertlein L, Furst S, Mayr D, Nagel D, et al. HE4 and CA125in benignandmalignantdiseases. Clinical Chemistry and Laboratory Medicine. 2011;49:S253. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133. Knafel A, Nocun A, Banas T, Wiechec M, Jach R, Pietrus M, et al. Iota simple ultrasound‐based rules: Why do we have inconclusive results? International Journal of Gynecological Cancer. 2013;1):155‐6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>134. Knudsen UB, Tabor A, Mosgaard B, Andersen ES, Kjer JJ, Hahn‐Pedersen S, et al. Management of ovarian cysts. Acta Obstetricia et Gynecologica Scandinavica. 2004;83(11):1012‐21. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>135. Koleva‐Topova V. Diagnostic usefulness of multi‐marker panels in preoperative prediction of ovarian cancer diagnosis. Clinica Chimica Acta. 2019;493 (Supplement 1):S147. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136. Konforte D, Diamandis EP. Is early detection of cancer with circulating biomarkers feasible? Clinical Chemistry. 2013;59(1):35‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>137. Kotowicz B, Fuksiewicz M, Kowalska M, Sobiczewski P, Skrzypczak M, Spiewankiewicz B, et al. He4 and ca125 in ovarian cancer patients. International Journal of Gynecological Cancer. 2013;1):923. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138. Kurjak A, Schulman H, Sosic A, Zalud I, Shalan H. Transvaginal ultrasound, color flow, and Doppler waveform of the postmenopausal adnexal mass. Obstetrics &amp; Gynecology. 1992;80(6):917‐21. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>139. Kurman RJ, Visvanathan K, Roden R, Wu TC, Shih IM. Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. American journal of obstetrics and gynecology. 2008;198(4):351‐6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>140. Lachance JA, Choudhri AF, Sarti M, Modesitt SC, Jazaeri AA, Stukenborg GJ. A nomogram for estimating the probability of ovarian cancer. Gynecologic Oncology. 2011;121(1):2‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>141. Lalwani N, Dubinsky TJ. Clinically suspected adnexal mass. Ultrasound Quarterly. 2013;29(1):87‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142. Langhe R, Norris L, Petzold M, Abu Saadeh F, Kamran W, Ibrahim N, et al. Roma index improves specificity of ovarian cancer diagnosis compared to CA125 alone. International Journal of Gynecological Cancer. 2013;1):588. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143. Langmar Z, Nemeth M, Vlesko G, Kiraly M, Hornyak L, Bosze P. HE4‐‐a novel promising serum marker in the diagnosis of ovarian carcinoma. European Journal of Gynaecological Oncology. 2011;32(6):605‐10. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>144. Lawicki S, Bedkowska GE, Gacuta‐Szumarska E, Szmitkowski M. The plasma concentration of VEGF, HE4 and CA125 as a new biomarkers panel in different stages and sub‐types of epithelial ovarian tumors. Journal of ovarian research. 2013;6(1):45. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>145. Leandersson P, Kalapotharakos G, Henic E, Borgfeldt H, Petzold M, Hoyer‐Hansen G, et al. A Biomarker Panel Increases the Diagnostic Performance for Epithelial Ovarian Cancer Type I and II in Young Women. Anticancer Research. 2016;36(3):957‐65 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146. Lee TS, Kim JW, Park NH, Song YS, Kang SB, Lee HP. Assessing clinical performance of gynecology residents: sonographic evaluation of adnexal masses based on morphological scoring systems. Ultrasound in Obstetrics &amp; Gynecology. 2005;26(7):776‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>147. Leeners B, Schild RL, Funk A, Hauptmann S, Kemp B, Schroder W, et al. Colour Doppler sonography improves the pre‐operative diagnosis of ovarian tumours made using conventional transvaginal sonography. European Journal of Obstetrics Gynecology and Reproductive Biology. 1996;64(1):79‐85. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>148. Lerner JP, Timor‐Tritsch IE, Federman A, Abramovich G. Transvaginal ultrasonographic characterization of ovarian masses with an improved, weighted scoring system. American Journal of Obstetrics &amp; Gynecology. 1994;170(1 Pt 1):81‐5. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>149. Levine D, Feldstein VA, Babcook CJ, Filly RA. Sonography of ovarian masses: poor sensitivity of resistive index for identifying malignant lesions. AJR American Journal of Roentgenology. 1994;162(6):1355‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150. Li AJ. New biomarkers for the diagnosis of ovarian carcinoma: OVA1 and ROMA. [Italian] Nuovi biomarcatori per la diagnosi di carcinoma ovarico: OVA1 e ROMA. Giornale Italiano di Ostetricia e Ginecologia. 2012;34(3):409‐14. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>151. Li J, Dowdy S, Tipton T, Podratz K, Lu W‐G, Xie X, et al. HE4 as a biomarker for ovarian and endometrial cancer management. Expert Review of Molecular Diagnostics. 2009;9(6):555‐66. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152. Likic I, Terzic MM, Bila J, Pilic I, Berisavac M, Dotlic J, et al. Adnexal masses: Reliability of serum tumor marker levels. International Journal of Gynecological Cancer. 2011;3):S363. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>153. Lin JY, Qin JB, Sangvatanakul V. Human epididymis protein 4 for differential diagnosis between benign gynecologic disease and ovarian cancer: a systematic review and meta‐analysis (Provisional abstract). European Journal of Obstetrics and Gynecology and Reproductive Biology [Internet]. 2013 [cited DARE Y/U]; (1):[81‐5 pp.]. Available from: http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE‐12013017358/frame.html. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>154. Liu JH, Zanotti KM. Management of the adnexal mass. Obstetrics &amp; Gynecology. 2011;117(6):1413‐28. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>155. Lutz AM, Willmann JK, Drescher CW, Ray P, Cochran FV, Urban N, et al. Early diagnosis of ovarian carcinoma: is a solution in sight? Radiology. 2011;259(2):329‐45. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156. Macuks R, Baidekalna I, Donina S. An ovarian cancer malignancy risk index composed of HE4, CA125, ultrasonographic score, and menopausal status: use in differentiation of ovarian cancers and benign lesions. Tumour Biology. 2012;33(5):1811‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>157. Malek M. Imaging strategy for diagnosis of adnexal masses including US,CT Scan and MRI. International Journal of Fertility and Sterility Conference: 13th Congress on Reproductive Biomedicine and 7th Royan Nursing and Midwifery Seminar Tehran Iran, Islamic Republic of Conference Start. 2012;6(pp 27). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>158. Manganaro L, Yazdanian D, Vinci V, Imperiale L, Anastasi E, Porpora MG. Avoiding inappropriate surgery on undetermined mass: May the combination of Magnetic Resonance Imaging (MRI) and ovarian markers be helpful? Journal of Minimally Invasive Gynecology. 2014;1):S69. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>159. Manolov V, Avramova V, Radenkov R. He 4 ‐ A new marker for ovarian cancer. Clinical Chemistry and Laboratory Medicine. 2011;49:S254. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160. Mark DH. Multianalyte testing for the evaluation of adnexal masses (Provisional abstract). Database of Abstracts of Reviews of Effects [Internet]. 2013 [cited DARE Y/U]; (1):[1 p.]. Available from: http://onlinelibrary.wiley.com/o/cochrane/cldare/articles/DARE‐12013062634/frame.html. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>161. Marret H, Ecochard R, Giraudeau B, Golfier F, Raudrant D, Lansac J. Color Doppler energy prediction of malignancy in adnexal masses using logistic regression models. Ultrasound in Obstetrics &amp; Gynecology. 2002;20(6):597‐604. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>162. Marret H, Sauget S, Giraudeau B, Brewer M, Ranger‐Moore J, Body G, et al. Contrast‐enhanced sonography helps in discrimination of benign from malignant adnexal masses. Journal of Ultrasound in Medicine. 2004;23(12):1629‐39; quiz 41‐42. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163. McGuckin MA, Ramm LE, Joy GJ, Free KE, Ward BG. Preoperative discrimination between ovarian‐carcinoma, non‐ovarian gynecological malignancy and benign adnexal masses using serum levels of ca125 and the polymorphic epithelial mucin antigens CASA, OSA AND MSA. International Journal of Gynecological Cancer. 1992;2(3):119‐28. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>164. McGuire WP. HE4‐‐another marker for gynecologic cancers: do we really need one? Oncology (Williston Park). 2013;27(6):563, 6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>165. McIntosh MW, Drescher C, Karlan B, Scholler N, Urban N, Hellstrom KE, et al. Combining CA 125 and SMR serum markers for diagnosis and early detection of ovarian carcinoma. Gynecol Oncol. 2004;95(1):9‐15. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>166. Medeiros LR, Rosa DD, da Rosa MI, Bozzetti MC. Accuracy of ultrasonography with color Doppler in ovarian tumor: a systematic quantitative review. International Journal of Gynecological Cancer. 2009;19(7):1214‐20. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167. Medeiros LR, Rosa DD, da Rosa MI, Bozzetti MC. Accuracy of CA 125 in the diagnosis of ovarian tumors: a quantitative systematic review. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology. 2009;142(2):99‐105. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>168. Miller RW, Ueland FR. Risk of malignancy in sonographically confirmed ovarian tumors. Clinical Obstetrics &amp; Gynecology. 2012;55(1):52‐64. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>169. Miller RW, van Nagell JR. Preoperative evaluation of adnexal masses. Women's health. 2011;7(1):37‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>170. Mohaghegh P, Rockall AG. Imaging strategy for early ovarian cancer: characterization of adnexal masses with conventional and advanced imaging techniques. Radiographics. 2012;32(6):1751‐73. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>171. Molina R, Escudero JM, Auge JM, Filella X. Evaluation of serum human epididymis protein 4 (HE4) in patients with malignant and non malignant diseases: Comparison with CA 125. Clinical Chemistry and Laboratory Medicine. 2011;49:S259. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>172. Molina R, Escudero JM, Auge JM, Filella X, Ferro L, Torne A, et al. HE‐4, CA 125 and ROMA in the differential diagnosis of patients with gynecological diseases. Tumor Biology. 2011;32:S17‐S8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>173. Molina R, Escudero JM, Auge JM, Filella X, Foj L, Torne A, et al. He4, CA 125 and roma in the differential diagnosis of patients with gynecological diseases. Clinical Chemistry and Laboratory Medicine. 2011;49:S258. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>174. Molina R, Escudero JM, Auge JM, Filella X, Torne A, Pahisa J, et al. CA 19.9 and useful complementary tumor marker in ovarian cancer: Comparison with HE4, CA 125 and ROMA in Gynaecological diseases. Tumor Biology. 2012;33:S39. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>175. Molina R, Escudero JM, Fuste P. HE‐4 levels in gynaecological patients undergoing surgical treatment for suspected malignancies. Systems to increase efficiency. Tumor Biology. 2014;35:S9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>176. Molina R, Stieber P, Heinz‐Jurgen R, Escudero JM, Auge JM, Filella X. A european multicenter study for the evaluation of the analytical and clinical performance of the Elecsys HE‐4 assay on Cobas e411 from roche diagnostics. Tumor Biology. 2012;33:S79. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>177. Molina R, Fernandez‐Bonifacio R, Mellado B, Fernandez‐Galan E, Carreras N, Rodriguez I et al. New algorithm ROMA (risk of ovarian malignancy algorithm)using CA 125 from Siemens and HE4 from Roche. Clinica Chimica Acta. 2019;493 (Supplement 1): S155 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>178. Momtaz M. 3D ultrasonography of ovarian tumors. International Journal of Fertility and Sterility Conference: 15th Congress on Reproductive Biomedicine and 9th Royan Nursing and Midwifery Seminar Tehran Iran, Islamic Republic of Conference Start. 2014;8(pp 23‐24). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179. Montagnana M, Lippi G, Ruzzenente O, Bresciani V, Danese E, Scevarolli S, et al. The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass. Journal of Clinical Laboratory Analysis. 2009;23(5):331‐5. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>180. Moore RG, Bast Jr RC. How do you distinguish a malignant pelvic mass from a benign pelvic mass? Imaging, biomarkers, or none of the above. Journal of Clinical Oncology. 2007;25(27):4159‐61. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>181. Moore RG, Maclaughlan S. Current clinical use of biomarkers for epithelial ovarian cancer. Current Opinion in Oncology. 2010;22(5):492‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>182. Moore RG, MacLaughlan S, Bast RC, Jr. Current state of biomarker development for clinical application in epithelial ovarian cancer. Gynecologic Oncology. 2010;116(2):240‐5. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>183. Morotti M, Menada MV, Gillott DJ, Venturini PL, Ferrero S. The preoperative diagnosis of borderline ovarian tumors: a review of current literature. Archives of Gynecology &amp; Obstetrics. 2012;285(4):1103‐12. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>184. Moszynski R, Zywica P, Wojtowicz A, Szubert S, Sajdak S, Stachowiak A, et al. Menopausal status strongly influences the utility of predictive models in differential diagnosis of ovarian tumors: an external validation of selected diagnostic tools. Ginekologia Polska. 2014;85(12):892‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>185. Mozaffari‐Kermani R, Montaser‐Kouhsari L. The role of pathologic results and clinical presentations in predictive value of transvaginal ultrasonographic findings: differentiating benign from malignant ovarian neoplasms. Virchows Archiv. 2009;455:310‐1. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>186. Murala KS, Ma K, Henry RJW, Snape S, Dwivedi R. Performance of IOTA simple rules and RMI in preoperative classification of adnexal lesions in DGH setting. BJOG: An International Journal of Obstetrics and Gynaecology. 2014;121:49‐50. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>187. Murta EFC, da Silva CS, Gomes RAS, Tavares‐Murta BM, Melo ALKO. Ultrasonographic criteria and tumor marker assay are good procedures for the diagnosis of ovarian neoplasia in preselected outpatients. European Journal of Gynaecological Oncology. 2004;25(6):707‐12. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>188. Murta EFC, Nomelini RS. Early diagnosis and predictors of malignancy of adnexal masses. Current Opinion in Obstetrics &amp; Gynecology. 2006;18(1):14‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>189. Myers ER, Bastian LA, Havrilesky LJ, Kulasingam SL, Terplan MS, Cline KE, et al. Management of adnexal mass. Evidence Report/Technology Assessment. 2006(130):1‐145. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>190. Nagy B, Krasznai ZT, Csoban M, Antal‐Szalmas P, Hernadi Z, Kappelmayer J. The emerging value of HE4 in the discrimination of ovarian cancer from other malignant and benign pelvic masses. Clinical Chemistry and Laboratory Medicine. 2011;49:S261. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>191. Negishi Y, Iwabuchi H, Sakunaga H, Sakamoto M, Okabe K, Sato H, et al. Serum and tissue measurements of CA72‐4 in ovarian cancer patients. Gynecologic Oncology. 1993;48(2):148‐54. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>192. Nikolova T, Dimitrov G, Antovska V, Eftimovska N, Nikolova N, Janusevska A. A comparison of HE4 with CA 125 as tumor markers in patients with ovarian cancer. International Journal of Gynecological Cancer. 2013;1):586. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>193. Nogales FF, Dulcey I, Preda O. Germ cell tumors of the ovary: an update. Archives of Pathology &amp; Laboratory Medicine. 2014;138(3):351‐62. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>194. Nolen BM, Lokshin AE. Multianalyte assay systems in the differential diagnosis of ovarian cancer. Expert Opinion on Medical Diagnostics. 2012;6(2):131‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>195. Nolen BM, Lokshin AE. Biomarker testing for ovarian cancer: clinical utility of multiplex assays. Molecular Diagnosis &amp; Therapy. 2013;17(3):139‐46. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>196. Ohel I, Sheiner E, Aricha‐Tamir B, Piura B, Meirovitz M, Silberstein T, et al. Three‐dimensional power Doppler ultrasound in ovarian cancer and its correlation with histology. Archives of Gynecology &amp; Obstetrics. 2010;281(5):919‐25. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>197. Ong N, Zakaria AR. Frozen section: The gatekeeper for radical ovarian cancer surgery. Medical Journal of Malaysia. 2018;73 (Supplement 1):48. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>198. Onsrud M, Shabana A, Austgulen R. Soluble tumor necrosis factor receptors and CA 125 in serum as markers for epithelial ovarian cancer. Tumor Biology. 1996;17(2):90‐6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>199. Osmers RG, Osmers M, von Maydell B, Wagner B, Kuhn W. Evaluation of ovarian tumors in postmenopausal women by transvaginal sonography. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology. 1998;77(1):81‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200. Osmers RGW, Kuhn W. Early diagnosis of ovarian cancer using ultrasonography. Archives of Gynecology and Obstetrics. 1997;260(1‐4):351‐5. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>201. Ozan H, Ozsoy S, Baykara S, Celik N. Review of 28 ovarian granulosa cell tumor cases. International Journal of Gynecological Cancer. 2011;3):S657. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>202. Park Y, Lee J‐H, Hong DJ, Lee EY, Kim H‐S. Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non‐gynecologic diseases. Clinical Biochemistry. 2011;44(10‐11):884‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>203. Pitta DdR, Sarian LO, Campos EA, Andrade LLDA, Sallum LF, Braganca JF, et al. HE4 can help discriminate women with malignant ovarian tumors only if CA125 levels are elevated. International Journal of Biological Markers. 2013;28(4):e377‐86. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>204. Presl J, Sefrhansova L, Sedlakova I, Vlasak P, Bouda J, Bartakova A, et al. Possibilities of preoperative prediction of the biological behavior of gynecological pelvic tumors. [Czech] </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>205. Moznosti poedoperaeni predikce biologickeho chovani gynekologickych panevnich tumoru. Aktualni Gynekologie a Porodnictvi. 2014;6:53‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>206. Prompeler HJ. [Ultrasonographic clarification of adnexal findings]. Radiologe. 2011;51(7):568‐80. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>207. Qiao J‐J, Yu J, Yu Z, Li N, Song C, Li M. Contrast‐enhanced ultrasonography in differential diagnosis of benign and malignant ovarian tumors. PLoS ONE [Electronic Resource]. 2015;10(3):e0118872. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>208. Quaranta M, Mehra G, Nath R and Sayasneh A. Why a benign ovarian mass can still undergo surgery by a gynaecological cancer surgeon? Australasian Journal of Ultrasound in Medicine. 2019;22 (2): 146. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>209. Redman C, Duffy S, Dobson C. Improving early detection of ovarian cancer. Practitioner. 2011;255(1741):27‐30, 3. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>210. Reina H, Buchel J, Butenschon A, Vigo F, Schoetzau A, Heinzelmann‐Schwarz V, et al. Estimating risk of malignancy in adnexal masses with ultrasound: A retrospective diagnostic accuracy study. Geburtshilfe und Frauenheilkunde Conference. 2018;78(10). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>211. Riman T, Dickman PW, Nilsson S, Correia N, Nordlinder H, Magnusson CM, et al. Risk factors for invasive epithelial ovarian cancer: results from a Swedish case‐control study. American journal of epidemiology. 2002;156(4):363‐73. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>212. Romagnolo C, Trivella G, Bonacina M, Fornale M, Maggino T, Ferrazzi E. Preoperative diagnosis of 221 consecutive ovarian masses: scoring system and expert evaluation. European Journal of Gynaecological Oncology. 2006;27(5):487‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>213. Roman LD, Muderspach LI, Stein SM, LaiferNarin S, Groshen S, Morrow CP. Pelvic examination, tumor marker level, and gray‐scale and Doppler sonography in the prediction of pelvic cancer. Obstetrics and Gynecology. 1997;89(4):493‐500. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>214. Ronco DA, Manahan KJ, Geisler JP. Ovarian cancer risk assessment: a tool for preoperative assessment. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology. 2011;158(2):325‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>215. Salem S, White LM, Lai J. Doppler sonography of adnexal masses: the predictive value of the pulsatility index in benign and malignant disease. AJR American Journal of Roentgenology. 1994;163(5):1147‐50. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>216. Sandhu N, Karlsen MA, Hogdall C, Laursen IA, Christensen IJ, Hogdall EVS. Stability of HE4 and CA125 in blood samples from patients diagnosed with ovarian cancer. Scandinavian Journal of Clinical &amp; Laboratory Investigation. 2014;74(6):477‐84. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>217. Sasaroli D, Coukos G, Scholler N. Beyond CA125: The coming of age of ovarian cancer biomarkers. Biomarkers in Medicine. 2009;3(3):275‐88. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>218. Sassone AM, Timor‐Tritsch IE, Artner A, Westhoff C, Warren WB. Transvaginal sonographic characterization of ovarian disease: evaluation of a new scoring system to predict ovarian malignancy. Obstetrics &amp; Gynecology. 1991;78(1):70‐6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>219. Sayasneh A, Preisler J, Stlader C, Husicka R, Naji O, Kaijser J, et al. A randomised controlled trial to compare the clinical impact of RMI versus LR2 to characterise adnexal masses: Interim analysis of phase 4 IOTA study. Bjog [Internet]. 2013 [cited CENTRAL Y/U]:[357‐8 pp.]. Available from: http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/086/CN‐01007086/frame.html http://onlinelibrary.wiley.com/store/10.1111/1471‐0528.12343/asset/bjo12343.pdf?v=1&amp;t=ic4hlb2n&amp;s=3c47dc39d6bc29d1bd842be48b583b830e2f86c6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>220. Scholler N, Crawford M, Sato A, Drescher CW, O'Briant KC, Kiviat N, et al. Bead‐based ELISA for validation of ovarian cancer early detection markers. Clinical Cancer Research. 2006;12(7 I):2117‐24. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>221. Schutter EM, Mijatovic V, Kok A, Van Kamp GJ, Verstraeten R, Verheijen RH. Urinary gonadotropin peptide (UGP) and serum CA 125 in gynaecologic practice, a clinical prospective study. Anticancer Research. 1999;19(6C):5551‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>222. Schutter EM, Sohn C, Kristen P, Mobus V, Crombach G, Kaufmann M, et al. Estimation of probability of malignancy using a logistic model combining physical examination, ultrasound, serum CA 125, and serum CA 72‐4 in postmenopausal women with a pelvic mass: an international multicenter study. Gynecologic Oncology. 1998;69(1):56‐63. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>223. Sconfienza LM, Perrone N, Delnevo A, Lacelli F, Murolo C, Gandolfo N, et al. Diagnostic value of contrast‐enhanced ultrasonography in the characterization of ovarian tumors(). Journal of Ultrasound. 2010;13(1):9‐15. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>224. Simmons AR, Baggerly K, Bast RC, Jr. The emerging role of HE4 in the evaluation of epithelial ovarian and endometrial carcinomas. Oncology (Williston Park). 2013;27(6):548‐56. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>225. Simon I, Katsaros D, de la Longrais IR, Massobrio M, Scorilas A, Kim NW, et al. B7‐H4 is over‐expressed in early‐stage ovarian cancer and is independent of CA125 expression. Gynecologic Oncology. 2007;106(2):334‐41. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>226. Singh D, Lowe K, Colllins C, Cohen L, Dungan J, Shulman L, et al. Utility of symptom index in women at increased risk for ovarian cancer. Gynecologic Oncology. 2011;121(1):S61‐S. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>227. Sinha A, Drews F, Lim K, Pugh ND. Retrospective analysis of suspicious pelvic masses using the Pelvic Mass Index (PMI) scoring system from 2007 to 2014. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology. 2016;201:79‐84. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>228. Smitz J, Ron‐El R, Tarlatzis BC. The use of gonadotrophin releasing hormone agonists for in vitro fertilization and other assisted procreation techniques: Experience from three centres. Human Reproduction. 1992;7(SUPPL. 1):49‐66. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>229. Stanculescu R, Russu M, Vladescu T, Bausic V, Teodorescu A. The combined value of CA125 determination and echographic ovarian imaging, in preoperative diagnosis of benign, borderline and malignant ovarian tumors. Giornale Italiano di Ostetricia e Ginecologia. 2012;34(1):311‐3. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>230. Stavros S, Drakakis P, Haidopoulos D, Konomos G, Rodolakis A, Mesogitis S, et al. 3D image analysis; Involvement in the preoperative characterization of ovarian masses as benign or malignant. International Journal of Gynecological Cancer. 2014;2). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>231. Stein SM, Laifer‐Narin S, Johnson MB, Roman LD, Muderspach LI, Tyszka JM, et al. Differentiation of benign and malignant adnexal masses: relative value of gray‐scale, color Doppler, and spectral Doppler sonography. AJR American Journal of Roentgenology. 1995;164(2):381‐6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>232. Stieber P, Kirschenhofer A, Furst S, Nagel D, Hertlein L, Lenhard M, et al. The ROMA score and the influencing factors upon the diagnostic accuracy. Tumor Biology. 2011;32:S19. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>233. Stukan M, Dudziak M, Ratajczak K, Grabowski JP. Usefulness of diagnostic indices comprising clinical, sonographic, and biomarker data for discriminating benign from malignant ovarian masses. Journal of Ultrasound in Medicine. 2015;34(2):207‐17. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>234. Su Z, Graybill WS, Zhu Y. Detection and monitoring of ovarian cancer. Clinica Chimica Acta. 2013;415:341‐5. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>235. Suh KS, Park SW, Castro A, Patel H, Blake P, Liang M, et al. Ovarian cancer biomarkers for molecular biosensors and translational medicine. Expert Review of Molecular Diagnostics. 2010;10(8):1069‐83. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>236. Sumpaico WW. Comparison of roma to rmi for ovarian carcinoma in asia. International Journal of Gynecology and Obstetrics. 2012;119:S248‐S9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>237. Tantipalakorn C, Wanapirak C, Khunamornpong S, Sukpan K, Tongsong T. IOTA simple rules in differentiating between benign and malignant ovarian tumors. Asian Pacific Journal of Cancer Prevention: Apjcp. 2014;15(13):5123‐6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>238. Terzic MM, Dotlic J, Likic I, Ladjevic N, Brndusic N, Arsenovic N, et al. Current diagnostic approach to patients with adnexal masses: which tools are relevant in routine praxis? Chinese Journal of Cancer Research. 2013;25(1):55‐62. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>239. Timmerman D, Ameye L, Fischerova D, Epstein E, Melis GB, Guerriero S, et al. Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: Prospective validation by IOTA group. Bmj. 2011;342(7788):94. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>240. Timmerman D, Valentin L, Bourne TH, Collins WP, Verrelst H, Vergote I, et al. Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the International Ovarian Tumor Analysis (IOTA) Group. Ultrasound in Obstetrics &amp; Gynecology. 2000;16(5):500‐5. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>241. Twickler DM, Moschos E. Ultrasound and assessment of ovarian cancer risk. AJR American Journal of Roentgenology. 2010;194(2):322‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>242. Ueland F, Goodrich S, Desimone C, Seamon L, Miller R, Podzielinski I, et al. Predicting the risk of malignancy for an ovarian tumor by combining imaging and OVA1. International Journal of Gynecological Cancer. 2011;3):S115. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>243. Utrilla‐Layna J, Olartecoechea B, Auba M, Ruiz‐Zambrana A, Pineda L, Alcazar JL. Predicting malignancy in entirely solid‐appearing adnexal masses on gray‐scale ultrasound based on additional ultrasound findings, clinical complaints and biochemical parameters: A retrospective study. Donald School Journal of Ultrasound in Obstetrics and Gynecology. 2013;7(1):80‐5. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>244. Vaes E, Manchanda R, Autier P, Nir R, Nir D, Bleiberg H, et al. Differential diagnosis of adnexal masses: sequential use of the risk of malignancy index and HistoScanning, a novel computer‐aided diagnostic tool. Ultrasound in Obstetrics &amp; Gynecology. 2012;39(1):91‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>245. Valentin L, Ameye L, Jurkovic D, Metzger U, Lecuru F, Van Huffel S, et al. Which extrauterine pelvic masses are difficult to correctly classify as benign or malignant on the basis of ultrasound findings and is there a way of making a correct diagnosis? Ultrasound in Obstetrics &amp; Gynecology. 2006;27(4):438‐44. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>246. Van Calster B, Valentin L, Van Holsbeke C, Zhang J, Jurkovic D, Lissoni AA, et al. A novel approach to predict the likelihood of specific ovarian tumor pathology based on serum CA‐125: a multicenter observational study. Cancer Epidemiology, Biomarkers &amp; Prevention. 2011;20(11):2420‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>247. van Nagell JR, Jr. Early detection of ovarian cancer in symptomatic women. Lancet Oncology. 2012;13(3):223‐4. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>248. Van Trappen PO, Rufford BD, Mills TD, Sohaib SA, Webb JAW, Sahdev A, et al. Differential diagnosis of adnexal masses: risk of malignancy index, ultrasonography, magnetic resonance imaging, and radioimmunoscintigraphy. International Journal of Gynecological Cancer. 2007;17(1):61‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>249. Veyer L, Marret H, Bleuzen A, Simon E, Body G, Tranquart F. Preoperative diagnosis of ovarian tumors using pelvic contrast‐enhanced sonography. Journal of Ultrasound in Medicine. 2010;29(7):1041‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>250. Vranes HS, Klaric P, Sonicki Z, Gall V, Jukic M, Vukovic A. Prediction of ovarian tumor malignancy. Collegium Antropologicum. 2011;35(3):775‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>251. Weinberger V, Minar L. Diagnostics of malign ovarian tumors by ultrosound and CA 125‐our experience. International Journal of Gynecological Cancer. 2013;1:498. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>252. Wu H‐H, Wang P‐H, Yeh J‐Y, Chen Y‐J, Yen M‐S, Huang R‐L, et al. Serum cytokeratin‐19 fragment (Cyfra 21‐1) is a prognostic indicator for epithelial ovarian cancer. Taiwanese Journal of Obstetrics &amp; Gynecology. 2014;53(1):30‐4. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>253. Wynants L, Timmerman D, Verbakel JY, Testa A, Savelli L, Fischerova D, et al. Clinical Utility of Risk Models to Refer Patients with Adnexal Masses to Specialized Oncology Care: Multicenter External Validation Using Decision Curve Analysis. Clinical Cancer Research. 2017; 23(17): 5082‐5090. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>254. Wynn ML, Chang S, Peipins LA. Temporal patterns of conditions and symptoms potentially associated with ovarian cancer. Journal of women's health (2002). 2007;16(7):971‐86. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>255. Yang Z, Luo Z, Zhao B, Zhang W, Zhang J, Li Z, et al. Diagnosis and preoperative predictive value of serum HE4 concentrations for optimal debulking in epithelial ovarian cancer. Oncology Letters. 2013;6(1):28‐34. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>256. Yasmin SY, A.; Asif, M. Frequency of benign and malignant ovarian tumours in a tertiary care hospital. J Postgrad Med Inst. 2006;20:393‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>257. Yavuzcan A, Caglar M, Ozgu E, Ustun Y, Dilbaz S, Ozdemir I, et al. Addition of parity to the risk of malignancy index score in evaluating adnexal masses. Taiwanese Journal of Obstetrics &amp; Gynecology. 2014;53(4):518‐22. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>258. Yazbek J, Raju SK, Ben‐Nagi J, Holland TK, Hillaby K, Jurkovic D. Effect of quality of gynaecological ultrasonography on management of patients with suspected ovarian cancer: a randomised controlled trial. The Lancet Oncology [Internet]. 2008 [cited UPDATE (1991‐2008) Y]; (2):[124‐31 pp.]. Available from: http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/305/CN‐00622305/frame.htmlhttp://ac.els‐cdn.com/S1470204508700056/1‐s2.0‐S1470204508700056‐main.pdf?_tid=b21772ca‐620a‐11e5‐8fbf‐00000aacb362&amp;acdnat=1443023558_910592ab86216e8621e934ba16a60306. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>259. Yilmaz Y, Demirel G, Ulu HO, Celik IH, Suna Oguz S, Erdeve O, et al. Four neonates with giant ovarian cysts: difficulties in diagnosis and decision making process. Journal of Maternal‐Fetal &amp; Neonatal Medicine. 2012;25(8):1508‐10. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>260. Yoruk P, Dundar O, Yildizhan B, Tutuncu L, Pekin T. Comparison of the risk of malignancy index and self‐constructed logistic regression models in preoperative evaluation of adnexal masses. Journal of Ultrasound in Medicine. 2008;27(10):1469‐77. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>261. Yoruk P, Dundar O, Yildizhan B, Tutuncu L, Pekin T. Comparison of the risk of malignancy index and self‐constructed logistic regression models in preoperative evaluation of adnexal masses. Journal of Ultrasound in Medicine. 2008;27(10):1469‐77. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>262. Yu S, Lee JK, Kim JH, Park H, Lee MY, et al. Diagnostic performance and establishment of reference limits of HE4 in Korean healthy women. Gynecologic Oncology. 2016;143(1): 128‐134. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>263. Zhang L, Cheng N, Ding J, Liu Z. The clinical value of HE4 in differential diagnosis of ovarian cancer and gynecological pelvic benign diseases. Biochimica Clinica. 2013;37:S203. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>264. Zhang L, Liu Z. HE4AS specific marker for ovarian cancer: Comparison with CA125 in differential diagnosis of ovarian cancer and gynecological pelvic benign diseases. Clinical Chemistry and Laboratory Medicine. 2011;49:S282. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>265. Zourou I, Beretouli E, Touplikioti P, Zioga C, Maroufidou T, Voutsas M, et al. HE4 a novel human biomarker for ovarian cancer. Cytopathology. 2014;25:69. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 11.</span> <span class="table-title">Excluded studies: no 2 × 2 table</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/appendices#CD011964-tbl-0013">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011964-tbl-0014"> <div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Excluded studies: data not reported separately by menopausal status</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Data not reported separately by menopausal status</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Anonymous. Comparison of HE4, CA125, and risk of ovarian malignancy algorithm (ROMA) in the prediction of ovarian cancer in Korean women. International Journal of Gynecological Cancer. 2015;1:991. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2. Abdalla N, Piorkowski R, Bachanek M, Stanirowski P, Cendrowski K, Sawicki W. Does the risk of ovarian malignancy algorithm provide better diagnostic performance than HE4 and CA125 in the presurgical differentiation of adnexal tumors in Polish women? Disease Markers. 2018;2018 (no pagination)(5289804). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3. Akturk E, Karaca RE, Alanbay I, Dede M, Karasahin E, Yenen MC, et al. Comparison of four malignancy risk indices in the detection of malignant ovarian masses. Journal of Gynecologic Oncology. 2011;22(3):177‐82. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4. Alcazar JL, Pascual MA, Graupera B, Auba M, Errasti T, Olartecoechea B, et al. External validation of IOTA simple descriptors and simple rules for classifying adnexal masses. Ultrasound in Obstetrics &amp; Gynecology. 2016;48(3):397‐402. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5. Arun‐Muthuvel V, Jaya V. Pre‐operative evaluation of ovarian tumors by risk of malignancy index, CA125 and ultrasound. Asian Pacific Journal of Cancer Prevention: Apjcp 2014;15(6):2929‐32. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6. Asif N, Sattar A, Dawood MM, Rafi T, Aamir M, Anwar M. Pre‐operative evaluation of ovarian mass: risk of malignancy index. Jcpsp, Journal of the College of Physicians &amp; Surgeons ‐ Pakistan 2004;14(3):128‐31 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7. Aslam N, Tailor A, Lawton F, Carr J, Savvas M, Jurkovic D. Prospective evaluation of three different models for the pre‐operative diagnosis of ovarian cancer. BJOG: An International Journal of Obstetrics &amp; Gynaecology. 2000;107(11):1347‐53. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8. Borges A, Rodrigues S, Aguino J, Bernardo M, Mahomed F, Djokovic D. Performance of the IOTA ADNEX model in preoperative discrimination of adnexal formations: A Portuguese prospective multicenter pilot study. Australasian Journal of Ultrasound in Medicine. 2019;22 (2):145. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5. Bouzari Z, Yazdani S, Ahmadi MH, Barat S, Kelagar ZS, Kutenaie MJ, et al. Comparison of three malignancy risk indices and CA‐125 in the preoperative evaluation of patients with pelvic masses. BMC Research Notes. 2011;4:206. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9. Campos C, Sarian LO, Jales RM, Hartman C, Araujo KG, Pitta D, et al. Performance of the Risk of Malignancy Index for Discriminating Malignant Tumors in Women With Adnexal Masses. Journal of Ultrasound in Medicine. 2016;35(1):143‐52. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10. Chen H, Qian L, Jiang M, Du Q, Yuan F, Feng W. IOTA ADNEX model for evaluating adnexal masses using data from a gynecologic oncology center in China. Ultrasound in obstetrics &amp; gynecology: the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2019;01. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11. Cho HY, Park SH, Park YH, Kim HB, Kang JB, Hong SH, et al. Comparison of HE4, CA125, and Risk of Ovarian Malignancy Algorithm in the Prediction of Ovarian Cancer in Korean Women. Journal of Korean Medical Science. 2015;30(12):1777‐83. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12. Clarke SE, Grimshaw R, Rittenberg P, Kieser K, Bentley J. Risk of malignancy index in the evaluation of patients with adnexal masses. Journal of Obstetrics &amp; Gynaecology Canada: JOGC. 2009;31(5):440‐5. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13. Cymbaluk‐Ploska A, Chudecka‐Glaz A, Surowiec A, Pius‐Sadowska E, Machalinski B, Menkiszak J. MMP3 in Comparison to CA 125, HE4 and the ROMA Algorithm in Differentiation of Ovarian Tumors. Asian Pacific Journal of Cancer Prevention: Apjcp. 2016;17(5):2597‐603. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14. Davies AP, Jacobs I, Woolas R, Fish A, Oram D. The adnexal mass: benign or malignant? Evaluation of a risk of malignancy index. Br J Obstet Gynaecol. 1993;100(10):927‐31. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15. Devey A, Lukas P, Cavalier E. Retrospective evaluation of CA125, HE4 and ROMA index values in a consecutive population of 124 women. Clinica Chimica Acta. 2019;493 (Supplement 1):S134. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16. Di Legge A, Testa AC, Ameye L, Van Calster B, Leone F, Savelli L, et al. Lesion size affects the diagnostic performance of the international ovarian tumor analysis (IOTA) logistic regression models, the IOTA simple rules and the risk of malignancy index to estimate the risk of malignancy in adnexal masses. International Journal of Gynecology and Obstetrics. 2012;119:S741. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17. Dotlic J, Terzic M, Likic I, Atanackovic J, Ladjevic N. Evaluation of adnexal masses: correlation between clinical, ultrasound and histopathological findings. Vojnosanitetski Pregled. 2011;68(10):861‐6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18. Enakpene CA, Omigbodun AO, Goecke TW, Odukogbe A‐T, Beckmann MW. Preoperative evaluation and triage of women with suspicious adnexal masses using risk of malignancy index. Journal of Obstetrics &amp; Gynaecology Research. 2009;35(1):131‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19. Hogdall E. Approaches to the detection of ovarian cancer. Scandinavian Journal of Clinical and Laboratory Investigation Supplement. 2016;245:S49‐53. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20. Huchon C, Metzger U, Bats A‐S, Bensaid C, Chatellier G, Azizi M, et al. Value of three‐dimensional contrast‐enhanced power Doppler ultrasound for characterizing adnexal masses. Journal of Obstetrics &amp; Gynaecology Research. 2012;38(5):832‐40. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21. Jabeen R, Khan SA, Naveed S. Risk of Malignancy index in the preoperative evaluation of patients with ovarian masses. Rawal Medical Journal 2015;40(1):78‐80. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22. Jacobs IJ, Rivera H, Oram DH, Bast RC. DIFFERENTIAL‐DIAGNOSIS OF OVARIAN‐CANCER WITH TUMOR‐MARKERS CA 125, CA 15‐3 AND TAG 72‐CENTER‐DOT‐3. British Journal of Obstetrics and Gynaecology. 1993;100(12):1120‐4. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23. Jafari‐Shobeiri M, Parizad M, Nazari F, Ouladsahebmadarek E, Sayyah‐Melli M, Mostafa‐Gharabaghi P, et al. Diagnostic value of HE4, CA125 and risk of ovarian malignancy algorithm in detecting ovarian cancer. International Journal of Women's Health and Reproduction Sciences. 2015;3(4):208‐11. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24. Kader Ali Mohan GR, Jaaback K, Proietto A, Robertson R, Angstetra D. Risk Malignancy Index (RMI) in patients with abnormal pelvic mass: Comparing RMI 1, 2 and 3 in an Australian population. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology. 2010;50(1):77‐80. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25. Karlsen MA, Hogdall EV, Christensen IJ, Borgfeldt C, Kalapotharakos G, Zdrazilova‐Dubska L, et al. A novel diagnostic index combining HE4, CA125 and age may improve triage of women with suspected ovarian cancer ‐ An international multicenter study in women with an ovarian mass. Gynecologic Oncology. 2015;138(3):640‐6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26. Lee HN, Lee KH, Park H. Diagnostic accuracy of risk of ovarian malignancy algorithm (ROMA) experienced in the clinical practice. Gynecologic Oncology. 2019;154 (Supplement 1):261. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27. Leone Roberti Maggiore U, Chiappa V, Ferrero S, Bogani G, Perotto S, Martinelli F, et al. Subjective ultrasound assessment and the ADNEX model to differentiate between benign and malignant ovarian tumors. Journal of Minimally Invasive Gynecology. 2017;24 (7 Supplement 1):S106. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>28. Lewis J, McKnight L, Das N, Lutchman‐Singh K. A prospective study comparing the performance of RMI, simple rules (IOTA) and MDT opinion for assessment of high risk masses. International Journal of Gynecological Cancer. 2018;28 (Supplement 2):752. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29. Li PL, Zhang X, Li TF, Wang LL, Du LT, Yang YM, et al. Combined detection of sialic acid and hydroxyproline in diagnosis of ovarian cancer and its comparison with human epididymis protein 4 and carbohydrate antigen 125. Clinica Chimica Acta. 2015;439:148‐53. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>30. Lokich E, Palisoul M, Romano N, Craig Miller M, Robison K, Stuckey A, et al. Assessing the risk of ovarian malignancy algorithm for the conservative management of women with a pelvic mass. Gynecologic Oncology. 2015;139(2):248‐52. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31. Madar I, Szabo G. Evaluation of IOTA simple rules and IOTA ADNEX model in the hands of expert examiners at the diagnosis of the adnexal tumors. Australasian Journal of Ultrasound in Medicine. 2019;22 (2):147. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32. Mallari RGO, Coloma MLB. Comparison of sassone scoring and adnex model in differentiating benign and malignant ovarian tumour. International Journal of Gynecology and Obstetrics. 2018;143 (Supplement 3):306‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33. Manjunath AP, Pratapkumar, Sujatha K, Vani R. Comparison of three risk of malignancy indices in evaluation of pelvic masses. Gynecologic Oncology. 2001;81(2):225‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34. Michalak M, Gasiorowska E, Markwitz EN. Diagnostic value of CA125, HE4, ROMA and logistic regression model in pelvic mass diagnostics ‐ our experience. Ginekologia Polska. 2015;86(4):256‐61. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35. Migda M, Bartosz M, Migda MS, Kierszk M, Katarzyna G, Malenczyk M. Diagnostic value of the gynecology imaging reporting and data system (GI‐RADS) with the ovarian malignancy marker CA‐125 in preoperative adnexal tumor assessment. Journal of ovarian research. 2018;11(1):92. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36. Minar L, Felsinger M, Cermakova Z, Zlamal F, Bienertova‐Vasku J. Comparison of the Copenhagen Index versus ROMA for the preoperative assessment of women with ovarian tumors. International Journal of Gynaecology &amp; Obstetrics. 2018;140(2):241‐6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37. Mol BW, Boll D, De Kanter M, Heintz AP, Sijmons EA, Oei SG, et al. Distinguishing the benign and malignant adnexal mass: an external validation of prognostic models. Gynecologic Oncology. 2001;80(2):162‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38. Moolthiya W, Yuenyao P. The risk of malignancy index (RMI) in diagnosis of ovarian malignancy. Asian Pacific Journal of Cancer Prevention: Apjcp. 2009;10(5):865‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39. Moore RG, Blackman A, Miller MC, Robison K, DiSilvestro PA, Eklund EE, et al. Multiple biomarker algorithms to predict epithelial ovarian cancer in women with a pelvic mass: Can additional makers improve performance? Gynecologic Oncology. 2019;154(1):150‐5. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40. Morgante G, la Marca A, Ditto A, De Leo V. Comparison of two malignancy risk indices based on serum CA125, ultrasound score and menopausal status in the diagnosis of ovarian masses. British Journal of Obstetrics &amp; Gynaecology. 1999;106(6):524‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41. Nakajima T, Nagaishi M, Maebayashi A, Miyakawa Y, Ikeda Y, Sato M, et al. Evaluation of HE4 in ovarian cancer. International Journal of Gynecological Cancer. 2018;28 (Supplement 2):785. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42. Nunes N, Ambler G, Foo X, Widschwendter M, Jurkovic D. Prospective evaluation of IOTA logistic regression models LR1 and LR2 in comparison with subjective pattern recognition for diagnosis of ovarian cancer in an outpatient setting. Ultrasound in Obstetrics &amp; Gynecology. 2018;51(6):829‐35. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43. Nunes N, Ambler G, Hoo WL, Naftalin J, Foo X, Widschwendter M, et al. Prospective validation of the iota logistic regression models (LR1/LR2) by a level‐2 ultrasound operator and comparison to pattern recognition for the diagnosis of ovarian cancer. International Journal of Gynecological Cancer. 2013;1):587. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44. Obeidat BR, Amarin ZO, Latimer JA, Crawford RA. Risk of malignancy index in the preoperative evaluation of pelvic masses. International Journal of Gynaecology &amp; Obstetrics. 2004;85(3):255‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45. Ong C, Biswas A, Choolani M, Low JJH. Comparison of risk of malignancy indices in evaluating ovarian masses in a Southeast Asian population. Singapore Medical Journal. 2013;54(3):136‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46. Oranratanaphan S, Wanishpongpan S, Termrungruanglert W, Triratanachat S. Assessment of diagnostic values among CA‐125, RMI, HE4, and ROMA for cancer prediction in women with nonfunctional ovarian cysts. Obstetrics and Gynecology International. 2018;2018 (no pagination)(7821574). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47. Ozbay PO, Ekinci T, Caltekin MD, Yilmaz HT, Temur M, Yilmaz O, et al. Comparative evaluation of the risk of malignancy index scoring systems (1‐4) used in differential diagnosis of adnexal masses. Asian Pacific Journal of Cancer Prevention: Apjcp. 2015;16(1):345‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48. Priyanka V, Karthiga S, Sivanesan B, Jagadeesan N, Balasubramani L. A Comparative Study of RMI and ROMA in Women Presenting with an Adnexal Mass. Indian Journal of Gynecologic Oncology. 2018;16 (1) (no pagination)(4). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49. Qiu L, Yang F, Luo H. A preliminary study the sequential use of the risk malignancy index and contrast‐enhanced ultrasonography in differential diagnosis of adnexal masses. Medicine (United States). 2018;97 (29) (no pagination)(e11536). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50. Radwan R, Falcone K, Raju S, Jones S, Gannon S, Le J, et al. A risk of ovarian malignancy algorithm (ROMA) derived from lumipulse G HE4 and lumipulse CA125II assays. Clinical Chemistry. 2016;62 (10 Supplement 1):S11. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51. Ristic A, Filimonovic D, Dzatic‐Smijkovic O, Dimitrijevic D, Anicic R, Mihajlovic S, et al. Risk of malignancy index in discrimination between benign and malignant adnexal masses. European Journal of Gynaecological Oncology. 2018;39(5):733‐6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52. Sandri MT, Bottari F, Franchi D, Boveri S, Candiani M, Ronzoni S, et al. Comparison of HE4, CA125 and ROMA algorithm in women with a pelvic mass: correlation with pathological outcome. Gynecologic Oncology. 2013;128(2):233‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53. Sayasneh A, Ferrara L, De Cock B, Saso S, Al‐Memar M, Johnson S, et al. Evaluating the risk of ovarian cancer before surgery using the ADNEX model: a multicentre external validation study. British Journal of Cancer. 2016;115(5):542‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54. Shimada K, Matsumoto K, Mimura T, Ishikawa T, Munechika J, Ohgiya Y, et al. Ultrasound‐based logistic regression model LR2 versus magnetic resonance imaging for discriminating between benign and malignant adnexal masses: a prospective study. International Journal of Clinical Oncology. 2018;23(3):514‐21 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>55. Shulman LP, Francis M, Bullock R, Pappas T. Clinical Performance Comparison of Two In‐Vitro Diagnostic Multivariate Index Assays (IVDMIAs) for Presurgical Assessment for Ovarian Cancer Risk. Advances in Therapy. 2019. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56. Simsek HS, Tokmak A, Ozgu E, Doganay M, Danisman N, Erkaya S, et al. Role of a risk of malignancy index in clinical approaches to adnexal masses. Asian Pacific Journal of Cancer Prevention: Apjcp. 2014;15(18):7793‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57. Sladkevicius P, Valentin L. Interobserver agreement in describing the ultrasound appearance of adnexal masses and in calculating the risk of malignancy using logistic regression models. Clinical Cancer Research. 2015;21(3):594‐601. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58. Stukan M, Badocha M, Ratajczak K. Development and validation of a model that includes two ultrasound parameters and the plasma D‐dimer level for predicting malignancy in adnexal masses: An observational study. BMC Cancer. 2019;19 (1) (no pagination)(564). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59. Tingulstad S, Hagen B, Skjeldestad FE, Onsrud M, Kiserud T, Halvorsen T, et al. Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the pre‐operative diagnosis of pelvic masses. British Journal of Obstetrics and Gynaecology. 1996;103(8):826‐31. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60. Ulusoy S, Akbayir O, Numanoglu C, Ulusoy N, Odabas E, Gulkilik A. The risk of malignancy index in discrimination of adnexal masses. International Journal of Gynaecology &amp; Obstetrics. 2007;96(3):186‐91. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61. Vanderstichele A, Busschaert P, Smeets D, Landolfo C, Van Nieuwenhuysen E, Leunen K, et al. Chromosomal instability in cell‐free DNA as a highly specific biomarker for detection of ovarian cancer in women with adnexal masses. Clinical Cancer Research. 2017;23(9):2223‐31. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62. Van Calster B, Timmerman D, Valentin L, McIndoe A, Ghaem‐Maghami S, Testa AC, et al. Triaging women with ovarian masses for surgery: observational diagnostic study to compare RCOG guidelines with an International Ovarian Tumour Analysis (IOTA) group protocol. BJOG: An International Journal of Obstetrics &amp; Gynaecology. 2012;119(6):662‐71. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63. Van Holsbeke C, Van Calster B, Valentin L, Testa AC, Ferrazzi E, Dimou I, et al. External validation of mathematical models to distinguish between benign and malignant adnexal tumors: a multicenter study by the International Ovarian Tumor Analysis Group. Clinical Cancer Research. 2007;13(15 Pt 1):4440‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>64. Wilailak S, Chan KK, Chen CA, Nam JH, Ochiai K, Aw TC, et al. Distinguishing benign from malignant pelvic mass utilizing an algorithm with HE4, menopausal status, and ultrasound findings. Journal of Gynecologic Oncology. 2015;26(1):46‐53. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65. Winarto H, Laihad BJ, Nuranna L. Modification of cutoff values for HE4, CA125, the Risk of Malignancy Index, and the Risk of Malignancy Algorithm for ovarian cancer detection in Jakarta, Indonesia. Asian Pacific Journal of Cancer Prevention: Apjcp. 2014;15(5):1949‐53. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66. Yehia M, Mansour A, Mekawy S. Human epididymis protein 4 (HE4) mRNA as a prognostic marker in ovarian tumors in relation to RMI and CA125. International Journal of Cancer Research. 2015;11(4):175‐85. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67. Yamamoto Y, Yamada R, Oguri H, Maeda N, Fukaya T. Comparison of four malignancy risk indices in the preoperative evaluation of patients with pelvic masses. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology. 2009;144(2):163‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68. Yamamoto Y, Tsuchida A, Ushiwaka T, Nagai R, Matsumoto M, Komatsu J, et al. Comparison of 4 risk‐of‐malignancy indexes in the preoperative evaluation of patients with pelvic masses: A prospective study. Clinical Ovarian and other Gynecologic Cancer 2015;7(1‐2):8‐12. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69. Yanaranop M, Jantarateptewan N, Tiyayon J, Nakrangsee S. Significance of Serum Human Epididymis Protein 4 and Cancer Antigen 125 in Distinguishing Type I and Type II Epithelial Ovarian Cancers. International Journal of Gynecological Cancer. 2018;28(6):1058‐65. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>70. Yanaranop M, Anakrat V, Siricharoenthai S, Nakrangsee S, Thinkhamrop B. Is the Risk of Ovarian Malignancy Algorithm Better Than Other Tests for Predicting Ovarian Malignancy in Women with Pelvic Masses? Gynecologic and Obstetric Investigation. 2017;82(1):47‐53. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>71. Yanaranop M, Tiyayon J, Siricharoenthai S, Nakrangsee S, Thinkhamrop B. Rajavithi‐ovarian cancer predictive score (R‐OPS): A new scoring system for predicting ovarian malignancy in women presenting with a pelvic mass. Gynecologic Oncology. 2016;141(3):479‐84. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72. Yoshida A, Derchain SF, Pitta DR, Andrade LA, Sarian LO. Comparing the Copenhagen Index (CPH‐I) and Risk of Ovarian Malignancy Algorithm (ROMA): Two equivalent ways to differentiate malignant from benign ovarian tumors before surgery? Gynecologic Oncology. 2016;140(3):481‐5. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>73. Zermeno‐Nava JDJ, Martinez‐Martinez MU, Ramirez‐De‐Avila AL, Hernandez‐Arteaga AC, Garcia‐Valdivieso MG, Hernandez‐Cedillo A, et al. Determination of sialic acid in saliva by means of surface‐enhanced Raman spectroscopy as a marker in adnexal mass patients: Ovarian cancer vs benign cases. Journal of Ovarian Research. 2018;11 (1) (no pagination)(61). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74. Zhang F, Zhang ZL. The Diagnostic Value of Transvaginal Sonograph (TVS), Color Doppler, and Serum Tumor Marker CA125, CEA, and AFP in Ovarian Cancer. Cell Biochemistry &amp; Biophysics. 2015;72(2):353‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75. Zhang P, Wang C, Cheng L, Zhang P, Guo L, Liu W, et al. Comparison of HE4, CA125, and ROMA Diagnostic Accuracy: A Prospective and Multicenter Study for Chinese Women With Epithelial Ovarian Cancer. Medicine. 2015;94(52):e2402. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8851</p> <p>Auekitrungreung, 2019 (not found in end note)</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 12.</span> <span class="table-title">Excluded studies: data not reported separately by menopausal status</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/appendices#CD011964-tbl-0014">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011964-tbl-0015"> <div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Excluded studies: duplicate data reporting</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Duplicate data reporting</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Abdalla N, Bachanek M, Timorek‐Lemieszczuk A, Cendrowski K, Sawicki W. Comparison of the diagnostic value of gynecologic imaging reporting and data system and Roma in the presurgical assesment of adnexal tumors. International Journal of Gynecological Cancer. 2015;1):374. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2. Ameye L, Valentin L, Testa AC, Van Holsbeke C, Domali E, Van Huffel S, et al. A scoring system to differentiate malignant from benign masses in specific ultrasound‐based subgroups of adnexal tumors. Ultrasound in Obstetrics &amp; Gynecology. 2009;33(1):92‐101. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3. Antonic J, Rakar S. Validity of colour and pulsed Doppler US and tumour marker CA 125 in differentiation between benign and malignant ovarian masses. European Journal of Gynaecological Oncology. 1996;17(1):29‐35. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4. Bouzari Z, Yazdani S, Shirkhani Kelagar Z, Abbaszadeh N. Risk of malignancy index as an evaluation of preoperative pelvic mass. Caspian Journal of Internal Medicine. 2011;2(4):331‐5. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5. Chudecka‐Glaz A, Cymbaluk‐Ploska A, Jastrzebska J, Menkiszak J. Can ROMA algorithm stratify ovarian tumor patients better when being based on specific age ranges instead of the premenopausal and postmenopausal status? Tumour Biology. 2016;37(7):8879‐87. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6. Chudecka‐Glaz A, Cymbaluk‐Ploska A, Luterek‐Puszynska K, Menkiszak J. Diagnostic usefulness of the Risk of Ovarian Malignancy Algorithm using the electrochemiluminescence immunoassay for HE4 and the chemiluminescence microparticle immunoassay for CA125. Oncology Letters. 2016;12(5):3101‐14. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7. Chen X, Zhou H, Chen R, He J, Wang Y, Huang L, et al. Development of a multimarker assay for differential diagnosis of benign and malignant pelvic masses. Clinica Chimica Acta. 2015;440:57‐63. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8. Derchain S, Pitta DR, Sarian LO, Barreta A, Campos EA, Angelo‐Andrade LL, et al. Analysis of symptoms for the preoperative prediction of malignancy of ovarian masses in brazilian women. International Journal of Gynecological Cancer. 2013;1):464. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9. Ertas S, Vural F, Tufekci EC, Ertas AC, Kose G, Aka N. Predictive Value of Malignancy Risk Indices for Ovarian Masses in Premenopausal and Postmenopausal Women. Asian Pacific journal of cancer prevention: APJCP. 2016;17(4):2177‐83. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10. Fujiwara H, Suzuki M, Takeshima N, Takizawa K, Kimura E, Nakanishi T, et al. Evaluation of human epididymis protein 4 (HE4) and Risk of Ovarian Malignancy Algorithm (ROMA) as diagnostic tools of type I and type II epithelial ovarian cancer in Japanese women. Tumor Biology. 2015;36(2):1045‐53. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11. Grenache DG, Heichman KA, Werner TL, Vucetic Z. Clinical performance of two multi‐marker blood tests for predicting malignancy in women with an adnexal mass. Clinica Chimica Acta. 2015;438:358‐63. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12. Janas L, Glowacka E, Wilczynski JR, Malinowski A, Nowak M. Evaluation of applicability of HE4 and ROMA in the preoperative diagnosis of adnexal masses. [Polish]. Ginekologia polska. 2015;86(3):193‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13. Krascsenits G, Balazs B, Dudnyikova A, Purcsi K, Orosz E, Pete I. Investigating the predictive value of RMI and ROMA indices in patients with ovarian tumors of uncertain dignity. [Hungarian]. Magyar onkologia. 2016;60(4):320‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14. Leone Roberti Maggiore U, Chiappa V, Bogani G, Perotto S, Signorelli M, Martinelli F, et al. Subjective ultrasound assessment and the adnex model to differentiate between benign and malignant ovarian tumors. International Journal of Gynecological Cancer. 2017;27 (Supplement 4):972. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15. Mahyuddin AP, Liu L, Zhao C, Kothandaraman N, Salto‐Tellez M, Pang BNK, et al. Diagnostic accuracy of haptoglobin within ovarian cyst fluid as a potential point‐of‐care test for epithelial ovarian cancer: an observational study. BJOG: An International Journal of Obstetrics and Gynaecology. 2018;125(4):421‐31. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16. Meys EMJ, Jeelof LS, Ramaekers BLT, Dirksen CD, Kooreman LFS, Slangen BFM, et al. Economic evaluation of an expert examiner and different ultrasound models in the diagnosis of ovarian cancer. European Journal of Cancer. 2018;100:55‐64. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Meys EMJ, Kaijser J, Kruitwagen RFPM, Slangen BFM, Van Calster B, Aertgeerts B, et al. Subjective assessment versus ultrasound models to diagnose ovarian cancer: A systematic review and meta‐analysis. European Journal of Cancer. 2016;58:17‐29. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17. Nunes N, Yazbek J, Ambler G, Hoo W, Naftalin J, Jurkovic D. Prospective evaluation of the IOTA logistic regression model LR2 for the diagnosis of ovarian cancer. Ultrasound in Obstetrics &amp; Gynecology. 2012;40(3):355‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18. Richards A, Herbst U, Pather S, Saidi S, Tejada‐Berges T, Williams P, et al. HE4, CA125, the Risk of Malignancy Algorithm (ROMA) and the Risk of Malignancy Index (RMI) and complex pelvic masses ‐ a prospective comparison in the preoperative evaluation of adnexal and pelvic masses in an Australian population. BJOG: An International Journal of Obstetrics and Gynaecology. 2015;2):150. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19. Sokalska A, Timmerman D, Testa AC, Van Holsbeke C, Lissoni AA, Leone FPG, et al. Diagnostic accuracy of transvaginal ultrasound examination for assigning a specific diagnosis to adnexal masses. Ultrasound in Obstetrics &amp; Gynecology. 2009;34(4):462‐70. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20. Van Den Akker PAJ, Zusterzeel PLM, Aalders AL, Snijders MPLM, Samlal RAK, Vollebergh JHA, et al. Use of risk of malignancy index to indicate frozen section analysis in the surgical care of women with ovarian tumors. International Journal of Gynecology and Obstetrics. 2016;133(3):355‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21. Yoshida A, Derchain SF, Pitta DR, De Angelo Andrade LAL, Sarian LO. Comparing the Copenhagen Index (CPH‐I) and Risk of Ovarian Malignancy Algorithm (ROMA): Two equivalent ways to differentiate malignant from benign ovarian tumors before surgery? Gynecologic Oncology. 2016;140(3):481‐5. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22. Zhang P, Wang C, Cheng L, Zhaang P, Guo L, Liu W, et al. Comparison of HE4, CA125, and ROMA diagnostic accuracy a prospective and multicenter study for Chinese women with epithelial ovarian cancer. Medicine (United States). 2015;94 (52) (no pagination)(e2402). </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 13.</span> <span class="table-title">Excluded studies: duplicate data reporting</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/appendices#CD011964-tbl-0015">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011964-tbl-0016"> <div class="table-heading"><span class="table-label">Table 14.</span> <span class="table-title">Excluded studies: full text not available</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Full text not available</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Castelli M, Battaglia F, Scambia G, Benedetti Panici P, Ferrandina G, Mileo AM, et al. Immunosuppressive acidic protein and CA 125 levels in patients with ovarian cancer. Oncology. 1991;48(1):13‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2. Gadducci A, Ferdeghini M, Rispoli G, Prontera C, Bianchi R, Fioretti P. Comparison of tumor‐associated trypsin inhibitor (TATI) with CA125 as a marker for diagnosis and monitoring of epithelial ovarian cancer. Scandinavian Journal of Clinical and Laboratory Investigation, Supplement. 1991;51(207):19‐24. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3. Inoue M, Fujita M, Nakazawa A, Ogawa H, Tanizawa O. Sialyl‐Tn, sialyl‐Lewis Xi, CA 19‐9 CA 125, carcinoembryonic antigen, and tissue polypeptide antigen in differentiating ovarian cancer from benign tumors. Obstetrics and Gynecology. 1992;79(3):434‐40. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Jabeen R, Khan SA, Naveed S. Risk of Malignancy index in the preoperative evaluation of patients with ovarian masses. Rawal Medical Journal. 2015;40(1):78‐80. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4. Kenemans P, Bon GG, Kessler AC, Verstraeten AA, Van Kamp GJ. Multicenter technical and clinical evaluation of a fully automated enzyme immunoassay for CA 125. Clinical Chemistry. 1992;38(8 Part 1):1466‐71. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5. Lotzniker M, Pavesi F, Scarabelli M, Vadacca G, Franchi M, Moratti R. Tumour associated antigens CA 15.3 and CA 125 in ovarian cancer. International Journal of Biological Markers. 1991;6(2):115‐21. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6. Paschalidis M, Tserkezoglou A, Fotiou S, Magiakos G, Voulgaris Z, Ferderigou A. CASA and CA125 in the preoperative evaluation of adnexal tumours. European Journal of Gynaecological Oncology. 1996;17(5):450. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7. PetersEngl C, Medl M, Ogris E, Leodolter S. Tumor‐associated trypsin inhibitor (TATI) and cancer antigen 125 (CA125) in patients with epithelial ovarian cancer. Anticancer Research. 1995;15(6B):2727‐30. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8. Shahzad N, Rashid N, Zahra S, Malik A. Role of malignancy index in prediction of malignancy in ovarian masses preoperative. Medical Forum Monthly. 2015;26(6):44‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9. Singer G, Guth U. Therapeutische Umschau. 2017;74(4):181‐9.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>10. Song HJ, Nam KM, Kim JD, Park CY, Kim YS. Looking for optimized weights of CA125 and HE4 in early screening system of ovarian cancer for Korean patients. Technology &amp; Health Care. 2015;24 Suppl 1:S163‐70. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11. Schwarzler P, Timmerman D. IOTA strategies for assessment of adnexal findings: Improving strategies for diagnosing ovarian cancer. [German]. Gynakologe. 2018;51(3):178‐87. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12. Wang Q, Wu Y, Zhang H, Yang K, Tong Y, Chen L, et al. Clinical value of serum HE4, CA125, CA72‐4, and ROMA index for diagnosis of ovarian cancer and prediction of postoperative recurrence. Clinical Laboratory. 2019;65(4):631‐40. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13. Zapardiel I, Gorostidi M, Ravaggi A, Allende MT, Silveira M, Macuks R. Utility of human epididymis protein 4 serum marker for the detection of adnexal malignancy: A multicentric prospective study. European Journal of Cancer Prevention. 2017;26(4):346‐50. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 14.</span> <span class="table-title">Excluded studies: full text not available</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/appendices#CD011964-tbl-0016">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011964-tbl-0017"> <div class="table-heading"><span class="table-label">Table 15.</span> <span class="table-title">Excluded studies: index test not applicable</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Index test not applicable</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Abdalla N, Bachanek M, Piorkowski R, Cendrowski K, Sawicki W. The role of risk of malignancy index RMI‐IV, CA125 and HE4 in the preoperative assesment of adnexal masses. International Journal of Gynecological Cancer. 2015;1):1266. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2. Abdel‐Azeez HA, Labib HA, Sharaf SM, Refai AN. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses. Asian Pacific Journal of Cancer Prevention: Apjcp. 2010;11(1):111‐6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3. Acharya U, Sree S, Saba L, Molinari F, Guerriero S, Suri J. Ovarian Tumor Characterization and Classification Using Ultrasound‐A New Online Paradigm. Journal of Digital Imaging. 2013;26(3):544‐53. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4. Acharya UR, Sree SV, Krishnan MMR, Saba L, Molinari F, Guerriero S, et al. Ovarian tumor characterization using 3D ultrasound. Technology in Cancer Research &amp; Treatment. 2012;11(6):543‐52. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5. Akturk E, Dede M, Yenen MC, Kocyitit YK, Ergun A. Comparison of nine morphological scoring systems to detect ovarian malignancy. European Journal of Gynaecological Oncology. 2015;36(3):304‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6. Akturk E, Karaca RE, Alanbay I, Dede M, Karasahin E, Yenen MC, et al. Comparison of four malignancy risk indices in the detection of malignant ovarian masses. Journal of Gynecologic Oncology. 2011;22(3):177‐82. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7. Al‐Asadi JN, Al‐Maliki SK, Al‐Dahhhan F, Al‐Naama L, Suood F. The accuracy of risk malignancy index in prediction of malignancy in women with adnexal mass in Basrah, Iraq. Nigerian Journal of Clinical Practice. 2018;21(10):1254‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8. Alcazar JL, Jurado M. Using a logistic model to predict malignancy of adnexal masses based on menopausal status, ultrasound morphology, and color Doppler findings. Gynecologic Oncology. 1998;69(2):146‐50. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9. Alcazar JL, Jurado M. Prospective evaluation of a logistic model based on sonographic morphologic and color Doppler findings developed to predict adnexal malignancy. Journal of Ultrasound in Medicine. 1999;18(12):837‐42. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10. Alcazar JL, Pascual MA, Olartecoechea B, Graupera B, Auba M, Ajossa S, et al. IOTA simple rules for discriminating between benign and malignant adnexal masses: prospective external validation. Ultrasound in Obstetrics &amp; Gynecology. 2013;42(4):467‐71. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11. Al‐Musalhi K, Al‐Kindi M, Ramadhan F, Al‐Rawahi T, Al‐Hatali K, Mula‐Abed WA. Validity of cancer antigen‐125 (CA‐125) and risk of malignancy index (RMI) in the diagnosis of ovarian cancer. Oman Medical Journal. 2015;30(6):428‐34. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12. Ameye L, Timmerman D, Valentin L, Paladini D, Zhang J, Van Holsbeke C, et al. Clinically oriented three‐step strategy for assessment of adnexal pathology. Ultrasound in Obstetrics &amp; Gynecology. 2012;40(5):582‐91. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13. Amonkar SD, Bertenshaw GP, Chen T‐H, Bergstrom KJ, Zhao J, Seshaiah P, et al. Development and preliminary evaluation of a multivariate index assay for ovarian cancer. PLoS ONE [Electronic Resource]. 2009;4(2):e4599. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14. Amor F, Alcazar JL, Vaccaro H, Leon M, Iturra A. GI‐RADS reporting system for ultrasound evaluation of adnexal masses in clinical practice: a prospective multicenter study. Ultrasound in Obstetrics &amp; Gynecology. 2011;38(4):450‐5. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15. Andersen ES, Knudsen A, Rix P, Johansen B. Risk of malignancy index in the preoperative evaluation of patients with adnexal masses. Gynecologic Oncology. 2003;90(1):109‐12. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16. Antovska SV, Bashevska N, Aleksioska N. Predictive values of the ultrasound parameters, CA‐125 and risk of malignancy index in patients with ovarian cancer. Klinicka Onkologie. 2011;24(6):435‐42. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17. Arab M, Yaseri M, Ashrafganjoi T, Maktabi M, Noghabaee G, Sheibani K. Comparison of two ovarian malignancy prediction models based on age sonographic findings and serum CA125 measurement. Asian Pacific Journal of Cancer Prevention: Apjcp. 2012;13(8):4199‐202. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18. Ashrafgangooei T, Rezaeezadeh M. Risk of malignancy index in preoperative evaluation of pelvic masses. Asian Pacific Journal of Cancer Prevention: Apjcp. 2011;12(7):1727‐30. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19. Bailey J, Tailor A, Naik R, Lopes A, Godfrey K, Hatem HM, et al. Risk of malignancy index for referral of ovarian cancer cases to a tertiary center: does it identify the correct cases? International Journal of Gynecological Cancer. 2006;16 Suppl 1:30‐4. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20. Bandiera E, Zanotti L, Bignotti E, Romani C, Tassi R, Todeschini P, et al. Human kallikrein 5: an interesting novel biomarker in ovarian cancer patients that elicits humoral response. International Journal of Gynecological Cancer. 2009;19(6):1015‐21. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>21. Barco A, Molina R, Carreras N, Rius M, Rodriguez I, Auge J, et al. Effectiveness of IOTA and ROMA algorithms in surgical management of adnexal masses. Clinica Chimica Acta. 2019;493 (Supplement 1):S134‐S5. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22. Barkauskas DA, An HJ, Kronewitter SR, de Leoz ML, Chew HK, de Vere White RW, et al. Detecting glycan cancer biomarkers in serum samples using MALDI FT‐ICR mass spectrometry data. Bioinformatics. 2009;25(2):251‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23. Barroilhet L, Vitonis A, Shipp T, Muto M, Benacerraf B. Sonographic predictors of ovarian malignancy. Journal of Clinical Ultrasound. 2013;41(5):269‐74. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24. Bastani A, Asghary A, Heidari MH, Karimi‐Busheri F. Evaluation of the sensitivity and specificity of serum level of prostasin, CA125, LDH, AFP, and hCG+beta in epithelial ovarian cancer patients. European Journal of Gynaecological Oncology. 2017;38(3):418‐24. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25. Bedkowska GE, Gacuta E, Zajkowska M, Glazewska EK, Osada J, Szmitkowski M, et al. Plasma levels of MMP‐7 and TIMP‐1 in laboratory diagnostics and differentiation of selected histological types of epithelial ovarian cancers. Journal of ovarian research. 2017;10(1):39. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>26. Bristow RE, Hodeib M, Smith A, Chan DW, Zhang Z, Fung ET, et al. Impact of a multivariate index assay on referral patterns for surgical management of an adnexal mass. American Journal of Obstetrics &amp; Gynecology 2013;209(6):581.e1‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27. Bristow RE, Smith A, Zhang Z, Chan DW, Crutcher G, Fung ET, et al. Ovarian malignancy risk stratification of the adnexal mass using a multivariate index assay. Gynecologic Oncology 2013;128(2):252‐9. [Other: Secondary publication‐ Bristow 2013a] </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28. Bromley B, Goodman H, Benacerraf BR. Comparison between sonographic morphology and Doppler waveform for the diagnosis of ovarian malignancy. Obstetrics and gynecology. 1994;83(3):434‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29. Brown DL, Doubilet PM, Miller FH, Frates MC, Laing FC, DiSalvo DN, et al. Benign and malignant ovarian masses: selection of the most discriminating gray‐scale and Doppler sonographic features. Radiology. 1998;208(1):103‐10. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30. Buckshee K, Temsu I, Bhatla N, Deka D. Pelvic examination, transvaginal ultrasound and transvaginal color Doppler sonography as predictors of ovarian cancer. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics. 1998;61(1):51‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31. Cao D, Guo S, Allan RW, Molberg KH, Peng Y. SALL4 is a novel sensitive and specific marker of ovarian primitive germ cell tumors and is particularly useful in distinguishing yolk sac tumor from clear cell carcinoma. American Journal of Surgical Pathology. 2009;33(6):894‐904. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32. Caruso A, Caforio L, Testa AC, Ciampelli M, Panici PB, Mancuso S. Transvaginal color Doppler ultrasonography in the presurgical characterization of adnexal masses. Gynecologic Oncology. 1996;63(2):184‐91. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33. Chirdchim W, Wanichsetakul P, Phinyo P, Patumanond J, Suwannarurk K, Srisomboon J. Development and Validation of a Predictive Score for Preoperative Diagnosis of Early Stage Epithelial Ovarian Cancer. Asian Pacific journal of cancer prevention: APJCP. 2019;20(4):1207‐13. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34. Choi H, Kim H. Diagnostic accuracy of inflammatory markers for distinguishing malignant and benign ovarian masses. International Journal of Gynecology and Obstetrics. 2018;143 (Supplement 3):896. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35. Ciledag N, Arda K, Aktas E, Aribas BK. A pilot study on real‐time transvaginal ultrasonographic elastography of cystic ovarian lesions. Indian Journal of Medical Research. 2013;137(6):1089‐92. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36. Clark BZ, Beriwal S, Dabbs DJ, Bhargava R. Semiquantitative GATA‐3 immunoreactivity in breast, bladder, gynecologic tract, and other cytokeratin 7‐positive carcinomas. American Journal of Clinical Pathology. 2014;142(1):64‐71. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37. Clayton RD, Snowden S, Weston MJ, Mogensen O, Eastaugh J, Lane G. Neural networks in the diagnosis of malignant ovarian tumours. British Journal of Obstetrics &amp; Gynaecology. 1999;106(10):1078‐82. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38. Coleman RL, Herzog TJ, Chan DW, Munroe DG, Pappas TC, Smith A, et al. Validation of a second‐generation multivariate index assay for malignancy risk of adnexal masses. American Journal of Obstetrics &amp; Gynecology. 2016;215(1):82.e1‐.e11. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39.Cortesi L, De Matteis E, Toss A, Marchi I, Medici V, Contu G, et al. Evaluation of Transvaginal Ultrasound plus CA‐125 Measurement and Prophylactic Salpingo‐Oophorectomy in Women at Different Risk Levels of Ovarian Cancer: The Modena Study Group Cohort Study. Oncology. 2017;93(6):377‐86. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40. Daemen A, Jurkovic D, Van Holsbeke C, Guerriero S, Testa AC, Czekierdowski A, et al. Effect of cancer prevalence on the use of risk‐assessment cut‐off levels and the performance of mathematical models to distinguish malignant from benign adnexal masses. Ultrasound in Obstetrics &amp; Gynecology. 2011;37(2):226‐31. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41. Daemen A, Valentin L, Fruscio R, Van Holsbeke C, Melis GB, Guerriero S, et al. Improving the preoperative classification of adnexal masses as benign or malignant by second‐stage tests. Ultrasound in Obstetrics &amp; Gynecology. 2011;37(1):100‐6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42. Dasari P, Catherine Leela Pannirselvan P, Sridhar MG. Ultrasonographic scoring and risk of malignancy index in preoperative prediction of ovarian malignancy. Journal of Gynecologic Surgery. 2013;29(2):61‐4. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43. Dearking AC, Aletti GD, McGree ME, Weaver AL, Sommerfield MK, Cliby WA. How relevant are ACOG and SGO guidelines for referral of adnexal mass? Obstetrics and Gynecology 2007;110(4):841‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44. Delic R, Weber V, Stefanovic M, Krivec S. Usefulness of HE4 and CA125 in the preoperative diagnosis of adnexal masses: Does age or menopausal status matter? International Journal of Gynecological Cancer. 2015;1):1327‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45. DePriest PD, Shenson D, Fried A, Hunter JE, Andrews SJ, Gallion HH, et al. A morphology index based on sonographic findings in ovarian cancer. Gynecologic Oncology. 1993;51(1):7‐11. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46. DePriest PD, Varner E, Powell J, Fried A, Puls L, Higgins R, et al. The efficacy of a sonographic morphology index in identifying ovarian cancer: a multi‐institutional investigation. Gynecologic Oncology. 1994;55(2):174‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47. Desai D, Desai VA, Verma RN, Shrivastava A. Role of gray scale and color Doppler in differentiating benign from malignant ovarian masses. Journal of Mid‐life Health. 2010;1(1):23‐5. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48. Dora SK, Dandapat AB, Pande B, Hota JP. A prospective study to evaluate the risk malignancy index and its diagnostic implication in patients with suspected ovarian mass. Journal of ovarian research. 2017;10(1):55. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49. Eskander RN, Carpenter BA, Wu HG, Wolf JK. The clinical utility of an elevated‐risk multivariate index assay score in ovarian cancer patients. Current Medical Research &amp; Opinion. 2016;32(6):1161‐5. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50. Fan HY, Duan DM, Liu YF. The diagnostic value of determination of serum GOLPH3 associated with CA125, CA19.9 in patients with ovarian cancer. European Review for Medical &amp; Pharmacological Sciences. 2017;21(18):4039‐44. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51. Ferrazzi E, Zanetta G, Dordoni D, Berlanda N, Mezzopane R, Lissoni G. Transvaginal ultrasonographic characterization of ovarian masses: comparison of five scoring systems in a multicenter study. Ultrasound in Obstetrics &amp; Gynecology. 1997;10(3):192‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52. Firoozabadi RD, Karimi Zarchi M, Mansurian HR, Moghadam BR, Teimoori S, Naseri A. Evaluation of diagnostic value of CT scan, physical examination and ultrasound based on pathological findings in patients with pelvic masses. Asian Pacific Journal of Cancer Prevention: Apjcp. 2011;12(7):1745‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53. Founta C, Ratnavelu N, Hoskins T, Addison C, Bradbury M, Handley G, et al. The diagnostic value of adding HE4 to CA125 for symptomatic women investigated for ovarian cancer in primary care: Final results of a prospective pilot study. International Journal of Gynecological Cancer. 2015;1):44‐5. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54. Geomini PMA, Kluivers KB, Moret E, Bremer GL, Kruitwagen RFP, Mol BWJ. Evaluation of adnexal masses with three‐dimensional ultrasonography. Obstetrics &amp; Gynecology. 2006;108(5):1167‐75. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55. Geomini PMAJ, Coppus SFPJ, Kluivers KB, Bremer GL, Kruitwagen RFPM, Mol BWJ. Is three‐dimensional ultrasonography of additional value in the assessment of adnexal masses? Gynecologic Oncology. 2007;106(1):153‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56. Goff BA, Agnew K, Neradilek MB, Gray HJ, Liao JB, Urban RR. Combining a symptom index, CA125 and HE4 (triple screen) to detect ovarian cancer in women with a pelvic mass. Gynecologic Oncology. 2017;147(2):291‐5. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57. Goff BA, Mandel L, Muntz HG, Melancon CH. Ovarian carcinoma diagnosis. Cancer. 2000;89(10):2068‐75. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58. Goff BA, Mandel LS, Melancon CH, Muntz HG. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics. Jama. 2004;291(22):2705‐12. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59. Goodrich ST, Bristow RE, Santoso JT, Miller RW, Smith A, Zhang Z, et al. The effect of ovarian imaging on the clinical interpretation of a multivariate index assay. American Journal of Obstetrics &amp; Gynecology 2014;211(1):65.e1‐65.e11. [Other: Secondary publication] </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60. Gong SP, Chen YN, Zhang YD, Yao W, Chen L, Liu SS, et al. [Diagnostic value of CA125, HE4 and Copenhagen Index in differentiating benign from malignant epithelial ovarian tumors]. Nan Fang Yi Ke Da Xue Xue Bao = Journal of Southern Medical University. 2017;37(5):628‐32 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61. Guerriero S, Ajossa S, Piras S, Angiolucci M, Marisa O, Melis GB. Diagnosis of paraovarian cysts using transvaginal sonography combined with CA 125 determination. Ultrasound in Obstetrics &amp; Gynecology. 2006;28(6):856‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62. Gupta D, Lis CG. Pretreatment serum albumin as a predictor of cancer survival: A systematic review of the epidemiological literature. Nutrition Journal. 2010;9(1):1‐16. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63. Gupta P, Weathers T, Stehman FB, Schilder JM, Method MW, Hess LM. Ovarian cancer symptoms and diagnosis: Patient reported symptoms and symptoms reported in patients' medical records. International Journal of Gynecological Cancer. 2011;2):119. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64. Hafeez S, Sufian S, Beg M, Hadi Q, Jamil Y, Masroor I. Role of ultrasound in characterization of ovarian masses. Asian Pacific Journal of Cancer Prevention: Apjcp. 2013;14(1):603‐6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>65. Hakansson F, Hogdall EVS, Nedergaard L, Lundvall L, Engelholm SA, Pedersen AT, et al. Risk of malignancy index used as a diagnostic tool in a tertiary centre for patients with a pelvic mass. Acta Obstetricia et Gynecologica Scandinavica. 2012;91(4):496‐502. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>66. Huang B, Lv G, Chen Q. Comparison of GI‐RADS ultrasonographic stratification and rmi4 in differentiating benign from malignant adnexal masses. Ultrasound in Medicine and Biology. 2017;43 (Supplement 1):S137. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>67. Im SS, Gordon AN, Buttin BM, Leath CA, 3rd, Gostout BS, Shah C, et al. Validation of referral guidelines for women with pelvic masses. Obstetrics &amp; Gynecology. 2005;105(1):35‐41. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68. Jain KA. Prospective evaluation of adnexal masses with endovaginal gray‐scale and duplex and color Doppler US: correlation with pathologic findings. Radiology. 1994;191(1):63‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69. Jeschke U, Wiest I, Schumacher AL, Kupka M, Rack B, Stahn R, et al. Determination of MUC1 in sera of ovarian cancer patients and in sera of patients with benign changes of the ovaries with CA15‐3, CA27.29, and PankoMab. Anticancer Research. 2012;32(5):2185‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70. Jokubkiene L, Sladkevicius P, Valentin L. Does three‐dimensional power Doppler ultrasound help in discrimination between benign and malignant ovarian masses? Ultrasound in Obstetrics &amp; Gynecology. 2007;29(2):215‐25. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71. Kalghatgi‐Kulkarni K, Kushtagi P. Ovarian crescent sign and sonomorphological indices in preoperative determination of malignancy in adnexal masses. Indian Journal of Medical Sciences. 2008;62(12):477‐83. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72. Kappelmayer J, Antal‐Szalmas P, Nagy B, Jr. Human epididymis protein 4 (HE4) in laboratory medicine and an algorithm in renal disorders. Clinica Chimica Acta. 2015;438:35‐42. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73. Karadag B, Kocak M, Kayikcioglu F, Ercan F, Dilbaz B, Kose M, et al. Risk for malignant and borderline ovarian neoplasms following basic preoperative evaluation by ultrasonography, ca125 level and age. Asian Pacific Journal of Cancer Prevention: Apjcp. 2014;15(19):8489‐93. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74. Karakaya BK, Ozgu E, Kansu HC, Evliyaoglu O, Sarikaya E, Coskun B, et al. Evaluation of Probably Benign Adnexal Masses in Postmenopausal Women. Revista Brasileira de Ginecologia e Obstetricia. 2017;39(5):229‐34. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>75. Karlsen MA, Sandhu N, Hogdall C, Christensen IJ, Nedergaard L, Lundvall L, et al. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass. Gynecologic Oncology. 2012;127(2):379‐83. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76. Khashper A, Addley HC, Abourokbah N, Nougaret S, Sala E, Reinhold C. T2‐hypointense adnexal lesions: an imaging algorithm. RadioGraphics. 2012;32(4):1047‐64. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77. Khazendar S, Sayasneh A, Al‐Assam H, Du H, Kaijser J, Ferrara L, et al. Automated characterisation of ultrasound images of ovarian tumours: the diagnostic accuracy of a support vector machine and image processing with a local binary pattern operator. Facts Views &amp; Vision in Obgyn. 2015;7(1):7‐15. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>78. Koneczny J, Czekierdowski A, Florczak M, Poziemski P, Stachowicz N, Borowski D. The use of sonographic subjective tumor assessment, IOTA logistic regression model 1, IOTA Simple Rules and GI‐RADS system in the preoperative prediction of malignancy in women with adnexal masses. Ginekologia Polska. 2017;88(12):647‐53. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79. Kumazawa S, Umezu T, Kanayama Y, Kamiyama N, Suzuki S, Mizuno M, et al. Contrast‐enhanced ultrasonography using Sonazoid is useful for diagnosis of malignant ovarian tumors: Comparison with Doppler ultrasound. Journal of Medical Ultrasonics. 2013;40(1):81‐4. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80. Kupesic S, Vujisic S, Kurjak A, Mihaljevic D, Radosevic S. Preoperative assessment of ovarian tumors by CA 125 measurement and transvaginal color Doppler ultrasound. Acta Medica Croatica. 2002;56(1):3‐10. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81. Kurjak A, Kupesic S, Anic T, Kosuta D. Three‐dimensional ultrasound and power doppler improve the diagnosis of ovarian lesions. Gynecologic Oncology. 2000;76(1):28‐32. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82. Kurjak A, Kupesic S, Sparac V, Prka M, Bekavac I. The detection of stage I ovarian cancer by three‐dimensional sonography and power Doppler. Gynecologic Oncology. 2003;90(2):258‐64. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83. Kurjak A, Predanic M. New scoring system for prediction of ovarian malignancy based on transvaginal color doppler sonography. Journal of Ultrasound in Medicine. 1992;11(12):631‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84. Kuyumcuoglu U, Guzel AI, Celik Y, Erdemoglu M, Komek H. 18F‐FDG PET‐CT and USG/CT in benign and malignant ovarian tumors with postoperative histopathological correlation. Ginekologia Polska. 2011;82(8):602‐6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85. Lee TS, Kim JW, Park NH, Song YS, Kang SB, Lee HP. Assessing clinical performance of gynecology residents: sonographic evaluation of adnexal masses based on morphological scoring systems. Ultrasound in Obstetrics &amp; Gynecology. 2005;26(7):776‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86. Lim J, Chew G. Evaluating the use of intraoperative frozen section in the diagnosis of ovarian neoplasms: SGH experience. International Journal of Gynecological Cancer. 2015;1):486. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>87. Longoria TC, Ueland FR, Zhang Z, Chan DW, Smith A, Fung ET, Munroe DG, Bristow RE. Clinical performance of a multivariate index assay for detecting early‐stage ovarian cancer. American Journal of Obstetrics &amp; Gynecology 2014;210(1):78.e1‐9. [Other: Secondary publication] </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88. Lu C, Van Gestel T, Suykens JA, Van Huffel S, Vergote I, Timmerman D. Preoperative prediction of malignancy of ovarian tumors using least squares support vector machines. Artificial intelligence in medicine. 2003;28(3):281‐306. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89. Lucidarme O, Akakpo JP, Granberg S, Sideri M, Levavi H, Schneider A, et al. A new computer‐aided diagnostic tool for non‐invasive characterisation of malignant ovarian masses: Results of a multicentre validation study. European Radiology. 2010;20(8):1822‐30. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>90. Lv XL, Zhu Y, Liu JW, Ai H. The application value of the detection of the level of tissue polypeptide antigen, ovarian cancer antigen X1, cathepsin L and CA125 on the diagnosis of epithelial ovarian cancer. European Review for Medical &amp; Pharmacological Sciences. 2016;20(24):5113‐6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91. Ma S, Shen K, Lang J. A risk of malignancy index in preoperative diagnosis of ovarian cancer. Chinese Medical Journal. 2003;116(3):396‐9 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>92. Mahyuddin AP, Liu L, Zhao C, Kothandaraman N, Salto‐Tellez M, Pang B, et al. Diagnostic accuracy of haptoglobin within ovarian cyst fluid as a potential point‐of‐care test for epithelial ovarian cancer: an observational study. BJOG: An International Journal of Obstetrics &amp; Gynaecology. 2018;125(4):421‐31. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93. Majeed H, Ramzan A, Imran F, Mahfooz ur R. Validity of resistive index for the diagnosis of malignant ovarian masses. JPMA ‐ Journal of the Pakistan Medical Association. 2011;61(11):1104‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94. Malla VG, Tuteja A, Singh P. Rethinking the role of serum cancer antigen 125 and risk of malignancy index in Indian women with ovarian masses: Newer perspectives and review of literature. Journal of SAFOG. 2018;10(2):110‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>95. Manganaro L, Anastasi E, Porpora MG, Vinci V, Saldari M, Bernardo S, et al. Biparametric Magnetic Resonance Imaging as an Adjunct to CA125 and HE4 to Improve Characterization of Large Ovarian Masses. Anticancer Research. 2015;35(11):6341‐51. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>96. Maturen KE, Blaty AD, Wasnik AP, Patel‐Lippmann K, Robbins JB, Barroilhet L, et al. Risk Stratification of Adnexal Cysts and Cystic Masses: Clinical Performance of Society of Radiologists in Ultrasound Guidelines. Radiology. 2017;285(2):650‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>97. Meng W, Ying W, Qichao Z, Ping L, Jie T. Clinical value of combining transvaginal contrast‐enhanced ultrasonography with serum human epididymisprotein‐4 and the resistance index for early‐stage epithelial ovarian cancer. Saudi Medical Journal. 2017;38(6):592‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>98. Meray O, Turkcuoglu I, Meydanli MM, Kafkasli A. Risk of malignancy index is not sensitive in detecting non‐epithelial ovarian cancer and borderline ovarian tumor. Journal of the Turkishgerman Gynecological Association. 2010;11(1):22‐6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>99. Mi D, Zhang YX, Wang CJ, Feng Q, Qi P, Chen SQ. Diagnostic and prognostic value of serum human epididymis protein 4 in patients with primary fallopian tube carcinoma. Journal of Obstetrics &amp; Gynaecology Research. 2016;42(10):1326‐35. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>100. Mohammed ABF, Ahuga VK, Taha M. Validation of the Risk of Malignancy Index in primary evaluation of ovarian masses. Middle East Fertility Society Journal. 2014;19(4):324‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101. Moore RG, Hawkins DM, Miller MC, Landrum LM, Gajewski W, Ball JJ, et al. Combining clinical assessment and the Risk of Ovarian Malignancy Algorithm for the prediction of ovarian cancer. Gynecologic Oncology. 2014;135(3):547‐51. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102. Moszynski R, Szpurek D, Smolen A, Sajdak S. Comparison of diagnostic usefulness of predictive models in preliminary differentiation of adnexal masses. International Journal of Gynecological Cancer. 2006;16(1):45‐51. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103. Moszynski R, Szpurek D, Szubert S, Sajdak S. Analysis of false negative results of subjective ultrasonography assessment of adnexal masses. Ginekologia Polska. 2013;84(2):102‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104. Mousavi AS, Borna S, Moeinoddini S. Estimation of probability of malignancy using a logistic model combining color Doppler ultrasonography, serum CA125 level in women with a pelvic mass. International Journal of Gynecological Cancer. 2006;16:92‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>105. Niewiadomska A, Bartczak M, Glowacka E, Zebrowska M, Swiatkowska E. Roma‐the golden mean in the diagnosis of ovarian cancer? Tumor Biology. 2015;36 (Supplement 1):S74. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>106. Ozcan HC, Balat O, Ugur MG, Kul S, Bozdag Z, Sucu S, et al. The management of adnexal masses in premenopausal patients: a ten‐year retrospective study at a single center. European Journal of Gynaecological Oncology. 2017;38(3):372‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>107. Paul P, Talukder S, Sangma MA, Saha PL, Begum M, Razi AZ, et al. Detection of Ovarian Tumor by Color Doppler Ultrasonography and CA‐125. Mymensingh Medical Journal: MMJ. 2017;26(4):705‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>108. Peces Rama A, Llanos Llanos MC, Sanchez Ferrer ML, Alcazar Zambrano JL, Martinez Mendoza A, Nieto Diaz A. Simple descriptors and simple rules of the International Ovarian Tumor Analysis (IOTA) Group: a prospective study of combined use for the description of adnexal masses. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology. 2015;195:7‐11. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>109. Pereira PN, Sarian LO, Yoshida A, Araujo KG, Barros RHO, Baiao AC, et al. Accuracy of the ADNEX MR scoring system based on a simplified MRI protocol for the assessment of adnexal masses. Diagnostic and Interventional Radiology. 2018;24(2):63‐71. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110. Petignat PG, G.; Vajda, D.; Joris, F. Ovarian Cancer: symptoms and pathology. Cases of a cantonal Cancer Registry (1989‐1995). Schweizerische Medizinische Wochenschrift. 1997;127(48):1993‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111. Prompeler HJ, Madjar H, Sauerbrei W. Classification of adnexal tumors by transvaginal color Doppler. Gynecologic Oncology. 1996;61(3):354‐63. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112. Prompeler HJ, Madjar H, Sauerbrei W, Lattermann U, Pfleiderer A. Diagnostic formula for the differentiation of adnexal tumors by transvaginal sonography. Obstetrics and Gynecology. 1997;89(3):428‐33. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113. Rajendra Acharya U, Vinitha Sree S, Kulshreshtha S, Molinari F, Koh JEW, Saba L, et al. GyneScan: An improved online paradigm for screening of ovarian cancer via tissue characterization. Technology in Cancer Research and Treatment. 2014;13(6):529‐40. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>114. Ribeiro B, Vieira C, Bivar L, Monteiro C, Serrano P, Reis I. Surgical approach of adnexial masses ‐ From clinical diagnosis to histological results. European Journal of Obstetrics Gynecology and Reproductive Biology. 2019;234:e44. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>115. Rogulski L, Strzelczyk J. Simple ultrasound rules used by general gynecologists supplemented with Roma assessment in differentiating malignant and benign adnexal masses. International Journal of Gynecological Cancer. 2015;1):1479. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>116. Rossi A, Braghin C, Soldano F, Isola M, Capodicasa V, Londero AP, et al. A proposal for a new scoring system to evaluate pelvic masses: Pelvic Masses Score (PMS). European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology. 2011;157(1):84‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>117. Ruiz M, Labauge P, Louboutin A, Limot O, Fauconnier A, Huchon C. External validation of the MR imaging scoring system for the management of adnexal masses. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology. 2016;205:115‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>118. Ruiz de Gauna B, Rodriguez D, Olartecoechea B, Auba M, Jurado M, Gomez Roig MD, et al. Diagnostic performance of IOTA simple rules for adnexal masses classification: a comparison between two centers with different ovarian cancer prevalence. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology. 2015;191:10‐4. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>119. Sasaguri K, Yamaguchi K, Nakazono T, Mizuguchi M, Aishima S, Yokoyama M, et al. External validation of ADNEX MR SCORING system: a single‐centre retrospective study. Clinical Radiology. 2019;74(2):131‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120. Schelling M, Braun M, Kuhn W, Bogner G, Gruber R, Gnirs J, et al. Combined transvaginal B‐mode and color Doppler sonography for differential diagnosis of ovarian tumors: results of a multivariate logistic regression analysis. Gynecologic Oncology. 2000;77(1):78‐86. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>121. Seebacher V, Aust S, D'Andrea D, Grimm C, Reiser E, Tiringer D, et al. Development of a tool for prediction of ovarian cancer in patients with adnexal masses: Value of plasma fibrinogen. PLoS ONE [Electronic Resource]. 2017;12(8):e0182383. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>122. Senel SA, Ozcam H, Ateser GB, Vatansever D. Risk of malignancy indices in differentiation of malignant adnexal masses from the benign adnexal masses. International Journal of Gynecological Cancer. 2015;1):1006. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123. Shah D, Shah S, Parikh J, Bhatt CJ, Vaishnav K, Bala DV. Doppler ultrasound: a good and reliable predictor of ovarian malignancy. Journal of Obstetrics &amp; Gynaecology of India. 2013;63(3):186‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>124. Shen ZY, He AQ, Xia GL, Wu MF, Li J, Ding YS. New sonographic morphology score for the differentiation of malignant from benign ovarian tumors. Journal of Obstetrics &amp; Gynaecology Research. 2016;42(8):1000‐12. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>125. Simmons AR, Clarke CH, Badgwell DB, Lu Z, Sokoll LJ, Lu KH, et al. Validation of a Biomarker Panel and Longitudinal Biomarker Performance for Early Detection of Ovarian Cancer. International Journal of Gynecological Cancer. 2016;26(6):1070‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126. Sladkevicius P, Jokubkiene L, Valentin L. Contribution of morphological assessment of the vessel tree by three‐dimensional ultrasound to a correct diagnosis of malignancy in ovarian masses. Ultrasound in Obstetrics &amp; Gynecology. 2007;30(6):874‐82. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127. Sladkevicius P, Valentin L. Interobserver agreement in describing the ultrasound appearance of adnexal masses and in calculating the risk of malignancy using logistic regression models. Clinical Cancer Research. 2015;21(3):594‐601. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>128. Stiekema A, Lok CAR, Kenter GG, van Driel WJ, Vincent AD, Korse CM. A predictive model combining human epididymal protein 4 and radiologic features for the diagnosis of ovarian cancer. Gynecologic Oncology. 2014;132(3):573‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>129. Strolyte D, Celkiene I, Paskauskas S, Vaitkiene D, Gaurilcikas A. Evaluation of a transvaginal ultrasound report quality in cases of borderline ovarian tumors: A retrospective study. International Journal of Gynecological Cancer. 2015;1):1351. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130. Sutantawibul A, Ruangvutilert P, Sunsaneevithayakul P, Boriboonhirunsarn D. A model for malignancy probability prediction of adnexal masses. Journal of the Medical Association of Thailand. 2003;86(8):742‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>131. Szpurek D, Moszyniki R, Sajdak S. Clinical value of the ultrasound Doppler index in determination of ovarian tumor malignancy. European Journal of Gynaecological Oncology. 2004;25(4):442‐4. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>132. Szpurek D, Moszynski R, Smolen A, Sajdak S. Artificial neural network computer prediction of ovarian malignancy in women with adnexal masses. International Journal of Gynaecology &amp; Obstetrics. 2005;89(2):108‐13. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133. Szpurek D, Moszynski R, Zietkowiak W, Spaczynski M, Sajdak S. An ultrasonographic morphological index for prediction of ovarian tumor malignancy. European Journal of Gynaecological Oncology. 2005;26(1):51‐4. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>134. Szubert S, Lojewski A, Moszynski R, Lisowski A, Sajdak S, Szpurek D. Ultrasonographic features and CA125 levels of hormonally active ovarian tumors. Ginekologia Polska. 2016;87(4):254‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135. Tailor A, Jurkovic D, Bourne TH, Collins WP, Campbell S. Sonographic prediction of malignancy in adnexal masses using multivariate logistic regression analysis. Ultrasound in Obstetrics &amp; Gynecology. 1997;10(1):41‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136. Tailor A, Jurkovic D, Bourne TH, Natucci M, Collins WP, Campbell S. Comparison of transvaginal color Doppler imaging and color Doppler energy for assessment of intraovarian blood flow. Obstetrics &amp; Gynecology. 1998;91(4):561‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>137.Tajima A, Suzuki C, Kikuchi I, Kasahara H, Koizumi A, Nojima M, et al. Efficacy of the echo pattern classification of ovarian tumors 2000 in conjunction with transvaginal ultrasonography for diagnosis of ovarian masses. Journal of Medical Ultrasonics. 2016;43(2):249‐55. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138. Takac I. Receiver operating characteristic curves of transvaginal Doppler blood flow measurements in benign and malignant adnexal tumors. Journal of Ultrasound in Medicine. 1998;17(10):637‐42. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>139.Takmaz OK, Angin AD, PiRiMoglu ZM. The worthiness of ovary symptom index, ca125 and transvaginal ultrasonography in screening malignancies of adnexial masses. Zeynep Kamil Tip Bulteni. 2018;49(1):54‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>140.Tanaka YO, Okada S, Satoh T, Matsumoto K, Oki A, Saida T, et al. Differentiation of epithelial ovarian cancer subtypes by use of imaging and clinical data: a detailed analysis. Cancer Imaging. 2016;16:3. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>141. Tay SK, Tan YY. Risk factors and a risk scoring system for the prediction of malignancy in ovarian cysts. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology. 1992;32(4):341‐5. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>142. Tekay A, Jouppila P. Validity of pulsatility and resistance indices in classification of adnexal tumors with transvaginal color Doppler ultrasound. Ultrasound in Obstetrics &amp; Gynecology. 1992;2(5):338‐44. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>143. Tepper R, Keselbrener L, Manor M, Eyal S, Beyth Y, Zimmer Y, et al. Decay constant of Doppler flow waveform as a possible indicator of ovarian malignancy. Ultrasound in Medicine &amp; Biology. 1997;23(8):1171‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>144. Testa AC, Ferrandina G, Fruscella E, Van Holsbeke C, Ferrazzi E, Leone FPG, et al. The use of contrasted transvaginal sonography in the diagnosis of gynecologic diseases: a preliminary study. Journal of Ultrasound in Medicine. 2005;24(9):1267‐78. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>145.Timmerman D, Van Calster B, Testa A, Savelli L, Fischerova D, Froyman W, et al. Predicting the risk of malignancy in adnexal masses based on the Simple Rules from the International Ovarian Tumor Analysis group. American Journal of Obstetrics &amp; Gynecology. 2016;214(4):424‐37. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146. Timmerman D, Schwarzler P, Collins WP, Claerhout F, Coenen M, Amant F, et al. Subjective assessment of adnexal masses with the use of ultrasonography: an analysis of interobserver variability and experience. Ultrasound in Obstetrics &amp; Gynecology. 1999;13(1):11‐6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>147. Timmerman D, Verrelst H, Bourne TH, De Moor B, Collins WP, Vergote I, et al. Artificial neural network models for the preoperative discrimination between malignant and benign adnexal masses. Ultrasound in Obstetrics &amp; Gynecology. 1999;13(1):17‐25. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>148.Tokmak A, Yildirim G, Oztas E, Akar S, Erkenekli K, Gulsen P, et al. Use of Neutrophil‐to‐Lymphocyte Ratio Combined With CA‐125 to Distinguish Endometriomas From Other Benign Ovarian Cysts. Reproductive Sciences. 2016;23(6):795‐802. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>149.Tongsong T, Tinnangwattana D, Vichak‐Ururote L, Tontivuthikul P, Charoenratana C, Lerthiranwong T. Comparison of Effectiveness in Differentiating Benign from Malignant Ovarian Masses between IOTA Simple Rules and Subjective Sonographic Assessment. Asian Pacific Journal of Cancer Prevention: Apjcp. 2016;17(9):4377‐80. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150. Tongsong T, Wanapirak C, Neeyalavira V, Khunamornpong S, Sukpan K. E‐flow doppler indices for prediction of benign and malignant ovarian tumors. Asian Pacific Journal of Cancer Prevention: Apjcp. 2009;10(1):139‐42. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>151.Torky HA, Sherif A, Abo‐Louz A, Ali M, Ahmed A, Ali A. Evaluation of Serum Nidogen‐2 as a Screening and Diagnostic Tool for Ovarian Cancer. Gynecologic &amp; Obstetric Investigation. 2018;83(5):461‐5. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152. Twickler DM, Forte TB, Santos‐Ramos R, McIntire D, Harris P, Scott D. The Ovarian Tumor Index predicts risk for malignancy. Cancer. 1999;86(11):2280‐90. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>153. Ueland FR, Desimone CP, Seamon LG, Miller RA, Goodrich S, Podzielinski I, et al. Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors. Obstetrics &amp; Gynecology 2011;6:1289‐97. [Other: Secondary publication] </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>154. Ueland FR, DePriest PD, Pavlik EJ, Kryscio RJ, van Nagell JR, Jr. Preoperative differentiation of malignant from benign ovarian tumors: the efficacy of morphology indexing and Doppler flow sonography. Gynecologic Oncology. 2003;91(1):46‐50. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>155. Urban RR, Pappas TC, Bullock RG, Munroe DG, Bonato V, Agnew K, et al. Combined symptom index and second‐generation multivariate biomarker test for prediction of ovarian cancer in patients with an adnexal mass. Gynecologic Oncology. 2018;150(2):318‐23. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>156. Urban RR, Smith A, Agnew K, Bonato V, Goff BA. Evaluation of a Validated Biomarker Test in Combination with a Symptom Index to Predict Ovarian Malignancy. International Journal of Gynecological Cancer. 2017;27(2):233‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>157. Utrilla‐Layna J, Alcazar JL, Auba M, Laparte C, Olartecoechea B, Errasti T, et al. Performance of three‐dimensional power Doppler angiography as third‐step assessment in differential diagnosis of adnexal masses. Ultrasound in Obstetrics &amp; Gynecology. 2015;45(5):613‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>158. Valentin L. Gray scale sonography, subjective evaluation of the color Doppler image and measurement of blood flow velocity for distinguishing benign and malignant tumors of suspected adnexal origin. European journal of obstetrics, gynecology, and reproductive biology. 1997;72(1):63‐72. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>159. Valentin L. Prospective cross‐validation of Doppler ultrasound examination and gray‐scale ultrasound imaging for discrimination of benign and malignant pelvic masses. Ultrasound in Obstetrics &amp; Gynecology. 1999;14(4):273‐83. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160. Valentin L. Pattern recognition of pelvic masses by gray‐scale ultrasound imaging: the contribution of Doppler ultrasound. Ultrasound in Obstetrics &amp; Gynecology. 1999;14(5):338‐47. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>161. Valentin L. Comparison of Lerner score, Doppler ultrasound examination, and their combination for discrimination between benign and malignant adnexal masses. Ultrasound in Obstetrics &amp; Gynecology. 2000;15(2):143‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>162. Valentin L, Hagen B, Tingulstad S, Eik‐Nes S. Comparison of 'pattern recognition' and logistic regression models for discrimination between benign and malignant pelvic masses: a prospective cross validation. Ultrasound in Obstetrics &amp; Gynecology. 2001;18(4):357‐65. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163. Valentin L, Sladkevicius P, Marsal K. Limited contribution of Doppler velocimetry to the differential diagnosis of extrauterine pelvic tumors. Obstetrics &amp; Gynecology. 1994;83(3):425‐33. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>164. Van Calster B, Timmerman D, Lu C, Suykens JAK, Valentin L, Van Holsbeke C, et al. Preoperative diagnosis of ovarian tumors using Bayesian kernel‐based methods. Ultrasound in Obstetrics &amp; Gynecology. 2007;29(5):496‐504. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>165. Van Calster B, Timmerman D, Nabney I, Valentin L, Testa A, Van Holsbeke C, et al. Using Bayesian neural networks with ARD input selection to detect malignant ovarian masses prior to surgery. Neural Comput &amp; Applic. 2008;17(5‐6):489‐500. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>166. Van Calster B, Valentin L, Van Holsbeke C, Testa AC, Bourne T, Van Huffel S, et al. Polytomous diagnosis of ovarian tumors as benign, borderline, primary invasive or metastatic: development and validation of standard and kernel‐based risk prediction models. BMC Medical Research Methodology. 2010;10:96. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167. van Haaften‐Day C, Shen Y, Xu FJ, Yu YH, Berchuck A, Havrilesky LJ, et al. OVX1, macrophage‐colony stimulating factor, and CA‐125‐II as tumor markers for epithelial ovarian carcinoma ‐ A critical appraisal. Cancer. 2001;92(11):2837‐44. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>168. Van Holsbeke C, Van Calster B, Bourne T, Ajossa S, Testa AC, Guerriero S, et al. External validation of diagnostic models to estimate the risk of malignancy in adnexal masses. Clinical Cancer Research. 2012;18(3):815‐25. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>169. Van Holsbeke C, Daemen A, Yazbek J, Holland TK, Bourne T, Mesens T, et al. Ultrasound experience substantially impacts on diagnostic performance and confidence when adnexal masses are classified using pattern recognition. Gynecologic and obstetric investigation. 2010;69(3):160‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>170. Van Holsbeke C, Van Belle V, Leone FPG, Guerriero S, Paladini D, Melis GB, et al. Prospective external validation of the 'ovarian crescent sign' as a single ultrasound parameter to distinguish between benign and malignant adnexal pathology. Ultrasound in Obstetrics &amp; Gynecology. 2010;36(1):81‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>171. Van Holsbeke C, Van Calster B, Testa AC, Domali E, Lu C, Van Huffel S, et al. Prospective internal validation of mathematical models to predict malignancy in adnexal masses: results from the international ovarian tumor analysis study. Clinical Cancer Research. 2009;15(2):684‐91. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>172. Wang T, Yang Y, Zhu Q. A three‐parameter logistic model to characterize ovarian tissue using polarization‐sensitive optical coherence tomography. Biomedical Optics Express. 2013;4(5):772‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>173. Ware Miller, R. W, Smith, A, DeSimone, C. P, et al. Performance of the American College of Obstetricians and Gynecologists' Ovarian Tumor Referral Guidelines With a Multivariate Index Assay. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>174. Watrowski R, Zeillinger R. Simple laboratory score improves the preoperative diagnosis of adnexal mass. Tumour Biology. 2016;37(4):4343‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>175. Winarto H, Laihad BJ, Nuranna L. Modification of cutoff values for HE4, CA125, the Risk of Malignancy Index, and the Risk of Malignancy Algorithm for ovarian cancer detection in Jakarta, Indonesia. Asian Pacific Journal of Cancer Prevention: Apjcp. 2014;15(5):1949‐53. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>176. Yadav G, Singh P, Gothwal M, Kathuria P. Correlation between pre‐operative clinical diagnosis, imaging and histopathology of adnexal masses: A cross‐sectional observational study. International Journal of Gynecological Cancer. 2018;28 (Supplement 2):216. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>177. Yamamoto Y, Kunimi Y, Wakikawa A, Ueno A, Nagai R, Komatsu J, et al. Comparison of benign, borderline, and malignant mucinous ovarian tumors. European Journal of Gynaecological Oncology. 2018;39(5):751‐4. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>178. Yazbek J, Ameye L, Testa AC, Valentin L, Timmerman D, Holland TK, et al. Confidence of expert ultrasound operators in making a diagnosis of adnexal tumor: effect on diagnostic accuracy and interobserver agreement. Ultrasound in Obstetrics &amp; Gynecology. 2010;35(1):89‐93. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179. Yazbek J, Ameye L, Timmerman D, Testa AC, Valentin L, Holland TK, et al. Use of ultrasound pattern recognition by expert operators to identify borderline ovarian tumors: a study of diagnostic performance and interobserver agreement. Ultrasound in Obstetrics &amp; Gynecology. 2010;35(1):84‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>200. Yoshida A, Derchain SF, Pitta DR, Crozatti N, Andrade L, da Silva RF, et al. Preoperative measurement of serum C‐reactive protein: is it useful in the differential diagnosis of adnexal masses? International Journal of Biological Markers. 2017;32(1):e83‐e9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>201. Zhang P, Wang C, Cheng L, Zhang P, Guo L, Liu W, et al. Development of a multi‐marker model combining HE4, CA125, progesterone, and estradiol for distinguishing benign from malignant pelvic masses in postmenopausal women. Tumour Biology. 2016;37(2):2183‐91. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>202. Zhang Q, Wang CR, Yu JP, Ma Q, Xu WW. The Establishment of an HE4‐CLIA Method and the Combined Analysis of HE4 and CA125 in Ovarian Cancer. Journal of Clinical Laboratory Analysis. 2016;30(5):709‐18. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>203. Zhao T, Hu W. CA125 and HE4: Measurement Tools for Ovarian Cancer. Gynecologic &amp; Obstetric Investigation. 2016;81(5):430‐5. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>204. Zhang T, Li F, Liu J, Zhang S. Diagnostic performance of the Gynecology Imaging Reporting and Data System for malignant adnexal masses. International Journal of Gynecology and Obstetrics. 2017;137(3):325‐31. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>205. Zheng H, Tie Y, Wang X, Yang Y, Wei X, Zhao X. Assessment of the diagnostic value of using serum CA125 and GI‐RADS system in the evaluation of adnexal masses. Medicine. 2019;98(7):e14577. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>206. Zhu L, Xia C, Chen Y, Liu J, Nie K, Xiao Y, et al. Ultrasound/CT combined with CA125 in the diagnosis and prognosis prediction of primary ovarian tumors. Minerva Medica. 2018;109(6):489‐91. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13999</p> <p>Seebacher 2017 (duplicate)</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 15.</span> <span class="table-title">Excluded studies: index test not applicable</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/appendices#CD011964-tbl-0017">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011964-tbl-0018"> <div class="table-heading"><span class="table-label">Table 16.</span> <span class="table-title">Excluded studies: no translation</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p><b>No translation</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Feng A, Zhang L, Chen YJ. The significance of serum HE4, CA125 and ROMA indexes in diagnosis of ovarian cancer to different menopausal status. [Chinese]. Journal of Xi'an Jiaotong University (Medical Sciences). 2018;39(1):78‐83. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2. Gao HF, Tian H, Zhao QJ. Diagnostic value of serum human epididymis protein 4 and carbohydrate antigen 125 combined with risk of ovarian malignancy algorithm index for ovarian cancer. [Chinese]. Cancer Research and Clinic. 2018;30(11):757‐62. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3. Gonzalez‐Burgos OM, Alvarez‐Licona NE, Lever‐Rosas CD. Comparison of three ultrasound index in evaluating the risk of malignancy of adnexal tumors. [Spanish]. Ginecologia y Obstetricia de Mexico. 2018;86(8):519‐29. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4. He P, Wu Q, Sun L, Wang J, Wang L, Han J, et al. Comparison of ADNEX model, simple rules risk model and risk of malignancy index in diagnosis of benign and malignant ovarian tumors. [Chinese]. Chinese Journal of Medical Imaging Technology. 2019;35(1):104‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>5. Janas L, Glowacka E, Wilczynski JR, Malinowski A, Nowak M. [Evaluation of applicability of HE4 and ROMA in the preoperative diagnosis of adnexal masses]. Ginekologia Polska. 2015;86(3):193‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6. Joyeux E, Miras T, Masquin I, Duglet PE, Astruc K, Douvier S. [Before surgery predictability of malignant ovarian tumors based on ADNEX model and its use in clinical practice]. Gynecologie, Obstetrique &amp; Fertilite. 2016;44(10):557‐64. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>7. Knafel A, Banas T, Nocun A, Wiechec M, Jach R, Ludwin A, et al. The Prospective External Validation of International Ovarian Tumor Analysis (IOTA) Simple Rules in the Hands of Level I and II Examiners. Ultraschall in der Medizin. 2016;37(5):516‐23. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8. Liu J, Chen Q, Lyu G. Comparison of ultrasound IOTA simple rules and GI‐RADS ultrasonographic stratification in diagnosis of ovarian neoplasms. [Chinese]. Chinese Journal of Medical Imaging Technology. 2017;33(5):739‐42. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9. Sandal K, Polat M, Yassa M, Gunay T, Erdem GY, Guzin K. Comparision of "risk of malignancy indices" and "assesment of different neoplasia in the adnexa" (ADNEX) model as preoperative malignancy evaluation methods for adnexal masses. [Turkish]. Zeynep Kamil Tip Bulteni. 2018;49(4):324‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="bottom"> <p>10. Tao X, Gu W, Zhou X, Zhao C. [New markers for diagnostic and prognostic evaluation of ovarian clear cell carcinoma]. Chung‐Hua Ping Li Hsueh Tsa Chih ‐ Chinese Journal of Pathology. 2015;44(9):686‐8. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 16.</span> <span class="table-title">Excluded studies: no translation</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/appendices#CD011964-tbl-0018">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011964-tbl-0019"> <div class="table-heading"><span class="table-label">Table 17.</span> <span class="table-title">Excluded studies: population not applicable</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Population not applicable</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Dual‐marker algorithm better predicts risk for ovarian cancer. Contemporary OB/GYN. 2010;55(11):22‐. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2. Adonakis GL, Paraskevaidis E, Tsiga S, Seferiadis K, Lolis DE. A combined approach for the early detection of ovarian cancer in asymptomatic women. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology. 1996;65(2):221‐5. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3. Agarwal S, Bodurka DC. Symptom research in gynecologic oncology: A review of available measurement tools. Gynecologic Oncology. 2010;119(2):384‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4. Alcazar JL, Castillo G. Comparison of 2‐dimensional and 3‐dimensional power‐Doppler imaging in complex adnexal masses for the prediction of ovarian cancer. American Journal of Obstetrics &amp; Gynecology. 2005;192(3):807‐12. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5. Alcazar JL, Errasti T, Zornoza A, Minguez JA, Galan MJ. Transvaginal color Doppler ultrasonography and CA‐125 in suspicious adnexal masses. International Journal of Gynecology &amp; Obstetrics. 1999;66(3):255‐61. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6. Alcazar JL, Guerriero S, Pascual MA, Ajossa S, Olartecoechea B, Hereter L. Clinical and sonographic features of uncommon primary ovarian malignancies. Journal of Clinical Ultrasound. 2012;40(6):323‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7. Alcazar JL, Iturra A, Sedda F, Auba M, Ajossa S, Guerriero S, et al. Three‐dimensional volume off‐line analysis as compared to real‐time ultrasound for assessing adnexal masses. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology. 2012;161(1):92‐5. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8. Alcazar JL, Miranda D, Unanue A, Novoa E, Aleman S, Madariaga L. CA‐125 levels in predicting optimal cytoreductive surgery in patients with advanced epithelial ovarian carcinoma. International Journal of Gynecology and Obstetrics. 2004;84(2):173‐4. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9. Anastasi E, Manganaro L, Granato T, Benedetti Panici P, Frati L, Porpora MG. Is CA72‐4 a useful biomarker in differential diagnosis between ovarian endometrioma and epithelial ovarian cancer? Disease Markers. 2013;35(5):331‐5. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10. Arakawa N, Miyagi E, Nomura A, Morita E, Ino Y, Ohtake N, et al. Secretome‐based identification of TFPI2, a novel serum biomarker for detection of ovarian clear cell adenocarcinoma. Journal of Proteome Research. 2013;12(10):4340‐50. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11. Araujo KG, Jales RM, Pereira PN, Yoshida A, de Angelo Andrade L, Sarian LO, et al. Performance of the IOTA ADNEX model in preoperative discrimination of adnexal masses in a gynecological oncology center. Ultrasound in obstetrics &amp; gynecology: the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2017;49(6):778‐83. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12. Awwad Y. New screening strategy may catch ovarian cancer at early stages. Women's Health. 2013;9(6):509. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13. BA IBA. Symptoms attributed to ovarian cancer by women with the disease1997. 122, 7‐8, 30 passim p. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14. Bashizadeh‐Fakhar H, Rezaie‐Tavirani M, Zali H, Faraji R, Nejad EK, Aghazadeh M. The diagnostic value of serum CEA, CA‐125, and ROMA index in low‐grade serous ovarian cancer. International Journal of Cancer Management. 2018;11 (5) (no pagination)(e63397). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15. Bensaid C, Le Frere Belda MA, Metzger U, Larousserie F, Clement D, Chatellier G, et al. Performance of laparoscopy in identifying malignant ovarian cysts. Surgical endoscopy. 2006;20(9):1410‐4. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16. Blyuss O, Gentry‐Maharaj A, Fourkala EO, Ryan A, Zaikin A, Menon U, et al. Serial Patterns of Ovarian Cancer Biomarkers in a Prediagnosis Longitudinal Dataset. BioMed Research International. 2015;2015:681416. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17. Bosse K, Rhiem K, Wappenschmidt B, Hellmich M, Madeja M, Ortmann M, et al. Screening for ovarian cancer by transvaginal ultrasound and serum CA125 measurement in women with a familial predisposition: A prospective cohort study. Gynecologic Oncology. 2006;103(3):1077‐82. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18. Botta G, Zarcone R. Trans‐vaginal ultrasound examination of ovarian masses in premenopausal women. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology. 1995;62(1):37‐41. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19. Bourne TH, Campbell S, Reynolds KM, Whitehead MI, Hampson J, Royston P, et al. Screening for early familial ovarian cancer with transvaginal ultrasonography and colour blood flow imaging. BMJ. 1993;306(6884):1025‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20. Bristow RE, Nugent AC, Zahurak ML, Khouzhami V, Fox HE. Impact of surgeon specialty on ovarian‐conserving surgery in young females with an adnexal mass. Journal of Adolescent Health. 2006;39(3):411‐6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21. Burger RA, Darcy KM, DiSaia PJ, Monk BJ, Grosen EA, Gatanaga T, et al. Association between serum levels of soluble tumor necrosis factor receptors/CA 125 and disease progression in patients with epithelial ovarian malignancy: a gynecologic oncology group study. Cancer. 2004;101(1):106‐15. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22. Chang HW, Lee SM, Goodman SN, Singer G, Cho SKR, Sokoll LJ, et al. Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer. Journal of the National Cancer Institute. 2002;94(22):1697‐703. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>23. Chen J, Chang C, Huang HC, Chung YC, Huang HJ, Liou WS, et al. Differentiating between borderline and invasive malignancies in ovarian tumors using a multivariate logistic regression model. Taiwanese Journal of Obstetrics &amp; Gynecology. 2015;54(4):398‐402. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24. Cho H‐y, Kim K, Jeon Y‐T, Kim Y‐B, No JH. CA19‐9 elevation in ovarian mature cystic teratoma: discrimination from ovarian cancer ‐ CA19‐9 level in teratoma. Medical Science Monitor. 2013;19:230‐5. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25. Cho H‐Y, Kyung MS. Serum CA19‐9 as a predictor of malignancy in primary ovarian mucinous tumors: a matched case‐control study. Medical Science Monitor. 2014;20:1334‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26. Cho S, Cho H, Nam A, Kim HY, Choi YS, Park KH, et al. Neutrophil‐to‐lymphocyte ratio as an adjunct to CA‐125 for the diagnosis of endometriosis. Fertility and Sterility. 2008;90(6):2073‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27. Chou CY, Chang CH, Yao BL, Kuo HC. Color Doppler ultrasonography and serum CA 125 in the differentiation of benign and malignant ovarian tumors. Journal of Clinical Ultrasound. 1994;22(8):491‐6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28. Dai S‐Y, Hata K, Inubashiri E, Kanenishi K, Shiota A, Ohno M, et al. Does three‐dimensional power Doppler ultrasound improve the diagnostic accuracy for the prediction of adnexal malignancy? Journal of Obstetrics and Gynaecology Research. 2008;34(3):364‐70. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29. Davelaar EM, Schutter EMJ, Von Mensdorff‐Pouilly S, Van Kamp GJ, Verstraeten RA, Kenemans P. Clinical and technical evaluation of the ACS:OV serum assay and comparison with three other CA125‐detecting assays. Annals of Clinical Biochemistry. 2003;40(6):663‐73. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30. Davies Q, Symonds IM, Perkins AC, Kerslake RW, Wastie ML, Worthington BS, et al. Magnetic resonance imaging, OC125 immunoscintigraphy and serum CA125 levels in the management of patients with suspected primary or recurrent ovarian carcinoma. Journal of Obstetrics and Gynaecology. 1996;16(2):108‐16. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31. Dehaghani AS, Ghiam AF, Hosseini M, Mansouri S, Ghaderi A. Factors influencing serum concentration of CA125 and CA15‐3 in Iranian healthy postmenopausal women. Pathology and Oncology Research. 2007;13(4):360‐4. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32. Demidov VN, Lipatenkova J, Vikhareva O, Van Holsbeke C, Timmerman D, Valentin L. Imaging of gynecological disease (2): clinical and ultrasound characteristics of Sertoli cell tumors, Sertoli‐Leydig cell tumors and Leydig cell tumors. Ultrasound in Obstetrics &amp; Gynecology. 2008;31(1):85‐91. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33. Devine PL, McGuckin MA, Quin RJ, Ward BG. Predictive value of the combination of serum markers, CA125, CASA and TPS in ovarian cancer. International Journal of Gynecological Cancer. 1995;5(3):170‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34. Dikensoy E, Balat O, Ugur MG, Ozkur A, Erkilic S. Serum CA‐125 is a good predictor of benign disease in patients with postmenopausal ovarian cysts. European Journal of Gynaecological Oncology. 2007;28(1):45‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>35. Epstein E, Van Calster B, Timmerman D, Nikman S. Subjective ultrasound assessment, the ADNEX model and ultrasound‐guided tru‐cut biopsy to differentiate disseminated primary ovarian cancer from metastatic non‐ovarian cancer. Ultrasound in Obstetrics &amp; Gynecology. 2016;47(1):110‐6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36. Fagotti A, Ludovisi M, De Blasis I, Virgilio B, Di Legge A, Mascilini F, et al. The sonographic prediction of invasive carcinoma in unilocular‐solid ovarian cysts in premenopausal patients: a pilot study. Human Reproduction. 2012;27(9):2676‐83. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37. Ferrazzi E, Lissoni AA, Dordoni D, Trio D, Redaelli L, Rusconi C, et al. Differentiation of small adnexal masses based on morphologic characteristics of transvaginal sonographic imaging ‐ A multicenter study. Journal of Ultrasound in Medicine. 2005;24(11):1467‐73. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38. Fishman DA, Cohen L, Blank SV, Shulman L, Singh D, Bozorgi K, et al. The role of ultrasound evaluation in the detection of early‐stage epithelial ovarian cancer. American journal of obstetrics and gynecology. 2005;192(4):1214‐21. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39. Fleischer AC, Lyshchik A, Jones HW, 3rd, Crispens MA, Andreotti RF, Williams PK, et al. Diagnostic parameters to differentiate benign from malignant ovarian masses with contrast‐enhanced transvaginal sonography. Journal of Ultrasound in Medicine. 2009;28(10):1273‐80. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40. Froyman W, Landolfo C, Bourne T, Cock BD, Testa A, Valentin L, et al. Performance of the RMI and IOTA ADNEX and Simple Rules risk model in the evaluation of adnexal masses not classifiable using the Easy Descriptors as first step. BJOG: An International Journal of Obstetrics and Gynaecology. 2016;123 (Supplement 2):83‐4. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41. Froyman W, Wynants L, Landolfo C, Bourne T, Valentin L, Testa A, et al. Validation of the performance of International Ovarian Tumor Analysis (IOTA) methods in the diagnosis of early stage ovarian cancer in a non‐screening population. Diagnostics. 2017;7 (2) (no pagination)(2). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42. Ghosh E, Levine D. Recommendations for adnexal cysts: have the Society of Radiologists in Ultrasound consensus conference guidelines affected utilization of ultrasound? Ultrasound Quarterly. 2013;29(1):21‐4. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43. Grab D, Flock F, Stohr I, Rieber A, Nussle S, Brambs HJ, et al. Premenopausal adnex masses: Diagnostic accuracy of sonography, magnetic resonance imaging, and positron emission tomography. [German] Diagnostische wertigkeit von sonographie, kernspintomographie und positronenemissions‐tomographie zur beurteilung tier dignitat von adnextumoren bei pramenopausalen patientinnen. Geburtshilfe und Frauenheilkunde. 2000;60(11):544‐52. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44. Grzybowski W, Beta J, Fritz A, Durczynski A, Bidzinski M, Grabiec M, et al. [Predictive value of CA 125 in detection of ovarian cancer in pre‐ and postmenopausal patients]. Ginekologia Polska. 2010;81(7):511‐5. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45. Guerriero S, Ajossa S, Mais V, Risalvato A, Lai MP, Melis GB. The diagnosis of endometriomas using colour Doppler energy imaging. Human Reproduction. 1998;13(6):1691‐5. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46. Guerriero S, Alcazar JL, Coccia ME, Ajossa S, Scarselli G, Boi M, et al. Complex pelvic mass as a target of evaluation of vessel distribution by color Doppler sonography for the diagnosis of adnexal malignancies: results of a multicenter European study. Journal of Ultrasound in Medicine. 2002;21(10):1105‐11. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47. Hellstrom I. The HE4 (WFDC2) Protein Is a Biomarker for Ovarian Carcinoma1. Cancer Research. 2003;63:3695‐700. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48. Hirai M, Hirai Y, Tsuchida T, Takada T, Iwase H, Utsugi K, et al. Stage IA ovarian cancers: comparison of sonographic findings and histopathologic types between patients with normal and elevated serum cancer antigen 125 levels. Journal of Ultrasound in Medicine. 2011;30(7):943‐52. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49. Huang C‐Q, Yang X‐J, Yu Y, Wu H‐T, Liu Y, Yonemura Y, et al. Cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy improves survival for patients with peritoneal carcinomatosis from colorectal cancer: a phase II study from a Chinese center. PLoS ONE [Electronic Resource]. 2014;9(9):e108509. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50. Huhtinen K, Suvitie P, Hiissa J, Junnila J, Huvila J, Kujari H, et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. British Journal of Cancer. 2009;100(8):1315‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51. Iatrakis GM, Zervoudis S, Tsikouras P, Iatrakis DG, Bothou A, Chardavelas T, et al. A new risk malignancy index to predict ovarian cancer: A bicentric preliminary study. Journal of BUON. 2018;23(5):1380‐3. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52. Ikeda Y, Hasegawa K, Kurosaki A, Miyara A, Hanaoka T, Shintani D, et al. The Risk of Ovarian Malignancy Algorithm (ROMA) as a Predictive Marker of Peritoneal Dissemination in Epithelial Ovarian Cancer Patients. Oncology research and treatment. 2015;38(6):276‐81. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53. Ind T, Iles R, Shepherd J, Chard T. Serum concentrations of cancer antigen 125, placental alkaline phosphatase, cancer‐associated serum antigen and free beta human chorionic gonadotrophin as prognostic markers for epithelial ovarian cancer. British Journal of Obstetrics and Gynaecology. 1997;104(9):1024‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54. Ionescu CA, Matei A, Navolan D, Dimitriu M, Bohaltea R, Neacsu A, et al. Correlation of ultrasound features and the Risk of Ovarian Malignancy Algorithm score for different histopathological subtypes of benign adnexal masses. Medicine (United States). 2018;97 (31) (no pagination)(e11762). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55. Jacobs I, Davies AP, Bridges J, Stabile I, Fay T, Lower A, et al. Prevalence screening for ovarian cancer in postmenopausal women by CA 125 measurement and ultrasonography. BMJ. 1993;306(6884):1030‐4. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56. Jacobs IJ, Skates S, Davies AP, Woolas RP, Jeyerajah A, Weidemann P, et al. Risk of diagnosis of ovarian cancer after raised serum CA 125 concentration: a prospective cohort study. BMJ (Clinical research ed) [Internet]. 1996 [cited PENDING (UPDATE 91‐08); (7069):[1355‐8 pp.]. Available from: http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/049/CN‐00251049/frame.html. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57. Johnson CC, Kessel B, Riley TL, Ragard LR, Williams CR, Xu JL, et al. The epidemiology of CA‐125 in women without evidence of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial. Gynecologic Oncology. 2008;110(3):383‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58. Julian‐Reynier C, Mancini J, Mouret‐Fourme E, Gauthier‐Villars M, Bonadona V, Berthet P, et al. Cancer risk management strategies and perceptions of unaffected women 5 years after predictive genetic testing for BRCA1/2 mutations. European Journal of Human Genetics. 2011;19(5):500‐6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59. Kalfa N, Sultan C. Juvenile ovarian granulosa cell tumor: a benign or malignant condition? Gynecological Endocrinology. 2009;25(5):299‐302. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60. Kaymak O, Ustunyurt E, Okyay RE, Kalyoncu S, Mollamahmutoglu L. Role of transvaginal sonography and serum CA‐125 values in determining the nature of the postmenopausal ovarian cysts. Journal of the Turkish German Gynecology Association. 2006;7(1):24‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61. Kelly PJ, Archbold P, Price JH, Cardwell C, McCluggage WG. Serum CA19.9 levels are commonly elevated in primary ovarian mucinous tumours but cannot be used to predict the histological subtype. Journal of Clinical Pathology. 2010;63(2):169‐73. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62. Kim HS, Park NH, Chung HH, Kim JW, Song YS, Kang SB. Significance of preoperative serum CA‐125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer. Acta Obstetricia et Gynecologica Scandinavica. 2008;87(11):1136‐42. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>63. Kinay T, Unlubilgin E, Cirik DA, Kayikcioglu F, Akgul MA, Dolen I. The value of ultrasonographic tubo‐ovarian abscess morphology in predicting whether patients will require surgical treatment. International Journal of Gynaecology &amp; Obstetrics. 2016;135(1):77‐81. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64. Kobayashi H, Yamada Y, Sado T, Sakata M, Yoshida S, Kawaguchi R, et al. A randomized study of screening for ovarian cancer: a multicenter study in Japan. International Journal of Gynecological Cancer [Internet]. 2008 [cited PENDING (UPDATE 91‐08); (3):[414‐20 pp.]. Available from: http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/881/CN‐00636881/frame.html. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65. Kobayashi H, Yamada Y, Sado T, Sakata M, Yoshida S, Kawaguchi R, et al. Prevalence of ovarian cancer among women with a CA125 level of 35 U/ml or less. Gynecologic &amp; Obstetric Investigation. 2008;65(2):133‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66. Koldjeski D, Kirkpatrick MK, Swanson M, Everett L, Brown S. Ovarian cancer: early symptom patterns. Oncology nursing forum. 2003;30(6):927‐33. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67. Kondalsamy‐Chennakesavan S, Hackethal A, Bowtell D, Australian Ovarian Cancer Study G, Obermair A. Differentiating stage 1 epithelial ovarian cancer from benign ovarian tumours using a combination of tumour markers HE4, CA125, and CEA and patient's age. Gynecologic Oncology. 2013;129(3):467‐71. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68. Kurjak A, Zalud I, Alfirevic Z. Evaluation of adnexal masses with transvaginal color ultrasound. Journal of Ultrasound in Medicine. 1991;10(6):295‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>69. Kotowicz B, Fuksiewicz M, Sobiczewski P, Spiewankiewicz B, Jonska‐Gmyrek J, Skrzypczak M, et al. Clinical value of human epididymis protein 4 and the Risk of Ovarian Malignancy Algorithm in differentiating borderline pelvic tumors from epithelial ovarian cancer in early stages. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology. 2015;194:141‐6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70. Kyung MS. Serum CA19‐9 as a predictor of malignancy in primary ovarian mucinous tumors: a matched case‐control study. Medical science monitor: international medical journal of experimental and clinical research. 2014;20:1334‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71. Lee EJ, Kim SH, Kim YH, Lee HJ. Is CA‐125 an additional help to radiologic findings for differentiation borderline ovarian tumor from stage I carcinoma? Acta Radiologica. 2011;52(4):458‐62. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>72. Li QL, Wang CJ, Qi P, Zhang YX. Correlation of preoperative ROMA scores with clinical stage in epithelial ovarian cancer patients. Clinical &amp; Translational Oncology: Official Publication of the Federation of Spanish Oncology Societes &amp; of the National Cancer Institute of Mexico. 2017;19(10):1260‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73. Lowe KA, Andersen MR, Urban N, Paley P, Dresher CW, Goff BA. The temporal stability of the Symptom Index among women at high‐risk for ovarian cancer. Gynecologic Oncology. 2009;114(2):225‐30. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74. Lurie G, Wilkens LR, Thompson PJ, Matsuno RK, Carney ME, Goodman MT. Symptom presentation in invasive ovarian carcinoma by tumor histological type and grade in a multiethnic population: a case analysis. Gynecologic Oncology. 2010;119(2):278‐84. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75. Meisel M, Straube W, Weise J, Burkhardt B. A study of serum CASA and CA 125 levels in patients with ovarian carcinoma. Archives of Gynecology and Obstetrics. 1995;256(1):9‐15. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76. Menon U, Jacobs I. Ovarian cancer screening in the general population. Ultrasound in Obstetrics and Gynecology. 2000;15(5):350‐3. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77. Menon U, Talaat A, Jeyarajah AR, Rosenthal AN, MacDonald ND, Skates SJ, et al. Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation. British Journal of Cancer. 1999;80(10):1644‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78. Menon U, Talaat A, Rosenthal AN, Macdonald ND, Jeyerajah AR, Skates SJ, et al. Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening. BJOG: An International Journal of Obstetrics &amp; Gynaecology. 2014;121 Suppl 7:35‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79. Moore RG, Miller MC, Steinhoff MM, Skates SJ, Lu KH, Lambert‐Messerlian G, et al. Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders. American Journal of Obstetrics &amp; Gynecology. 2012;206(4):351.e1‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80. Moszynski R, Szubert S, Szpurek D, Michalak S, Krygowska J, Sajdak S. Usefulness of the HE4 biomarker as a second‐line test in the assessment of suspicious ovarian tumors. Archives of Gynecology &amp; Obstetrics. 2013;288(6):1377‐83. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>81. Niemi RJ, Saarelainen SK, Luukkaala TH, Maenpaa JU. Reliability of preoperative evaluation of postmenopausal ovarian tumors. Journal of Ovarian Research. 2017;10 (1) (no pagination)(15). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82. Nigam PK, Jain A, Goyal P, Chitra R. Role of heat stable fraction of alkaline phosphatase as an adjunct to CA 125 in monitoring patients of epithelial ovarian carcinoma. Indian Journal of Clinical Biochemistry. 2005;20(2):43‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>83. Nikolova T, Zivadinovic R, Nikolova N, Klisarovska V, Evtimovska N, Stanojevic M. Comparison of diagnostic performances of HE4, risk of malignancy algorithm and morphology index in discrimination of ovarian endometriosis from epithelial ovarian cancer in premenopausal women. International Journal of Gynecological Cancer. 2017;27 (Supplement 4):515. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84. Nishimura S, Ito YM, Tsuda H, Ohnishi Y, Kataoka F, Nomura H, et al. The sensitivity and specificity of a new formula to distinguish endometrioid type endometrial carcinoma from ovarian endometrial carcinoma. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology. 2010;148(1):67‐72. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85. Nohuz E, De Simone L, Chene G. Reliability of IOTA score and ADNEX model in the screening of ovarian malignancy in postmenopausal women. Journal of Gynecology Obstetrics and Human Reproduction. 2019;48(2):103‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>86. Nunes N, Ambler G, Foo X, Naftalin J, Derdelis G, Widschwendter M, et al. Comparison of two protocols for the management of asymptomatic postmenopausal women with adnexal tumours‐a randomised controlled trial of RMI/RCOG vs Simple Rules. British Journal of Cancer. 2017;116(5):584‐91. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87. Olivier RI, Lubsen‐Brandsma MAC, Verhoef S, van Beurden M. CA125 and transvaginal ultrasound monitoring in high‐risk women cannot prevent the diagnosis of advanced ovarian cancer. Gynecologic Oncology. 2006;100(1):20‐6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88. Oltmann SC, Garcia N, Barber R, Huang R, Hicks B, Fischer A. Can we preoperatively risk stratify ovarian masses for malignancy? Journal of Pediatric Surgery. 2010;45(1):130‐4. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89. Osman N, O'Leary N, Mulcahy E, Barrett N, Wallis F, Hickey K, et al. Correlation of serum CA125 with stage, grade and survival of patients with epithelial ovarian cancer at a single centre. Irish Medical Journal. 2008;101(8). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90. Paramasivam S, Tripcony L, Crandon A, Quinn M, Hammond I, Marsden D, et al. Prognostic importance of preoperative CA‐125 in International Federation of Gynecology and Obstetrics stage I epithelial ovarian cancer: an Australian multicenter study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2005;23(25):5938‐42. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>91. Park JW, Han M, Cho YJ. Four risk of malignancy indices in evaluation between borderline and malignant pelvic masses. International Journal of Gynecological Cancer. 2017;27 (Supplement 4):1621. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92. Pitts MK, Heywood W, Ryall R, Smith AM, Shelley JM, Richters J, et al. High prevalence of symptoms associated with ovarian cancer among Australian women. Australian &amp; New Zealand Journal of Obstetrics &amp; Gynaecology. 2011;51(1):71‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>93. Pitynski K, Sporek A, Lipinska I, Banas T, Ludwin A, Balajewicz‐Nowak M. Significance of adding progesterone to the Risk of Ovarian Malignancy Algorithm for early stage ovarian cancer detection in patients with a pelvic mass: A single‐center case‐control study. Taiwanese Journal of Obstetrics &amp; Gynecology. 2015;54(6):766‐72. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>94. Ra OS, Woo PJ, Myoungseok H, Woon BJ, Jean CY. Clinical utility of the risk of malignancy indices for preoperative differentiation between ovarian cancer and borderline ovarian tumor. International Journal of Gynecological Cancer. 2018;28 (Supplement 3):27. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95. Raza A, Mould T, Wilson M, Burnell M, Bernhardt L. Increasing the effectiveness of referral of ovarian masses from cancer unit to cancer center by using a higher referral value of the risk of malignancy index. International Journal of Gynecological Cancer. 2010;20(4):552‐4. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>96. Robertson DM, Cahir N, Burger HG, Mamers P, McCloud PI, Pettersson K, et al. Combined inhibin and CA125 assays in the detection of ovarian cancer. Clinical Chemistry. 1999;45(5):651‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97. Rogers EM, Casadiego Cubides G, Lacy J, Gerstle JT, Kives S, Allen L. Preoperative risk stratification of adnexal masses: can we predict the optimal surgical management? Journal of Pediatric &amp; Adolescent Gynecology. 2014;27(3):125‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98. Rosen DG, Wang L, Atkinson JN, Yu Y, Lu KH, Diamandis EP, et al. Potential markers that complement expression of CA125 in epithelial ovarian cancer. Gynecologic Oncology. 2005;99(2):267‐77. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99. Roupa Z, Faros E, Raftopoulos V, Tzavelas G, Kotrotsiou E, Sotiropoulou P, et al. Serum CA 125 combined with transvaginal ultrasonography for ovarian cancer screening. In Vivo. 2004;18(6):831‐6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100. Ruggeri G, Bandiera E, Zanotti L, Belloli S, Ravaggi A, Romani C, et al. HE4 and epithelial ovarian cancer: comparison and clinical evaluation of two immunoassays and a combination algorithm. Clinica Chimica Acta. 2011;412(15‐16):1447‐53. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>101. Ryuko K, Iwanari O, Nakayama S, Iida K, Kitao M. Clinical evaluation of serum sialosyl‐Tn antigen levels in comparison with CA 125 levels in gynecologic cancers. Cancer. 1992;69(9):2368‐78. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102. Sarandakou A, Phocas I, Botsis D, Sikiotis K, Rizos D, Kalambokis D, et al. Tumour‐associated antigens CEA, CA125, SCC and TPS in gynaecological cancer. European Journal of Gynaecological Oncology. 1998;19(1):73‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103. Saraswathi A, Malati T. Superiority of CA 125 over CA 19‐9 and CEA for epithelial ovarian malignancies. Indian Journal of Clinical Biochemistry. 1995;10(1):23‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104. Sasaki H, Oda M, Ohmura M, Akiyama M, Liu C, Tsugane S, et al. Follow up of women with simple ovarian cysts detected by transvaginal sonography in the Tokyo metropolitan area. British Journal of Obstetrics &amp; Gynaecology. 1999;106(5):415‐20. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>105. Seda HB, Selvi DG, Omer D, Levent A, Huseyin Y. A clinico‐pathological evaluation of 194 patients with ovarian teratoma: 7‐year experience in a single center. Ginekologia Polska. 2013;84(2):108‐11. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>106. Seow KM, Lin YH, Hsieh BC, Huang LW, Pan HS, Chang JZ, et al. Transvaginal three‐dimensional ultrasonography combined with serum CA 125 level for the diagnosis of pelvic adhesions before laparoscopic surgery. Journal of the American Association of Gynecologic Laparoscopists. 2003;10(3):320‐6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107. Sharma A, Gentry‐Maharaj A, Burnell M, Fourkala EO, Campbell S, Amso N, et al. Assessing the malignant potential of ovarian inclusion cysts in postmenopausal women within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a prospective cohort study. BJOG: An International Journal of Obstetrics &amp; Gynaecology. 2012;119(2):207‐19. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>108. Sichel F, Salaun V, Bar E, Gauduchon P, Malas JP, Goussard J, et al. Biological markers and ovarian carcinomas: galactosyltransferase, CA 125, isoenzymes of amylase and alkaline phosphatase. Clinica Chimica Acta. 1994;227(1‐2):87‐96. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109. Sobiczewski P, Danska‐Bidzinska A, Rzepka J, Kupryjanczyk J, Gujski M, Bidzinski M, et al. Evaluation of selected ultrasonographic parameters and marker levels in the preoperative differentiation of borderline ovarian tumors and ovarian cancers. Archives of Gynecology &amp; Obstetrics. 2012;286(6):1513‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110. Sorensen SS, Mosgaard BJ. Combination of cancer antigen 125 and carcinoembryonic antigen can improve ovarian cancer diagnosis. Danish Medical Bulletin. 2011;58(11):A4331. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111. Stine JE, Suri A, Gehrig PA, Chiu M, Erickson BK, Huh WK, et al. Pre‐operative imaging with CA125 is a poor predictor for granulosa cell tumors. Gynecologic Oncology. 2013;131(1):59‐62. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112. Suh‐Burgmann E, Hung Y‐Y, Kinney W. Outcomes from ultrasound follow‐up of small complex adnexal masses in women over 50. American Journal of Obstetrics &amp; Gynecology. 2014;211(6):623.e1‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>113. Takeshima N, Shimizu Y, Umezawa S, Hirai Y, Chen JT, Fujimoto I, et al. Combined assay of serum levels of ca125 and ca19‐9 in endometrial carcinoma. Gynecologic Oncology. 1994;54(3):321‐6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>114. Tan PL, Willatt JM, Lindsell D. The ability of ultrasound to detect gynaecological neoplasms and their ultrasound morphological features. Australasian Radiology. 2007;51(3):260‐6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115. Testa AC, Ajossa S, Ferrandina G, Fruscella E, Ludovisi M, Malaggese M, et al. Does quantitative analysis of three‐dimensional power Doppler angiography have a role in the diagnosis of malignant pelvic solid tumors? A preliminary study. Ultrasound in Obstetrics &amp; Gynecology. 2005;26(1):67‐72. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116. Testa AC, Timmerman D, Van Belle V, Fruscella E, Van Holsbeke C, Savelli L, et al. Intravenous contrast ultrasound examination using contrast‐tuned imaging (CnTI) and the contrast medium SonoVue for discrimination between benign and malignant adnexal masses with solid components. Ultrasound in Obstetrics &amp; Gynecology. 2009;34(6):699‐710. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117. Theodoridis TD, Zepiridis L, Mikos T, Grimbizis GF, Dinas K, Athanasiadis A, et al. Comparison of diagnostic accuracy of transvaginal ultrasound with laparoscopy in the management of patients with adnexal masses. Archives of Gynecology &amp; Obstetrics. 2009;280(5):767‐73. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>118. Thrall MM, Paley P, Pizer E, Garcia R, Goff BA. Patterns of spread and recurrence of sex cord‐stromal tumors of the ovary. Gynecologic Oncology. 2011;122(2):242‐5. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>119. Tingulstad S, Hagen B, Skjeldestad FE, Halvorsen T, Nustad K, Onsrud M. The risk‐of‐malignancy index to evaluate potential ovarian cancers in local hospitals. Obstetrics &amp; Gynecology. 1999;93(3):448‐52. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120. Tornos C, Soslow R, Chen S, Akram M, Hummer AJ, Abu‐Rustum N, et al. Expression of WT1, CA 125, and GCDFP‐15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary. American Journal of Surgical Pathology. 2005;29(11):1482‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121. Valentin L, Ameye L, Franchi D, Guerriero S, Jurkovic D, Savelli L, et al. Risk of malignancy in unilocular cysts: a study of 1148 adnexal masses classified as unilocular cysts at transvaginal ultrasound and review of the literature. Ultrasound in Obstetrics &amp; Gynecology. 2013;41(1):80‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122. Valentin L, Ameye L, Savelli L, Fruscio R, Leone FP, Czekierdowski A, et al. Unilocular adnexal cysts with papillary projections but no other solid components: is there a diagnostic method that can classify them reliably as benign or malignant before surgery? Ultrasound in obstetrics &amp; gynecology: the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2013;41(5):570‐81. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123. Valentin L, Ameye L, Savelli L, Fruscio R, Leone FPG, Czekierdowski A, et al. Adnexal masses difficult to classify as benign or malignant using subjective assessment of gray‐scale and Doppler ultrasound findings: logistic regression models do not help. Ultrasound in Obstetrics &amp; Gynecology. 2011;38(4):456‐65. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124. Valentin L, Ameye L, Savelli L, Fruscio R, Leone FPG, Czekierdowski A, et al. Unilocular adnexal cysts with papillary projections but no other solid components: is there a diagnostic method that can classify them reliably as benign or malignant before surgery? Ultrasound in Obstetrics &amp; Gynecology. 2013;41(5):570‐81. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125. Van den Akker PAJ, Aalders AL, Snijders MPLM, Kluivers KB, Samlal RAK, Vollebergh JHA, et al. Evaluation of the Risk of Malignancy Index in daily clinical management of adnexal masses. Gynecologic Oncology. 2010;116(3):384‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126. van den Akker PAJ, Zusterzeel PLM, Aalders AL, Snijders MPLM, Samlal RAK, Vollebergh JHA, et al. External validation of the adapted Risk of Malignancy Index incorporating tumor size in the preoperative evaluation of adnexal masses. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology. 2011;159(2):422‐5. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127. Van Holsbeke C, Daemen A, Yazbek J, Holland TK, Bourne T, Mesens T, et al. Ultrasound methods to distinguish between malignant and benign adnexal masses in the hands of examiners with different levels of experience. Ultrasound in Obstetrics &amp; Gynecology. 2009;34(4):454‐61. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>128. van Nagell JR, Depriest PD, Reedy MB, Gallion HH, Ueland FR, Pavlik EJ, et al. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecologic Oncology. 2000;77(3):350‐6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>129. Vuento MH, Stenman UH, Pirhonen JP, Makinen JI, Laippala PJ, Salmi TA. Significance of a single CA 125 assay combined with ultrasound in the early detection of ovarian and endometrial cancer. Gynecologic Oncology. 1997;64(1):141‐6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>130. Wang S, Johnson S. Prediction of benignity of solid adnexal masses. Archives of Gynecology &amp; Obstetrics. 2012;285(3):721‐6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>131. Wei S, Li H, Zhang B. The diagnostic value of serum HE4 and CA‐125 and ROMA index in ovarian cancer. Biomedical Reports. 2016;5(1):41‐4. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>132. Weinberger V, Fischerova D, Semeradova I, Slama J, Dundr P, Dusek L, et al. Prospective Evaluation of Ultrasound Accuracy in the Detection of Pelvic Carcinomatosis in Patients with Ovarian Cancer. Ultrasound in Medicine &amp; Biology. 2016;42(9):2196‐202. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>133. Woodward E, Sleightholme H, Considine A, Williamson S, McHugo J, Cruger D. Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high‐risk and population risk women is ineffective. BJOG: An International Journal of Obstetrics &amp; Gynaecology. 2007;114(12):1500‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>134. Yazbek J, Aslam N, Tailor A, Hillaby K, Raju KS, Jurkovic D. A comparative study of the risk of malignancy index and the ovarian crescent sign for the diagnosis of invasive ovarian cancer. Ultrasound in Obstetrics &amp; Gynecology. 2006;28(3):320‐4. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>135. Yesilyurt H, Tokmak A, Guzel AI, Simsek HS, Terzioglu SG, Erkaya S, et al. Parameters for predicting granulosa cell tumor of the ovary: a single center retrospective comparative study. Asian Pacific Journal of Cancer Prevention: Apjcp. 2014;15(19):8447‐50. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136. Zacharakis D, Thomakos N, Biliatis I, Rodolakis A, Simou M, Daskalakis G, et al. Ultrasonographic markers and preoperative CA‐125 to distinguish between borderline ovarian tumors and stage I ovarian cancer. Acta Obstetricia et Gynecologica Scandinavica. 2013;92(3):285‐92. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>137. Zapardiel I, Gorostidi M, Ravaggi A, Allende MT, Silveira M, Abehsera D, et al. Utility Serum Marker HE4 for the Differential Diagnosis Between Endometriosis and Adnexal Malignancy. International Journal of Gynecological Cancer. 2016;26(1):52‐5. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>138. Zhang M, Zhuang G, Sun X, Shen Y, Zhao A, Di W. Risk prediction model for epithelial ovarian cancer using molecular markers and clinical characteristics. Journal of ovarian research. 2015;8:67. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>139. Zygmunt A, Madry R, Markowska J, Fischer Z. Estimation of the usefulness of neoplastic markers TPS and CA 125 in diagnosis and monitoring of ovarian cancer. European Journal of Gynaecological Oncology. 1999;20(4):298‐301. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 17.</span> <span class="table-title">Excluded studies: population not applicable</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/appendices#CD011964-tbl-0019">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011964-tbl-0020"> <div class="table-heading"><span class="table-label">Table 18.</span> <span class="table-title">Excluded studies: publication pre‐1991</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Publication pre 1991</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Chen DX, Schwartz PE, Li XG, Yang Z. Evaluation of CA 125 levels in differentiating malignant from benign tumors in patients with pelvic masses. Obstetrics and gynecology. 1988;72(1):23‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2. Einhorn N, Bast RC, Jr, Knapp RC, Tjernberg B, Zurawski VR, Jr. Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer. Obstetrics and gynecology. 1986;67(3):414‐6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3. Einhorn N, Knapp RC, Bast RC, Zurawski VR. Ca 125 Assay Used in Conjunction with Ca 15–3 and Tag‐72 Assays for Discrimination Between Malignant and Non‐Malignant Diseases of the Ovary. Acta Oncologica. 1989;28(5):655‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4. FINKLER NJ, BENACERRAF B, LAVIN PT, WOJCIECHOWSKI C, KNAPP RC. Comparison of Serum CA 125, Clinical Impression, and Ultrasound in the Preoperative Evaluation of Ovarian Masses. Obstetrics &amp; Gynecology. 1988;72(4):659‐64. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5. Gadducci A, Capriello P, Bartolini T, Barale E, Cappelli N, Facchini V, et al. The association of ultrasonography and CA‐125 test in the preoperative evaluation of ovarian carcinoma. European Journal of Gynaecological Oncology. 1988;9(5):373‐6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6. Hawkins RE, Roberts K, Wiltshaw E, Mundy J, McCready VR. The clinical correlates of serum CA125 in 169 patients with epithelial ovarian carcinoma. Br J Cancer. 1989;60(4):634‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7. Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol. 1990;97(10):922‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8. Malkasian GD, Jr, Knapp RC, Lavin PT, Zurawski VR, Jr, Podratz KC, Stanhope CR, et al. Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. American journal of obstetrics and gynecology. 1988;159(2):341‐6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9. Mogensen O, Mogensen B, Jakobsen A. CA 125 in the diagnosis of pelvic masses. European Journal of Cancer and Clinical Oncology. 1989;25(8):1187‐90. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10. O'Connell GJ, Ryan E, Murphy KJ, Prefontaine M. Predictive value of CA 125 for ovarian carcinoma in patients presenting with pelvic masses. Obstetrics and gynecology. 1987;70(6):930‐2. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11. Patsner B, Mann WJ. The value of preoperative serum CA 125 levels in patients with a pelvic mass. American journal of obstetrics and gynecology. 1988;159(4):873‐6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12. SOPER JT, HUNTER VJ, DALY L, TANNER M, CREASMAN WT, BAST RCJ. Preoperative Serum Tumor‐Associated Antigen Levels in Women With Pelvic Masses. Obstetrics &amp; Gynecology. 1990;75(2):249‐54. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13. Vasilev SA, Schlaerth JB, Campeau J, Morrow CP. Serum CA 125 levels in preoperative evaluation of pelvic masses. Obstetrics and Gynecology. 1988;71(5):751‐6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14. Yedema C, Massuger L, Hilgers J, Servaas J, Poels L, Thomas C, et al. Pre‐operative discrimination between benign and malignant ovarian tumors using a combination of CA125 and CA15.3 serum assays. International journal of cancer Supplement = Journal international du cancer Supplement. 1988;3:61‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15. Zurawski VR, Jr, Knapp RC, Einhorn N, Kenemans P, Mortel R, Ohmi K, et al. An initial analysis of preoperative serum CA 125 levels in patients with early stage ovarian carcinoma. Gynecol Oncol. 1988;30(1):7‐14. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 18.</span> <span class="table-title">Excluded studies: publication pre‐1991</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/appendices#CD011964-tbl-0020">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011964-tbl-0021"> <div class="table-heading"><span class="table-label">Table 19.</span> <span class="table-title">Excluded studies: study design</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Study design</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Aguirre A, Ardeshirpour Y, Sanders MM, Brewer M, Zhu Q. Potential role of coregistered photoacoustic and ultrasound imaging in ovarian cancer detection and characterization. Clinical &amp; translational oncology. 2011;4(1):29‐37. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2. Alongkronrusmee D, Bitterman P, Abramowicz JS, Bahr JM, Basu S, Grasso S, et al. GRP78 in association with VEGFR‐2 detects early stage ovarian cancer. Cancer Research. 2013;1). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3. Alqasemi U, Kumavor P, Aguirre A, Zhu Q. Recognition algorithm for assisting ovarian cancer diagnosis from coregistered ultrasound and photoacoustic images: ex vivo study. Journal of Biomedical Optics. 2012;17(12):126003. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4. Anastasi E, Giovanna Marchei G, Viggiani V, Gennarini G, Frati L, Reale MG. HE4: A new potential early biomarker for the recurrence of ovarian cancer. Tumor Biology. 2010;31(2):113‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5. Avsar AF, Keskin HL, Catma T, Kaya B, Sivaslioglu AA. A large primary vaginal calculus in a woman with paraplegia. Journal of Lower Genital Tract Disease. 2013;17(1):61‐5. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6. Balasubramaniam K, Ravn P, Larsen PV, Sondergaard J, Jarbol DE. Specific and unspecific gynecological alarm symptoms ‐ Prevalence estimates in different age groups: A population‐based study. Acta Obstetricia et Gynecologica Scandinavica. 2014;94(2):191‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7. Barnsfather K, Fitzpatrick CB, Wilson J, Linn CL, Brizendine E, Schilder JM. The Morphology Index: predictive value of malignancy among clinicians at various levels of training. Gynecologic Oncology. 2012;127(1):94‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8. Baron AT, Boardman CH, Lafky JM, Rademaker A, Liu D, Fishman DA, et al. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.[Erratum appears in Cancer Epidemiol Biomarkers Prev. 2005 Jun;14(6):1583]. Cancer Epidemiology, Biomarkers &amp; Prevention. 2005;14(2):306‐18. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9. Barrett J, Sharp DJ, Stapley S, Stabb C, Hamilton W. Pathways to the diagnosis of ovarian cancer in the UK: a cohort study in primary care. BJOG: An International Journal of Obstetrics &amp; Gynaecology. 2010;117(5):610‐4. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10. Bast RC, Jr. Early detection of ovarian cancer: new technologies in pursuit of a disease that is neither common nor rare. Transactions of the American Clinical &amp; Climatological Association. 2004;115:233‐47; discussion 47‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11. Begum FD, Hogdall E, Kjaer SK, Blaakaer J, Christensen IJ, Christensen L, et al. Preoperative serum tetranectin, CA125 and menopausal status used as single markers in screening and in a risk assessment index (RAI) in discriminating between benign and malignant ovarian tumors. Gynecologic Oncology. 2009;113(2):221‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12. Braga F, Ferraro S, Mozzi R, Panteghini M. The importance of individual biology in the clinical use of serum biomarkers for ovarian cancer. Clinical Chemistry &amp; Laboratory Medicine. 2014;52(11):1625‐31. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13. Covens AL, Dodge JE, Lacchetti C, Elit LM, Le T, Devries‐Aboud M, et al. Surgical management of a suspicious adnexal mass: a systematic review. Gynecologic Oncology. 2012;126(1):149‐56. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14. Dai W, Shi Y, He F, Gu C, Kong Y. Two case of androgen‐secreting ovary tumor. [Chinese]. Zhongguo yi xue ke xue yuan xue bao. 1995;Acta Academiae Medicinae Sinicae. 17(4):317‐20. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15. Drescher CW, Shah C, Thorpe J, O'Briant K, Anderson GL, Berg CD, et al. Longitudinal screening algorithm that incorporates change over time in CA125 levels identifies ovarian cancer earlier than a single‐threshold rule. Journal of Clinical Oncology. 2013;31(3):387‐92. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16. Dursun H, Albayrak F, Yildirim R, Uyanik A, Yilmaz O, Okcu N, et al. Giant mesenteric cyst can present as pseudoascites with raised Ca125. Turkish Journal of Gastroenterology. 2009;20(4):305‐6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17. Eiriksson LR, Millar HC, Lennox GK, Reade CJM, Leung F, Diamandis EP, et al. The usefulness of ovarian cancer risk scoring in the discrimination of an isolated pelvic mass. Gynecologic Oncology. 2014;133:82‐3. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18. Eisenkop SM, Spirtos NM, Montag TW, Nalick RH, Wang HJ. The impact of subspecialty training on the management of advanced ovarian cancer. Gynecol Oncol. 1992;47(2):203‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19. Elder JW, Pavlik EJ, Long A, Miller RW, DeSimone CP, Hoff JT, et al. Serial ultrasonographic evaluation of ovarian abnormalities with a morphology index. Gynecologic Oncology. 2014;135(1):8‐12. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20. Filipova I, Chakalova G. Ca 125, he 4 and roma‐index in patients with epithelial ovarian cancer. International Journal of Gynecological Cancer. 2013;1):883. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21. Fritz‐Rdzanek A, Grzybowski W, Beta J, Durczynski A, Jakimiuk A. HE4 protein and SMRP: Potential novel biomarkers in ovarian cancer detection. Oncology Letters. 2012;4(3):385‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22. Galgano MT, Hampton GM, Frierson Jr HF. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Modern Pathology. 2006;19(6):847‐53. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23. Gasiorowska E, Walkowiak G, Michalak M, Jankowska A, Nowak‐Markwitz E, Spaczynski M. HE4 gene expression in ovary, fallopian tube and ovarian cancer. International Journal of Gynecological Cancer. 2013;1):480. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24. Goff B, Lowe K, Kane J, Robertson M, Gaul M, Andersen M. The safety of symptom based screening for ovarian cancer. Gynecologic Oncology. 2012;127 (1):S10. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25. Goff BA, Lowe KA, Kane JC, Robertson MD, Gaul MA, Andersen MR. Symptom triggered screening for ovarian cancer: a pilot study of feasibility and acceptability. Gynecologic Oncology. 2012;124(2):230‐5. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26. Goff BA, Matthews B, Andrilla CHA, Miller JW, Trivers KF, Berry D, et al. How are symptoms of ovarian cancer managed? A study of primary care physicians. Cancer. 2011;117(19):4414‐23. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27. Guadagni F, Marth C, Zeimet AG, Ferroni P, Spila A, Abbolito R, et al. Evaluation of tumor‐associated glycoprotein‐72 and CA 125 serum markers in patients with gynecologic diseases. American journal of obstetrics and gynecology. 1994;171(5):1183‐91. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28. Hakama M, Stenman UH, Knekt P, Jarvisalo J, Hakulinen T, Maatela J, et al. CA 125 as a screening test for ovarian cancer. Journal of Medical Screening. 1996;3(1):40‐2. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29. Hamilton W, Menon U. Easily missed? Ovarian cancer. British Medical Journal. 2009;339.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30. Hartge P, Hayes R, Reding D, Sherman ME, Prorok P, Schiffman M, et al. Complex ovarian cysts in postmenopausal women are not associated with ovarian cancer risk factors: preliminary data from the prostate, lung, colon, and ovarian cancer screening trial. American journal of obstetrics and gynecology [Internet]. 2000 [cited PENDING (UPDATE 91‐08); (5):[1232‐7 pp.]. Available from: http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/182/CN‐00331182/frame.html. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31. Havrilesky L, Sfakianos G, Barnett J, Myers E. Comparative effectiveness of three triage strategies for women presenting to a gynecologist with a pelvic mass. Gynecologic Oncology. 2012;125:S75. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32. Hennessey A. Detection of a Unilateral Mucinous Borderline Ovarian Tumor With Sonography and Magnetic Resonance Imaging. Journal of Diagnostic Medical Sonography. 2013;29(1):30‐5. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33. Hess LM, Stehman FB, Method MW, Weathers TD, Gupta P, Schilder JM. Identification of the optimal pathway to reach an accurate diagnosis in the absence of an early detection strategy for ovarian cancer. Gynecologic Oncology. 2012;127(3):564‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34. Holcomb K, Miller C, Vucetic Z, Knapp R. Human epididymis protein 4 increases specificity for the detection of invasiive epithelial ovarian cancer in premenopausal women presenting with an adnexal mass. Gynecologic Oncology. 2011;120:S69‐S70. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35. Jacobs IJ, Skates SJ, MacDonald N, Menon U, Rosenthal AN, Davies AP, et al. Screening for ovarian cancer: a pilot randomised controlled trial. Lancet (London, England) [Internet]. 1999 [cited PENDING (UPDATE 91‐08); (9160):[1207‐10 pp.]. Available from: http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/328/CN‐00162328/frame.html. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36. Kang S, Hwang J, Yoo H, Lim M, Seo S, Park S. Is serum HE4 measurement useful in early detection of ovarian cancer? Gynecologic Oncology. 2012;125:S100. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37. Kenemans P, Verstraeten AA, Van Kamp GJ, Von Mensdorff‐Pouilly S. The second generation CA 125 assays. Annals of Medicine. 1995;27(1):107‐13. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38. Kim J‐A, Chun YK, Moon MH, Lee YH, Cho HC, Lee MS, et al. High‐resolution sonographic findings of ovarian granulosa cell tumors: correlation with pathologic findings. Journal of Ultrasound in Medicine. 2010;29(2):187‐93. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39. Kim KH, Zsebik GN, Straughn JM, Landen CN. Management of complex pelvic masses using a multivariate index assay: a decision analysis (Provisional abstract). Gynecologic Oncology [Internet]. 2012 [cited EED Y/U]; (3):[364‐8 pp.]. Available from: http://onlinelibrary.wiley.com/o/cochrane/cleed/articles/NHSEED‐22012030548/frame.html. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40. Kommoss S, Anglesio MS, Mackenzie R, Yang W, Senz J, Ho J, et al. FOXL2 molecular testing in ovarian neoplasms: diagnostic approach and procedural guidelines. Modern Pathology. 2013;26(6):860‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41. Kong F, Nicole White C, Xiao X, Feng Y, Xu C, He D, et al. Using proteomic approaches to identify new biomarkers for detection and monitoring of ovarian cancer. Gynecologic Oncology. 2006;100(2):247‐53. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42. Kuhlmann JD, Schwarzenbach H, Otterbach F, Heubner M, Wimberger P, Worm KH, et al. Primary tumor loss of heterozygosity proximal to M6P/IGF2R locus is predictive for the presence and persistence of disseminated tumor cells in the bone marrow of ovarian cancer patients. Cancer Research. 2011;1). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43. Kupets R, Fernandes K, Miroshnichenko G, Paszat L. Are too many imaging tests being performed in women with an adnexal mass? Journal of Obstetrics &amp; Gynaecology Canada: JOGC. 2013;35(3):246‐51. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44. Lataifeh I, Marsden DE, Robertson G, Gebski V, Hacker NF. Presenting symptoms of epithelial ovarian cancer. The Australian &amp; New Zealand journal of obstetrics &amp; gynaecology. 2005;45(3):211‐4. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45. Latifi A, Abubaker K, Castrechini N, Ward AC, Liongue C, Dobill F, et al. Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell‐like profile. Journal of Cellular Biochemistry. 2011;112(10):2850‐64. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46. Lazebnik N, Balog A, Bennett S, Redline R, Liu J. Ovarian dysgerminoma: a challenging clinical and sonographic diagnosis. Journal of Ultrasound in Medicine. 2009;28(10):1409‐15. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47. Lu KH, Skates S, Hernandez MA, Bedi D, Bevers T, Leeds L, et al. A 2‐stage ovarian cancer screening strategy using the Risk of Ovarian Cancer Algorithm (ROCA) identifies early‐stage incident cancers and demonstrates high positive predictive value. Cancer. 2013;119(19):3454‐61. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48. Meinhold‐Heerlein I, Fehm T, Haltmeier C, Brautigam K, Neubauer H, Maass N, et al. The potential of novel molecular markers to serve as therapeutical targets or serum tumor markers of serous ovarian cancer. Onkologie. 2010;33:114‐. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49. Menon U. Sensitivity and Specificity of Multimodal and Ultrasound Screening for Ovarian Cancer, and Stage Distribution of Detected Cancers: Results of the Prevalence Screen of the United Kingdom Collaborative Trial of Ovarian Cancer Screening COMMENT. Obstetrical &amp; Gynecological Survey. 2009;64(9):592‐5. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50. Mohan S, Kapoor G, Nagpal PK, Aggarwal R, Gami N. Managing adnexal masses: a medical quandary. Journal of Clinical and Diagnostic Research JCDR. 2013;7(9):1971‐4. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51. Molina R, Ojeda B, Filella X, Borras G, Jo J, Mas E, et al. A prospective study of tumor markers CA 125 and CA 19.9 in patients with epithelial ovarian carcinomas. Tumor Biology. 1992;13(5‐6):278‐86. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52. Montagnana M, Danese E, Ruzzenente O, Bresciani V, Nuzzo T, Gelati M, et al. The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful? Clinical Chemistry &amp; Laboratory Medicine. 2011;49(3):521‐5. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53. Moore R, Miller C, DiSilvestro P, Landrum L, Gajewski W, Renneisen P, et al. Evaluation of the risk of ovarian malignancy algorithm in women with a pelvic mass presenting to general gynecologists. Gynecologic Oncology. 2011;121(1):S68‐S. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54. Mozina B. Usefulness of ROMA (Risk of Ovarian Malignancy Algorithm) based on tumor markers CA125 and HE4. Tumor Biology. 2014;35:S37. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55. Murphy P, Adams M, Martin B, Horlick E, Malinowski D. Correlation of mRNA and protein expression of CA125 and HE4 in ovarian cancer tissues using real‐time RT‐PCR and reverse phase protein array technologies. Cancer Research. 2010;1). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56. Nishimura S, Tsuda H, Ito K, Takano M, Terai Y, Jobo T, et al. Differential expression of hypoxia‐inducible protein 2 among different histological types of epithelial ovarian cancer and in clear cell adenocarcinomas. International Journal of Gynecological Cancer. 2010;20(2):220‐6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57. Orre M, Lotfi‐Miri M, Mamers P, Rogers PA. Increased microvessel density in mucinous compared with malignant serous and benign tumours of the ovary. British Journal of Cancer. 1998;77(12):2204‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58. Ota T, Clayton AC, Minot DM, Hartmann LC, Shridhar V, Gilks B, et al. Mini‐chromosome maintenance protein 7 as a potential theranostic biomarker in epithelial ovarian cancer. Cancer Research. 2010;1). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59. Pascual MA, Graupera B, Hereter L, Rotili A, Rodriguez I, Alcazar JL. Intra‐ and interobserver variability of 2D and 3D transvaginal sonography in the diagnosis of benign versus malignant adnexal masses. Journal of Clinical Ultrasound. 2011;39(6):316‐21. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60. Peng D, Xu T, Mason TJ, Wu W. A study of ovarian cancer biomarker amplification using ultrasound for early stage detection. Ultrasonics. 2014;54(2):451‐4. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61. Perkins G, Dukes J, Pope L, Clark J, Yap TA, Riisnaes R, et al. Prospective study of genetic mutations in matched tumor and plasma specimens in advanced cancer patients referred to phase I trials. Cancer Research. 2011;1). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62. Phocas I, Sarandakou A, Sikiotis K, Rizos D, Kalambokis D, Zourlas PA. A comparative study of serum alpha‐beta A immunoreactive inhibin and tumor‐associated antigens CA125 and CEA in ovarian cancer. Anticancer Research [Internet]. 1996 [cited PENDING (UPDATE 91‐08); (6b):[3827‐31 pp.]. Available from: http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/922/CN‐00136922/frame.html. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63. Pinsky PF, Zhu CS. Building multi‐marker algorithms for disease prediction‐the role of correlations among markers. Biomark Insights. 2011;6:83‐93. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64. Poncelet C, Fauvet R, Yazbeck C, Coutant C, Darai E. Impact of serum tumor marker determination on the management of women with borderline ovarian tumors: multivariate analysis of a French multicentre study. European Journal of Surgical Oncology. 2010;36(11):1066‐72. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65. Rana R, Padwick M. Accuracy of imaging in adnexal masses: An audit. BJOG: An International Journal of Obstetrics and Gynaecology. 2013;120:375. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66. Ricardo S, Marcos‐Silva L, Pereira D, Pinto R, Almeida R, Soderberg O, et al. Detection of glyco‐mucin profiles improves specificity of MUC16 and MUC1 biomarkers in ovarian serous tumours. Molecular Oncology. 2015;9(2):503‐12. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67. Ricci F, Bernasconi S, Erba E, Mangioni C, Fruscio R, Broggini M, et al. Characterization of markers associated with tumorigenicity in ovarian cancer tumors. Cytometry Part A. 2010;77A(2):200‐. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68. Rohilla M, Chopra S, Aggrawal N, Suri V, Rajvanshi A, Acharya G. Diagnostic dilemma of adnexal mass in a postmenopausal woman. Journal of Obstetrics &amp; Gynaecology. 2012;32(3):315‐6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69. Rufford B, Jacobs I, Menon U. Feasibility of screening for ovarian cancer using symptoms as selection criteria. BJOG: An International Journal of Obstetrics &amp; Gynaecology. 2007;114(1):59‐64. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70. Rychlik U, Kulpa JK, Wojcik E, Tarapacz J, Stasik Z. CA 125, HE4 in relation to inflammation in ovarian cancer patients. Tumor Biology. 2011;32:S76. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71. Sarkar M, Konar H, Raut D. Symptomatology of gynecological malignancies: experiences in the gynecology out‐patient clinic of a tertiary care hospital in kolkata, India. Asian Pacific Journal of Cancer Prevention: Apjcp. 2010;11(3):785‐91. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72. Sarkar M, Konar H, Raut D. Clinico‐pathological features of gynecological malignancies in a tertiary care hospital in eastern India: importance of strengthening primary health care in prevention and early detection. Asian Pacific Journal of Cancer Prevention: Apjcp. 2013;14(6):3541‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73. Scholler N, Lowe KA, Bergan LA, Kampani A, Ng V, Forrest RM, et al. Use of yeast‐secreted in vivo biotinylated recombinant antibodies (biobodies) in bead‐based ELISA. Clinical Cancer Research. 2008;14(9):2647‐55. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74. Skates SJ, Horick N, Yu Y, Xu F, Berchuck A, Havrilesky LJ, et al. Preoperative sensitivity and specificity for early‐stage ovarian cancer when combining cancer antigen CA‐125II, CA 15‐3, CA 72‐4, and macrophage colony‐stimulating factor using mixtures of multivariate normal distributions. Journal of Clinical Oncology. 2004;22(20):4059‐66. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75. Skates SJ, Menon U, MacDonald N, Rosenthal AN, Oram DH, Knapp RC, et al. Calculation of the risk of ovarian cancer from serial CA‐125 values for preclinical detection in postmenopausal women. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2003;21(10 Suppl):206s‐10s. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76. Sladkevicius P, Valentin L. Interobserver agreement in the results of Doppler examinations of extrauterine pelvic tumors. Ultrasound in Obstetrics &amp; Gynecology. 1995;6(2):91‐6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77. Sladkevicius P, Valentin L. Intra‐ and interobserver agreement when describing adnexal masses using the International Ovarian Tumor Analysis terms and definitions: a study on three‐dimensional ultrasound volumes. Ultrasound in Obstetrics &amp; Gynecology. 2013;41(3):318‐27. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78. Stalbovskaya V, Ifeachor EC, Van Huffel S, Timmerman D. Preoperative prediction of malignancy of ovarian tumours using modified sequential non‐uniform procedure. Conference proceedings: 2007;Annual International Conference of the IEEE Engineering in Medicine and Biology Society. IEEE Engineering in Medicine and Biology Society. Conference. 2007:5403‐6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>79. Szkandera J, Ploner F, Bauernhofer T, Kasparek A‐K, Payer F, Balic M, et al. Paraneoplastic limbic encephalitis in a patient with extragonadal choriocarcinoma‐‐significance of onconeural antibodies. Onkologie. 2010;33(8‐9):452‐4. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80. Toftager‐Larsen K, Hording U, Dreisler A, Daugaard S, Lund B, Bock J, et al. CA‐125, placental alkaline phosphatase and tissue polypeptide antigen as preoperative serum markers in ovarian carcinoma. Gynecologic and Obstetric Investigation. 1992;33(3):177‐82. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81. Ueland FR, Elder JW, Long A, Desimone CP, Miller RW, Podzielinski I, et al. Serial tumor morphology indexing predicts risk of ovarian malignancy. International Journal of Gynecological Cancer. 2012;22:E107. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82. Van Calster B, Van Belle V, Vergouwe Y, Timmerman D, Van Huffel S, Steyerberg EW. Extending the c‐statistic to nominal polytomous outcomes: the Polytomous Discrimination Index. Statistics in Medicine. 2012;31(23):2610‐26. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>83. Van Calster B, Vergouwe Y, Looman CWN, Van Belle V, Timmerman D, Steyerberg EW. Assessing the discriminative ability of risk models for more than two outcome categories. European Journal of Epidemiology. 2012;27(10):761‐70. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84. Vergote IB, Abeler VM, Bormer OP, Stigbrand T, Trope C, Nustad K. CA125 and placental alkaline phosphatase as serum tumor markers in epithelial ovarian carcinoma. Tumor Biology. 1992;13(3):168‐74. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85. Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, et al. Diagnostic markers for early detection of ovarian cancer. Clinical Cancer Research. 2008;14(4):1065‐72. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86. Wang BL, Shu‐Zheng; Zheng, Rong‐Shou; Zhang, Fang; Chen, Wan‐Qing; Sun, Xi‐Bin. Time Trends of Ovarian Cancer Incidence in China. Asian Pacific Journal of Cancer Prevention. 2014;15(1):191‐3. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87. Wang J, Lv F, Fei X, Cui Q, Wang L, Gao X, et al. Study on the characteristics of contrast‐enhanced ultrasound and its utility in assessing the microvessel density in ovarian tumors or tumor‐like lesions. International Journal of Biological Sciences [Electronic Resource]. 2011;7(5):600‐6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88. Webb PM, Purdie DM, Grover S, Jordan S, Dick ML, Green AC. Symptoms and diagnosis of borderline, early and advanced epithelial ovarian cancer. Gynecol Oncol. 2004;92(1):232‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>89. Wojcik‐Krowiranda K, Litwinska M, Bienkiewicz A. Usefulness of determination of CA125 concentration as a marker for ovarian tumours with special consideration of ovarian endometriotic cysts. [Polish] Przydatnosc oceny stezenia markera CA125 w diagnostyce guzow jajnika ze szczegolnym uwzglednieniem torbieli endometrialnych. Przeglad Menopauzalny. 2010;14(6):362‐5. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90. Woolas RP, Oram DH, Jeyarajah AR, Bast Jr RC, Jacobs IJ. Ovarian cancer identified through screening with serum markers but not by pelvic imaging. International Journal of Gynecological Cancer. 1999;9(6):497‐501. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91. Zalel Y, Tepper R, Altaras M, Beyth Y. Transvaginal sonographic measurements of postmenopausal ovarian volume as a possible detection of ovarian neoplasia. Acta Obstetricia et Gynecologica Scandinavica. 1996;75(7):668‐71. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92. Zannoni L, Savelli L, Jokubkiene L, Di Legge A, Condous G, Testa AC, et al. Intra‐ and interobserver agreement with regard to describing adnexal masses using International Ovarian Tumor Analysis terminology: reproducibility study involving seven observers. Ultrasound in Obstetrics &amp; Gynecology. 2014;44(1):100‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93. Zhu Y‐F, Gao G‐L, Zhang Z‐D, Huang Q‐S. Expression of human WFDC2 protein from patients with serous carcinomas by the two‐tier system. Chinese Medical Journal. 2013;126(18):3576‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94. Zhu Y‐F, He L‐S, Zhang Z‐D, Huang Q‐S. Expression of serum human epididymal secretory protein E4 at low grade and high grade serous carcinomas. Asian Pacific Journal of Tropical Medicine. 2012;5(12):925‐30. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95. Zouboulis CC, Achenbach A, Makrantonaki E. Acne tarda and male‐pattern baldness unmasking primary ovarian insufficiency: a case and review. Dermatology. 2014;229(2):51‐4. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Correspondence/opinions/reviews</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Enhanced ovarian cancer detection. Two‐test combo may identify disease early enough to cure it. Duke Medicine Health News. 2009;15(6):8‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2. Combining CA‐125 and U/S best approach to ovarian Ca screening. Contemporary OB/GYN. 2009;54(4):22‐. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3. Markers for ovarian cancer may show up years earlier. Healthcare Traveler. 2010;17(8):6.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4. Biomarkers for ovarian cancer. British Journal of Hospital Medicine (17508460). 2010;71(1):8‐. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5. OVA1 test for the assessment of suspected ovarian cancer (Structured abstract). Health Technology Assessment Database [Internet]. 2011 [cited MEDLINE N]; (1). Available from: http://onlinelibrary.wiley.com/o/cochrane/clhta/articles/HTA‐32011001101/frame.html. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6. New guidelines for early detection of ovarian cancer. The Lancet. 2011;377(9777):1544.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7. Researchers discover antibody that may help detect ovarian cancer in its earliest stages. NEWS‐Line for Laboratory Professionals. 2011;6(9‐10):4‐5. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8. Ovarian cancer screening strategy may allow earlier detection. British Journal of Hospital Medicine (17508460). 2013;74(9):490‐. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9. Abraham J, Ueland FR. OVA1 test for preoperative assessment of ovarian cancer. Community Oncology. 2010;7(6):249‐50. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10. Acharya UR, Sree SV, Saba L, Molinari F, Guerriero S, Suri JS. Ovarian tumor characterization and classification using ultrasound‐a new online paradigm. Journal of Digital Imaging. 2013;26(3):544‐53. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11. Alcazar JL. Re: Intra‐ and interobserver reproducibility of assessment of Doppler ultrasound findings in adnexal masses. L. Zannoni, L. Savelli, L. Jokubkiene, A. Di Legge, G. Condous, A. C. Testa, P. Sladkevicius and L. Valentin. Ultrasound Obstet Gynecol 2013; 42: 93‐101. Ultrasound in Obstetrics &amp; Gynecology. 2013;42(1):4‐5. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12. Amarin ZO, Jamal H. Serum CA 125 and fallopian tube carcinoma [1]. Annals of Saudi Medicine. 2001;21(1‐2):130. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13. Azvolinsky A. Diagnostic lens turns to difficult‐to‐detect ovarian cancer. Nature Medicine. 2013;19(2):117. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14. Baron AT, Maihle N. Nadir CA125 concentration as a prognostic indicator in ovarian cancer. Nature Clinical Practice Oncology. 2005;2(6):288‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15. Bast Jr RC, Brewer M, Zou C, Hernandez MA, Daley M, Ozols R, et al. Prevention and early detection of ovarian cancer: mission impossible? Recent Results in Cancer Research. 2007;Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer. 174:91‐100. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16. Bast RC, Badgwell D, Lu Z, Marquez R, Rosen D, Liu J, et al. New tumor markers: CA125 and beyond. International Journal of Gynecological Cancer. 2005;15:274‐81. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17. Berek JS, Bast Jr RC. Ovarian cancer screening: The use of serial complementary tumor markers to improve sensitivity and specificity for early detection. Cancer. 1995;76(10 SUPPL.):2092‐6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18. Campbell S. Ovarian cancer: role of ultrasound in preoperative diagnosis and population screening. Ultrasound in Obstetrics &amp; Gynecology. 2012;40(3):245‐54. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19. Candido‐dos‐Reis FJ. Ovarian Cancer risk model needs more meaningful clinical parameter... in response to VanCalster B, Van Hoorde K, Valentin L, Testa AC, Fischerova D, Van Holsbekeet C, et al: International Ovarian Tumor Analysis (IOTA) Group. Evaluating the risk of ovarian cancer before surgery using the ADNEX moded to differentiate between benign, borderline, early and advanced state invasive, and secondary metastatic tumours: prospective multicentre diagnostic study. BMJ 2014;349:g5920. (15 October.). BMJ: British Medical Journal. 2014;349(7894):g6689‐2. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20. Cass I. The Search for Meaning‐Symptoms and Transvaginal Sonography Screening for Ovarian Cancer Silent No More. Cancer. 2009;115(16):3606‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21. Chan KK, Selman TJ. Testing for ovarian cancer. Best Practice &amp; Research: Clinical Obstetrics &amp; Gynaecology. 2006;20(6):977. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22. Cohen CJ, Jennings TS. Screening for ovarian cancer: the role of noninvasive imaging techniques. American Journal of Obstetrics &amp; Gynecology. 1994;170(4):1088‐94. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23. Crum CP. Screening of symptomatic women for ovarian cancer. Lancet Oncology. 2012;13(4):e137; author reply e9‐40. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24. Finkler NJ. Clinical utility of CA 125 in preoperative diagnosis of patients with pelvic masses. European Journal of Obstetrics, Gynecology, &amp; Reproductive Biology. 1993;49(1‐2):105‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25. Gentry‐Maharaj A, Kalsi J, Burnell M, Manchanda R, Menon U. Screening of symptomatic women for ovarian cancer. Lancet Oncology. 2012;13(4):e138‐9; author reply e9‐40. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26. Hamilton W. Computer assisted diagnosis of ovarian cancer in primary care. BMJ (Online). 2012;344(7841). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27. Hartge P. Designing early detection programs for ovarian cancer. Journal of the National Cancer Institute. 2010;102(1):3‐4. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28. Hartge P. Reducing ovarian cancer death rates through screening. Cancer (0008543X). 2011;117(3):449‐50. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29. Hartge P, Speyer JL. Finding ovarian cancer. JNCI: Journal of the National Cancer Institute. 2012;104(2):82‐3. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30. Hellstrom I, Hellstrom KE. SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other. Ovarian Cancer: State of the Art and Future Directions in Translational Research. 2008;Advances in Experimental Medicine and Biology. 622:15‐21. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31. Herzog TJ. Enhancing the needle count in the haystack: serial ultrasonography for low‐to‐moderate risk adnexal masses. Obstetrics &amp; Gynecology. 2013;122(2 Pt 1):198‐200. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32. Javitt MC. Risk assessment for ovarian carcinoma: hope or hype? AJR American Journal of Roentgenology. 2010;194(2):308. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33. Jones HW, III. [Commentary on] Does three‐dimensional power Doppler ultrasound help in discrimination between benign and malignant ovarian masses? Obstetrical &amp; Gynecological Survey. 2007;62(5):308‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34. Jordan SJ, Coory MD, Webb PM. Re: predictive value of symptoms for early detection of ovarian cancer. JNCI: Journal of the National Cancer Institute. 2010;102(20):1599‐601. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35. Jurkovic D. Re: Intra‐ and interobserver agreement when describing adnexal masses using the International Ovarian Tumor Analysis terms and definitions: a study on three‐dimensional ultrasound volumes. P. Sladkevicius and L. Valentin. Ultrasound Obstet Gynecol 2013; 41: 318‐327. Ultrasound in Obstetrics &amp; Gynecology. 2013;41(3):245‐6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36. Jurkovic D, Alfirevic Z. DISQ 4: Serum CA 125 and benign looking adnexal masses. Ultrasound in Obstetrics and Gynecology. 2006;27(4):466. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37. Kaijser J, Sayasneh A, Van Calster B, Timmerman D, Bourne T. Preoperative identification of a suspicious adnexal mass. Gynecologic Oncology. 2012;127(1):260‐2. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38. Kaijser J, Van Gorp T, Sayasneh A, Vergote I, Bourne T, Van Calster B, et al. Differentiating stage I epithelial ovarian cancer from benign disease in women with adnexal tumors using biomarkers or the ROMA algorithm. Gynecologic Oncology. 2013;130(2):398‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39. Karlan BY, McIntosh M. The quest for ovarian cancer's holy grail: Can CA‐125 still be the chalice of early detection? Journal of Clinical Oncology. 2007;25(11):1303‐4. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40. Kenemans P, Yedema CA, Bon GG, Von Mensdorff‐Pouilly S. CA 125 in gynecological pathology ‐ A review. European Journal of Obstetrics Gynecology and Reproductive Biology. 1993;49(1‐2):115‐24. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41. Kim YH, Kim SC. Recent advances in the biomarkers for epithelial ovarian cancer. Journal of Gynecologic Oncology. 2011;22(4):219‐21. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42. Kim YT. A hospital‐based case‐control study of identifying ovarian cancer using symptom index. Journal of Gynecologic Oncology. 2010;21(1):65. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43. Ko HS, Kim N, Park YG. Re: interobserver agreement in describing adnexal masses using the International Ovarian Tumor Analysis simple rules in a real‐time setting and using three‐dimensional ultrasound volumes and digital clips. Ultrasound in Obstetrics &amp; Gynecology. 2015;45(2):238. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44. Kondalsamy‐Chennakesavan S, Obermair A. Differentiating stage I epithelial ovarian cancer from benign disease in women with adnexal tumours using biomarkers or the ROMA algorithm. Gynecologic Oncology. 2013;130(2):400. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45. Langmar Z, Nemeth M, Szekely B, Borgulya G. The performance of the risk of ovarian malignancy algorithm. British Journal of Cancer. 2011;105(1):185‐6; author reply 7‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46. Leahy Y. Are serum protein biomarkers effective in detecting ovarian cancer in its early stages? Clinical Journal of Oncology Nursing. 2009;13(4):443‐5. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47. Mano A, Godinho I, Falcao AC. CA 125 half‐life breakpoint between a "good" and "poor" prognosis in patients with ovarian cancer. International Journal of Gynecology and Obstetrics. 2005;88(3):333‐5. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48. Markman M. Limitations to the use of the CA‐125 antigen level in ovarian cancer. Current Oncology Reports. 2003;5(4):263‐4. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49. Markowska J, Manys G, Kubaszewska M. Value of CA 125 as a marker of ovarian cancer. European Journal of Gynaecological Oncology. 1992;13(4):360‐5. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50. McGuire WP. CA‐125 and early ovarian cancer: does this help the clinician or further muddy the water? Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2005;23(25):5862‐4. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51. Melichar B. Human epididymis protein 4: the start of a post‐ROMAn era? Clinical Chemistry and Laboratory Medicine. 2012;50(12):2069‐73. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52. Mourits MJ, de Bock GH. Symptoms are not early signs of ovarian cancer. BMJ: British Medical Journal (Overseas &amp; Retired Doctors Edition). 2009;339:b3955‐b. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53. Murta EFC. Tumour markers, ultrasonography, and ovarian cancer diagnosis. European Journal of Gynaecological Oncology. 2014;35(2):111. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54. Nossov V, Amneus M, Su F, Lang J, Janco JM, Reddy ST, et al. The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA‐125? American Journal of Obstetrics &amp; Gynecology. 2008;199(3):215‐23. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55. Olaitan A. NICE on ovarian cancer. Recommendations for detection in primary care are flawed. BMJ. 2011;342:d3022. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56. Olovsson M. Immunological aspects of endometriosis. Acta Obstetricia et Gynecologica Scandinavica. 2012;91:24‐5. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57. Pedersen A. Higher levels of HE4 may be sign of ovarian cancer, study reveals. Diagnostics &amp; Imaging Week. 2007;10(51):3‐. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58. Plebani M, Melichar B. ROMA or death: advances in epithelial ovarian cancer diagnosis. Clinical Chemistry &amp; Laboratory Medicine. 2011;49(3):443‐5. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59. Rasool R, Shah ZA, Salahuddin M, Bashir M. CA‐125 tumour marker for ovarian malignancies. JK Practitioner. 2003;10(3):224‐5. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60. Rosenthal AN, Jacobs IJ. The role of CA 125 in screening for ovarian cancer. International Journal of Biological Markers [Internet]. 1998 [cited PENDING (UPDATE 91‐08); (4):[216‐20 pp.]. Available from: http://onlinelibrary.wiley.com/o/cochrane/clcentral/articles/182/CN‐00487182/frame.html. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61. Sanchez Munoz A, Gonzalez Martin A, Mendiola Fernandez C. Lights and shadows of the tumoral marker CA‐125 in ovarian cancer. Clinical &amp; translational oncology: official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 2008;10(8):449‐52. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62. Sundar S, O'Byrne KJ. CA‐125 criteria for response evaluation in ovarian cancer. Gynecologic Oncology. 2005;98(3):520‐1. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63. Timmerman D, Van Calster B, Vergote I, Van Hoorde K, Van Gorp T, Valentin L, et al. Performance of the American College of Obstetricians and Gynecologists' ovarian tumor referral guidelines with a multivariate index assay. Obstetrics &amp; Gynecology. 2011;118(5):1179‐81; author reply 81. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64. Timmerman D, Verrelst H, Collins WP, Bourne TH, Vergote I. Re: Mol et al. Distinguishing the benign and malignant adnexal mass: an external validation of prognostic models. Gynecol Oncol 2001;80:162‐7. Gynecol Oncol. 2001;83(1):166‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65. Tone AA, Huntsman DG, Miller DM. Screening of symptomatic women for ovarian cancer. Lancet Oncology. 2012;13(4):e137‐8; author reply e9‐40. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66. Tummala MK, McGuire WP. Ovarian cancer, CA‐125 addiction, and informed confusion: Much ado about less. Journal of Clinical Oncology. 2007;25(24):3570‐1. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67. Urban N, McIntosh MW, Andersen M, Karlan BY. Ovarian cancer screening. Hematology ‐ Oncology Clinics of North America. 2003;17(4):989‐1005, ix. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68. Van Calster B, Wynants L, Kaijser J, Van Huffel S, Timmerman D. The independent effect of tumor size in predicting ovarian malignancy. European Journal of Obstetrics Gynecology and Reproductive Biology. 2012;162(2):237‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69. Wacholder S, Han SS, Weinberg CR. Inference from a multiplicative model of joint genetic effects or ovarian cancer risk. JNCI: Journal of the National Cancer Institute. 2011;103(2):82‐3. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70. Whitehouse C, Solomon E. Current status of the molecular characterization of the ovarian cancer antigen CA125 and implications for its use in clinical screening. Gynecologic Oncology. 2003;88(1 Pt 2):S152‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71. Wilson B, Nielsen HO. The carcinoid syndrome caused by retroperitoneal carcinoid tumors. Neuroendocrinology. 2011;94:49‐50. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72. Wiwanitkit V. HE4, CA‐125, and cystic ovarian mass. Journal of Gynecologic Oncology. 2012;23(2):133. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Developmental model superseded by model validation (N=4)</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Hillaby K, Aslam N, Salim R, Lawrence A, Raju KS, Jurkovic D. The value of detection of normal ovarian tissue (the 'ovarian crescent sign') in the differential diagnosis of adnexal masses. Ultrasound in Obstetrics &amp; Gynecology. 2004;23(1):63‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2. Timmerman D, Bourne TH, Tailor A, Collins WP, Verrelst H, Vandenberghe K, et al. A comparison of methods for preoperative discrimination between malignant and benign adnexal masses: the development of a new logistic regression model. American journal of obstetrics and gynecology. 1999;181(1):57‐65. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3. Timmerman D, Testa AC, Bourne T, Ameye L, Jurkovic D, Van Holsbeke C, et al. Simple ultrasound‐based rules for the diagnosis of ovarian cancer. Ultrasound in Obstetrics &amp; Gynecology. 2008;31(6):681‐90. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4. Timmerman D, Testa AC, Bourne T, Ferrazzi E, Ameye L, Konstantinovic ML, et al. Logistic regression model to distinguish between the benign and malignant adnexal mass </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Case control study with healthy controls</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1. Abdalla N, Winiarek J, Bachanek M, Cendrowski K, Sawicki W. Clinical, ultrasound parameters and tumor marker‐based mathematical models and scoring systems in pre‐surgical diagnosis of adnexal tumors. Ginekologia polska. 2016;87(12):824‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2. Abdel‐Hay NH, Mansour AA, El Sherbini MA, Motaleb FIA, El‐Shalakany AH. Forkhead box protein 3 (FoxP3) mRNA as a diagnostic marker in ovarian tumors: a pilot study. European Journal of Gynaecological Oncology. 2017;38(2):251‐6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3. Abramowicz JS, Timmerman D. Ovarian mass‐differentiating benign from malignant: the value of the International Ovarian Tumor Analysis ultrasound rules. American Journal of Obstetrics &amp; Gynecology. 2017;217(6):652‐60. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4. Alcazar JL. Ultrasound‐based IOTA simple rules allow accurate malignancy risk estimation for adnexal masses. Evidence Based Medicine. 2016;21(5):197. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>5. Anastasi E, Capoccia D, Granato T, Viggiani V, Tartaglione S, Manganaro L, et al. Assessing the association between 25‐OH vitamin D levels and ROMA score in a population of obese women. Journal of Biological Regulators &amp; Homeostatic Agents. 2016;30(4):1165‐71. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>6. Aydin DS, Turkyilmaz E, Goksedef BP, Aydin S, Aslan O, Ateser G, et al. 1,138 women with adnexal mass: pathologic findings according to age. European Journal of Gynaecological Oncology. 2017;38(1):102‐5. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7. Anastasi E, Granato T, Falzarano R, Storelli P, Ticino A, Frati L, et al. The use of HE4, CA125 and CA72‐4 biomarkers for differential diagnosis between ovarian endometrioma and epithelial ovarian cancer. Journal of ovarian research. 2013;6(1):44. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8. Ankita S, Shrivastav BR, Kumar SA. Clinical utility of CA125, HE4 and risk of ovarian malignancy algorithm (ROMA) for early detection of ovarian carcinoma. International Research Journal of Pharmacy. 2017;8(6):39‐45. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>9. Bendifallah S, Body G, Darai E, Ouldamer L. Diagnostic and prognostic value of tumor markers, scores (clinical and biological) algorithms, in front of an ovarian mass suspected of an epithelial ovarian cancer: Article drafted from the French Guidelines in oncology entitled "Initial management of patients with epithelial ovarian cancer" developed by FRANCOGYN, CNGOF, SFOG, GINECO‐ARCAGY under the aegis of CNGOF and endorsed by INCa. Gynecologie Obstetrique Fertilite et Senologie. 2019;47(2):134‐54. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10. Bian J, Li B, Kou X‐J, Liu T‐Z, Ming L. Clinical significance of combined detection of serum tumor markers in diagnosis of patients with ovarian cancer. Asian Pacific Journal of Cancer Prevention: Apjcp. 2013;14(11):6241‐3. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11. Broder JC, Jimenez JJ, Flye CW. R‐SCAN: Follow‐Up for Adnexal Cysts. Journal of the American College of Radiology. 2017;14(7):944‐6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>12. Bromley B. Pelvic ultrasound: a powerful tool in managing the patient with an adnexal mass. Menopause. 2017;24(6):599‐601. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13. Carvalho VP, Grassi ML, Palma CS, Carrara HHA, Faca VM, Candido Dos Reis FJ, et al. The contribution and perspectives of proteomics to uncover ovarian cancer tumor markers. Translational Research: The Journal Of Laboratory &amp; Clinical Medicine. 2019;206:71‐90. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>14. Choi JI, Park SB, Han BH, Kim YH, Lee YH, Park HJ, et al. Imaging features of complex solid and multicystic ovarian lesions: proposed algorithm for differential diagnosis. Clinical Imaging. 2016;40(1):46‐56 </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>15. Cui R, Wang Y, Li Y. Clinical value of ROMA index in diagnosis of ovarian cancer: Meta‐analysis. Cancer Management and Research. 2019;11:2545‐51. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>16. Chudecka‐Glaz AM. ROMA, an algorithm for ovarian cancer. Clinica Chimica Acta. 2015;440:143‐51. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>17. Dayyani F, Uhlig S, Colson B, Simon K, Rolny V, Morgenstern D, et al. Diagnostic Performance of Risk of Ovarian Malignancy Algorithm Against CA125 and HE4 in Connection With Ovarian Cancer: A Meta‐analysis. International Journal of Gynecological Cancer. 2016;26(9):1586‐93. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>18. Dochez V, Caillon H, Vaucel E, Dimet J, Winer N, Ducarme G. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. Journal of Ovarian Research. 2019;12 (1) (no pagination)(28). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>19. El Bairi K, Kandhro AH, Gouri A, Mahfoud W, Louanjli N, Saadani B, et al. Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer. Cellular Oncology. 2017;40(2):105‐18. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>20. Fakhar HB, Rezaie‐Tavirani M, Zali H, Faraji Darkhaneh R, Nejad leili EK, Aghazadeh MH. Comparison of Serum Human Epididymis Protein (HE4), Carbohydrate Antigen 125(CA125) and Risk of Ovarian Malignancy Algorithm (ROMA) as Markers in Ovarian Cancer: A Systematic Review and a Meta‐analysis. Indian Journal of Gynecologic Oncology. 2018;16 (1) (no pagination)(10). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21. Falzarano R, Viggiani V, Michienzi S, Colaprisca B, Longo F, Frati L, et al. CLEIA CA125 evidences: good analytical performance avoiding "Hook effect". Tumour Biology. 2013;34(1):387‐93. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22. Fawzy A, Mohamed MR, Ali MA, Abd El‐Magied MH, Helal AM. Tissue CA125 and HE4 Gene Expression Levels Offer Superior Accuracy in Discriminating Benign from Malignant Pelvic Masses. Asian Pacific Journal of Cancer Prevention: Apjcp. 2016;17(1):323‐33. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23. Friedman GD, Skilling JS, Udaltsova NV, Smith LH. Early symptoms of ovarian cancer: a case‐control study without recall bias. Family practice. 2005;22(5):548‐53. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24. Froyman W, Landolfo C, Amant F, Van den Bosch T, Vergote I, Coosemans A, et al. Morcellation and risk of malignancy in presumed ovarian fibromas/fibrothecomas. Lancet Oncology. 2016;17(3):273‐4. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25. Gao Y, Hernandez C, Yuan HX, Lilly J, Kota P, Zhou H, et al. Ultrasound molecular imaging of ovarian cancer with CA‐125 targeted nanobubble contrast agents. Nanomedicine. 2017;13(7):2159‐68. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26. Ghasemi N, Ghobadzadeh S, Zahraei M, Mohammadpour H, Bahrami S, Ganje MB, et al. HE4 combined with CA125: favorable screening tool for ovarian cancer. Medical Oncology. 2014;31(1):808. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>27. Giampaolino P, Della Corte L, Foreste V, Vitale SG, Chiofalo B, Cianci S, et al. Unraveling a difficult diagnosis: the tricks for early recognition of ovarian cancer. Minerva medica. 2019;06. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28. Havrilesky LJ, Whitehead CM, Rubatt JM, Cheek RL, Groelke J, He Q, et al. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence. Gynecologic Oncology. 2008;110(3):374‐82. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>29. Hidalgo Mora JJ, Rams Llop N, Ros Bernal F, Alcazar Zambrano JL. Classification systems and prediction of risk of malignancy of the adnexal masses. Clinica e Investigacion en Ginecologia y Obstetricia. 2018;45(1):24‐31. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30. Jacob F, Meier M, Caduff R, Goldstein D, Pochechueva T, Hacker N, et al. No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. Gynecologic Oncology. 2011;121(3):487‐91. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>31. Jeong TD, Cho EJ, Ko DH, Lee W, Chun S, Kwon HJ, et al. A new strategy for calculating the risk of ovarian malignancy algorithm (ROMA). Clinical Chemistry and Laboratory Medicine. 2017;55(8):1209‐14. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>32. Jia LT, Zhang YC, Li J, Tian Y, Li JF. The role of human epididymis protein 4 in the diagnosis of epithelial ovarian cancer. Clinical &amp; Translational Oncology: Official Publication of the Federation of Spanish Oncology Societes &amp; of the National Cancer Institute of Mexico. 2016;18(3):233‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>33. Jiang ZH, Li KT, Tian JW, Ren M. An overview of the development and application of the sonographic scoring system: differentiation of malignant from benign ovarian tumors. Archives of Gynecology &amp; Obstetrics. 2016;293(2):303‐10. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>34. Karimi‐Zarchi M, Behtash N, Mousavi A, Maghami FG, Gilani MM, Chiti Z, et al. A survey on the role of cancer antigen 125 (CA125), human epididymis protein 4 (HE4), risk of ovarian malignancy algorithm (ROMA), and risk of malignancy index (RMI) in pelvic mass. International Journal of Cancer Management. 2018;11 (12) (no pagination)(e79189). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>36. Kim B, Park Y, Kim B, Ahn HJ, Lee KA, Chung JE, et al. Diagnostic performance of CA 125, HE4, and risk of Ovarian Malignancy Algorithm for ovarian cancer. Journal of Clinical Laboratory Analysis. 2019;33(1):e22624. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>37. Lang S, Armstrong N, Deshpande S, Ramaekers B, Grimm S, de Kock S, et al. Clinically inappropriate post hoc exclusion of study participants from test accuracy calculations: the ROMA score, an example from a recent NICE diagnostic assessment. Annals of Clinical Biochemistry. 2019;56(1):72‐81. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>38. Lennox GK, Eiriksson LR, Reade CJ, Leung F, Mojtahedi G, Atenafu EG, et al. Effectiveness of the risk of malignancy index and the risk of ovarian malignancy algorithm in a cohort of women with ovarian cancer: does histotype and stage matter? International Journal of Gynecological Cancer. 2015;25(5):809‐14. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>39. Mapelli P, Incerti E, Fallanca F, Gianolli L, Picchio M. Imaging biomarkers in ovarian cancer: the role of 18F‐FDG PET/CT. The Quarterly Journal of Nuclear Medicine. 2016;60(2):93‐102. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40. Montagnana M, Benati M, Danese E. Circulating biomarkers in epithelial ovarian cancer diagnosis: From present to future perspective. Annals of Translational Medicine. 2017;5 (13) (no pagination)(276). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>41. Meys EMJ, Jeelof LS, Ramaekers BLT, Dirksen CD, Kooreman LFS, Slangen BFM, et al. Economic evaluation of an expert examiner and different ultrasound models in the diagnosis of ovarian cancer. European Journal of Cancer. 2018;100:55‐64. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>42. Meys EM, Kaijser J, Kruitwagen RF, Slangen BF, Van Calster B, Aertgeerts B, et al. Subjective assessment versus ultrasound models to diagnose ovarian cancer: A systematic review and meta‐analysis. European Journal of Cancer. 2016;58:17‐29. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>43. Meys EMJ, Kaijser J, Kruitwagen RFPM, Slangen BFM, Van Calster B, Aertgeerts B, et al. Subjective assessment versus ultrasound models to diagnose ovarian cancer: A review and meta‐analysis. International Journal of Gynecological Cancer. 2015;1):33‐4. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>44. Mills P, Court S, Giamougiannis P, Daines L. Is the risk of malignancy (RMI) score useful in deciding management when below 250? A 2‐year retrospective surgical study. BJOG: An International Journal of Obstetrics and Gynaecology. 2015;2):144‐5. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>45. Nandamuru D, Collins MK, Tarney CM. Evaluation and management of adnexal masses in postmenopausal women. Current Women's Health Reviews. 2019;15(1):41‐5. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>46. Ohler A, Pawlowski M, Dudziak M, Sznurkowski JJ. The new FIGO staging system and the review of current methods of detection of ovarian cancer. Onkologia i Radioterapia. 2015;32(2):9‐18. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47. Petrovic‐Simovic V. Comparing ROMA score for the same two periods in 2015 and 2018 in patients on observation. Clinica Chimica Acta. 2019;493 (Supplement 1):S116‐S7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48. Prskalo ZS, Gace M, Dobrijevic S, Mayer L. Benefits human epidydimis protein (HE4) compared to traditional used tumor markers in gynecological oncology. Libri Oncologici. 2015;43(1‐3):9‐14. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>49. Puljiz M, Mayer L. Multidisciplinary approach to diagnostics, treatment and follow up of patients with ovarian cancer: Potential of he4 and roma index. Libri Oncologici. 2015;43(1‐3):1. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>50. Sadowski EA, Robbins JB, Rockall AG, Thomassin‐Naggara I. A systematic approach to adnexal masses discovered on ultrasound: the ADNEx MR scoring system. Abdominal Radiology. 2018;43(3):679‐95. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>51. Shetty M. Imaging and Differential Diagnosis of Ovarian Cancer. Seminars in Ultrasound, CT and MRI. 2019. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52. Skates SJ. EPIC Early Detection of Ovarian Cancer. Clinical Cancer Research. 2016;22(18):4542‐4.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>53. Soletormos G, Duffy MJ, Othman Abu Hassan S, Verheijen RH, Tholander B, Bast RC, Jr, et al. Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers. International Journal of Gynecological Cancer. 2016;26(1):43‐51. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>54. Stukan M, Dudziak M, Ratajczak K, Grabowski JP. Usefulness of diagnostic indices comprising clinical, sonographic, and biomarker data for discriminating benign from malignant ovarian masses. Journal of Ultrasound in Medicine. 2015;34(2):207‐17. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55. Tcherkassova J, Abramovich C, Moro R, Chen C, Schmit R, Gerber A, et al. Combination of CA125 and RECAF biomarkers for early detection of ovarian cancer. Tumour Biology. 2011;32(4):831‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>56. Terry KL, Schock H, Fortner RT, Husing A, Fichorova RN, Yamamoto HS, et al. A Prospective Evaluation of Early Detection Biomarkers for Ovarian Cancer in the European EPIC Cohort. Clinical Cancer Research. 2016;22(18):4664‐75. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>57. Thakur M, Timmerman D. Imaging of Adnexal Masses. Clinical Obstetrics and Gynecology. 2017;60(1):38‐45. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>58. Thomassin‐Naggara I, Fedida B, Kermarrec E. Adnexal masses: Characterization of benign adnexal masses. Medical Radiology. 2019:273‐85. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>59. Van Calster B. External validation of ADNEX model for diagnosing ovarian cancer: evaluating performance of differentiation between tumor subgroups. Ultrasound in obstetrics &amp; gynecology: the official journal of the International Society of Ultrasound in Obstetrics and Gynecology. 2017;50(3):406‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>60. van Nagell JR, Jr, Miller RW. Evaluation and Management of Ultrasonographically Detected Ovarian Tumors in Asymptomatic Women. Obstetrics &amp; Gynecology. 2016;127(5):848‐58. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>61. Walker M, Sobel M. Diagnosing ovarian cancer. Cmaj. 2018;190(42):E1259.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>62. Westwood M, Ramaekers B, Lang S, Grimm S, Deshpande S, de Kock S, et al. Risk scores to guide referral decisions for people with suspected ovarian cancer in secondary care: a systematic review and cost‐effectiveness analysis. Health Technology Assessment (Winchester, England). 2018;22(44):1‐264. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63. Zhang Z, Barnhill SD, Zhang H, Xu F, Yu Y, Jacobs I, et al. Combination of multiple serum markers using an artificial neural network to improve specificity in discriminating malignant from benign pelvic masses. Gynecologic Oncology. 1999;73(1):56‐61. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 19.</span> <span class="table-title">Excluded studies: study design</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/appendices#CD011964-tbl-0021">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD011964-tbl-0022"> <div class="table-heading"><span class="table-label">Table 20.</span> <span class="table-title">Excluded studies: test positivity threshold</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Test positivity threshold</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1. Banu SA, Khatun S, Shamsuddin L. Assesment of adnexal masses by transvaginal sonography and serum CA125 assay in pre‐ and postmenopausal women. Bangladesh Journal of Obstetrics and Gynecology. 2009;24(2):56‐62. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2. Byler T, Nsouli I. Incidental CT bladder wall abnormalities: Harbinger or herring? Urology. 2014;1:S193‐S4. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3. Bouzari Z, Rahimi H, Gholinia H, Yazdani S, Hajian‐Tilaki K, Soleimani MJ. Cancer antigen 125 (CA125), human epididymis protein 4 (HE4), risk of malignancy index (RMI), and risk of ovarian malignancy algorithm (ROMA) as diagnostic tests in ovarian cancer. International Journal of Cancer Management. 2019;12 (1) (no pagination)(e59395). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>4. Cradic KW, Lasho MA, Algeciras‐Schimnich A. Validation of the Cut‐points Recommended for ROMA Using the Roche Elecsys CA125 and HE4 Assays. Annals of Clinical &amp; Laboratory Science. 2018;48(1):90‐3. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5. Ferdeghini M, Gadducci A, Prontera C, Malagnino G, Annicchiarico C, Prato B, et al. COMBINED EVALUATION OF SERUM CA‐125 AND CAM‐29 IN PATIENTS WITH EPITHELIAL OVARIAN‐CANCER. Tumor Biology. 1992;13(5‐6):287‐93. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6. Franchi M, Beretta P, Ghezzi F, Zanaboni F, Goddi A, Salvatore S. DIAGNOSIS OF PELVIC MASSES WITH TRANSABDOMINAL COLOR DOPPLER, CA‐125 AND ULTRASONOGRAPHY. Acta Obstetricia et Gynecologica Scandinavica. 1995;74(9):734‐9. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7. Kadayifci A, Simsek H, Savas MC. Serum CA 125 levels in patients with ovarian cancer and liver cirrhosis. Medical Principles and Practice. 1997;6(3):137‐41. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>8. Katsyuba M, Khasanov R, Usmanova G, Ratner E, Muratova G, Nigmatulina N. Can copenhagen index replace risk of ovarian malignancy algorithm (ROMA) in a triage of patients with pelvic mass? International Journal of Gynecological Cancer. 2017;27 (Supplement 4):303. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9. Le Page C, Ouellet V, Madore J, Hudson TJ, Tonin PN, Provencher DM, et al. From gene profiling to diagnostic markers: IL‐18 and FGF‐2 complement CA125 as serum‐based markers in epithelial ovarian cancer. International Journal of Cancer. 2006;118(7):1750‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10. Lenhard M, Stieber P, Hertlein L, Kirschenhofer A, Furst S, Mayr D, et al. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses. Clinical Chemistry &amp; Laboratory Medicine. 2011;49(12):2081‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11. Mansour GM, El‐Lamie IK, El‐Sayed HM, Ibrahim AM, Laban M, Abou‐Louz SK, et al. Adnexal mass vascularity assessed by 3‐dimensional power Doppler: does it add to the risk of malignancy index in prediction of ovarian malignancy?: four hundred‐case study. International journal of gynaecological Cancer. 2009;19(5):867‐72. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12. Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, et al. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecologic Oncology. 2008;108(2):402‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13. Moore RG, Jabre‐Raughley M, Brown AK, Robison KM, Miller MC, Allard WJ, et al. Comparison of a novel multiple marker assay vs the Risk of Malignancy Index for the prediction of epithelial ovarian cancer in patients with a pelvic mass. American Journal of Obstetrics &amp; Gynecology. 2010;203(3):228.e1‐6. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14. Nolen B, Velikokhatnaya L, Marrangoni A, De Geest K, Lomakin A, Bast RC, Jr, et al. Serum biomarker panels for the discrimination of benign from malignant cases in patients with an adnexal mass. Gynecologic Oncology. 2010;117(3):440‐5. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15. Shabana A, Onsrud M. Tissue polypeptide‐specific antigen and CA 125 as serum tumor markers in ovarian carcinoma. Tumor Biology. 1994;15(6):361‐7. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16. Shah CA, Lowe KA, Paley P, Wallace E, Anderson GL, McIntosh MW, et al. Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125. Cancer Epidemiology Biomarkers and Prevention. 2009;18(5):1365‐72. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17. Timmerman D, Van Calster B, Jurkovic D, Valentin L, Testa AC, Bernard J‐P, et al. Inclusion of CA‐125 does not improve mathematical models developed to distinguish between benign and malignant adnexal tumors. Journal of Clinical Oncology. 2007;25(27):4194‐200. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18. Vinokurov VL, Dudarev AL, Jurkova LE, Lapchenkov VI, Barbanel EJ. Tumor marker CA 125 in diagnosis, monitoring management and follow‐up of patients with ovarian tumors. European Journal of Gynaecological Oncology. 1992;13(2):205‐8. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19. Zheng H, Gao Y. Serum HE4 as a useful biomarker in discriminating ovarian cancer from benign pelvic disease. International Journal of Gynecological Cancer. 2012;22(6):1000‐5. </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 20.</span> <span class="table-title">Excluded studies: test positivity threshold</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/appendices#CD011964-tbl-0022">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD011964-tbl-0012"> <div class="table-heading"><span class="table-label">Table Tests.</span> <span class="table-title">Data tables by test</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p>Test</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">1 ROMA 7.4 (± 2) premenopausal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3223</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">2 ROMA 25.3 (± 2) postmenopausal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>15</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2599</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">3 ROMA 12.5 premenopausal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>302</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">4 ROMA 14.4 postmenopausal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>299</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">5 ROMA 13.1 (± 2) premenopausal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>27</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4463</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">6 ROMA 27.7 (± 2) postmenopausal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2002</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">7 ROMA 7.4 premenopausal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3051</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">8 ROMA 25.3 postmenopausal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1386</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">9 ROMA 7.4/25.3 all <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>681</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">10 ROMA 12.5/14.4 all <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>601</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">11 ROMA 13.1 premenopausal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>8</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1353</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">12 ROMA 27.7 postmenopausal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1265</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">13 ROMA 13.1/27.7 all <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1615</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">14 ROMA 11.4 premenopausal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2281</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">15 ROMA 29.9 postmenopausal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1797</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">18 ROMA mixed premenopausal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>38</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>7616</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">19 ROMA mixed postmenopausal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>6099</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">20 ROMA mixed all <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2897</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">21 RMI I 200 premenopausal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5233</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">22 RMI I 200 postmenopausal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>17</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4369</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">23 RMI I 200 all <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4559</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">24 RMI I 250 premenopausal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>461</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">25 RMI I 250 postmenopausal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>220</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">26 RMI I 250 all <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>540</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">35 RMI mixed premenopausal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2990</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">36 RMI mixed postmenopausal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2099</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">37 RMI mixed all <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5099</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">38 LR2 premenopausal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2843</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">39 LR2 postmenopausal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2157</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">40 LR2 all <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4596</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">41 ADNEX 3% D+ probability all <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2403</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">42 ADNEX 3% D+ probability premenopausal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1354</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">43 ADNEX 3% D+ probability postmenopausal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1049</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">44 ADNEX 5% D+ probability all <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2403</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">45 ADNEX 5% D+ probability premenopausal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1354</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">46 ADNEX 5% D+ probability postmenopausal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1049</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">47 ADNEX 10% D+ probability all <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2403</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">48 ADNEX 10% D+ probability premenopausal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1696</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">49 ADNEX 10% D+ probability postmenopausal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1365</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">50 ADNEX 15% D+ probability all <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2403</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">51 ADNEX 15% D+ probability premenopausal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1354</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">52 ADNEX 15% D+ probability postmenopausal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1049</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">67 RMI I mixed premenopausal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>5694</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Test" rowspan="1" valign=""> <p class="subgroupTitle">68 RMI I mixed postmenopausal <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>4589</p> </td> </tr> <tr class="figure-image"> <td colspan="3"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table Tests.</span> <span class="table-title">Data tables by test</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD011964.pub2/references#CD011964-tbl-0012">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD011964.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD011964-note-0031">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD011964-note-0027">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD011964-note-0029">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD011964-note-0025">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD011964-note-0023">日本語</a> </li> <li class="section-language"> <a class="" href="ms#CD011964-note-0021">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD011964-note-0019">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD011964-note-0015">简体中文</a> </li> <li class="section-language"> <a class="" href="zh_HANT#CD011964-note-0017">繁體中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br/> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011964\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011964\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011964\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011964\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011964\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011964\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011964\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011964\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011964\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011964\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011964\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011964\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011964\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011964\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011964\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD011964\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD011964\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD011964\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=loVWuZlx&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011964.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD011964.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD011964.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD011964.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD011964.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740719915646"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011964.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740719915649"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD011964.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918df45e8ffd937f',t:'MTc0MDcxOTkxNi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 